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Abstract I executive summary 
Background 
Clinical trial investigators and research ethics committees are obliged to ensure the 
that clinical trials are methodologically sound, and that the results of those trials are 
made publicly available in an open and honest fashion that is not misleading and does 
not misrepresent the data. This will ensure that only the best research is conducted, 
and that clinical decision making is based on the best possible,evidence. 
Objective 
The objective of this thesis was to explore issues in the design, conduct and reporting 
of clinical trials that impact on the quality of decision making by research ethics 
committees, as well as health care providers and consumers. 
Methods 
Three studies were conducted, the first of which was a follow-up study of 103 
randomised trials submitted to a human research ethics committee in central Sydney. 
Information in the trial protocol was compared with that reported in the trial 
publication, the intention being to identify discrepancies between the two documents, 
particularly in relation to the primary outcomes. The second study reported is a 
systematic review of published studies evaluating the impact of shared scientific or 
ethical review of multi-centre clinical trial protocols on the quality of clinical research 
and the research process. The third is a prospective cohort study oftrials submitted to 
a central committee for scientific review, and the impact that review had on the 
functioning and decision-making of human research ethics committees. 
Results 
Selective reporting of primary outcomes encompasses selection of which outcomes 
are reported (discrepancy in identity), how the outcome is defined (discrepancy in 
definition) and selection of the amount of information reported for an outcome 
(completeness of reporting). Selective reporting of the primary outcome existed in 
some form in a significant proportion of trial publications. 17% of outcomes declared 
as a primary in the protocol were not reported as the primary outcome in the 
publication, and 15% of outcomes declared as a primary in the publication were not 
declared as primary outcomes in the protocol. Lack of adequate outcome definition in 
protocols and publications meant it was not possible to assess discrepancy in definition. 
76% of trials completely reported all of their comparisons. Statistically significant 
comparisons were more likely to be completely reported. Trials with a completely or 
partially documented sample size calculation in the protocol were significantly less 
likely to selectively report the primary outcome, and this variable may be a proxy 
measure for the quality of the trial based on the protocol. 
The quality of the trial based on information obtained from its protocol is a 
fundamental component in the decision-making process of an ethics committee to 
approve or reject an application. Evidence for this is reflected by the nature of the 
changes requested by ethics in committees as a condition of approval. There is 
insufficient evidence provided by the identifiable published studies to be able to 
determine whether centralised scientific or ethical review improves the quality of 
trials or the quality of decisions made by RECs. 
The prospective study revealed that the 22 ethics committees affiliated with NSW 
Health spend a considerable amount of time each year on scientific review: an 
estimated 2,315 hours - equivalent to approximately 1.4 full-time equivalent 
positions. RECs found the information provided by the central committee useful, and 
believed that it reduced the overall time taken to consider the trial at their meeting and 
improved the level of confidence they had in their decision making. 
Discussion 
Reporting of clinical trials should be consistent with original trial design as outlined 
in the clinical trial protocol. In the follow-up study of randomised trials, incomplete 
reporting of the primary outcome was a particularly problem among trials with 
outcomes that were not conventionally significant statistically. This may compromise 
the abil ity to undertake unbiased systematic reviews of all relevant trials. 
The research also identified that there can be changes in one or more aspects of a 
primary outcome between the protocol and the publication, such as a change in the 
definition of a positive test, or a change in the time frame for measurement. These 
ii 
changes could potentially bias estimates of treatment effects, if based on knowledge 
of trial results. It was not possible in most cases to be able to judge whether these 
changes were appropriate due to insufficient documentation provided in either the 
trial protocol or the final publication. 
This research has identified the importance (when considering the scientific quality of 
clinical trials) of having processes for ensuring that trial reporting is consistent with 
the original trial protocol and subsequent protocol amendments. Ethics committees 
may be in a good position to help with this process. 
Currently ethics committees are responsible for ensuring that trials of appropriate 
scientific quality are undertaken. A variety of models currently exist for reviewing 
scientific quality either directly or indirectly for such committees. A systematic 
review of a centralised process of scientific or ethical review found very little 
evidence on whether this improved scientific quality. A pilot project in NSW has been 
exploring more efficient models for assessing scientific quality centrally for 
multicentre trials. An assessment of this scheme's value was limited in scope and 
further efforts to improve and assess strategies for ensuring high scientific quality of 
clinical trials in protocol design and reporting are warranted. 
Conclusion 
There would appear to be a direct relationship between the quality of clinical trials. 
based on information available in trial protocols, and the quality of reporting of the 
results of the trial in a peer-reviewed publication. The quality of clinical trial 
protocols is an important part of the decision to allow a trial to proceed to recruiting 
participants. Further research is required to evaluate the effectiveness of measures 
taken to improve the method of evaluating the science of a trial as part of the ethical 
review process, including the value of centralising all or part of the process. 
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Glossary 
Term 
Adverse event 
Allocation 
concealment 
Bias 
Blinding 
(or masking) 
Clinical drug trial 
Clinical trial 
Definition 
An undesirable or unwanted experience (expected or 
unexpected) that results from an intervention, including toxicity, 
injury or hypersensitivity. 
The most important requirement of a treatment allocation scheme 
is that it is not possible for the next treatment to be allocated to be 
identified before the participant enters the trial. In this thesis 
allocation concealment is classified as: 
Adequate: if the individual enrolling trial participants was kept 
unaware of the randomisation sequence in advance through the 
use of central randomisation, independent preparation of drugs 
in sequential unmarked containers, sealed opaque envelopes, 
post-enrolment randomisation such as a coin toss, or variations 
thereof. 
Inadequate: if the allocation sequence was predictable or 
known prior to patient enrolment, or was not described. 
A distortion in the selection of patients, collection of data, 
determination of endpoints, and final analyses which might result 
in misleading conclusions. 
Concealing the identity of the treatment to which the patient has 
been allocated to the patient, the health care practitioner, the 
outcome assessor, the statistician, the data monitoring committee, 
or any combination of these. In this thesis the blinding of trials is 
classified as: 
Open label: no treatment blinding is used. 
Patient is blinded: the person receiving treatment is not aware 
of the nature ofthe intervention. 
Person administering treatment is blinded: the person 
administering the treatment is not aware of the nature of the 
intervention. 
Double blind: where both the person receiving the treatment, 
and the person administering the treatment, are unaware of the 
nature of the intervention. 
In the SSAS evaluation, a clinical drug trial was any trial 
involving a drug requiring notification to the Therapeutic Goods 
Administration (TGA) through the Clinical Trials Notification 
(CTN) or Clinical Trials Exemption (CTX) schemes. 
A prospective study comparing the effect and value of 
interventions in human beings. 
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Confinnatory trial 
Control group 
Date of actionable 
approval document 
Effectiveness 
Efficacy 
Experimental 
study 
Explanatory trial 
Exploratory trial 
A confinnatory trial is an adequately controlled trial in which 
the hypotheses are stated in advance and evaluated. As a rule, 
confinnatory trials are necessary to provide finn evidence of 
efficacy or safety. The rationale and design of confirmatory 
studies nearly always rests on earlier clinical work carried out in 
a series of exploratory studies. (International Conference on 
Hannonisation 1998) 
Used for comparison with the investigational treatment. In cancer 
trials this can be the current standard treatment. 
In the SSAS evaluation, the date of an actionable approval 
document is the date a trial could technically start recruiting 
patients at the site/s the REC covers. This is barring practical 
issues such as drug availability, etc. 
Does the intervention work in the people to whom it has been 
offered. (Jadad 1998) Effectiveness trials tend to be pragmatic. 
Does the intervention work in the people who have received it. 
(Jadad 1998) Efficacy trials tend to be explanatory. 
A study in which the investigator controlled one or more 
variables in order to monitor the effect on a process or outcome. 
Designed to learn more about the population under study rather 
than about the procedure or treatment. (Easterbrook & Matthews 
1992) 
Pose specific scientific hypotheses aimed at improving basic 
understanding of how treatments work, provide a scientific basis 
for modifying therapies and for introducing novel approaches to 
medical treatment. An explanatory trial recruits as homogeneous 
a population as possible to maximise the chances of 
demonstrating treatment effects. (Roland & Torgerson 
1998;Simes 1998) 
In contrast to confinnatory trials, the objectives of an 
exploratory trial may not always lead to simple tests of pre-
defined hypotheses. Their analysis may entail data exploration; 
tests of hypotheses may be carried out, but the choice of 
hypothesis may be data dependent. Such trials cannot be the 
basis of the fonnal proof of efficacy, although they may 
contribute to the total body of relevant evidence. An individual 
trial may have both exploratory and confirmatory aspects. 
(International Conference on Hannonisation 1998) 
REC Executive The individual responsible for managing the work of the REC. 
Officer May also be known by other tenns such as REC Secretary. 
xv 
Interim analysis An interim analysis of a clinical trial is conducted after a 
proportion of the anticipated total sample size has been 
randomised. The purpose is to monitor the progress of the trial 
and to assess whether there is a significant difference between the 
groups that may warrant early closure ofthe trial. 
Intervention group The interventionls in a clinical trial which are being compared 
with the control (or standard) treatment. 
Multi-centre 
Observational 
study 
Outcome 
Placebo 
Pragmatic trial 
Primary outcome 
Protocol 
Refers to clinical trials involving more than one health care 
institution (such as hospitals). 
A study in which the investigator observed a process or disease 
without intending to alter it during observation. (Easterbrook & 
Matthews 1992) 
A variable intended to be assessed in all study participants for 
the purpose of comparing the effects of interventions between 
randomised groups. (Chan A W & Altman 2005) 
An inactive agent given to a participant as a substitute for an 
active agent. (Meinert 1986b) Double-dummy designs involve 2 
or more arms with an active intervention where there is a 
placebo for each intervention. 
Primarily concerned with identifying the optimal treatment from 
the patient's perspective. The patient population in a pragmatic 
trial is likely to be more heterogeneous than an explanatory trial, 
reflecting variations between patients that occur in clinical 
practice. They aim to inform choice between treatments. 
Outcome measures in pragmatic trials are patient-oriented and 
represent the full range of health gains. (Roland & Torgerson 
1998;Simes 1998) 
A primary outcome is clearly distinguishable if there is a clear 
statement that it is the primary (main) outcome. If there is no 
clear statement then it assumed that the primary outcome is that 
used to calculate the sample size, or stated in the aims or 
objectives (in that order). 
A written description of a clinical trial including the objectives, 
eligibility criteria, treatment regimens, statistical and 
administrative details. A blueprint for an experiment. 
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Randomisation The process by which patients are randomly assigned to one ofthe 
interventions on a randomised clinical trial. The purpose of 
randomisation is to ensure that the types of patient in each 
treatment group are as similar as possible, and hence "to eliminate 
possible biases that may lead to systematic differences between 
the treatment groups". (Altman 1991) 
Research Ethics Or Ethical Review Committee (ERC): entitIes or committees 
Committee responsible for reviewing the ethical aspects of a clinical trial. 
Safety trial 
Sample size 
Scientific review 
Sequence 
generation 
Sponsor 
Includes, but is not restricted to: institutional review boards 
(IRB - the term commonly used, for eJ>ample, in the USA), 
human research ethics committees (REC - used in Australia), 
institutional ethics committees (lEC) and research ethics boards 
(REB: used in Canada). 
The main aim of the study is to evaluate whether the 
intervention is safe to use in the target population, in what dose / 
schedule and at what cost (in terms of toxicity). 
The total number of participants to be recruited to a clinical trial. 
Refers to a review of the science (but not the ethics) of a clinical 
trial. The "science" includes the methodological quality of the 
design of the clinical trial (eg randomisation, sample size 
calculation), and/or safety issues (including toxicology), and/or 
the quality of the clinical aspects of the trial (relevance of the 
question, appropriateness of outcomes, etc). 
The method used to generate the order in which participants are 
allocated to treatment. In this thesis sequence generation is 
classified as: 
Adequate: if a truly random method was described, including a 
random number table, computer-generated random sequence, 
coin toss, draw of numbers from a container, or variation 
thereof. 
Inadequate: if the method was described and is not truly 
random, or was not described. 
The organisation (eg pharmaceutical company or collaborative 
group), institution or individual (eg Principal Investigator) 
responsible for the initiation, management and / or financing of 
a clinical trial. 
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Chapter 1: Background to this Thesis 
This chapter will document background information that is relevant to the thesis as a 
whole. The issues addressed in this chapter include: 
• Misleading the reader 
• Trial quality 
• Publication bias 
• Multiplicity 
• The impact these issues have on the work of research etliics committees 
Introduction 
"Both authors and publishers have ethical obligations. In publication of the 
results of research, the investigators are obliged to preserve the accuracy of 
the results. Negative as well as positive results should be published or 
otherwise publicly available. " 
(World Medical Association 2000) 
Clinical trial investigators and RECs are obliged to ensure that clinical trials approved 
to recruit patients are methodologically sound, and that the results of those trials are 
made publicly available in an openly honest fashion that is not misleading. This will 
ensure that only the best research is conducted, and that clinical decision making is 
based on the best possible evidence. 
The objective of this thesis was to explore issues in the design, conduct and reporting 
of clinical trials that impact on the quality of decision making by research ethics 
committees, as well as health care providers and consumers. 
This thesis will investigate ways in which the quality of randomised controlled trials 
might be improved at the design stage (before participants have been recruited) to ensure 
that decisions made based on the results of those trials are reliable. Of particular interest 
is the role ethics committees could potentially play in improving the quality of clinical 
trials through improving the quality of clinical trial protocols. 
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The volume of clinical trials research 
The practice of medicine over the last two decades has emphasized the importance of 
basing treatment decisions on evidence that has demonstrated those treatments to be safe 
and effective. It is now generally accepted that the highest level of evidence for assessing 
the effects of interventions is provided by systematic reviews of all relevant randomised 
controlled trials or at least one properly designed randomised clinical trial. (Quality of 
Care & Health Outcomes Committee 1995) A clinical trial, as defined by the 
International Committee of Medical Journal Editors, is "any research project that 
prospectively assigns human subjects to intervention or comparison groups to study 
the cause-and-effect relationship between a medical intervention and a health 
outcome." (De Angelis et al. 2004) Randomised controlled trials (that is, when 
allocation to an intervention is by a chance process) are the closest thing to a true 
experiment available to those involved in the evaluation and provision of health care. 
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The recognition of the importance of high level evidence in clinical decision-making 
has resulted in a dramatic increase in the volume of clinical trials research in the last 
15 years. Based on references indexed on the Medline database of the National 
Library of Medicine, for example, there was a three-fold increase in the number of 
publications reporting the results of randomized clinical trials from almost 35,000 in 
the I980s, to 93,000 in the 1990s, and over 60,000 between 2000 and 2005 (Figure 1). 
One USA-based source (CenterWatch) estimated that 80,000 trials were under way in 
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that country alone in 2001 (Lemonick & Goldstein 2002). As Australia did not have a 
prospective clinical trials register until June 2005 it is not yet possible to obtain 
accurate figures on the number of clinical trials that have been (or are being) 
conducted that involve Australians. During the first 5 months of the Australian 
Clinical Trials Register (July to November inclusive) almost 800 trials were submitted 
for registration, although registration during that time was voluntary. 
As well as increasing in number, clinical trials are increasing in size and complexity . 
• 
It is not uncommon for a trial to enrol thousands of patients across multiple centres in 
multiple countries. These large sample sizes are required to reliably detect the 
relatively small effects that can now be expected of most new treatments. (Peto, 
Collins, & Gray 1995) As clinical trials are both time and resource consuming, and 
considering the finite number of potentially eligible participants, it is important that 
they adopt design features that maximise their methodological efficiency. Features 
such as factorial designs, crossover designs, cluster designs, multiple treatment arms, 
and placebo run-in periods to identify potential non-compliers, eligibility criteria to 
identify and exclude participants who may be lost to follow-up are all intended to 
improve the efficiency of the trials that utilise them. 
Misleading the reader 
The chances of reaching a reliable and valid conclusion when conducting a clinical trial 
is dependent on the ability of the trial's design to provide an unbiased, meaningful 
answer to the question being addressed. The results of a trial which does not take 
measures to minimise bias, or is not statistically capable of answering the question, will 
mislead and confuse those attempting to interpret the results and incorporate them into 
clinical practice. The report of a clinical trial could also mislead if it is not an accurate 
reflection of the trial as it was originally designed. That is, there are unreported 
differences between the protocol and the publication that could influence the reader's 
interpretation of the results of the trial. Some examples of situations where this may 
be problematic are outlined in Table 1. Even an inconclusive ("null") result may 
mislead if the lack of a conclusive result is misinterpreted as the treatment being 
ineffective, when there may in fact be an effect which the trial was simply incapable of 
detecting. The fault in many cases will not lie with the treatment strategy under 
investigation, but will be due to inadequacies in the trial's design and interpretation. 
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(Fisher 1989) When calculating the sample size, for example, the investigators may have 
overestimated the expected benefit of the investigational treatment resulting in an 
underestimate of the number of patients required to answer the question. Or it may have 
been possible for the investigator to identil); the next treatment to be allocated before 
randomisation took place due to the way in which randomisation was achieved, thereby 
enabling investigators to selectively exclude patients. 
Table 1: Ways in wbich elements of a trial protocol may cbange between tbe initial protocol and 
tbe publication • 
Element Example of bow it miEbt cban!!e Wby could a cbaDl!e be misleadinl! 
Eligibility Addition of criteria that may result If a per-protocol analysis is performed the 
criteria in the post-hoc exclusion of eligibility criteria might be changed by 
patients previously considered to investigators after the data has been looked at. It 
be eligible is not always possible to determine from a trial 
publication if analysis was per protocol or 
intention to treat and, if the latter, investigators 
do not always use this term correctly. 
The Dose or schedule of a drug; timing The intervention may be deliberately changed 
intervention of a procedure; therapist; etc (eg dose increased) as a result of something that 
or comparator happened in the trial (eg adverse events). 
Interventions may end up being confounded but 
the confounding factor is not always evident to 
the investigator or the reader of the trial report. 
Outcomes Change in (or lack of) the A problem ifthe definition changed after 
definition looking at the data. Lack of definition includes 
the non-specification of a time-point of interest 
(when applicable) 
Outcome Change in the way the outcome is For example, the use ofa more (or less) 
evaluation measured accurate test or instrument which increases (or 
decreases) the event rate 
Outcome Change in the freq uency with Although follow-up may be planned at regular 
evaluation which it is measured intervals using the same schedule for all trial 
arms. subjects on one arm may end up being 
followed more intensivel}' 
Design Crossover design becomes parallel; Has implications for the power calculation and 
The termination I non·reporting I hence the ability of the trial to answer the 
merging of trial arms question posed 
Method of The integrity of randomisation may Investigators should report problems 
randomisation be challenged (eg blinding is not encountered with achieving randomisation and 
being maintained) and hence the measures taken to resolve these problems. 
method chaneed. 
Sample size Change in the outcome used, These could be as the result of interim analyses 
estimated size of effect. total or other looks at the data. 
number to be recruited. etc 
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A poor quality clinical trial may mislead by: 
I. Providing a biased estimate of the treatment effect. That is, there is a 
distortion in some aspect of the trial (such as the selection of patients, 
collection of data, determination of endpoints, the final analyses) which 
might result in misleading conclusions. 
2. Providing an imprecise estimate of the treatment effect. That is the accuracy 
of the parameter estimates and their differences and is a result of inadequate 
power. 
3. Underestimating the treatment effect due to partial treatment (for example, 
through poor compliance or high drop-out (or drop-in) rates). 
The reader could also be misled through overemphasis of positive results, or 
underplaying of negative results, particularly when the reader does not have the skills 
necessary to interpret the information presented accurately, or to determine if the 
authors have interpreted it appropriately. (Pocock 2002) In addition, the authors of 
publications reporting the results of trials often fail to put their trial into an 
appropriate context, with many not including reference to relevant systematic reviews 
addressing the same or similar questions. (Clarke, Alderson, & Chalmers 2002) 
It is important to note that a change made to any aspect of a clinical trial (to design, 
outcomes, treatment, etc) is not necessarily a problem as long as the reader of a 
resulting publication is provided with adequate information so they can evaluate the 
potential impact of the change. When a change is made to a protocol the trial (or 
publication) "user" needs to consider if the change was made as a consequence of 
knowledge of the results of the trial (including interim results). If the trial is still 
active then the user will also need to consider ifthe change is such that its existence in 
the original protocol would have impacted on the decisions made by ethics 
committees, funding agencies, etc at the time the trial was originally considered. 
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The impact of misleading results 
Misleading results can have a devastating impact on the health outcomes of 
individuals treated as a result of this misleading research. In the 1950s, as an example, 
acetazolamide (alone or with furosemide) became standard practice in the 
management of post-haemorrhagic hydrocephalus in preterm infants, even though it 
was evident that there were side effects of cause for concern. In 1992 an adequately 
powered, randomised trial in preterm infants was conducted, the results of which 
indicated that the drug was associated with signi ficantly poorer health outcomes 
including a higher rate of shunt placement and increased neurological morbidity. 
(Silverman 1999) During the 40 year period in which this drug was standard practice 
many babies will have suffered as the result of a change in practice not based on 
sound evidence. 
"When the first few tries indicate that a new procedure 'works', all too ofien 
the exciting results are published and enthusiastic investigators become so 
convinced of the value of the intervention, it is baptised and named 'Standard 
Practice '. Moreover, the innovators are now unwilling to conduct a trial with 
concurrent controls . .. (Silverman 1999) 
A recent example is the use of selective serotonin reuptake inhibitors (SSRls) in the 
treatment of depression, which are now known to be associated with an increased risk 
of suicide and suicidal ideation. At the heart of the heated and very public debate 
surrounding these drugs is the selective interpretation and reporting of data from 
clinical trials on suicidal behaviour. Cynics have suggested that it is only as the result 
of threatened legal action that one manufacturer, GlaxoSmithKline, made the 
unpublished results of the relevant trials available. (Tonkin & lureidini 2005;Wessely 
& Kerwin 2004) The unpublished trials in children revealed an increased suicide risk 
and little evidence of efficacy. (Tonkin & lureidini 2005) 
Exhibits submitted in the case of Fentress v Lilly demonstrate that there was debate 
within another company manufacturing SSRls (Lilly) as to whether some of the safety 
outcomes should be reclassified. Such reclassification would have lead to the under-
interpretation of the significance of the results pertaining to those outcomes, including 
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a request that "suicide attempt" be change to "overdose", and "suicidal ideation" to 
"depression" .(Bouchy 1990) 
"the physician has reported a suicide attempt. Do we have a right to change it 
to some terminology which we may consider to be more specific, e.g. 
overdose, but which is not free from ambiguity and could be regarded as 
inaccurate or misleading. The term overdose is not free from ambiguity 
because there are clearly forms of overdose which are not related to suicide 
, 
attempts, for instance wrong dose prescribed or dispensed, error on the part 
of the patient, etc. " 
Further, the massaging of clinical trials to show a desired result can start at the very 
early stages of the study - for example, with the design of data collection forms. It has 
been suggested in the case of the SSRls that the trials did not record suicidal 
behaviour "owing to a lack of boxes corresponding to the side effect in question. This 
lack of recorded data has then been used against claimants as evidence that the 
supposed problem doesn't happen. " (Healy 2002) 
The probability of reporting a false positive 
A result will mislead if it turns out to be falsely positive: that is, a treatment is 
reported to be effective when in reality it is not. Tannock suggests that there are at 
least three factors that increase the probability that the results in a report of a clinical 
trial will be false positive: (Tannock 1996) 
• The low probability that new treatments will lead to therapeutic advances, 
implying a low prevalence of true-positive trials 
• Publication bias - the selective reporting of trials 
• The performance of multiple significance tests, only some of which may be 
reported in an article 
Low probability of new therapeutic advances 
Most medical advances come in small steps rather than giant leaps. Large treatment 
effects are rare and the smaller, more realistic, treatment effects require very large 
sample sizes if they are to be detected with any degree of accuracy. (Meinert 
1986a;Peto, Collins, & Gray I 993;Peto, Collins, & Gray 1995) A recognised problem 
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with many clinical trials is the tendency to underestimate the required sample size due 
largely to investigators overestimating the expected benefit of the investigational 
treatment. (peto, Collins, & Gray 1995) Lack of precision can lead to type II error (i.e. 
false negative) if a null result is interpreted as the treatment having no effect, when such 
a result could in fact be due to the trial not having sufficient power rather than a genuine 
lack of treatment effect. The precision could be improved by increasing the number of 
events in each arm of a trial, thereby increasing the trial's ability to detect differences 
between the treatments. 
Table 2: Type I and Type n error 
Is there really a Statistical significance 
difference between Significant Not significant 
treatments 
(The "truth") 
Yes True positive False negative" 
No False positive True negative 
Note I: the significance level (a) ~ the probability of Type 1 error 
Note 2: the power (1-13) ~ 1 - the probability ofa type n error 
A number of studies have demonstrated the inadequacy of trial sample sizes and their 
calculation. An early survey by Freiman et al examined 71 trials which did not reach a 
statistical significance level of 0.05 (referred to by the authors as "negative" trials) 
published in a selection of 20 journals between 1960 and 1977. (Freiman et al. 1978) 
The survey found that only 15% of trials had sample sizes large enough to detect a 25% 
improvement in response (32% were large enough to detect a 50% improvement) with 
90% power. The authors concluded that sample sizes are often too small to "offer a 
reasonable chance of successfully rejecting the null hypothesis in favor of the treatment". 
(Freiman, Chalmers, Smith, Jr., & Kuebler 1978) 
A second study by Meinert et al investigated a random sample of 180 papers published 
in 1980. Of 113 reports indexed as a clinical trial, only 2 showed any evidence of having 
calculated a sample size prior to the commencement of the trial. (Meinert 1986b) In a 
similar study, Pocock et al evaluated 45 clinical trial reports published in the latter half 
8 
of 1985 in the British Medical Journal, the Lancet and the New England Journal of 
Medicine. (Pocock, Hughes, & Lee 1987a) Only 5 reports mentioned the number of 
patients it was originally intended to recruit, and supported this with a statement of 
statistical power. In most cases it was impossible to tell whether there had actually been 
a sample size calculation before the trial started, whether trials had reached their target 
accrual, whether accrual had been deliberately exceeded to increase power, or whether 
the trial had stopped early due to a statistically significant difference demonstrated at 
interim analysis. 
In 1995 Moher et al reviewed all 383 trials published in JAMA, the Lancet and the New 
England Journal of Medicine during 1975, 1980, 1985 and 1990. (Moher et al. 1995) A 
statistically non-significant result was reported by 102 trials, only 33 of which reported a 
sample size calculation, although the number of articles reporting such a calculation 
improved over time. This study also revealed various other problems with reporting, 
including lack of reporting of the statistical test on which the calculation was based, the 
event rate in the control group, and the alternative treatment hypothesis. Only 30% of 
trial reports provided sufficient detail to enable the sample size calculation to be 
duplicated. 
Components of the sample size calculation 
The components of the sample size calculation are important markers of the quality of 
a clinical trial in that they are a clear statement of the intent of the investigators 
conducting the trial. The key components are the outcome chosen and the expected 
effect of treatment on this outcome, and the level of error protection. 
The outcome 
The outcome used in the sample size calculation is critical as the rate of occurrence of 
the outcome event will affect the power of the study and the length of time it is required 
to run. (Meinert 1986b) The outcome used in the sample size calculation should be the 
primary outcome, and an accepted measure of the effectiveness of treatment both in the 
context of the trial as well as in existing routine clinical practice. Higher priority should 
be given to serious morbid events, such as death, than to softer non-clinical outcomes (or 
surrogate end points) such as a change in a laboratory value. The latter may not be 
directly relevant to clinical practice or accurately capture the effect on the true outcome. 
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(Grimes & Schulz 2005;Meinert 1986b) Some examples of inappropriate surrogate 
endpoints include breakage and slippage instead of pregnancy to evaluate condoms, 
bone mineral density instead of fracture to assess the safety of depo-
medroxyprogesterone acetate, and ventricular arrhythmia instead of death to evaluate 
anti-arrhythmic drugs.(Grimes & Schulz 2005) 
"Although many surrogate markers correlate with an outcome, few have been 
shown to capture the effect of a treatment (for example, oral contraceptives) on 
the outcome (venous thrombOSis). As a result, thousands of useless and 
misleading reports on surrogate endpoints litter the medical literature. New 
drugs have been shown to benefit a surrogate marker, but, paradoxically, triple 
the risk of death. Thousands of patients have died needlessly because of reliance 
on invalid surrogate markers . ... Clinical research should focus on outcomes that 
matter. " (Meinert 1986b) 
A single, clinically relevant outcome used to calculate sample size will make the trial 
easier to interpret and understand. The potential problem with a single outcome is the 
number of expected events which, if relatively small, will increase the sample size. One 
way to reduce sample size is to increase the number of events through the use of a 
composite outcome (that is, a combination of2 or more outcomes into a single outcome) 
in its calculation. When a composite outcome is used to determine sample size it will 
increase the number of events and reduce the number of patients required, although it 
can be difficult to interpret in clinical practice. (Meinert 1986b) A composite outcome 
can also pose problems if investigators are tempted during the analysis of the trial to 
separate this grouped outcome into the individual outcomes, for which it is most unlikely 
there will be adequate statistical power to investigate owing to the small numbers in each 
group. 
Using the chosen outcome, investigators need to determine the minimum treatment 
difference they wish to detect under the alternative hypothesis. (Meinert 1986b) The 
estimated size of the expected treatment effect is a critical component in the calculation 
of sample size, although it is usually not selected for statistical but for clinical, economic, 
ethical and pragmatic reasons. (Raju, Langenberg, & Sen 1993) This may explain why 
some investigators tend to overestimate the size of the expected effect. This tendency 
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was demonstrated by Raju et al in their study of 21 trials which were being considered 
for inclusion in a meta-analysis of artificial surfactant trials for neonatal respiratory 
distress syndrome. (Raju, Langenberg, & Sen 1993) The expected and the observed 
effect sizes were compared and every one of the 21 trials investigated had overestimated 
the potential benefit of treatment. 
When designing a trial it is also important that investigators consider whether the 
expected size of the effect is the smallest considered clinically worthwhile and if, when 
the trial is completed, such a difference would be sufficient to change clinical practice. If 
the evidence supporting the benefit of treatment is sufficiently strong it may in such 
cases obviate the need to conduct a randomised trial. (Raju, Langenberg, & Sen 1993) 
As discussed previously, the expected benefit of any new treatment is most likely to be 
relatively small, although even small benefits have the potential to have a major public 
health impact, particularly if the intervention is of low financial cost and simple to 
administer, and the disease is common. 
Error Protection 
The significance level (a) is the probability of a type I error (i.e. false positive). The 
smaller the value of a, the larger the sample size required. If at the time of the analysis of 
the trial results the p value is less than or equal to a, then the null hypothesis of no 
difference between the treatments will be rejected. That is, the difference between the 
treatment groups is unlikely to be due to chance. 
The choice of a p value is arbitrary, although it has become accepted to use cut-offs of 
om or 0.05. (Friedman, Furberg, & DeMets I985b) There is, however, very little 
difference between a p value of 0.04 and 0.06 and any value from 0.01 to 0.10 could be 
conceivably justified. The founders of statistical inference certainly did not intend for 
the p value to be dichotomised into significant and non-significant. (Sterne & Davey 
Smith 200 I) It is therefore "preferable to think of the significance test probability as an 
index of the strength of evidence against the null hypothesis". (Bland et al. 1985) 
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The power of the study is the probability of correctly rejecting the null hypothesis. That 
is, I minus the probability of a Type 1I error (I - /3; i.e. false negative) occurring. The 
larger the expected treatment effect, the greater the power of the trial is to detect it. 
Traditionally the power of a study is set between 0.80 or 0.95, that is, an 80% to 95% 
chance of finding a statistically significant difference between the event rates, given that 
a difference actually exists. (Friedman, Furberg, & DeMets 1985a) Evidence suggests 
that randomised trials tend not to have adequate power to detect the differences in 
treatment anticipated by the in vestigators. In the previously cited study by Moher et ai, 
for example, there were 70 trials with a simple two-group parallel design of which 52 
had dichotomous and 18 had continuous primary outcomes. (Moher, Jadad, Nichol, 
Penman, Tugwell, & Walsh 1995) Only 16% of the former and 36% of the latter had a 
sample size large enough to detect, respectively, a 25% or a 50% treatment difference 
with at least 80% power. 
The significance level and power the investigators elect to use to calculate sample size is 
a decision based largely on the need for the trial results to ultimately be accepted by the 
scientific community. Being arbitrary, there is a temptation to adjust the power (and the 
other components of the sample size calculation such as the estimated size of the 
treatment effect) in order to obtain the "desired" result. This is not a desirable practice 
and is considered by some to be unethical as it will result in the conduct of a trial that is 
incapable of addressing the research question. (Halpern, Karlawish, & Berlin 2002) Such 
manipUlation may be somewhat inevitable when investigators are faced with a limited 
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target population (eg within their institution, region or country), particularly when 
diseases are relatively rare. 
Other trial quality measures 
Moher et al suggests, and many others agree, that there are four content areas which 
influence the internal validity of a randomised clinical trial: (Chalmers et al. 
1990;Chalmers et al. 1981 ;Detsky et al. 1992;Jadad et at. 1996;Moher, Jadad, Nichol, 
Penman, Tugwell, & Walsh 1995) 
• Patient assignment (randomisation) 
• Masking (blinding) 
• Patient follow-up 
• Statistical analysis 
The way in which patients are assigned to treatment (that is, randomised), and the degree 
of masking (or blinding) are two areas which should be discussed in the trial protocol. 
Both of these issues have been addressed in further detail below. It is unlikely that a 
protocol would document the measures to be taken to ensure complete patient follow-up 
as this would usually be considered to be a matter of good data management practice and 
not something that would vary across trials. We would expect to see information on 
follow-up reported in the publication. Whether an analysis plan should be documented in 
the protocol is debatable, and this issue will be addressed in further detail in Chapter 5. 
Randomisation (patient assignment) 
The purpose of randomisation is to ensure that the types of patient in each treatment 
group are as similar as possible. It can then justifiably be concluded at the end of the 
trial that any differences demonstrated between the treatment groups are not due to the 
selection of patients or other known (and unknown) underlying differences between the 
groups (although it should be emphasised that the play of chance alone could still lead to 
a false positive result in even the best conducted randomised trial). (Chalmers, Smith, Jr., 
Blackburn, Silverman, Schroeder, Reitman, & Ambroz 1981;Fisher 1989) The purpose 
of randomisation therefore is "to eliminate possible biases that may lead to systematic 
differences between the treatment groups" and is perhaps the most important measure of 
the quality ofa clinical trial. (Altman 1991)To ensure the benefits of randomisation are 
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protected it is necessary to ascertain the method of randomisation to confirm that the trial 
really is randomised, and that the allocation schedule is concealed. 
The most important requirement of a treatment allocation scheme is that it is not possible 
for the treatment to be allocated to be identified before entry into the trial. In a study 
conducted by Schulz et al it was demonstrated that inadequate concealment of the 
treatment allocation schedule is associated with larger estimates of treatment effect. 
(Schulz et al. 1994;Schulz et al. 1995) The study involved an assessment of the quality 
• 
of 250 reports of randomised trials included in the Cochrane Pregnancy and Childbirth 
Database. Only 79 trials used a method of allocation which successfully concealed the 
identity of the next treatment to be allocated. The exaggerated estimates of treatment 
effect were also seen when it was unclear whether treatment identity had been 
adequately concealed. The odds ratios for inadequately concealed trials were on average, 
30% lower than those for adequately concealed trials, resulting in larger estimates of 
treatment effect. In these trials the differences in treatment effect may have resulted from 
the bias caused by knowledge of the treatment allocation prior to randomisation 
influencing a practitioner's decision to include a patient in a trial. 
The term "random allocation" may also be misinterpreted as meaning "haphazard" 
which it is not. (Altman 1991) Systematic methods of allocating treatment, unit number 
or date of birth for example, are not considered to be truly random as it is possible to 
identify the treatment before entry to the trial and patients may therefore be 
systematically excluded, thereby introducing selection bias. Pre-randomised envelopes 
are also open to abuse due to the opportunity to open the envelope and identify the 
treatment prior to randomisation. If the randomisation method involves the use of pre-
randomised (and perhaps pre-stratified) blocks, but these are too small, it may be 
possible to accurately guess the next treatment to be allocated by recalling the result of 
previous randomisations. 
In a historical review of randomised controlled trials published in the British Journal of 
General Practice, Silagy and Jewell found that, of 90 trials identified, allocation was 
stated to be by randomisation for 74%. Only 19 of these described the method of 
randomisation, thereby making it impossible to tell whether or not the trial was actually 
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randomised, and thus whether it was possible to determine the identity of the next 
treatment to be allocated before study entry. (Silagy & Jewell 1994) 
Randomisation should occur at a time as close to the commencement of treatment as 
possible. If a trial involves the recruitment of the seriously ill, for example, a treatment 
delay could result in patients dying before treatment is received. This could be 
particularly problematic if the delay is differential, that is, there is a delay on one arm of 
the trial and not on other/so 
Masking (Blinding) 
Knowledge of treatment assignment after the allocation has been made may also 
influence the assessment of treatment effectiveness. One important way of protecting 
against this treatment related bias is masking (also known as blinding). (Fisher 
1989;Meinert 1986b) In a masked trial the identity of the treatment assignment is 
withheld to improve the objectivity of the treatment administration and assessment, data 
collection, reporting and analysis processes. (Meinert 1986b) The identity of the 
allocated treatment may be withheld from the patient, the health care practitioner, from 
those involved in the assessment and analysis of outcomes, or a combination of the four. 
It should be possible to unblind the treatment should it be necessary to do so during the 
course of the trial (due to an unforeseen adverse effect, for example). 
In their study of the methodological quality of the 250 trials in the Cochrane Pregnancy 
and Childbirth Database (referred to previously in 2.1), Schulz et af demonstrated that 
the lack of double blinding was associated with treatment effects which were larger. In 
their case the odds ratios for non-blinded trials were, on average, 17% larger than 
blinded trials. (Meinert 1986b;Schulz, Chalmers, Grimes, & Altman 1994) 
Double blind trials which are comparing an investigational treatment with no treatment 
will use a placebo - a "pharmacologically inactive agent given to a patient as a substitute 
for an active agent". (Meinert 1986b) The purpose ofa placebo in a controlled clinical 
trial is to attempt to remove the bias that exists when a patient is aware of the treatment 
they are receiving and their expectations of its effects and side effects. 
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Publication bias 
"All policymakers must be vigilant to the possibility of research data being 
manipulated by corporate bodies and of scientific colleagues being seduced by 
the material charms of industry. Trust is no defence against an aggressively 
deceptive corporate sector . .. 
(Lancet Editorial 2000) 
There is now good evidence to demonstrate the specific problem of publication bias. 
That is, when the decision to publish (or to delay publication) is influenced by the 
direction or strength of the results of the trial. (Dickersin 1990;Easterbrook et al. 
1991;Simes 1986;Stem & Simes 1997) It is of particular importance in the conduct 
and interpretation of systematic reviews of clinical trials, where the exclusion of 
unpublished results will introduce bias if the unpublished results differ from those which 
have been published. 
There is evidence that this selective reporting extends to progress reports submitted to 
organisations such as regulatory agencies. A cohort of 274 clinical drug trials 
submitted to the Finnish National Agency for Medicines in 1987 were followed to 
December 1993, by which time final reports had been received for 68, and 24 had 
been suspended. (Bardy 1998) The current status of each trial was obtained from the 
Sponsors of all but one trial. Each sponsor was asked to classify the trial as positive 
(defined as "investigational drug better than comparator"), inconclusive (defined as 
"investigational drug not clinically significantly different to comparator") or negative 
(defined as "objective of the study confirmed"). Based on the 188 trials with a 
classifiable outcome, the authors concluded that there was substantial evidence of 
selective reporting with a statistically significant association (p=0.023) between trial 
outcome and submission of the final report to the regulatory agency. 
In addition to publication bias in the classic form, there may bias in the selection of data 
for inclusion in the publication. In 2003, Chan et al were able to provide evidence of the 
selective reporting of the outcomes of clinical trials. (Chan A W 2003;Chan AW & 
Altman 2003) The authors conducted a cohort study of 102 trials submitted to a 
16 
Danish ethics committee and demonstrated that 50% of efficacy and 65% of harm 
outcomes were incompletely reported. They also demonstrated that statistically 
significant outcomes were more likely to be completely reported. 
Another issue with the reporting of outcomes are changes in the outcome that may 
occur at some point between the protocol and the publication. In 62% of trials in the 
study by Chan et af, there was at least I primary outcome that had been changed, 
introduced or omitted. (Chan AW 2003;Chan A W & Altman 2003) 
As discussed in more detail in Chapter 2, composite outcomes combine 2 or more 
outcomes into a single outcome. Potential for bias arises when one or more of the 
components of the composite are altered in some way. This could involve the addition or 
removal of a component from the composite, or a change in the definition of one or more 
of the components. Freemantle et af reviewed the use of composite primary outcomes 
incorporating all-cause mortality in 167 clinical trials published in 9 major joumals. 
(Freemantle et al. 2003;Meinert 1986b) The findings suggested that the reporting of 
composite outcomes is generally inadequate, with the specific problem of the authors 
implying that the results apply to the individual components of the composite 
outcome rather than only to the overall composite. 
It has been suggested that the source of funding of a clinical trial has a direct impact 
on the reporting of trial results. The most comprehensive analysis of this issue was a 
systematic review conducted by Lexchin and Bero .. (Lexchin et al. 2003) The authors 
searched Medline from 1966 to December 2002 looking for studies that had analysed 
research sponsored by the pharmaceutical industry and had compared methodological 
quality or outcomes with studies with other sources of funding. Based on the 30 
studies identified the authors concluded that research sponsored by pharmaceutical 
companies was more likely to have outcomes favouring the sponsor than were studies 
with other sponsors. 
It could be argued that another aspect to publication bias is the interpretation made by 
the authors around a positive or negative finding by either the authors or the readers of 
a manuscript. Inadequate pre-specification of the primary hypotheses, or post-hoc 
emphasis on the most positive findings, can result in "unduly assertive claims of 
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treatment benefit" (Pocock 2002) It has been suggested that the effect size is 
exaggerated when based on small trials and that the authors of these manuscripts have 
a "predilection for overly optimistic conclusions", particularly when the nature of the 
interventions being investigated cannot be masked. (Silverman 1999) 
Multiple tests for statistical significance 
Considering the cost of conducting clinical trials it is perhaps not surprising that 
investigators are tempted to collect as much data as possible, .and to perform multiple 
tests on that data. Even with the best of intentions, the quest to ensure that a 
potentially important difference between treatments is not missed, can lead to 
misleading significance values and incorrect conclusions. 
The problem with performing multiple tests of comparisons in the same study is how 
to interpret the results of those tests given that, by chance alone, 5% will reject the 
null hypothesis at the "conventional" 5% significance level (referred to as Type I 
error). The probability of at least one false-positive finding can be written as 1-(1-a)" 
where a is the p value and n is the number of independent comparisons. (Smith et al. 
1987) Based on this formula, if 10 independent tests are performed at a significance 
level of .05 then the probability of rejecting the null hypothesis in at least one test 
when the null hypothesis is true in all cases is 1-(1-0.05)10 = 0.4. i.e. a 40% chance of 
declaring a difference when none exists (Fieller 2003) 
There are numerous sources of multiplicity in clinical trials, including: 
• the conduct of multiple comparisons 
• the use of mUltiple outcomes 
• multiple looks at the data 
• repeated measures 
Multiple comparisons 
Multiple comparisons result from the conduct of several treatment comparisons all 
involving the same outcome measure and all at the same time point. There are many 
general settings where it occurs. One is the investigation of subgroups which should 
be clinically justifiable and clearly defined in the trial protocol. The results of 
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subgroup analyses are more likely to differ from the main treatment effect when the 
latter is small. Subgroups have the additional problem of poor statistical power. Most 
trials will aim to recruit sufficient participants to be able to address the primary 
research question, and statistical tests on subgroups will only have power to detect 
larger treatment effects than those anticipated for the primary comparison. 
Assmann et at examined the use of baseline data in the publications of 50 consecutive 
clinical trials published in 4 major journals over a 3 month period in 1997. (Assmann 
et al. 2000) It was found that two-thirds of the publications presented subgroup 
findings. Less than half of these tested for statistical interaction, it was difficult to 
determine if the subgroups were declared a priori and most trials only had sufficient 
power to detect very large subgroup effects. Most of the trials reporting subgroup 
analyses claimed a treatment difference dependent on the subgroup, and most of these 
were included in the trial summary or conclusions. 
Another setting for multiple comparisons is when there are more than 2 treatment 
arms, resulting in multiple pair-wise comparisons. A 3-armed trial (arms A, Band C) 
investigating a single outcome, for example, could compare AvB, BvC, AvC, 
AvB+C, BvA+C, CvA+B. The primary comparison of interest may not be clearly 
evident. 
The CONSORT authors suggest that multiple comparisons should not be applied 
unless an overall single statistical test (if possible) is significant. (CONSORT Group 
2005) It should also be clear in a trial report if the subgroup was declared a priori or 
was the result of post-hoc looks at the data. 
Multiple outcomes I endpoints 
Most trials are interested in the effect of the investigational treatment on more than 
one outcome. Although it is possible to calculate sample size to ensure sufficient 
statistical power to investigate multiple primary outcomes, it is not always clear which 
outcomes are primary or were used to calculate the sample size in a trial publication. The 
problem of multiple outcomes is further complicated by the likely interdependence of 
primary and secondary outcomes. (Meinert 1986a) The relationship between cause-
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specific mortality and overall mortality in cancer or cardiovascular disease, for 
example. (Pocock 1997) 
Multiple outcomes increase the risk of Type I error as they result in multiple analyses. 
For example, there is approximately a 20% chance of a trial with a genuine difference 
between treatments, and five not strongly correlated endpoints, of detecting at least one 
treatment difference with a p value of less than 0.05. (Pocock, Hughes, & Lee 1987a) 
Multiple looks 
During the course of a clinical trial it may be necessary to conduct of a number of 
interim analyses, usually for the purposes of safety or other data monitoring. Looking 
at the data mUltiple times during the course of a trial increases the probability of 
obtaining a significant result. Problems arise when those using the results of interim 
analyses interpret each look as if it is the only analysis that has been performed. 
Stopping rules that specify pre-determined conditions for the significance level at 
each time point that would result in termination of a trial should those rules be met are 
one way to deal with the problem of multiple looks. A major problem is the 
assumption that all of the contingencies that may arise during the course of a trial may 
be difficult to predict. (Meinert 1986a) 
Repeated measures 
An outcome may be measured at more than one time point during the course of a trial. 
It is not uncommon, for example, for routine tests (eg blood) and procedures (eg 
application of instruments such as quality of life scales) to be performed at each 
follow-up visit. The temptation for investigators is to report the results at each time 
point, and to plot these results on a diagram, which can trick the eye into seeing an 
effect that may not exist statistically. The results at each time point are likely to be 
highly correlated. Multivariate analysis techniques can account for the observations 
being obtained in a sequence and incorporate the correlation across time points. 
Going fishing 
The practice of conducting ad hoc analyses on data sets, usually without a pre-
specified hypothesis, as a means of identifying comparisons (specifically subgroups) 
of interest is referred to as "exploratory analyses", "data dredging" or "fishing 
expeditions" - depending on the degree of cynicism of the individual in relation to the 
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data being explored. It is a technique commonly used in epidemiological research to 
identify aetiological disease factors, and in clinical trials to identify subgroups that 
may benefit or be harmed by the intervention. (Meinert 1986a) 
The problem with data dredging is its post-hoc nature and issues around how a 
statistically significant difference should be interpreted. Meinert proposes ground 
rules for data dredging via subgroup analyses, including making a distinction between 
a priori and post hoc subgroups, avoiding conventional interpretation of significance 
, 
tests and caution in making conclusions based on post hoc subgroups. (Meinert 
I 986a) 
The danger is that investigators can "try out" various analyses before deciding which 
method they use as it offers "obvious opportunities for selecting a favourable analysis 
strategy". (The European Agency for the Evaluation of Medicinal Products 2002) 
Poor reporting of clinical trials can make it difficult to assess when such opportunities 
have been taken advantage of. 
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Methods to correct for multiple testing 
"If you torture the data often enough it will eventually conftss" 
(Fieller 2003) 
The best overall solution to multiple testing is, when possible and practicable, to focus 
on a single, primary comparison which is clearly declared a priori in the trial 
protocol. The best statistical solution is debatable and opinions differ as to whether or 
not adjustments should be made to analyses to account for multiple testing in a 
clinical trial. Proschan and Waclawiw suggest guidelines for multiplicity adjustment 
based on how related the questions are (interim analyses, for example, address the 
same question at mUltiple time points), the number of comparisons, the degree of 
controversy (have there been conflicting results in previous studies), who stands to 
benefit and the nature of the alternative hypothesis. (Proschan & Waclawiw 2000) 
Bonferroni described criteria by which it should be possible to judge whether 
statistical significance is impaired by the analysis of multiple comparisons. (Smith, 
Clemens, Crede, Harvey, & Gracely 1987) When n mUltiple independent comparisons 
are performed, and a p value of 0.05 is considered to be statistically significant, then 
the difference should be significant at p = 0.05/n to reduce the number of falsely 
significant findings. (Smith, Clemens, Crede, Harvey, & Gracely 1987) 
Smith et al attempted to describe the level of attention given to the issue of multiple 
comparisons by evaluating all randomised trials published in 4 major journals over a 6 
month period in 1982. (Smith, Clemens, Crede, Harvey, & Gracely 1987) Using a 
threshold of 0.01 (rather than 0.05) they determined whether the statistical 
significance of therapeutic comparisons were "impaired", basing their judgement on 
an adaptation of the Bonferroni criteria. Of the 67 trials identified 50 had a least one 
comparison whose claim of statistical significance was impaired, and in none of the 
trials publications reporting an impaired comparison was the potential impact of 
multiplicity discussed. 
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The traditional approach to deal with false positive findings is to control the 
familywise error rate (FEW); that is, the probability of at least I Type I error 
(Proschan & Waclawiw 2000) or, "the probability of rejecting at least one true null 
hypothesis in the given family of the hypotheses". (Hsueh, Chen, & Kode1l2003) The 
two main methods to statistically correct for multiple testing are: 
I. Adjusting the nominal significance levels to allow for the multiplicity 
The best known method to adjust significance levels is the Bonferroni correction, 
where the observed p value is multiplied by the number of tests performed. This is a 
simple but very conservative method of adjustment, and problems arise if a large 
number of tests are to be performed as the p value required will be extremely small. It 
does not take the fact that outcomes are usually correlated into consideration, assumes 
that all outcomes are equally important and reduces the power to detect real treatment 
effects. (Pocock 1997) 
2. Multivariate statistical techniques 
Multivariate techniques allow for correlated observations but can be complex and are 
not commonly used. (Pocock, Hughes, & Lee I 987a) Their advantage is that they deal 
with all measurements simultaneously and return a single p value. (Fieller 2003) It 
can, however, be difficult to interpret the nature of any difference that may be 
detected. 
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Impact of clinical trials on modem Research Ethics 
Committees 
"Among the essential values for research is that of the integrity of 
researchers. This includes the commitment to research questions that are 
designed to contribute to knowledge, a commitment to the pursuit and 
protection of truth, a commitment to reliance on research methods 
appropriate to the discipline and honesty. " (NHMRC ~OO I) 
The increased attention given to clinical trials has had a direct impact on the workload 
of modem Research Ethics Committees (RECs). A review of US institutional review 
boards (lRBs) by the US Department of Health and Human Services reported that the 
amount of work conducted by most IRBs had increased by 42% since 1974-75, when 
the average number of proposals reviewed by an IRB was 43 per year. (Lemonick & 
Goldstein 2002;US Dept Health and Human Services 1998) By 1998, some IRBs had 
as many as 2000 proposals per year to review. 
Pich et al reviewed the trials submitted to the Hospital Clinic Ethics Committee 
(HCEC), the REC to which most clinical-trial protocols are submitted for approval in 
Spain, as the Committee had become concerned about the effect lack of resources and 
workload had had on its ability to meet its ethical obligations: specifically its inability 
to adequately follow-up approved trials. (Pich et al. 2003) In 2001 the HCEC 
surveyed the investigators of all 158 clinical trials approved by the committee in 
1997. By 200 I only 29 of the 123 trials that had closed to recruitment had published 
results in peer-reviewed journals. The committee reported that they were worried by 
these findings, believing that "public dissemination of clinical-research results is an 
important ethical requirement." (Pich, Came, Arnaiz, Gomez, Trilla, & Rodes 2003) 
As clearly stated in the Declaration of Helsinki, all clinical research should have a 
protocol which is submitted for evaluation by a Research Ethics Committee. (World 
Medical Association 2000) Although specific expectations vary across countries, 
RECs are expected to consider the relevance of each clinical trial (to clinical practice) 
and the appropriateness of the design. (European Commission. 200 I) (See Table 3 
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and Appendix I: Expectations of a Human Research Ethics Committee regarding the 
science of a clinical trial) 
Table 3: AutraIian REC. and clinical trials 
An REC must consider all aspects of the design of a clinical trial and be satisfied that: 
(a) the trial is directed to answering a specific question or questions; 
(b) there is a scientifically valid hypothesis being tested which offers a realistic possibility that 
the interventions being studied will be at least as effective as standard treatment; 
(c) where the research is therapeutic. and is therefore intended and likely to be of direct benefit 
to participants. there is an acceptable balance between the risks and benefits of the trial; 
(d) the methodology provides: 
(i) a rationale for the selection of appropriate participants; 
(il) an appropriate method of recruitment,· 
(iii) adequate, understandable information/or the purpose of obtaining participant consent; 
(iv) a clear description of the intervention and observation to be conducted; and 
(v) a sample size adequate to demonstrate clinically and statistically significant effects 
National Statement on Ethical Conduct in Research Involving Humans; Section 12.2 (NHMRC 2001) 
In addition to being responsible for the ethical aspects and considering the relevance 
and design of each trial, are also expected to assume responsibility for monitoring the 
trial (primarily for adverse events) and to review amendments to research protocols. 
They are also expected to assume other responsibilities, the nature of which varies 
across countries and regions. In Australia they include regulatory, legal and insurance 
responsibilities. The burden on RECs is further complicated by external pressure to 
make decisions quickly. (European Commission. 2001) 
RECs are established in accordance with the laws and regulations applicable in each 
country which, in tum, comply with international requirements. They are composed 
primarily of volunteers who, as a group, should be capable of ensuring the competent, 
unbiased review of research projects submitted to them. (NHMRC 2001;NHMRC 
2002) Membership is expected to include lay people but such individuals are required 
to have sufficient scientific knowledge to meet their ethical obligations. They are 
generally a group made up of "conscientious, sincere, and disinterested" amateurs 
who are "reviewing too much, too quickly, with too little expertise". (Pierce 1997) 
In many cases, RECs themselves recognise that they do not have the necessary 
expertise to fully assess scientific issues. The members of RECs from 6 hospitals in 
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the Netherlands, for example, were asked to rate their perceived level of competence 
in the evaluation of scientific issues relating to phase 2 clinical trial protocols. (Van 
Luijn et al. 2002) Although most of the respondents were medical or para-medical 
professionals, they reported that they found it very difficult to evaluate the feasibility 
of these trials (34%), the scientific methodology (30%) and how the data were to be 
analysed (42%). 
RECs must also deal with trial investigators who are themse Ives often not properly 
trained in research methods. Poor training has been suggested as one reason for 
investigators not adequately evaluating the currently available evidence before 
initiating new trials, and for new trials not being designed to address some of the 
issues raised in the previous research, including the choice of appropriate outcomes. 
(Halpern, Karlawish, & Berlin 2002) 
Relieving the burden 
In the case of multi-centre clinical trials, it is common practice for the research 
protocol to be approved by the REC at every institution participating in the trial. Thus, 
if participants in a trial are to be recruited in 20 hospitals, there are usually 20 
associated RECs, often with 20 different application forms, all with different 
requirements. If the trial involves more than one country, cross-cultural issues can add 
further complications. As a result, there is a perception among clinical researchers that 
there is unnecessary duplication of effort across multiple ethics committees for the 
same multi-centre clinical trial. (Burman et al. 200 I; Wolf, Croughan, & Lo 2002) 
Several countries have implemented centralised systems that aim to improve the 
assessment process, mainly in terms of the time taken for trials to receive ethical 
approval and thus for recruitment to begin. (Christian et al. 2002) There is potential 
for these centralised systems to relieve some of the burden carried by RECs by 
reducing duplication, particularly in those areas where they consider themselves to be 
less capable (such as scientific methodology). 
These centralised systems vary in detail, and might involve centralisation of the entire 
process of ethical review (eg, in the UK), or parts of the process of ethical review -
especially scientific review. (Ghersi & Dickersin 2004) Critics of centralised systems 
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of review suggest that these systems will increase the burden on researchers and ethics 
committees by the addition of another level of bureaucracy, and also maintain that 
their effectiveness has yet to be ascertained. (Alberti 2000) 
Project Objectives 
The overall aim of the projects included in this thesis is to explore issues in the 
design, conduct and reporting of clinical trials that impact on the quality of decision 
making by health care providers, health care consumers and RBCs. 
This thesis has 3 major components: 
I. A follow-up study of submissions to an institutional REC 
• Aim: To identify and quantify discrepancies between the trial 
protocol and the trial publication, particularly regarding the 
reporting of trial primary outcomes. 
• Aim: To determine if these discrepancies are influenced by the 
statistical significance (and direction) of individual trial results. 
2. A systematic review of published research: 
• Aim: To evaluate the impact of central (or "shared") scientific 
and/or ethical review of multi-centre clinical trial protocols on 
the quality of clinical research and the clinical research process. 
3. A prospective cohort study of trials submitted to a central scientific 
committee 
• Aim: to assess the influence of a central (shared) scientific 
committee on the functioning and decision-making of Human 
Research Ethics Committees, and on multi-centre clinical trials. 
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Chapter 2: Background and Methods for follow-up 
study 
This chapter is the first of 4 chapters documenting the background, methods, results 
and discussion of a follow-up study of trials submitted over a 5 year period to a 
research ethics committee, Chapter 2 documents the background and methods 
specifically for the follow-up study including: 
• Background to the follow-up study 
• Background information on the rationale for clinical trial protocols 
• Specification of the study's objectives, design, eligibility criteria, data 
collection methods and endpoints 
• Issues in the identification and definition of primary outcomes 
• Other issues pertinent to the conduct of the follow-up study 
Background to follow-up study 
As discussed in Chapter 1, a number of studies have now been conducted and 
published that demonstrate the existence and impact of publication bias (Dickersin 
1990;Dickersin & Min 1993;Easterbrook, Berlin, Gopalan, & Matthews 1991 ;Simes 
1986;Stern & Simes 1997). Research into the selective reporting of clinical trials is, 
however, relatively sparse. In addition, while the adequacy of reported sample size 
calculations has been investigated (Freiman, Chalmers, Smith, Jr., & Kuebler 
1978;Moher, Dulberg, & Wells 1994;Pocock, Hughes, & Lee 1987b), studies 
examining the sample size calculations as proposed in the trial protocol have not. 
The impact of selective reporting of analyses was investigated by Melander et at who 
examined the application documentation for 42 placebo controlled studies of 5 drugs 
submitted to a regulatory agency and compared each application with the related 
publications. (Melander et al. 2003) The authors found evidence of selective reporting 
of analyses, with many publications preferring the "more favourable" per-protocol 
analyses (that is, including only those patients treated according to the protocol and 
excluding non-compliers) to the results of intention to treat analyses (that is, the 
inclusion of all patients randomised in the arm they were randomised to). 
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A pilot study conducted in the UK by Hahn et af attempted to examine within-study 
selective reporting by comparing the original study protocol with the subsequent study 
report for applications approved by a single REC in the UK. (Hahn, Williamson, & 
Hutton 2002) The 15 studies included in their project were not restricted to 
randomised trials and the authors were unable to achieve their aims due to lack of 
information in the protocols available to them. 
The authors of a cohort study of 102 published randomised trials submitted to ethics 
committees in Denmark were more successful. (Chan et al. 2004a) The aim of this 
study was to examine the extent and nature of outcome reporting bias by comparing 
information in protocols and protocol amendments with that in the relevant trial 
publication. A "fully reported" outcome was defined in this study as one with 
sufficient data to enable the results to be included in a meta-analysis. Of the 99 trials 
measuring efficacy 91 (92%) had at least I incompletely reported efficacy outcome, 
and of the 72 trials measuring harms 58 (81 %) had at least I incompletely reported 
harm outcome. They were able to demonstrate that completeness of reporting of an 
outcome was related to the statistical significance of the results, with outcomes with 
positive results (p<0.05) having greater odds of being fully reported. The study also 
reported a large number of discrepancies in the reporting of primary outcomes. In this 
case, a discrepancy was a difference in the identification of a primary outcome 
between the protocol and the publication. For example, a primary outcome in the 
protocol reported as a secondary or unspecified outcome in the publication. 
In a sub-study of the Danish cohort described above, Pildal et af compared the 
descriptions of allocation concealment in the protocol and the resulting publications. 
(Pildal J et al. 2005) Using strict criteria (based on the criteria required for Cochrane 
systematic reviews, method of allocation concealment was unclear in 96 of the 102 
trials based on the publication, and in 80 trials based on the protocol. It was concluded 
that, when using the protocol or the publication, most randomised trials have unclear 
allocation concealment. 
Using the same definition of reporting completeness as the Danish cohort, Chan et af 
examined the protocols and resulting publications for 105 randomised trials funded by 
the Canadian Institutes of Health Research (a government funding agency) between 
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1990 and 1998 (Chan et al. 2004b). Again there was evidence of incomplete 
reporting, with efficacy outcomes with positive results (p<0.05) having greater odds 
of being fully reported. The discrepancies in the identification of the primary outcome 
noted in the Danish study were also noted in this cohort, with 19% of trials having the 
same discrepancies relating to the primary outcome. 
In a third study, Chan and Altman attempted to determine the prevalence of 
incomplete outcome reporting by surveying the authors of all trials published in 
December 2000 and indexed on PubMed by August 2002. (Chan A W & Altman 
2005) They found that 75% of the 505 trials reporting efficacy outcomes did not fully 
report all of their outcomes. 232 trials defined primary outcomes in the publication 
and 36% incompletely reported at least one. Again, statistically significant outcomes 
had greater odds of being fully reported. Reasons given by survey respondents for not 
reporting outcomes included journal space constraints, a result that was not clinically 
important or statistically significant, or not yet submitted or analysed. 
Using the ability to utilise the outcome data as reported in the publication in a meta-
analysis as a definition of complete reporting is useful for those who conduct those 
meta-analyses, however, a trial may still report sufficient information on the outcome 
to enable inferences to be made by other users of trial publications. It is therefore 
useful to (at least conceptually) distinguish between selective reporting that may be 
misleading, and incomplete reporting. 
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What is a clinical trial protocol 
Protocol n - Specifications, rules and procedures for performing some activity 
or function. 
(Meinert I 986b) 
As the follow-up study will compared clinical trial protocols with their resulting 
publications, this section will describe what a protocol consists of, and what it is for. 
A clinical trial protocol is a written description of the trial including the objectives, 
eligibility criteria, and treatment regimens, statistical and administrative details. It is the 
blueprint for the planned experiment and ensures consistency of management of each 
participant in the trial. 
There are multiple purposes for a clinical trial protocol and the contents required will 
vary depending on that purpose and the point the trial has reached in its progress 
(Figure 3). They are often required, for example, as part of an application to funding 
agencies, regulatory agencies as well as ethics committees along with accompanying 
documentation such as product brochures, indemnity and insurance information, 
patient information sheets and consent forms, etc. Most recently, there have been 
suggestions that details from the protocol and associated documentation (such as 
product brochures, consent forms, participant information sheets, contracts and 
financial arrangements, etc) should be submitted to and made publicly available on 
prospective clinical trials registries (The Ottawa Group 2006). 
The Guideline on Good Clinical Practice (GCP) produced by the International 
Conference on Harmonisation (ICH) lists its requirements of a trial protocol, stating 
that is should include information on trial design, the selection and withdrawal of 
subjects, assessment of efficacy, direct access to source data documents and data 
handling and record keeping. (International Conference on Harmonisation 1996) The 
CONSORT statement describes various aspects of the protocol that need to be 
included in the trial publication when reporting results, including the planned study 
population, the planned interventions and their timing, primary and secondary 
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outcome measures, the minimum important difference and how sample size was 
projected. (CONSORT Group 1996) 
Figure 3: Framework for undertaldng a cUnlcal trial 
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A clinical trial protocol submitted to an Australian REC must address all aspects of 
the design of a clinical trial (including the specific question the trial is designed to 
address). (NHMRC 2001) 
"An REC must ensure that it is sufficiently informed on all aspects of a 
research protocol, including its scientific and statistical validity, that are 
relevant to deciding whether the protocol is both acceptable on ethical 
grounds and conforms with this Statement." (NHMRC 2001) 
Trial investigators must also demonstrate to each REC that the conduct of the trial 
will conform to the National Statement (and hence the Declaration of Helsinki), and 
comply with the relevant regulatory and legal requirements. (NHMRC 2001) Please 
refer to Appendix I: Expectations of a Human Research Ethics Committee regarding 
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the science of a clinical trial, the guidance provided to ethics committees in Australia 
regarding the review of scientific and statistical validity. 
Can a protocol contain too much information? 
There may be an argument in favour of deliberately excluding information from a trial 
protocol. A trial using a permuted block randomisation scheme, for example, should 
not reveal the block size in the trial. Similarly, a trial using a minimisation scheme to 
randomise should not specify which stratification factors will be used to perform the 
minimisation in the protocol. In both cases documenting s\lch information could 
potentially allow unblinding of the randomisation process, resulting in an increased 
ability to predict the next treatment to be allocated. 
Discrepancies between a protocol and a publication 
A clinical trial protocol is not a static document and may be amended numerous times 
during the course of the trial. It is therefore inevitable that there will be changes made 
to the trial leading to differences between the original protocol and the resulting 
publication. While the National Statement requires researchers to conduct a trial in 
accordance with the protocol, and to seek approval for amendments, the exact 
circumstances under which approval should be sought are somewhat vague and are 
simply stated as including those that "significantly affect the conduct of the trial" 
(NHMRC 2001). (See Appendix 2: Australian RECs and monitoring responsibilities) 
The Human Research Ethics Handbook indicates that the need to seek approval for 
protocol amendments is at the discretion of each REC, and encourages them to 
"establish procedures to assess these changes and determine whether their approval 
requires a full meeting of the REC or, in cases where they can be regarded as of 
minimal risk, by some other arrangement" (NHMRC 2002). When reviewing protocol 
amendments RECs are primarily concerned with changes that have a direct impact on 
trial participants (NHMRC 2002). 
From a methodological perspective changes made to a trial protocol may be relatively 
minor (such as a change in an administrative process) or may have a significant impact 
on the trial (a change in the eligibility criteria, a reduction in the dose of a drug, an 
increase in the target sample size, etc) (Figure 3). It is also possible that changes will be 
made to a trial that are methodologically relevant but not of traditional interest to an 
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ethics committee and hence may not require a protocol amendment. Should, for 
example, a trial with a higher event rate than expected notify an REC of the increased 
power the trial will have if the target number of patients are recruited? 
There are other agencies that use trial protocols that may have access to additional 
information not required by ethics committees. These include funding agencies, 
clinical trial registers and regulatory agencies such as the Australian Therepeutic 
Goods Administration (TGA) and the US Food and Drug Administration (FDA). A 
, 
specific document of interest, for example, is the analysis plan which may not be 
available until after the trial has closed and data collection is complete. The key issue 
is the need to confirm that decisions regarding the analysis were made without 
knowledge of the results of the trial. A change made to the definition of an outcome, 
for example, may be appropriate if the change was made before analysis by allocated 
treatment of that outcome had been performed, and the same criteria for that outcome 
were applied to every participant in the study. It is reasonable to expect that these 
types of changes would be documented in the trial publication. 
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Objectives 
Primary objective 
To investigate the selective reporting of primary outcomes. 
a. Do randomised clinical trials start to address multiplicity early in the history of 
the clinical trial through the clear declaration of a primary outcome in the 
protocol? 
b. Are there discrepancies between the trial protocol and the trial publication in 
relation to the identity of the primary outcome (or outcomes)? 
c. Are there discrepancies between the trial protocol and the trial publication in 
relation to the definition of the primary outcome (or outcomes)? 
d. Are primary outcomes "fully" reported 
e. What factors in the protocol influence the selective reporting of clinical trials 
f What other (non-protocol) factors influence the selective reporting of clinical 
trials 
Secondary objectives 
1: To explore issues relating to the sample size, its calculation and reporting 
a. Do randomised clinical trials provide adequate details in the protocol of the 
target sample size? 
b. What is the completeness of documentation of the sample size calculation in the 
protocol? 
c. What factors in the protocol are associated with the completeness of 
documentation of the sample size calculation in the protocol? 
d. Is the completeness of documentation of the sample size calculation in the 
protocol related to the adequacy of reporting of the power calculation in the 
publication? 
e. What other trial-related factors are associated with the adequacy of reporting of 
the power calculation in the publication? 
2: To explore other relationships between the protocol and the publication 
a. Allocation concealment and sequence generation 
b. The use of blinding and placebo 
c. Adverse events 
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d. Journal type 
e. Exclusions 
3: To explore the impact of the availability of commercial funding on the trial 
protocol and publication 
Design 
This is a follow-up study of all randomised controlled trials considered by the Central 
Sydney Area Health Service (CSAHS) Ethics Review Committee between I st January 
1992 and 31 st December 1996 that were subsequently published. Including trials 
submitted to the REC in between these dates allows for a minimum of 9 years (a 
maximum of 13 years) follow-up (to 2005) on eligible trials. 
Note: the term "protocol" is used throughout this follow-up study as a collective term 
for the protocol as well as any other documentation submitted to the REC, including 
protocol amendments. 
Eligibility 
Studies were included in the follow-up study if they met the following inclusion and 
exclusion criteria. 
Inclusion criteria 
• Randomised controlled trials 
o The trial investigator (or sponsor) indicated in their application to the 
REC that the intention was to prospectively allocate participants (or 
groups of participants) to an intervention using a random method. It 
mayor may not have been possible to verify using the REC files (or in 
any resulting publication) that the study was actually randomised. 
o While some randomised trials included nested case-control studies, or 
other sub-studies, the comparison of interest in this study is the 
randomised comparison. 
• Trials reported as full publications in peer-reviewed journals. 
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o Records were kept of other publications including short reports, letters 
and conference abstracts. 
• Submitted to the REC for the first time between 1992 and 1996. 
o Note that approval to conduct a study is not given for an indefinite 
period and it must submitted for re-approval if there is a major change 
such as extension of the trial beyond the time period initially requested. 
Previously approved trials re-submitted during this time period were 
not considered eligible. 
Exclusion criteria 
• Abandoned trials 
o During the time period covered by this study many of the major 
funding agencies (including the NHMRC) required investigators to 
obtain ethics approval from at least one institution before submitting an 
application for funding. If a trial was successful in obtaining ethics 
approval, but was unsuccessful in obtaining funding, it was usual for it 
to subsequently be abandoned. 
o It is usually clearly evident in the REC file (based on the last annual 
report submitted by the trial investigator) if a trial was abandoned. 
o This includes trials ongoing elsewhere but abandoned at the site/s 
covered by the REC. Abandoned studies lacked complete 
documentation as the REC would not have been privy to protocol 
amendments and other relevant documentation. 
o Multi-centre trials that did not recruit patients at the site were not 
considered abandoned unless it had been reported as such to the REC. 
• Trials published in short form only, including conference proceedings and letters, 
as there is usually too little information to assess completeness of reporting 
• Trials reported in report form only (eg internal reports for the funding agency or 
sponsor, postgraduate theses, etc) and not published in a peer-reviewed journal. 
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Data collection 
As files were not to be removed from the REC offices, all data were extracted on-site 
directly from the REC records. All data were extracted by the author. A second 
opinion was sought where necessary. 
The data set was determined based on work previously conducted by the author and 
the need to address the research questions posed, and was also informed by the work 
of Chan and Altman (Chan A W 2003) and the requirements of the CONSORT 
statement (CONSORT Group 1996). 
Definitions were determined for each data item to ensure consistency of definition and 
data extraction (see "Glossary"). 
Data were first extracted from the trial publication (see Appendix 5: Data collection 
forms (follow-up study). The REC file was then re-accessed and the remaining data 
on the trial extracted. The data from the publication was cross-checked with the data 
in the REC file and inconsistencies identified and coded. Data extracted from the 
protocol was kept distinct from the data extracted from the publication. The method of 
allocation concealment, for example, was collected both as documented in the 
protocol and as it was reported in the publication. 
Study Endpoints 
To avoid confusion the outcomes of the follow-up study will be referred to throughout 
this thesis as "endpoints", and the outcomes in trials as "outcomes". The details of 
each endpoint are addressed below. 
As defined by Chan et ai, an outcome is "a variable intended to be assessed in all 
study participants for the purpose of comparing the effects of interventions between 
randomised groups". (Chan A W & Altman 2005) Trial protocols and publications 
should declare at least one primary outcome, which should be the same in both 
documents. The primary outcome should be clearly declared however, if it is not, it is 
reasonable to infer that an outcome is a primary outcome if it is used to calculate the 
trial sample size, or is the outcome included in the trial's statement of main objectives 
or aims. 
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I. Is there a primary outcome in the protocol? 
A trial was considered to have primary outcome in the protocol if between I and 4 
outcomes could be clearly identified (or reasonably inferred) as being a primary. A 
primary outcome was considered to be clearly distinguishable if there is a clear 
statement that it is the primary (main) outcome. If there was no clear statement then 
was inferred that the primary outcome is that used to calculate the sample size, or 
stated in the aims or objectives. This was coded as: 
0: No 
I: Yes 
If a primary outcome was reasonably inferred this was coded as: 
0: outcome used to calculate sample size 
I: outcome referred to in aims or objectives 
2. Discrepancy in the identity of the primary outcome 
This was coded as: 
0: the outcome was identified in both documents as being a primary outcome 
I: the outcome was identified in the protocol but not in the publication as 
being a primary outcome 
2: the outcome was identified in the publication but not in the protocol as 
being a primary outcome 
3. Discrepancy in the definition of the primary outcome 
Much as a clinical research question is composed of a number of parts (patient / 
intervention / comparator / outcome) an outcome in a clinical trial can be composed of 
the name of the outcome, the time frame in which it will be measured and the 
instrument used to measure the outcome. For example: 
quality of life measured every 3 months using the SF36 (and how it will be 
reported: for example, as a single, global measure) 
airway responsiveness as indicated by a fall in FEV before and after 
treatment measured by spirometer 
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nausea and vomiting over a 24 hour post-operative period measured by 
keeping a log of episodes (meeting pre-defined criteria) 
An outcome definition was considered to be discrepant if one or more of the elements 
of the outcome had changed between the protocol and the publication. This was coded 
as: 
0: the definition was the same in both documents 
I: unable to judge if the definition was the same, either because the outcome was 
, 
not recorded in one of the documents, or a definition was not provided 
2: definitions were provided in both documents and they were different 
4. Completeness of reporting of the primary outcome 
Completeness of reporting of each comparison was classified based on the criteria 
described by in Appendix 4: Completeness of reporting. Each comparison was 
classified as: 
Fully reported 
Partially reported 
Qualitatively reported 
Not reported 
In binary logistic regression analyses this outcome was coded as: 
0: not fully reported (included partially reported, qualitatively reported and 
not reported) 
I: fully reported 
5. Is there a target sample size in the protocol? 
Defined as any mention of a target number of participants to be recruited, with or 
without mention of a sample size calculation. This was coded as: 
0: Yes, but no evidence of an appropriate calculation 
I: Yes, with evidence of an appropriate calculation 
Note: "No" was a third option however there were no studies without a target sample 
size included. Potential trial investigators are asked to provide the target sample size 
on the application form that is submitted to the REC. 
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6. Completeness of documentation of the sample size calculation in the protocol. 
This was coded as: 
0: Incomplete: there was no evidence of a sample size calculation OR there was 
some evidence of a sample size calculation but the outcome used was not 
determinable 
I: Partial: there was evidence of a sample size calculation and as a minimum the 
outcome used was determinable. 
2: Complete: there was evidence of a sample size calculation and the outcome, 
, 
effect size, power and significance level were all provided. 
7. Adequacy of reporting of the power calculation in the publication 
This was coded as: 
0: Inadequate: if no power calculation was mentioned in the report 
I: Adequate: if a power calculation was mentioned with any amount of data in the 
report 
8. Exclusions from analysis 
Regardless of a claim by the authors of a publication that an intention-to-treat analysis 
was conducted, each trial was classified according to whether or not there were any 
participants excluded from the analysis. This was coded as: 
0: no exclusions reported (either explicitly reported or reasonably inferred that 
there were no exclusions. Eg denominators reported in analyses the same as 
the number randomised) 
I: there were exclusions (either explicitly reported that there were exclusions 
or reasonably inferred that there were exclusions) 
9. Journal type 
Coded as: 
0: specialty journal (eg the Journal of Cardiac Failure, the Journal of Clinical 
Oncology, etc) 
I: general journal (eg the Lancet, lAMA, etc) 
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The context for this follow-up study 
This study will examine randomised trials submitted to an Australian REC (see The 
CSAHS Human Research Ethics Committee on page 43) for the first time between 
1992 and 1996 (inclusive). The year 1992 was chosen as the starting year owing to the 
important changes in the process of ethical review resulting from the deregulation of 
the clinical trials industry the previous year. The Australian Therapeutic Goods Act 
shifted some of the responsibilities from the Commonwealth Government to RECs 
(also referred to as institutional ethics committees (IECs)). A'S described in Table 4, 
the main impact of deregulation on the work of RECs was the new responsibility to 
assess toxicology and safety. (Australian Government 1984;Commonwealth 
Department of Health and Ageing 200 I b)). Although the primary role of RECs is to 
protect participants in research by "refusing approval to research projects which do 
not conform to acceptable ethical standards" (NHMRC 200 I), deregulation had a 
substantial impact on the nature and volume of work conducted by those committees. 
Table 4: The Commonwealth Therapeutic Goods Regulations (NBMRC 1995) 
Under these Regulations. the institution has responsibility for: 
• Conducting the trial 
• Taking advice from the lEG on the conduct of the trial 
• Giving approval to the trial (the institution may be responsible for more than one site) 
• setting tenns of approval for the trial which are no less restrictive than the ethics committee's advice; and 
• withdrawing approval for the trial if the ethics committee advises that continuation of the trial is not 
appropriate. 
The main impact of the deregulation of clinical trials, from the point of view of lEGs, has been an expansion of their 
tasks and responsibilities to include assessment of toxicological and safety data for trials submitted under the 
Clinical Trials Notification (CTN) scheme. 
If adequate experlise is not available amongst the members of an lEG to properly assess the scientific validity of a 
research protocol, or the data to CTX Or GTN application, or for any other reason, the IEC should seek such 
experlise from outside its institution. 
Under the Therapeutic Goods Act it is an offence to supply a therapeutic good unless 
it is listed on the Australian Register of Therapeutic Goods, which specifies the 
circumstances under which the good may be supplied. The exception are goods 
supplied for the purpose of research in humans (that is, for use in clinical trials), in 
which case the supplier of the good (that is, the trial Sponsor) must obtain approval 
from at least one AHEC-registered REC that has undertaken to monitor the trial. 
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AHEC-registered RECs must formally undertake to comply with the National 
Statement. (NHMRC 200 I) 
Another factor impacting on the work of RECs during the years examined in this 
follow-up study was the requirement of the National Health and Medical Research 
Council (NHMRC), Australia's major public funder of health and medical research at 
the time, that all grant applications must obtain ethics approval before submission to 
the NHMRC. As a result, a large number of applications receiving ethics approval 
, 
were ultimately abandoned as the result of inability to obtain funding. 
The CSAHS Human Research Ethics Committee 
The Central Sydney Area Health Service (CSAHS) Human Research Ethics 
Committee (REC) is a registered REC with the NHMRC. It reviews proposals for 
research in humans to be conducted in \0 institutions (including 4 hospitals and 4 
research institutes) in the central suburbs of Sydney. (See Appendix 3: About CSAHS 
REC) The Committee meets once each month and in the year 2004 reviewed more 
than 300 new protocols. It also monitors the progress and compliance of all ongoing 
and previously approved studies. 
A Clinical Trials Sub-Committee (CTS) reviews all proposals for clinical trials in 
drugs or devices before the proposal is considered by the REC. The CTS includes 
individuals with appropriate scientific and clinical trial expertise and is responsible for 
reviewing all of the scientific data (including toxicology and phanmacology). External 
experts are also consulted if and when required. The recommendations of the CTS are 
forwarded to the REC who then take them into consideration when reviewing the 
remaining ethical requirements of the trial and respond to the individuals who 
submitted the application. The CTS was first established in 1991 in response to the 
additional expectations placed on the committee as the result of the deregulation of 
clinical trials that year. 
The files kept by the REC included all documentation provided to the committee by 
the applicant including protocol amendments and annual reports. The files also 
included copies of all outgoing correspondence sent from the REC to the applicant. 
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Data was extracted from the most up-to-date version of the trial protocol, which often 
required sorting through protocol amendments to ensure the correct data was being 
obtained. 
Identification of eligible randomised trials 
As there was no paper summary or computerised record of the study type of each 
submission to the REC, potentially eligible trials were identified by systematically 
searching the file containing all correspondence (including the trial protocol) kept for 
each submission by the Research Office (RO) at Central Sydney Area Health Service 
(CSAHS). All records for each eligible year were accessed and a notation made of the 
study type (or types in the case of multiple studies in a single submission). All 
submissions to the REC are allocated a sequential identifying number, starting with 
the year of submission. The records for the years accessed are stored by year in 
archive boxes, and filed in the order of the REC identifying number. 
When an RCT was identified a note was made of the status of the trial at the time of 
the last annual report, the date of the last annual report, and the details of any 
publications or presentations that had been notified to the REC. 
The Sponsor (or Principal Investigator, as named in the REC file) of each trial was 
asked to give permission for their trial to be used in the follow-up study, and to 
provide additional information on the status of their trial and any resulting 
publications (see Appendices 5 and 6: Investigator Form and Letter of Invitation). 
Identification of publications 
Efforts were made to identify all publications reporting the results of each potentially 
eligible trial. 
When investigators were contacted they were asked to give citation details for any 
publications resulting from the research. In addition, the MEDLINE database was 
searched using a combination of: 
• the named principal investigators or collaborative group 
• the intervention/s being investigated 
• the patient population 
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In addition to Medline, specialty databases were also searched depending on the 
clinical area in which the research was being conducted: PSYCH INFO (for 
psychology) and CINAHL (for nursing), for example. 
If the REC had been notified of any abstracts / conference proceedings (eg in an 
annual report) then a search of Medline (and/or other databases) was conducted using 
the authors and keywords identifiable in the abstract title. 
A publication was deemed related to a particular trial if it could be reasonably 
ascertained that: 
• the patient population was the same (allowing for possible unreported changes 
in the eligibility criteria) 
• the interventionls were the same or similar (allowing for possible unreported 
changes in the intervention such as the dose or schedule of a drug) 
• the sample size calculation (if reported) was the same or similar 
• the sample size achieved was the same as or similar to the sample size 
proposed in the REC file (allowing for possible problems in achieving the 
target sample size) 
• the date of publication, and other dates mentioned in the publication (such as 
accrual dates) were aligned with the dates mentioned in the REC file 
• the investigator provided citation details (although in two cases the incorrect 
citation was provided) 
In the case of collaborative group studies, which are usually published under a group 
name, the appendix of the publication was searched for the name of the institution or 
the investigators at that institution, or the name of the collaborative group. 
The date of the last search of Medline for possible publications was July 2005. In 
September 2005 the REC files for each RCT were revisited and updated information 
noted for each study regarding published abstracts or manuscripts. The relevant 
databases were searched only for those trials with new information. 
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Feasibility 
As mentioned previously, Hahn et al attempted to conduct a similar study comparing 
15 submissions (not restricted to randomised trials) made to an REC with their 
subsequent publications. The authors found that the lack of information in the 
protocols available to them made it difficult to assess selective reporting in this way. 
(Hahn, Williamson, & Hutton 2002) The current study was similar in design to that 
conducted by Hahn et ai, but involved a much larger number of trials, and the sample 
was limited to randomised controlled trials, with the expectation that the protocols for 
randomised trials would be more comprehensive than appiications made for non-
randomised studies. 
The data collection process was evaluated after data from the first 20 eligible trials 
submitted in 1992 had been extracted. The intention was to assess the feasibility of 
continuing the study and make improvements to the design and the data collection 
instruments if necessary. Alterations were made to the data collection instruments as a 
result of this pilot. All data collected on the first 20 eligible trials was re-collected 
using the updated instruments. As none of these trials documented the analysis plan it 
was decided to remove this item from the data collection forms. 
Issues in the Identification and definition of primary outcomes 
The identity of the primary outcome was not always clear in either the protocol or the 
publication. In many cases it was necessary to infer that an outcome was a primary 
outcome based on other information, such as the sample size calculation or the trial 
aims and objectives. A distinction was therefore made between primary outcomes that 
were clearly stated and those that needed to be inferred. A record was also kept of the 
way in which an outcome was inferred. 
Outcome complexity 
The complexity of outcome definition and construct made determining a mechanism 
for simply classifying the type of outcome in a way that would render it quantifiable a 
major challenge. The key issue is that outcomes are essentially multi-dimensional. A 
single outcome, for example, may be measured using multiple instruments over 
multiple time points. Each instrument may have mUltiple "dimensions" and each 
dimension may have multiple components or questions. 
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Each primary outcome was classified according to its complexity: 
• Single outcome: where it is possible to identify a single comparison resulting in a 
single statistical test. 
o Single outcomes measured with multiple instruments were handled by 
treating each instrument as measuring a separate outcome. 
• Composite outcome: combines 2 or more outcomes into a single outcome. 
• Global outcome: is measured with an instrument composed of multiple 
, 
dimensions (see Global Outcomes below). 
• Multiple time points: where a single, composite or global outcome is measured 
over more than two time points (see Multiple time points on page 48) 
Global Outcomes 
The term "global outcome" is used to describe those outcomes where either a single 
or summary score could be calculated based on several components (eg quality of 
life), or is a multiple-item outcome with a method of analysis that includes all 
components in a single statistical test. The particular problem with these outcomes is 
that it is rarely clear if the outcome is an overall summary "score", or if each of the 
dimensions is to be reported separately. Some examples of global outcomes are: 
• Ouality of life: Quality of life instrument tend to be composed of multiple 
dimensions measuring the various aspects of quality of life as they pertain to the 
condition being investigated. An overall quality of life score mayor may not be 
calculated and reported, and some/all of the components may be reported 
separately. In addition, each component may be further divided into sub-
components eg specific questions. The protocol mayor may not specifY how 
quality of life will be reported (overall or component results). 
• Multiple tests measuring a single outcome: eg lung function. It is likely that the 
multiple component assessments are reported with an assessment of overall 
function based on the test results. A specific example is lung function which may 
be measured using FEVl, FVC, FEVIIFVC. This type of outcome is common in 
exploratory trials. 
• Calculated outcomes: An outcome calculated using two or more single outcomes 
where the component parts mayor may not be reported separately. Eg infant 
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growth, which could be 3 simple measures of length, head circumference and 
weight, or as one or more calculations based on these components, eg length x 
weight, head circumference x length. 
• Compliance: In a trial comparing two lipid-lowering diets compliance was 
measured using various blood levels including saturate fat, mono-unsaturated fat, 
complex carbohydrate, etc. No single measure of compliance was specified. 
Multiple time points 
Outcomes measured over multiple time points mayor may, not have specified a 
particular time point as the primary outcome. If each time point is counted as a 
separate outcome then this may place undue emphasis on outcomes with multiple time 
points. Outcomes with mUltiple time points were classified as: 
• Multiple time points measured but clear single time point is identifiable as the 
primary timepoint 
• 2 time points specified 
• More than 2 time points specified 
Composite outcomes 
Composite outcomes are usually used to increase the event rate and hence increase the 
power of the study to detect a difference. Issues in the reporting of composite 
outcomes are: 
• The addition or removal of one or more outcomes from (components of) a 
composite outcome between the protocol and the publication 
• The separate reporting of the composite outcome and each of the elements of the 
composite. It mayor may not have been intended to report both the composite and 
one or more elements as primary outcomes. This issue may appear in trials where 
the ideal situation would be an available target population that would enable the 
single primary outcome of interest to be addressed, but where the available target 
population is limited. 
• The elements of the composite might be reported in various combinations and it 
may be difficult to ascertain which one, if any, is the "primary" combination. 
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Multiple calculations based on a single instrument 
There were occasions when the results of a single test or instrument were applied and 
used in multiple ways. Trial investigators may be interested in the actual value, the 
number of participants with a value over or under a specific value (threshold), or the 
change in a value. Some examples include: 
• Crohn's Disease Activity Index (COAl), used to calculate an overall score at 
multiple time points which was in tum used to determine change in COAl score, 
and relapse (defined as a particular COAl score). 
• sperm count, used to calculate: total sperm concentration, azoospermia and 
oligozoospermia (both defined as a particular levels of sperm concentration) 
In these situations, each use of the test or instrument was considered to be a different 
outcome unless it was explicitly declared otherwise in either the protocol or the 
publication. 
Multiple measures 
Some outcomes can be measured using more than one instrument or test. There are 
multiple instruments that could be used to measure the outcome "depression", for 
example. It is not uncommon for a single outcome (such as depression) to be clearly 
stated as being the primary outcome, with a number of instruments used to measure 
this single outcome. Problems arise when a single instrument is not declared as the 
primary instrument of interest. In this follow-up study, each instrument was 
considered to be a separate primary outcome. 
Trials with more than 4 primary outcomes 
Trials with more than 4 primary outcomes in either the protocol or the publication 
were not considered to have a clearly identifiable primary outcome. 
In cases where 4 or less outcomes were identified in the protocol, and 4 or less 
outcomes were identified in the publication, but 1 or more was a new outcome (ie 
resulting in more than 4 outcomes overall) then all of the outcomes were included. 
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Process issues 
A number of issues related to the conduct of the trial may impact on the way in which 
data on a primary outcome is collected or interpreted. It was not possible to address 
these issues in this study as they are unlikely to be detected in the trial protocol or the 
publication. Process issues include: 
• Outcomes that are adjudicated (by a central process such as a committee) versus 
the same outcome as reported by investigator 
• The way in which an instrument is administered. One example is the participant 
who completes the instrument themselves versus the investigator or a study nurse 
asking the questions on the instrument and completing it on behalf of the 
participant. Another example might be when the participant is asked to complete 
the instrument in the clinic while another may be invited to take the instrument 
home. The environment may influence the responses. 
Notes re reported p values 
When a p value for a comparison was not reported, but the publication states "there 
was no significant difference" or similar, then the comparison was classified as 
p>0.05. If there was no mention of the significance level then this was recorded as 
"not reported". 
The outcomes from one trial (a small (28 participants), 7-period crossover, dose-
response, exploratory study in a healthy population) had multiple pair-wise 
comparisons. Although no p value was reported the 95%Cls indicate that there was a 
significant difference so the p values for the relevant comparisons in this trial were 
entered as <0.05. 
Other considerations 
During the course of conducting the study and extracting the data from the REC files 
it became evident that there were a number of factors that needed to be taken into 
consideration in order to make conducting the study feasible and meaningful. 
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Multi-arm trials 
A trial with 3 treatment arms could potentially contain up to 6 discrete treatment 
comparisons: AvB, AvC, BvC, AvBorC, BvAorC, CvAorB; each of which might be 
subject to an analysis. Data on primary outcomes for trials with more than two arms 
were entered according to the comparisons reported in the publication. The way in 
which comparisons were handled in the analysis is described in more detail in Chapter 
3 ("Creating trial-based measures" on page 57). 
• Data for all comparisons reported were collected regardless as to whether or not 
they were specified in the protocol. 
• There were trials that randomised to I of 3 or more arms where the primary 
comparisons were explicitly reported. Eg one included trial specified that the 
primary comparisons were: AvBorC, AvB and AvC. The BvC comparison was 
also reported although it was clearly stated that this was not a primary 
comparison. Data from this comparison was therefore not collected in this case. 
• The "control" arm may change from comparison to comparison in trials with more 
than 2 arms. A decision regarding the identity of the control arm (or arms) was 
determined based on data reported in the publication. 
• If there were 3 or more arms and a simple statement along the lines of "no 
significant difference was detected" then it was assumed that all possible pair-wise 
comparisons were tested. 
Safety and adverse events 
"While there is an ethical obligation to monitor for serious unexpected 
adverse events, one suspects the process of reporting and categorizing is often 
inconsistent. Usually the lack of any prespecijied hypotheses or priorities 
leaves one at risk of data dredging". (Pocock 1997) 
Pocock describes reporting of adverse events as multiple outcomes "gone crazy". 
(Pocock 1997) In many clinical trials the protocol will state that safety (also referred 
to as toxicity or tolerability) is an outcome, or that a number of tests may be 
performed routinely to monitor safety, without describing a specific safety outcome of 
interest. A general comparison will be made between the protocol (that is, was there 
evidence that the intention was to monitor safety) and the publication (were any safety 
outcomes reported). 
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Choosing a comparator 
It is not always clear which arm of a trial is the comparator. For example, when both 
arms of a 2-armed trial are considered to be "standard treatment". In such cases, even 
if there was a statistically significant difference, the direction of the treatment effect 
was coded as "not applicable". Trials with more than 2 arms, where it is not possible 
to determine which arm (or arms) are the comparator arms, were handled in the same 
way. 
Explanatory versus pragmatic trials 
The purpose of a trial, ie whether it is explanatory or pragmatic, is a trial characteristic 
that may be associated with selective reporting, and hence is a variable included in the 
regression modelling described on page 56. Although a distinction is often made 
between explanatory (also referred to as exploratory or efficacy) and pragmatic trials 
(or effectiveness, sometimes referred to as confirmatory), there is no universally 
agreed definition, and many trials fit somewhere between the two. 
It is generally agreed that explanatory research asks whether an intervention works 
under ideal or selected conditions. It is more concerned with how and why an 
intervention works. Explanatory trials: 
• generally measure efficacy 
• recruit as homogeneous a population as possible 
• often use intermediate (or surrogate) outcomes 
• are more relevant to examining biological effects 
• endeavour to discover whether a treatment effect exists 
• are highly controlled and idealised in the spirit of a laboratory experiment 
Pragmatic research asks whether an intervention works under "real-life" conditions 
and in terms that matter to the patient. It is concerned with whether the intervention 
works, not how or why. 
Explanatory trials may have smaller sample sizes so one way to distinguish between 
explanatory and pragmatic trials might be to use a threshold for sample size. A 
problem with this approach is that in some situations, smaller sample sizes may 
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simply reflect the nature of the target population (eg a rare condition) rather than the 
purpose of the trial. 
Explanatory versus pragmatic designs are considered to be a potential prognostic 
factor for reporting of outcomes (eg latter more likely to conduct exploratory 
analyses). Trials were therefore categorised as explanatory or pragmatic based on the 
judgement of the author using the above definitions. 
Issues in the conduct of methodological research in this area 
In this series of trials it has been necessary to make judgements about clinical trials 
based on the information documented in the protocol and other records kept by the 
REC. This mayor may not be an accurate reflection of the trial as actually planned. 
Although there are no doubt problems with relying on the quality of the recorded 
documentation, it is the best source of information available. Absence of the detail 
required for the purposes of this follow-up study does not mean each trial did not 
perform particular tasks - it may just mean that they did not write them down. Lack of 
information in the protocol on allocation concealment and sequence generation, for 
example, does not mean they did not adequately manage the randomisation process. 
Following initial approval, if significant changes are made to the protocol, it is usual 
for a protocol amendment (or some other form of communication) to be submitted to 
the REC. It is likely that not all changes made to a protocol during the course of a 
study will be captured. 
Another issue to keep in mind is that the documentation from which data was 
extracted was created for a specific purpose: that is, to obtain ethics approval. 
Although the information required for the purpose of ethical review is aligned with 
that required for this follow-up study it is possible that the ethics committee was privy 
to additional information as part of its decision-making process. It is not uncommon, 
for example, for investigators to attend the ethics committee meeting at which their 
proposal is being discussed. This will give them the opportunity to deal with specific 
questions that may not be documented in the REC record. In the case of CSAHS REC 
issues raised during the course of an REC meeting are usually documented in formal 
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minutes, and those minutes form the basis of written communication following the 
meeting with the investigator. A copy of all such communication is kept in the REC 
record, and the complete file was accessed for this follow-up study. 
Some issues are time-dependant and difficult to assess retrospectively. The 
appropriateness of the comparator, for example, or the size of the treatment effect, are 
very much dependant on our understanding of the condition and the appropriate 
standards of care at the time the trial was submitted to the REC. 
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Chapter 3: Description of trials included in follow-up 
study 
This chapter includes: 
• information on the analyses conducted, including 
o factors that may be associated with selective reporting (used as 
covariates in logistic regression) 
o how trial-based measures were created 
• the identification of eligible trials 
• descriptive information about the identified trials 
• descriptive details extracted from the trial protocol 
• descriptive details extracted from the trial publication 
Data analysis 
All analyses were conducted using the statistical package SPSS 13.0 for Windows 
(SPSS Inc., 233 S. Wacker Drive, Chicago, Illinois 60606). 
Features of the protocol and publication are described as frequencies in tables, with 
2x2 tables constructed to investigate relationships within protocols, and within 
publications, and tested using Chi square (Fisher's exact test) when appropriate. 
Trial characteristics reported in the protocol (listed on page 56) that may be associated 
with the endpoints relating to selective reporting were investigated using logistic 
regression. The endpoints relating to selective reporting are: 
• Discrepancy in the identity of the primary outcome 
• Completeness of reporting 
These outcomes were investigated in the logistic regression models as trial-based 
endpoints, rather than outcome or comparison-based endpoints. The method used to 
create trial-based endpoints is described on page 57). 
All variables were investigated univariately, as well as adjusted for the number of 
outcomes (for the trial-based endpoint for "Discrepancy in the identity of the primary 
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outcome") or the number of comparisons (for trial-based endpoint for "Completeness 
of reporting"). Independent variables that were significant either on univariate 
analysis, or adjusted for the single covariate number of outcomes or comparisons, 
were included in a multivariate model. 
Trial characteristics that may be associated with selective 
reporting 
Trial characteristics in the protocol that may be associated with the reporting of the 
trial were selected a priori for investigation using logistic regression. The coding of 
each ofthese variables for inclusion in the regression model is described in Chapter 4 
(Table 28). 
• Design (crossover or parallel) 
• Purpose (exploratory or pragmatic) 
• Administration (single centre, multi-centre national, multi-centre international) 
• Commercial funding available at the time of submission to the REC 
• Proposed sample size 
• Completeness of documentation of the sample size calculation in the protocol 
• Allocation concealment (adequate or inadequate) 
• Sequence generation (adequate or inadequate) 
• Blinding 
• Number of outcomes in a single trial for the endpoint "Discrepancy in the 
identity of the primary outcome" OR number of comparisons in a single trial 
for the endpoint "Completeness of reporting" 
Note: see Glossary for definitions used for each variable. 
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Creating trial-based measures 
A single trial can have more than one primary outcome, and each outcome can 
involve more than one comparison. Take, for example, a trial with 3 treatment arms 
(A, Band C) and 2 primary outcomes (X and Y). Such a trial could potentially have 6 
treatment comparisons: 
• Comparison I: AvB for outcome X 
• Comparison 2: AvC for outcome X 
• Comparison 3: BvC for outcome X 
• Comparison 4: AvB for outcome Y 
• Comparison 5: AvC for outcome Y 
• Comparison 6: BvC for outcome Y 
Most of the trial characteristics considered to be potentially associated with the 
reporting of trials are trial-based. They include, for example, information on trial 
design, purpose, sample size, etc. A number of the follow-up study endpoint variables 
are, however, either outcome or comparison-dependant. That is, the value of those 
variables will not be the same for each outcome or comparison within each trial 
(Table 5). 
Table 5: Outcome-dependant and comparison-dependant variables 
The outcome ---<lependant endpoint is: 
• Discrepancy in the identity of the primary outcome 
The comparison---<lependant endpoint is: 
• Completeness of reporting 
The comparison-dependant covariate is: 
• Level of statistical significance 
Comparisons within a trial are unlikely to be independent, and it would not be 
appropriate to treat each comparison as a separate event when investigating the above 
variables. For this reason a trial-based measure was created for each of the events 
described in Table 5 by determining the frequency of values for each variable for each 
trial. Building on the above example, and using the variable "statistical significance", 
the result could be: 
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• Comparison I: AvB for outcome X: p>O.05 
• Comparison 2: AvC for outcome X: p>O.05 
• Comparison 3: BvC for outcome X: p<=O.05 
• Comparison 4: AvB for outcome Y: p>O.05 
• Comparison 5: AvC for outcome Y: p>O.05 
• Comparison 6: BvC for outcome Y: p value not reported 
The frequency of statistically significant comparisons for this trial is 17% (\ in 6). 
That is, 17% of comparisons in this trial met conventional statistical significance 
(p<=O.05). A threshold for a "positive" trial can then be set based on the expected 
acceptable frequency of a statistically significant result. It is possible to raise or lower 
the threshold depending on the level considered acceptable for the specific variable 
under investigation. 
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Identification of trials 
There were 1170 submissions to the REC between 111/92 and 31112/96. (See Figure 4 
and Table 6) Randomised trials were involved in 319 (27%) submissions of which 92 
(29%) were ultimately abandoned, and I was rejected. The search strategy described 
in Chapter 2 was applied to each of the remaining 226 submissions, and a publication 
was identified for \06 (46%): two publications were short reports and I was a letter 
hence full publications were available for 103 trials. One submission involved 2 
related trials published in a single publication. 
FIgure 4: Identill""tlon of studies 
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As it was a requirement of the REC that permission be obtained to use each trial in the 
follow-up study, the site-specific Principal Investigator for each trial (that is, the 
individual responsible for the submission at the site) was approached to inform them 
of the objectives of the study, to obtain permission to include their trial in the follow-
up study, and to request information on publications resulting from the trial. If the 
Principal Investigator was not contactable (that is, was now deceased, or was no 
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longer employed at the hospital and not locatable) then one or more of the remaining 
investigators was contacted. Permission was obtained from at least one investigator 
for each trial for which a publication was identified. 
In one submission the trial could be considered to be either one or two trials, with 2 
sample size calculations for 2 similar patient populations (differing only by stage of 
disease). This trial has been treated as a single trial for the purposes of describing and 
comparing trial details, but the outcome details for each trial have been considered 
separately. 
Most trials were in cardiovascular disease (20%) or cancer (19%) followed by 
respiratory medicine (8%) and gastroenterology (7%). (See Table 7). A total of 28% 
were placebo controlled and most (70%) had at least one comparator arm that 
involved one or more drugs (See Table 8). Most trials in cardiovascular disease and 
cancer (90% and 84% respectively) had at least one comparator arm that involved one 
or more drugs (See Table 9). 
The majority of trials had either two (72) or three (24) treatment arms and were multi-
centre (70), 76% of which (53) were international (See Table 10). Most were parallel, 
pragmatic trials by design (See Table 11). 
Table 6: Identification oUrials 
Submissions Vaar Of submission 
1992 1993 1994 1995 1996 Totals 
Number made 225 213 218 261 253 1170 
Number involving ReTs 63 61 53 74 68 319 
Number involving abandoned ReTs (% of ReTs 24 15 16 21 17 92 
identified) (38%) (25%) (30%) (28%) (25%) (29%) 
Number rejected 0 0 0 0 1 1 
Number not abandoned 39 46 37 53 50 226 
Number ReTs with publications identified (% of 21 17 14 24 30 106 
those not abandoned) (54%) (37%) (38%) (45%) (60%) (47%) 
Note 1: each submission could involve more than one study 
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Table 7: Patient population 
Patient population Numbarof Patient population Numbarof 
trials triala 
Cardiovascular disease 20 Nephrology 
Critical Care Neurology 4 
Dermatology 3 Obstetrics and gynaecology 4 
Drug and alcohol 3 Oncology 19 
Endocrinology 3 Paediatrics 4 
Fertility 3 Physiology 
Gastroenterology 7 Psychology 2 
Geriatric care 2 Respiratory medicine 8 
HIV / AIDS 6 Rheumatology 2 
Haematology 2 Surgery 1 
Immunology 2 healthy/normal 5 
Table 8: Interventions 
Natura of intervention ann 1 (control) ann 2 ann 3 ann 4 
Placebo 29 0 0 0 
Drugs 46 72 26 6 
Surgery/Procedure 5 4 0 0 
Device 0 1 1 0 
Lifestyle 2 2 0 0 
Counselling 3 3 1 0 
Rehabilitation 1 1 0 0 
Other intervention 17 20 4 0 
Total 103 103 32 6 
Table 9: Intervention by patient population 
Drug v Placebo Placebo Surgery v Lifestyle Couns- other 
drua v drug vdevtce surgery ellina 
Cardiovascular 10 8 0 1 1 
Oncology 15 1 0 1 2 
Respiratory 1 5 1 1 
Gastroenterology 5 1 1 
HIV/AIDS 4 1 1 
Healthy/normal 2 1 2 
----
... 
--
Note: For areas with 5 or more trials, based on arml x arm2 
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Table 10: Trial details (n = 103) 
Characteristic Cla •• lfication Numbe. 
Number of trial arms 2 72 
3 24 
4 4 
5 1 
6 1 
7 1 
Single or multi-centre Multi centre 70 
Single centre 33 
National or international Internabonal 53 
National 17 
not applicable 33 
Design Crossover 12 
Parallel 91 
Purpose Explanatory 23 
Pragmatic 80 
Table 11: Trial d .. ign by purpose 
Design Trial Purpose Total 
I Explanatory Pragmatic 
i 
Crossover 11 1 12 , 
: 
Parallel 12 79 91 
Total 23 80 103 I 
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From the trial protocol 
The median target sample size for trials as a whole was 240 (range 20-40,000), with 
30% of trials having a target sample size of 100 or fewer (Figure 5). 
Figure 5: Target sample size 
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At the time of submission to the REC most trials (65) reported that commercial 
funding was available to support the conduct of the trial (See Table 12). 
lnfollllation on allocation concealment and sequence generation was poorly 
documented in the protocols evaluated. A total of 60 trials used some fOlln of masking 
of the interventions being compared, and 48 used a placebo of which 31 described the 
placebo but only 17 adequately. 
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Table 12: Descriptive details in trial protocol 
Characteristic Classification Number 
Was any commercial funding available to support the conduct No 38 
of the trials at the time of submission to the REG? Yes 65 
Is there at least one clearly distinguishable primary outcome No 9 
in the protocol Yes 94 
The description of allocation concealment was adequate Adequate 44 
Inadequate 59 
The description of sequence generation was adequate Adequate 31 
Inadequate 72 
Does randomisation occur at a time as close to the Yes 21 
commencement of treatment as possible? No 82 
Use of blinding Both patient and HGP 55 
Open label 42 
Patient is blinded 4 
Treatment HGP blinded 2 
Was a placebo used? Yes 48 
No 54 
Unclear 1 
Was there a description of the placebo? Yes 31 
No 17 I 
Not applicable 55 
Was the description of the placebo adequate? Yes 17 
No 14 
Not applicable 72 
Did the protocol state that adverse events would be Yes 82 
monitored? No 21 
Did the protocol include a section on the handling of Yes 57 
withdrawals? No 46 
Note: the wording for some of the questions presented above differs slightly from the wording on the data collection 
forms. The data collection forms used shorthand terms and were applied in combination with a set of standard 
operating procedures developed specifically for the purpose. All tables are an accurate reflection of these SOPs. 
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From the trial publication 
Most trials were published in speciality journals (Table 13). The median sample size 
achieved (by trials as a whole) was 230 (range 6-58,000). There was mention of a 
power calculation in 69 of the publications resulting from the 103 trials. Use of a 
placebo was reported in 48 trials, only 7 of which provided a description that allowed 
the reader to determine that the placebo was adequate (Table 14). 
In the publication, allocation concealment was clearly described as using a centralised 
telephone, fax or computerised system in 15 trials. In a further 9 trials it was stated 
that randomisation was conducted "centrally" but it was unclear what this actually 
entailed (Table 15). Envelopes systems were used in 9 trials but only 1 provided clear 
evidence that the envelopes were free from the potential biases inherent in such 
systems. Three trials described methods of allocation concealment that were 
inadequate. 
The methods of sequence generation reported in the publication included schemes 
generated by a computer (16), dynamic balancing (4) or minimisation (5) techniques, 
random number tables (6) and permuted blocks (7). In one trial the patient appeared to 
select their treatment (clearly not adequate). The remaining 64 trials did not report the 
method of sequence generation. 
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Table 13: About the publication 
Charactaristic Classification Number 
Journal type General 26 
Soecialty 77 
Type of report full publication 103 
short report 2 
letter 1 
Was any commercial funding mentioned in the publication? No 39 
Yes 64 
Number of subjects randomised S100 33 
101-500 37
1 
501-1000 12 
>1000 21 , 
Was there at least one clearly distinguishable primary No 13 
outcome in the publication? Yes 90 
Were any safety outcomes reported? No 15 
Not applicable 11 
Yes 77 
The reporting of the power calculation was: Adequate 69 
Inadequate 34 
Table 14: Blinding and placebo in publication 
Charactaristic Classification Number 
Was a placebo used? No 54 
Yes 48 
Unclear 1 
If a placebo, the description of the placebo adequate 7 
was: inadequate 42 
not applicable 54 
If no placebo, is masking used? Yes 9 
not applicable 94 
If masked, the description of masking was: adequate 3 
inadequate 2 
unclear 5 
not aoplicable 
.. _- .. _-
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Table 15: Allocation concealment and .equence generation in publication 
Charactaristic ClaSSification Number 
The method of allocation concealment Central phone, fax or online 15 
Central system: method unclear 9 
Sealed envelopes: acceptable 1 
Sealed envelopes: not acceptable 8 
Other 3 
Not reported 67 
Classification of allocation concealment Adequate 16 
inadequate 87 
The method of sequence generation Computer 16 
Dynamic balancing 4 
Minimisation 5 
Permuted blocks 7 
Random number table 6 
Other 1 
Not reported 64 
Classification of sequence generation adequate 38 
inadequate 65 
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Chapter 4: Results 
This chapter includes the main results of the follow-up study. These will be reported 
as follows: 
• Primary objective: to investigate the selective reporting of primary outcomes 
• Multiple time points and global outcomes 
• Secondary objective I: to explore issues relating to the sample size, its 
calculation and reporting 
• Secondary objective 2: to explore other relationships between the protocol and 
the publication 
• Secondary objective 3: to explore the impact of the availability of commercial 
funding on the trial protocol and publication 
As outlined in Figure 4, 103 trials have been included, 97 of which had at least one 
primary outcome (a total of 162 outcomes). Excluding global outcomes and outcomes 
with more than 2 time points resulted in the inclusion of 90 trials with 134 outcomes 
and 194 comparisons. The data set used to address each question within each 
objective will therefore differ depending on the nature of the question. 
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Primary Objective: to investigate the selective reporting of 
primary outcomes 
a. Do randomised clinical trials start to address multiplicity early in 
the history of the trial through the clear declaration of a primary 
outcome in the protocol? 
Of the 103 trials in the study, six listed so many outcomes in the protocol and the 
publication that it was not possible to identifY 4 or less as primary outcomes, leaving 
97 trials reporting a total of 162 primary outcomes (including global outcomes and 
outcomes with more than 2 time points). It was possible to identify a single primary 
outcome in 59 trials, 2 primary outcomes in 20 trials and 3 or more primary outcomes 
in 18 trials (see Table 16). 60% of explanatory trials and 59% of pragmatic trials had a 
single outcome. 
Table 16: Number of primary outcomes by trial purpose 
Number of P~ose 
outcomes Total 
E~anatorv Pr~matic 
0 2 4 6 
1 12 47 59 
2 7 13 20 
3 2 8 10 
4 0 6 6 
5 0 1 1 
6 0 1 1 
Total 23 80 103 
Note: In the case of 2 included trials there were up to 4 primary outcomes identifiable 
in each document (ie 4 in the protocol and 4 the publication, however the identity of 
the outcomes differed in each document resulting in more than 4 primary outcomes 
for these 2 trials. 
b. Are there discrepancies between the trial protocol and the trial 
publication in relation to the identity of the primary outcome? 
Using the 97 trials with at least one primary outcome identified, there were 
coincidentally 97 of 162 outcomes (60%) that were clearly stated as being primary 
outcomes in the protocol, plus 40 (25%) that could be reasonably inferred as being 
primary outcomes (based on the sample size calculation or the aims and objectives) 
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(Table 17). In 25 cases (15%) the primary outcome subsequently identified in the 
publication was not documented as being a primary outcome in the protocol. Of these 
25, 9 were declared as being a secondary and not a primary outcome in the protocol, 5 
were mentioned in the protocol as an unspecified outcome, and II were not 
mentioned at all in the protocol. 
64% of pragmatic trials clearly state the primary outcome in the protocol (62% in the 
publication), compared to 44% of explanatory trials (25% in the publication) (Table 
18 and Table 19).47% of explanatory trials reasonably infer the outcome is a primary 
in the protocol (50% in the publication) compared to 19% of pragmatic trials (24% in 
the publication). 
There were 27 outcomes that were either reasonably inferred (12) or clearly stated 
(15) as being a primary outcome in the protocol, but were not reported as a primary 
outcome in the publication. Most (21 (78%)) were reported but the nature of the 
outcome was not specified, 5 were reported as secondary outcomes and I was not 
reported at all. The level of significance of a comparison did not appear to be 
associated with the decision to change the identity of the primary outcome in the time 
between the protocol and the publication (Table 20) (this was not tested statistically). 
Table 17: How you cau teD It Is the primary outcome 
How can you tell the outcome is a primary outcome 
How can you tell the outcome in the publication? 
is a primary outcome in the Reasonably 
protocol? Not stated inferred Clearly stated Total 
Not stated 0 13 12 25 
Reasonably 12 18 10 40 inferred 
Clearly 15 16 66 97 stated 
Total 27 47 88 162 
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Table 18: How you c:au ten it is tbe primary outcome (protocol) by trial purpose 
How can you tell it is a primary Pu~ ose Total I 
outcome in the protocol Explanatory Pr~gmatic I 
Not.taled 3 (9%) 22 (17%) 25 
Reasonably Inferred 15 (47%) 25 (19%) 40 
Clearly stated 14 (44%) 83 (64%) 97 
Total 32 130 162 
Table 19: How you c:an ten it is tbe primary ontcome (publlc:ation) by trial purpose 
How can you tell it is a primary P"",-ose Total 
outcome in the publication Explanatory Pragmatic 
Not staled 8 (25%) 19 (15%) 27 
Reasonably Inferred 16 (50%) 31 (24%) 47 
Clearly staled 8 (25%) 80 (62%) 88 
Total 32 130 162 
Table 20: Cbange in identity of primary outcome by statistic:al signiflc:ance 
Change in identity of primary outcome 
Outcome used for Outcome used for 
Outcome used for comparison comparison 
comparison declared declared as primary declared as primary 
as primary outcome in in protocol but not in both protocol and 
Level of statistical publication but not in in publication (% of publication (% of Total 
significance protocol (% of total) total) total) 
P value 
not 4 (13%) 8 (25%) 20 (63%) 32 
reported 
P sO.05 8 (13%) 10 (16%) 45 (71%) 63 
P > 0.05 8 (8%) 13 (13%) 78 (79%) 99 
Total 20 (10%) 31 (16%) 143 (74%) 194 
-- --
.-
--
L.. 
---- -- -
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c. Are there discrepancies between the trial protocol and the trial 
publication in relation to the definition of the primary outcome 
Using all 103 trials, it was possible to reasonably deduce that the definitions for 98 (of 
162, or 60%) outcomes were the same in both the protocol and the publication. It was 
not possible to judge in the case of 51 outcomes (3\ %), primarily because the 
outcome was not declared in either the protocol or the publication. 
It was possible to ascertain that the definitions were different in the case of \3 (8%) 
primary outcomes (see Table 2 I). These differences can be summarised as: 
• addition of an event (or outcome) to a composite outcome (1 outcome) 
• change in the tests performed (or the way in which the tests were performed) 
that were used to determine the primary outcome (2 outcomes) 
• change in the definition of a positive test or an event (7 outcomes) 
• change in the specified time point of interest (3 outcomes) 
Table 21: Nature oftbe difference in defiDitlon 
Trial Nature of the difference In definition 
A (2 trials) There was a change in the definition of the outcome during the course of the trial, and 
this change was documented in the publication, however, appear to use a different 
definition aQain for reportinQ 
B Added an outcome to a composite outcome 
C There was a change in the definition of the outcome during the course of the trial, and 
this chanQe was documented in the publication. 
0 This outcome was "safety" and the definitions in the protocol and the publication were 
sliQhtlv different, and the impact of the difference is unclear. 
E Time period is different, and quite important in this trial. Protocol specifies week 4 and 
the publication specifies week 1. In addition, the outcome measurement in the protocol 
uses 2 specific tests with specific values required; the publication uses one of these tests 
but specificallv excludes the results of the second test. 
F (2 The test used to measure the outcome is different. PartiCipants were asked to perform a 
outcomes) repetitive task a given number of times during a specific time period. The number of 
repetitions was double in the publication to the number described in the protocol. 
G (2 The outcome was measured by the total dose of a drug administered over a given time 
outcomes) period. The protocol states the time period as being 2 days, while the publication states it 
as being over 5 days. The second outcome was based on 4 criteria in the protocol, and 5 
criteria in the publication with overlap of 3 criteria. 
H The outcome is "cure" with specific tests and results required. The protocol and 
publication both require these at week 4, but the publication states an additional test with 
a specific resu It was a Iso required at the end of week 1. 
I The difference in the definition of the outcome could potentially result in a different event 
rate. 
J The outcome of this trial was willingness to perform one of 2 tasks. One of the tasks was 
abandoned for practical reasons. This change in the outcome was reported and unlikely 
to have an impact on the findings of the trial. 
---
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d. Are primary outcomes "fully" reported? 
As described in Chapter 3, a single trial may have more than one primary outcome, 
and each outcome may involve more than one comparison if the trial has more than 2 
treatment arms. As the completeness of reporting may be comparison-dependent it is 
necessary to divide each outcome down into its comparisons to look at whether and 
how each of these was reported in order to be able to investigate completeness of 
reporting. 
Difficulties in quantifying outcomes with multiple time points and global outcomes in 
a meaningful way mean that these outcomes have not been included in the analysis of 
completeness of reporting of primary outcomes and have been discussed separately 
(see Multiple time points and global outcomes). A total of \3 trials did not contribute 
to the analysis of completeness of reporting of primary outcomes: 6 that did not have 
identifiable primary outcomes, and 7 where the only primary outcomes in the trial 
involved multiple time points or were global outcomes. The remaining 90 trials 
contributed 134 primary outcomes to the analysis ofthe selective reporting of primary 
outcomes. Twenty (15%) of the \34 were composite outcomes. 
Breaking the outcomes with 2 identifiable time points, and trials with more than 2 
treatment arms, into comparisons resulted in a total of 194 comparisons available for 
analysis of completeness of reporting of the primary outcome. 45 trials contributed a 
single comparison and 15 contributed 4 or more (Table 22). Most comparisons 
involved binary (39%) or continuous (36%) data (Table 23 and Table 24). 
Table 22: Number of comparisons in a trial by trial pnrpose 
Purpose Total 
Number of 
comparisons Exploratory Pragmatic 
1 7 38 45 
2 7 10 17 
3 4 9 13 
4 1 6 7 
5 0 2 2 
6 1 4 5 
8 0 1 1 
Total 20 70 90 
72 
Table 23: Comparison classification by data type 
Data type 
not time to 
Comparison classification binary categorical continuous reported event Total 
additional 
21 2 22 0 5 50 
comparison 
composite 
15 0 0 0 5 20 
outcome 
extra time point 3 0 7 0 0 10 
single outcome 36 3 41 5 29 114 
Total 75 5 70 5 39 194 
--
Table 24: Number of comparisons by data type 
Data type 
Number of 
comparisons binary categorical continuous not reported time to event Total 
1 52 3 41 5 34 135 
2 9 1 19 0 3 32 
3 6 1 9 0 2 18 
4 2 0 1 0 0 3 
5 2 0 0 0 0 2 
6 2 0 0 0 0 2 
7 1 0 0 0 0 1 
8 1 0 0 0 0 1 
Total 75 5 70 5 39 194 
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Completeness of reporting of comparisons 
The majority of comparisons were either fully (77%) or partially (12%) reported 
(Table 25) (See Appendix 4: Completeness of reporting for definition). 93% of binary 
outcomes and 69% of continuous outcomes were fully reported. possibly reflecting 
the greater level of detail required for a continuous outcome to be considered fully 
reported. 
Table 25: Completen ... of reporting of comparisons by data type 
Data type 
not time to 
Completeness of reporting binary cateaorical continuous reported event Total 
fully reported 70 5 48 0 26 149 
not reported 2 0 3 5 3 13 
partially 0 0 18 0 5 23 
reported 
qualitative 3 0 1 0 5 9 
Total 75 5 70 5 39 194 
Trial-based measure of completeness of reporting 
Using the method described in Chapter 3, a trial-based measure was created for 
completeness of reporting. Based on this measure, 76% of trials fully reported all of 
their primary outcomes, 10% did not fully report any of their primary outcomes, and 
14% fully reported some but not all of their primary outcomes (Table 26). 
Table 26: Nnmber of trials and proportion of comparison. completely reported 
Proportion of 
comparisons Number of 
fullv reported trials Percent 
0% 9 10.0 
25% 3 3.3 
33% 1.1 
40% 1 1.1 
50% 2 2.2 
67% 3 3.3 
75% 2 2.2 
80% 1 1.1 
100% 68 75.6 
Total 90 100.0 
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Threshold for a fully reported trial 
The threshold for a fully reported trial was set at 100%. That is, trials that fully report 
all (ie 100%) of their comparisons are considered to be fully reported, and are 
compared with those that fully report less than 100% of their comparisons. A 
sensitivity analysis was conducted by changing the threshold for a completely 
reported trial to 66% (that is, a completely reported trial is one that fully reports more 
than 66% of its comparisons). The impact of changing the threshold to 0% (trials that 
do not fully report any of their comparisons are compared with those that fully report 
at least one comparison) was also investigated. It should be noted that there are only 9 
trials that do not fully report any of their comparisons, and the small numbers make 
this analysis unreliable. 
There were 45 trials with a single comparison, of which 39 (87%) were fully reported 
(Table 27). 
If the threshold for a fully reported trial is 100% then 68 trials (76%) would be 
classified as fully reported. If it is changed to 66% then 74 trials (82%) would be 
considered to be fully reported. A threshold of 0% indicates that 81 trials (90%) fully 
report at least one comparison. 
Table 27: Number of comparisons by number of trials with 100% fully reported comparisons 
Proportion of trials with 100% of outcomes 
Number of comparisons in fully reported 
a trial >1 and 
0% <100 100% Total 
1 6 0 39 45 
2 0 2 15 17 
3 0 3 10 13 
4 1 5 1 7 
5 0 2 0 2 
6 2 1 2 5 
8 0 0 1 1 
Total 9 13 68 90 
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e. To explore trial characteristics in the protocol that may be 
associated with the selective reporting of clinical trials 
Variables in the protocol that might be associated with selective reporting were 
investigated using binary logistic regression. There are two endpoints related to 
selective reporting: 
I. Discrepancy in the identity of the primary outcome 
2. Completeness of reporting 
The covariates included in the models are listed in Table 28. All univariate analyses 
are detailed in Appendix 6: Univariate analyses (including analyses adjusted for 
number of outcomes or number of comparisons) and multivariate analyses in 
Appendix 7: Multivariate models. 
Table 28: Variables in tbe protocol that might predict selective reporting 
Covariate Variable short name Classification 
DeSign Not included in model as only 8/90 0: crossover 
trials were crossover designs in the 1: parallel 
comparison data set (and 12/97 in 
trials with at least one identifiable 
primary) 
Purpose purpose 0: exploratory 
1: pragmatic 
Administration administration 0: single centre 
1: multi-centre national 
2: multi-centre international 
Commercial funding (protocol) hrecdrugfund 0: no commercial funding 
1: commercial funding available 
Proposed sample size hrecss200c0de 1: s 200 
2: > 200 
Completeness of the sample sscompcode2 0: nil 
size calculation 1: partial 
2: complete 
Allocation concealment hrecalloc 0: not adequate 
1: adequate 
Sequence generation hrecseqgen 0: not adequate 
1: adequate 
Blinding hrecblind 0: not double blind 
1: double blind 
Number of comparisons numbercomp 0: 2: 2 comparisons 
1: 1 comparison 
Note: Variable short name is listed here to facilitate interpretation of the regressIOn 
models in the appendices. 
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Results of logistic regression for the endpoint "Discrepancy in the 
identity of the primary outcome" 
The analysis for the endpoint "Discrepancy in the identity of the primary outcome" 
was conducted using the 97 trials for which 1 to 4 primary outcomes were 
identifiable. Of these 97 trials, 64 (66%) declared all of their outcomes in both the 
protocol and the publication (Table 29). 
Table 29: Proportion or outcomes declared in both protocol and pubUeation by number or 
outcomes 
Proportion of outcomes declared in both the protocol 
and the publication 
Number of outcomes 0% >0% but <100% 100% Total 
1 7 0 48 
2 6 7 10 
3 or more 1 12 6 
Total 14 .~ 64 .- '-- -- -- -- - '-------
55 
23 
19 
-'£ 
If it is assumed that in order for a trial to be without selective reporting that 100% of 
its outcomes must be declared in both the protocol and the publication, then trials with 
commercial funding, a sample size over 200, complete documentation of the sample 
size calculation and a single outcome are less likely to selectively report when 
investigated in a univariate analysis (See Table 30). When each variable is adjusted 
for the number of outcomes in the trial the same variables remain significant (Table 
31). The significant variables were included in a multivariate analysis, the results of 
which indicate that trials with a partial (OR3.9, 95%CI 0.53-28.1) or completely 
(ORI2.9, 95%CI 1.9-86.1) documented sample size calculation are more likely to 
report their outcomes in both the protocol and the publication than those without a 
sample size calculation (Table 32). The multivariate model also indicates that trials 
with more than one outcome (OR 0.04, 95%CI 0.01 - 0.17) are less likely to report 
their outcomes in both the protocol and the publication than those with a single 
outcome (Table 32). 
Note that in all results tables a p value marked with an asterisk (*) denotes a global p 
value for that variable. 
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Table 30: Univariate analyses for the endpoint discrepancy in the identity of the primary 
outeome (threshold 100%) 
Covariate Categories P value Odds ratio 95%CI 
lower upper I 
Design 0: crossover 
.96 .97 .23 4.14 ' 1: carallel 
Purpose 0: exploratory 
.66 1.26 .46 3.42 1: craQmatic 
Administration 0: single centre 1.35 .39 4.72 1: multi-centre national ".26 
2: multi-centre international 2.21 .85 5.73 
Commercial funding 0: no commercial funding 
.03 2.72 1.13 6.50 1: commercial fundinQ available 
Target sample size 1: s 200 
.09 2.12 .90 4.97 2: > 200 
Completeness of 0: nil 7.22 1.44 36.22 
sample size calculation 1: partial ".007 
2: complete 9.41 2.31 38.31 
Allocation concealment 0: not adequate 
.48 1.36 .59 3.19 1: adequate 
Sequence generation 0: not adequate 
.92 1.05 .42 2.60 1: adequate 
Blinding 0: not double blind 
.31 1.55 .67 3.62 1: double blind 
Number of outcomes 1: 1 outcome 
<0.001 .08 .03 .22 2: more than 1 outcome 
Table 31: Variables adjusted for number ofouteomes for the endpoint discrepancy in the Identity 
of the primary outeome (threshold 1000;.) 
Covariate Categories P value Odds ratio 95%CI 
lower upper 
Design 0: crossover 
.79 .79 .14 4.39 1: carallel 
Purpose 0: exploratory 
.78 1.18 .36 3.90 1: craQmatic 
Administration 0: single centre 1.09 .25 4.85 
1: multi-centre national *.46 
2: multi-centre international 1.95 .63 6.05 
Commercial funding 0: no commercial funding 
.02 3.50 1.18 10.39 1: commercial funding available 
Target sample size 1: S 200 
.04 3.11 1.06 9.12 2: > 200 
Completeness of 0: nil 5.44 .82 36.22 
sample size calculation 1: partial ".004 
3.34 130.67 2: com-",ete 20.9 
Allocation concealment 0: not adequate 
.73 1.19 .44 3.28 1: adeauate 
Sequence generation 0: not adequate 
.92 .95 .32 2.79 1: adequate 
Blinding 0: not double blind 
.15 2.13 .75 6.03 1: double blind 
-- --- ---
Table 31: Multivariate model for the endpoint discrepancy in the Identity of the primary outcome 
(threshold 100%) 
Covariate Categories P value Odds ratio 95%CI 
Lower UDOer 
Commercial funding 0: no commercial funding 
.091 2.77 .85 9.00 1: commercial fundinQ available 
Completeness of 0: nil 3.86 .53 28.1 
sample size calculation 1: partial ".027 
2: comclete 12.89 1.93 86.08 
Number of outcomes 1: 1 outcome 
<0.001 .04 .01 .17 2: more than 1 outcome 
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Results oflogistic regression for the endpoint "Completeness of 
reporting" 
The analysis for the endpoint "Completeness of reporting" was conducted using the 
90 trials for which I to 4 primary outcomes were identifiable that did not involve 
global outcomes or multiple comparisons. 
If it is assumed that in order for a trial to be completely reported it must fully report 
100% of its primary outcomes then the only variable significant in univariate analysis 
is the number of comparisons, with trials with single comparisons being more likely 
to fully report than those with 2 or more comparisons (Table 33 and Table 35). 
Repeating the univariate analyses adjusting for the number of comparisons, then the 
completeness of documentation of the sample size calculation also becomes 
significant with trials with a partial or completely documented sample size calculation 
being more likely to fully report than those without (Table 34 and Table 36). The final 
model therefore included the completeness of the sample size calculation and the 
number of comparisons (Table 37). 
Trials with only one comparison were 4.5 times more likely to fully report all of their 
comparisons than trials with more than one comparison. Trials with a partially 
documented sample size calculation in the protocol were 7.6 times as likely as those 
without such a calculation, and trials with a complete sample size calculation were 4.8 
times as likely as those without a calculation to fully report all of their comparisons. 
If the threshold for fully reported is changed to 66% then the completeness of 
documentation of the sample size calculation is the only variable that remains 
significant (OR 8.5 for partially documented compared with nil, and OR 6.4 for 
completely documented compared with nil). 
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Table 33: Number of comparisons by proportion of trials with fUlly reported comparisons 
Proportion of trials wtth fully reported comparisons Total 
0% fully >0% but 100% fully 
Number of comparisons reported <100% reported 
1 6 0 39 4~ I 2 0 2 15 17, 
3 0 3 10 13 
4 1 5 1 7 
5 0 2 0 2 
6 2 1 2 5 
8 0 0 1 1 : 
Total 9 13 68 90 I 
Table 34: Completeness of sample size calculation by proportion of trials witb fnlly reported 
comparisons 
Proportion of trials with fully reported 
comparlsons 
Completeness of sample size <100% fully 100% fully 
calculaijon reported re~orted Total 
nil 6 6 12 
Partial 3 16 19 
Complete 13 46 59 
Total 22 68 90 
Table 35: Univariate analysis for tbe endpoint completen .. s of reporting (threshold 100%) 
Covariate Categories Pvalue Odds ratio 95%CI 
Lower upper 
Purpose 0: exploratory 
.95 1.04 .39 3.28 1: oraamatic 
Administration 0: single centre .95 1.28 .28 5.98 1: multi-centre national 
2: multi-centre international 1.08 .37 3.18 
Commercial funding 0: no commercial funding 
.18 1.96 .74 5.19 1: commercial fundin~ available 
Target sample size 1: S 200 
.91 1.06 .40 2.77 2: > 200 
Completeness of 0: nil 5.33 1.00 28.44 
sample size calculation 1: partial .09 
2: compJete 3.54 .98 12.83 
Allocation concealment 0: not adequate 
.95 .36 2.49 1: adequate 
Sequence generation 0: not adequate 
.46 .68 .25 1.88 1: adequate 
Blinding 0: not double blind 
.72 1.19 .46 3.13 1: double blind 
Number of 0: :=?: 2 comparisons 
.02 3.59 1.25 10.29 comparisons 1: 1 comparlson 
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Table 36: Variables adju.ted for number of outcomes for tbe endpoint completenes. of reporting 
(threshold 100%) 
Covariate Categories P value Odds ratio 95%CI 
Lower upper 
Purpose 0: exploratory 
.74 .82 .25 2.71 1: praqmatic 
Administration 0: single centre .96 1.10 .22 5.47 1: mulH-centre national 
2: multi-centre international 1.18 .39 3.64 
Commercial funding 0: no commercial funding 
.16 2.06 .75 5.69 1: commercial fundi"R available 
Target sample size 1: s 200 
.73 1.19 .44 3.26 2: > 200 
Completeness of 0: nil 7.65 1.26 46.47 
sample size calculation 1: partial .05 
4.80 1.16 19.81 2: complete 
Allocation concealment 0: not adequate 
.64 1.27 .46 3.56 1: adequate 
Sequence generation 0: not adequate 
.56 .73 .25 2.1 1: adequate 
Blinding 0: not double blind 
.34 1.67 .59 4.71 1: double blind 
Table 37: Multivariate model for the endpoint completenes. of reporting (threshold 1000/0) 
Covariate Categories P value Odds ratio 95%CI 
Lower upper 
Completeness of 0: nil 7.650 1.26 46.47 
sample size calculation 1: partial .053 
2: complete 4.802 1.16 19.81 
Number of 0: ~ 2 comparisons 
.010 4.465 1.43 13.98 comparisons 1: 1 comparison 
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f. To explore other (non-protocol) factors that may be associated 
with the selective reporting of clinical trials 
Trial-based investigation of statistical significance 
In 26 trials, all of the comparisons were statistically significant, of which 24 fully 
reported all of their comparisons (Table 38). Trials where all of the comparisons are 
statistically significant are more likely to fully report all of their comparisons 
(p=0.06). Of the 45 trials with a single comparison, 20 (44%) were statistically 
significant (Table 39). All comparisons were statistically significant in 6 (13%) of the 
45 trials with more than one comparison. 
Table 38: Proportion statistically significant and proportion fully reported 
Proportion of trials with a comparison where 
Proportion of trials with a comparison 
the primary outcome was fully reported in the 
oublication Total 
p<=0.05 >0% but 
0% <100% 100% 
0% 8 6 34 48 
>0% but <100% 0 6 10 16 
100% 1 1 24 26 
Total 9 13 68 ~ ----
Exact ordered categorical test: p=O.06 
Table 39: Number of comparisons by proportion statistically significant 
Proportion of trials with a comparison that 
was statisticallv sianificant Total 
Number of comparisons >0% but 
0% <100% 100% 
1 25 0 20 45
1 2 11 2 4 17 
3 6 6 1 13 
4 2 5 0 7 
5 0 1 1 2 
6 3 2 0 5 
8 1 0 0 1 
Total 48 16 26 90, 
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Comparison-based investigation of statistical significance 
Of the 194 comparisons a p value was not reported for 32 (Table 40). The odds of 
fully reporting a comparison are greater if the result is statistically significant when 
compared to those that are not statistically significant (OR 2.2, 95% CI 0.9-5.3, 
p=0.08). 
Table 40: Statistical .ignificance by completen ... of reporting of comparison 
Completeness of reportinQ 
Partially 
P value Not reported reported Fully reported Qualitative Total 
p>0.05 0 18 75 6 99 
P not 13 0 19 0 32 
reported 
P <= 0 5 55 3 63 0.05 
Total 13 23 149 9 194 
Multiple time points and global outcomes 
There were 14 global outcomes and 19 involving multiple time points (that is, more 
than 2 time points), including 5 outcomes that met both criteria. 
Global outcomes are those where the outcome consists of multiple components and 
could be reported with a single global measure with or without measures for each of 
the components. There were 14 trials with global outcomes, 5 of which came from 
one trial. (Note: this trial had a total of 5 primary global outcomes including 2 quality 
of life measures, both specified in the protocol as being the primary outcome 
measures. The publication reported 3 additional global outcomes specified as primary 
in the publication but not in the protocol.) 
Thirteen of the 14 trials with global outcomes could have been considered to be trials 
with no identifiable primary outcome owing to the very broad "definition" of the 
outcome that was used in each case. The global outcomes identified included 
"biochemical response", "anthropometric measures", "compliance", "dissatisfaction", 
"growth" and "return to normal physiological functions". In all cases, a number of 
tests or measures were used with no clear single outcome and no overall summary 
measure anticipated. "Safety" (in 2 trials), when recorded as a primary outcome for 
which there is no specific definition, also comes under this category. 
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The primary outcome in 2 trials was quality of life, the most obvious example of a 
global outcome. Instruments used to measure quality of life usually consist of multiple 
dimensions, and each dimension consists of multiple questions. A single, global 
measure of quality of life may be reported, with results for each dimension, and 
results for each question. To further complicate matters, this outcome is often 
measured over multiple time points. 
There were 19 primary outcomes where there were more than 2 time points involved. 
In all cases either the protocol or the publication described that the outcome was (to 
be) routinely measured at multiple, specified intervals during the course of trial, but 
did not specify a particular time point of interest. The most common way to present 
multiple time points was to present the results for each time point at which the 
outcome was measured, or to present the change in the value between one or more 
time points. One option is to assume that the primary time point is the final measure, 
although it is not usually evident in either the protocol or the publication that this is 
the case. The ideal situation would be an analysis that included a single, global test, or 
individual tests adjusted for mUltiple outcomes. Insufficient detail was reported in the 
protocols and most publications to be able to determine the degree to which multiple 
time points had been taken into account. 
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Secondary Objective 1: to explore issues relating to the 
sample size, its calculation and reporting 
a. Do trial protocols contain adequate details of the target sample 
size? 
All trials had a target sample size mentioned in the protocol, although in 15 cases 
there was no evidence that this number was based on a formal power calculation 
(Table 41). 
Table 41: Sample size details in protocol 
Characteristic Classification Number 
Is there a target sample size? yes - appropriate fonnula 88 
yes - but no calculation 15 
The sample size is S200 49 
201-500 23 
>500 31 
The completeness of the sample size calculation Incomplete 16 
Partial 20 
Complete 67 
The outcome used to calculate sample size Yes 86 
No 17 
The expected treatment effect Yes 84 
No 19 
Was the a error pre-specified Yes 73 
No 30 
The speCified value of a 0.01 2 
0.025 1 
0.05 70 
Not reported 30 
Was the power pre-specified Yes 80 
No 23 
The specified power <0.8 2 
0.8 59 
0.85 4 
0.9 13 
0.95 2 
Not reported 23 
Was the alternative hypothesis specified? Yes 38 
No 65 
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b. What is the completeness of documentation of the sample size 
calculation in the protocol? 
The completeness of reporting of the sample size calculation in the protocol was 
classified as complete (reported the outcome used, the estimated size of the effect of 
the intervention, the level of significance and power), partial (as a minimum reported 
the outcome used for the power calculation) or nil/none. Sixteen trials were classified 
as not having a sample size calculation in the protocol, and none of these provided 
any details of the elements of the sample size calculation except for two which 
documented some elements but not the outcome used. Of the 19 trials classified as 
partially reported all but 4 documented the expected effect size, 5 documented the 
significance level and 11 the power level. 
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c. What factors in the protocol are associated with the 
completeness of documentation of the sample size calculation in 
the protocol? 
Variables that were considered to potentially be associated with the completeness of 
documentation of the sample size calculation in the protocol (nil v complete or partial) 
were the purpose of the trial, administration and the availability of commercial 
funding. Univariate analysis suggested that multi-centre international trials were more 
likely than single trials, and trials with commercial funding available at the time of 
submission to the REC, were significantly more likely to have a complete or partial 
sample size calculation in the protocol (See Appendix 6.3: Univariate analyses for 
completeness of documentation of the sample size calculation). When all of these 
variables were included in a multivariate model, multi-centre international trials 
remained significant with such trials being more likely to include a complete or partial 
sample size calculation in the protocol than single centre trials (OR 15, 95%CI 3-71, 
p=O.OOI) (See Appendix 7.3: Multivariate models for completeness of documentation 
of the sample size calculation). 
Table 42: Administration by completeness or the sample size calculation 
Completeness of documentation of the 
samDle size calculation 
Complete or 
Total Administration Nil oartial 
Single 8 19 27 
centre 
Multi-centre 2 12 14 
national 
Multi-centre 2 47 49 international 
Total 12 78 90 
---- -
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d. Is the completeness of documentation of the sample size 
calculation in the protocol related to the adequacy of reporting of 
the power calculation in the publication? 
There were 67 trials with a complete sample size calculation in the protocol of which 
50 had an adequately reported power calculation in the publication (see Table 43). 
The odds of a power calculation being adequately reported in the publication were 
almost 5 times greater if the sample size was completely documented in the protocol 
when compared to those that were not documented (Table 44). 
Table 43: Completeness of the sample size calculation <a> 
Completeness of the documentation of the 
Adequacy of the reporting of the sample size calculation in the protocol 
power calculation Nil Partial Complete Total 
Not 
10 7 17 34 
adequate 
adequate 6 13 50 69 
Total 16 20 67 103 
~ -_._--- ~~--
-
Table 44: Completeness of the sample size calculation (b > 
Completeness of the Odds P value 95.0%C.1. Global p value 
documentation of the ratio 
sample size calculation in 
the crotocol Lower Upper 
nil 1 .03 
partial 3~ 1 .11 .8 12.14 0025 
complete 4.9 .007 1.55 15~51 
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e. What other trial-related factors are associated with the adequacy 
of reporting of the power calculation in the publication? 
Variables in the protocol that might be associated with the adequacy of reporting of 
the power calculation in the publication include the purpose, administration, 
availability of commercial funding and the completeness of the sample size 
calculation in the protocol. Univariate analysis suggested that multi-centre 
international, pragmatic trials with a complete sample size calculation in the protocol 
were more likely to adequately report the power calculation in the publication (See 
Appendix 6.4: Univariate analyses for adequacy of reporting of the power 
calculation). When all of these variables were included in a multivariate model, multi-
centre international trials were more likely than single centre trials (OR 15, 95%CI 3-
71, p=O.OOI) to adequately report a power calculation in the publication. 
The protocol was more likely to have a complete or partial sample size calculation in 
trials with sample sizes over 200 (p=0.005) (see Table 45). The publication was also 
more likely to adequately report a power calculation if the number of patients 
randomised was more than 200 (see Table 46). 
Table 45: Sample size and completeness of re of power calculation in protocol 
Completeness of the sample size 
calculation in the protocol 
Complete or 
Nil partial Total 
Sample size in protocol <=200 14 35 49 
>200 3 51 54 
Total 17 86 103 
Fisher's Exact test (2 sided) p=0.003 
Table 46: Completeness of sample size calentation in protocol and adequacy of reporting of 
1"'"". - Iculation in onbU ., _- au ... 
Adequacy of reporting of power 
calculation in publication 
Inadequate adequate Total 
Completeness of the sample Nil 11 6 
size calculation in the 17 
protocol Partial or 23 63 86 
complete 
Total 34 69 103 
Fisher's Exact test (2 sided) p=0.004 
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Table 47: Reported commercial funding and adequacy or reporting or power calcnlation in 
_ ....... _ ......... 
Reporting of Dower calculation in~ublicaUon Total 
Commercial funding reported in publication Inadequate Adequate 
No commercial 12 27 39 funding available 
Commercial 22 42 64 funding available 
Total 34 69 103 
Fisher's Exact test (2 sided) p=0.83 
Tabl. -----.-.~. be ---- ----- !sed andadequa, r 01 _ •• __ --- - ...... -_ .. _---.. 
Reporting of power calculation in publication Total 
Inadeauate Adeauate 
Number of participants S200 
randomised 24 21 45 
>200 10 48 58 
Total 34 69 103 
-
.. _-
---
.-
Fisher's Exact test (2 sided) p<0.001 
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Secondary Objective 2: to explore other relationships between 
the protocol and the publication 
f allocation concealment and sequence generation 
g. use of blinding and placebo 
h. adverse events 
i. journal 
j. exclusions 
a. Allocation concealment and sequence generation 
The methods of sequence generation and allocation concealment were inconsistently 
and poorly documented in both protocols and publications (Table 49). A code of 
"adequate" was assigned only when the method was both documented and the method 
described was sufficient to minimise bias. For example, a trial that reports that an 
envelope system was used but either does not describe how the system was 
implemented, or describes a system of implementation that could introduce bias, was 
deemed to have an inadequate method of allocation concealment. 
16 trials had an adequate method of allocation concealment described in both the 
protocol and the publication (Table 49). An adequate method of sequence generation 
was described in 31 protocols and 38 publications, but only 16 described an adequate 
method in both documents. 
Table 49: Allocation concealment and sequence generation 
In protocol In publicaHon 
Allocation Concealment Sequence Generation 
Adequate Inadequate Total Adequate Inadequate Total 
Adequate 16 28 44 16 15 31 
Inadequate 0 59 59 22 50 72 
Total 16 87 103 38 65 103 
- - - - ----- - - --- -- - ---
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The method of allocation concealment was described in 36 trial publications (Table 
50). Of these, 9 reported that sealed envelopes were used (in only I case was it 
possible to ascertain that the method used was adequate), 15 utilised a central 
telephone service and 9 reported that randomisation was centralised but the method 
used was unclear. 
The method of sequence generation was described in 39 publications. Of these, 38 
reported a method that was considered to be adequate (5 used minimisation, 7 
perllluted blocks, 6 random number tables, 4 dynamic balancing and 16 stated that a 
computer was used to generate the sequence). 
T.ble 50: Metbod of .Uocotioo coocealmeot aod sequeoce geoer:atioo (publicatioo) 
Adequate 
b. Use of blinding and placebo 
There were 49 trial protocols that mentioned the use of a placebo in the protocol (48 
of the 55 double blind trials and I single blind trial used a placebo) of which 31 
provided a description of the placebo. In only 17 cases was the description of the 
placebo such that it was possible to ascertain that the placebo was adequate. 
Two of the 55 trials declared as double blind in the protocol were not reported as 
double blind in the publication, and 2 of the 48 trials not declared as double blind in 
the protocol were reported as double blind in the publication. Three trials that 
declared that either the health care practitioner or the patient would be blinded in the 
protocol did not mention this blinding in the publication. 
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Table 51: Blinding in protocol and publication 
BlindirlQ mentioned in...QUblication 
Blinding mentioned in protocol Not double blind Double blind Total 
Not double 46 2 48 blind 
Double 2 53 55 blind 
Total 48 55 103 
c. Adverse events 
In 82 protocols it was stated that there would be some form of monitoring for adverse 
events, and 77 reported adverse events in some form in the publication (Table 52). 
Table 52: Adverse events in protocol and pUblication 
Adverse events reported (in publication) 
No Yes Total 
Adverse events to No 15 6 21 
be monitored (in Yes 11 71 82 protocol) 
Total 26 77 103 
d. Journal type 
Univariate analyses suggest that pragmatic, multi-centre national trials and 
international trials, sample sizes over 200, with a complete sample size calculation in 
the protocol and adequate documentation of allocation concealment in the protocol are 
all more likely to be published in general than specialty journals (see Appendix 6.5: 
Univariate analyses for journal type). 
The multivariate model reveals that a projected sample size of more than 200 (OR II, 
95% CI 2-51, p=0.003) and adequate allocation concealment (OR 3.8, 95% CI 1.2-12, 
p=0.021) remain significant (see Appendix 7.5: Multivariate model for journal type). 
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8. Exclusions 
There was an explicit statement that intention-to-treat analyses were to be conducted 
in 45 trials (See Table 53). Of the 40 trials reporting that there were exclusions, 25 
(63%) reported the number excluded by treatment arm and 6 reported that the same 
criteria were applied to each treatment arm (See Table 54). 
Table 53: Exclusions from analysis 
Characteristics Classification Number 
Did the publication explicitly state that Yes 45 
intention to treat analYses were conducted? No 58 
Did the publication report that patients were Explicitly reported no exclusions 19 
excluded from the analysis (of the primary Gave impression no exclusions 30 
outcome)? Explicitly reported that there were 41 
exclusions 
Exclusions not mentioned or unclear 7+6 
If the publication explicitly reported that there No 16 
were exclusions, were the number excluded Yes 25 
bytreatrnentann reported? Not applicable 62 ' 
If the publication explicitly reported that there No 35 
were exclusions. was it reported that the Yes 6! 
same criteria were applied to each oroup? Not applicable 62 
Reasons for exclusions did not start allocated intervention 12 
false inclusions (ineligible) 6 
non-compliers 6 
other 19 
not applicable 60 
Table 54: Intention to treat and exclusions 
Participants excluded from analysis (of Intention-ta-treat analvses conducted Total 
primary outcome/s) Yes No 
Explicitly reported no exclusions 17 2 19 
Gave impression no exclusions 11 19 30 
Explicitly reported that there were 14 27 41 
exclusions 
Exclusions not mentioned or unclear 2 5 7 
Ex licitly reported no exclusions 1 5 6 
Total 45 58 103 
The protocol-specific variables purpose, administration, commercial funding, 
allocation concealment, sequence generation, sample size and completeness of 
documentation of the sample size calculation were investigated both in univariate 
analyses and in the multivariate model (see Appendix 6.6: Univariate analyses for 
exclusions). There was no evidence ofa relationship between any of the variables and 
exclusions from the trial analysis. 
94 
Secondary Objective 3: to explore the Impact of the 
availability of commercial funding on the trial protocol and 
publication 
Of the 65 trials indicating that commercial funding was available at the time of 
submission to the REC, 56 acknowledged that funding in the publication (Table 55). 
For 30 trials there was no indication that commercial funding was available in either 
the REC submission or the publication. Eight of the 38 trials indicating that 
commercial funding was not available at the time of submission to the REC, 
acknowledged a commercial funding source in the publication. Of the commercially 
funded trials 63% were multi-centre and international (Table 59), and 72% had a 
complete sample size calculation in the protocol (Table 60). 
Table 55: Declaration of commercial funding 
Commercial funding declared in 
publication 
Commercial funding declared in protocol No Yes Total 
No 30 8 38 
Yes 9 56 65 
Total 39 64 103 
[n univariate analysis, trials with commercial funding available at the time of 
submission to the REC were significantly more likely to: 
• Have at least one clearly identifiable primary outcome in the protocol (OR 4.7, 
95%C[ 1.1-19.3, p=0.033) (Table 56) 
• State that adverse events would be monitored in the protocol (OR 19, 95%CI 5-70, 
p<O.OO I) (Table 57) 
• Mention adverse events in the publication (OR 6, 95%CI 2-13, p=O.OOI) (Table 
58) 
The relationship between the trial characteristics described in Table 28 and 
commercial funding available at the time of submission to the REC were explored 
univariately. This suggested that double-blind, multicentre trials with a complete or 
partial sample size calculation and adequate description of sequence generation were 
more likely to be commercially funded. The variables that were significant in 
univariate analysis were included in a multivariate model (see Appendix 7.6: 
Multivariate model for commercial funding in protocol). Commercially funded trials 
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were significantly more likely to be double blind (OR 2.6, 95%CI 1.1-6.4, p=.04) and 
multi-centre national (OR 2.6, 95%CI .7-9) or international trials (OR 4, 95%CI 1.5-
II, global p=.02). 
Table 56: Commercial funding by primary outcome in protocol 
Primary outcome identifiable in protocol Total 
No Yes 
Commercial funding available No 7 31 38 
Yes 3 62 65 
Total 10 93 103 
Table 57: Commercial funding by adverse events monitored 
Adverse events to be monitored (in 
orotocoll 
No Yes Total 
Commercial funding available No 18 20 38 
Yes 3 62 65 
Total 21 82 103 
Table 58: Commercial funding by adverse events reported 
Adverse events re~orted (in 
publication 
0 1 Total 
Commercial funding available No 17 21 38 
Yes 9 56 65 
Total 26 77 103 
Table 59: Commercial funding by administration 
Administration 
Multi-centre Multi-centre 
Single centre national intemational Total 
Commercial funding No 20 6 12 38 
available Yes 13 11 41 65 
Total 33 17 53 103 
Table 60: Commercial funding by sample size calculation 
Completeness of sample size calculation 
Incomplete Partial Complete Total 
Commercial funding No 11 7 20 38 
available Yes 5 13 47 65 
Total 16 20 67 103 
.. -
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Chapter 5: Discussion and conclusions of follow-up 
study 
In Chapters 2, 3 and 4 the background, methods and results of the follow-up study 
were described. This chapter will attempt to put these results into context through a 
discussion of: 
• Summary of key findings 
• Discussion 
o Issues pertaining to the selective reporting of primary outcomes 
o Issues pertaining to sample size 
o Other issues 
• Limitations of the project 
• Implications 
• Conclusions 
Summary of key findings 
This study set out to examine issues in the selective reporting of the primary outcomes 
of randomised controlled trials through the conduct of a follow-up study of trials 
submitted to a research ethics committee. It was demonstrated that selective reporting 
exists in some form in a significant proportion of trial publications. In relation to the 
specific primary objectives of the study it was found that: 
• Most trials had at least 1 identifiable primary outcome (97 of 103). 
• Many trials declared more than one primary outcome in the protocol (59 of 103). 
• There was evidence of the selective reporting of the identity of the primary outcome 
with 15% of outcomes declared in the publication as being the primary outcome not 
being declared as such in the protocol, and almost half of these were not mentioned 
as outcomes in the protocol at all. Similarly, 17% of outcomes declared as the 
primary outcome in the protocol were not declared as being the primary outcome in 
the publication. 
• Half of the trials included in the analysis of completeness of reporting (45 of 90) 
reported more than one comparison based on a primary outcome. 
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• Most trials (68 of 90) completely reported all of their comparisons. Trials were 
more likely to completely report all of their comparisons if there was a single 
primary comparison and a completely documented sample size calculation in the 
protocoL 
• Although all of the outcomes that were reported as the primary outcomes in the 
publication were the same as all of the primary outcomes declared in the protocol 
in most trials (64 of 97), there were often discrepancies between the trial protocol 
and the trial publication in relation to the identity of the primary outcome (or 
outcomes). The identity of the primary outcomes was more likely to be the same 
in the protocol and the publication in trials with a complete sample size 
calculation in the protocol (and possibly those with commercial funding), and was 
less likely to be the same if the trial had more than one outcome. 
• The documented definitions of primary outcomes were insufficient to allow 
readers to determine if there were discrepancies between the trial protocol and the 
trial publication in relation to those definitions. 
• Trials where all comparisons were statistically significant were more likely to 
fully report all of their comparisons. 
• Trials with a completely or partially documented sample size calculation in the 
protocol consistently appeared in the multivariate regression models as being 
significantly less likely to selectively report the primary outcome. 
• Multi-centre, international trials were more likely to have a complete or partial 
sample size calculation in the protocol, and were also more likely to adequately 
report a power calculation in the publication. 
• Randomisation details (allocation concealment and sequence generation) were 
poorly documented in most trial protocols. 
• Trials with commercial funding available at the time the protocol was submitted to 
the REC were more likely to be double-blind, multi-centre national or 
international trials. 
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Discussion 
Issues pertaining to the selective reporting of primary outcomes 
As described in Chapter I, a good solution to multiple testing in most studies is to focus 
on a single primary outcome and, to ensure that the choice of outcome is not data 
derived, that outcome should be clearly specified before the trial commences. It is not 
inappropriate, however, for a trial to have more than one primary outcome (or 
comparison) but trials intending to address more than one outcome need to take the 
mUltiplicity into consideration through the use of appropriate statistical methods. The 
two main methods available are to adjust the nominal significance level or use a 
multivariate technique. It was not possible to investigate whether appropriate adjustment 
was made for multiple comparisons in the publications oftrials included in this study as 
the feasibility study indicated that this information was poorly reported in trial 
publications. 
In around 25% of protocols it was necessary to infer that the outcome was a primary 
outcome based on the sample size calculation or objectives as there was no clear 
statement of the primary outcome in the protocol. Although it may be reasonable to 
make such inferences, it is not uncommon for a trial to be powered to address an 
intermediate outcome rather than the outcome of primary clinical interest. It is therefore 
possible that at least some outcomes were misclassified as being primary outcomes. 
Pragmatic trials were more likely to clearly state the primary outcome in both the 
protocol and the publication, and it was more common to have to infer the primary 
outcomes in explanatory trials. This is not unexpected given the more investigative 
nature of the latter. Although the purpose of the trial did not appear as a significant factor 
in any of the multivariate models, it would be wise to treat primary outcome information 
inferred from the publications of explanatory trials with a degree of caution. 
While it is not possible to ascertain the motive for elevating an outcome to, or demoting 
an outcome from being the primary, in many cases it is likely to be a post hoc, data-
derived decision. There was evidence that selective reporting of the identity of the 
primary was less likely if the sample size was larger, there was a complete sample size 
calculation in the protocol and the trial had a single comparison. If these 3 factors can be 
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thought to be surrogate measure for the quality of the trial protocol, then it would suggest 
that trials with better quality protocols are less likely to be guilty ofthis form of selective 
reporting when it comes to the publication of the trial's results. 
A concept worthy of further thought is a method by which the degree of severity of 
selective reporting of outcomes could be classified, some forms of selective reporting 
potentially having greater importance and impact than others. An outcome declared as 
the primary in the protocol, which is not reported in the publication, implies a greater 
degree of selection, for example, than a change in the process for adjudicating the 
outcome. A possible framework for a severity scale is described in Table 61. This 
represents my interpretation of a possible framework and more work would be 
required to obtain a range of opinions regarding what is more and less severe selective 
reporting if this was to be developed into an assessment tool with wider applicability. 
Table 61: Classification of severity of selective reporting 
Severity of Level Details 
selective 
reporting of 
outcome 
Severe 1 • Primary outcome in protocol not reported in publication 
• Primary outcome in publication not mentioned in protocol 
2 • Primary outcome in protocol reported in publication but not as 
primary outcome 
• Primary outcome in publication mentioned in protocol but not as 
primary outcome 
• Primary outcome is a composite outcome that has been changed 
between the protocol and the publication through addition or 
removal of a component 
Moderate 3 • A change in the measurement criteria. This could include: 
0 A change in the instrument used 
0 A change in the definition of the outcome. eg a new (more 
accurate) test is introduced; eg new criteria for defining an 
event are introduced 
4 • A change in the primary time pOint (given that an outcome is 
measured over multiple time points) 
Mild 5 • Change in statistical analysis (eg analysis unadjusted versus 
ac!iusted for other variables; a change in the statistical test used) 
6 • Change in processes for adjudication (eg committee, data review, 
pathology review. etc) 
The manner in which the outcome is to be assessed should be clearly defined to ensure 
consistency across patients. The choice of outcome measure, particularly if it involves a 
specific test or other investigation, should be documented in sufficient detail for people 
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reading the protocol to be able to apply the same measure in the same way across 
individuals and sites, and would ideally be supported by evidence of the measure's 
reliability, validity, repeatability, sensitivity and specificity. All of these details should be 
recorded in the trial protocol. More than 30% of the primary outcomes included in this 
study were poorly defined in either the protocol or the publication to the extent that it 
was not possible to determine ifthe outcomes were in fact the same. 
In some cases, trial investigators may assume that it is "understood" that a standard 
definition applies to a particular term, and that explicit definition in the protocol is not 
required. An example is time to event outcomes where the point at which the time period 
of interest is judged to start and end should be clearly defined. It is often assumed that 
time starts at the date of randomisation, but this is not always a valid assumption, with 
some trials starting the clock at the time the participant commences treatment, rather than 
when randomised. In addition, if this time point ends at the date of a specific event then 
what defines an event, and on what basis do we measure whether and when an event has 
occurred? 
Alternatively, the instrument or test to be used to measure the outcome may be 
documented in detail, with a number of investigations to occur over a specified time 
period (eg specific test performed at baseline and once a month for 12 months). 
Problems arise when the way in which the data will be interpreted is not declared. In the 
example of monthly measurements for 12 months, the trial investigators could intend to 
report the results for all time points, for selected time points, for a single time point (eg 
the last time point). In addition, the change in a value between any 2 time points may be 
reported, or a pooled measure such as an area-under-the-curve may be used. This opens 
the way for trial investigators to select the time point or analysis method that places the 
results of their trial in the best light. 
There was a relationship between the number of comparisons and full reporting, with the 
proportion of trials fully reporting all of their comparisons decreasing as the number of 
comparisons increased (87% of those with a single comparison compared to 27% of 
those with 4 or more comparisons). This finding is not surprising given that trials with a 
single comparison have fewer options to choose from, and that the investigators of trials 
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with more than one comparison may place higher priority on one comparison over 
another. They mayor may not have documented this priority in the trial protocol. 
One reason for completely reporting one comparison but not another is statistical 
significance. Although the current study focused on the reporting of primary outcomes 
rather than all outcomes, it was still able to demonstrate that trials in which all of the 
comparisons were statistically significant were more likely to fully report all of those 
comparisons, confirming the results of the landmark studies completed by Chan et at 
(Chan A W & Altman 2003;Chan, Hrobjartsson A, Haahr, Gotzsche, & Altman 2004a). 
who demonstrated an association between completeness of reporting and statistical 
significance. In their study, the odds of an efficacy outcome being fully reported was 
more than doubled if that outcome was statistically significant (OR 2.4, 95%CI 1.4-
4.0). The odds of a harm (or safety) outcome being reported if it was statistically 
significant was even greater (OR 4.7, 95%CI 1.8 - 12.0). This is consistent with the 
findings of my cohort which also found that the odds of fully reporting a comparison 
were greater if the result was statistically significant (OR 2.2, 95% CI 0.9-5.3, p=0.08). 
While the current study and that performed by Chan et at are similar, there are key 
differences. The former focuses on the primary outcome and, for the analysis of 
completeness of reporting, breaks each trial down to the level of the comparison rather 
than the outcome. This was necessary in order to take into account the substantial 
number of trials with more than 2 arms, and more than I outcome. The previous study 
did not find it necessary to break the data down into comparisons, and analysed it by 
creating 2x2 tables for each trial (completeness of reporting x statistical significance), 
calculating an odds ratio for each trial, then pooling the data in a meta-analysis using a 
random effects model. Trials with empty rows or columns were not included, resulting in 
the exclusion of 49 trials from the analysis of efficacy outcomes, and 54 from the 
analysis of harm outcomes. The current study analysed the data based on the frequency 
of significant comparisons in each trial allowing me to explore the impact of changing 
the threshold for what could be considered a "positive" trial, and allowed all trials with 
eligible outcomes to be included in the analysis. 
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Issues pertaining to sample size 
A fixed sample size calculated before the trial begins enables the investigator to assess 
the feasibility of the trial and to make adjustments where appropriate. The number of 
participants required to detect a useful treatment difference may, for example, necessitate 
a multi-centre rather than single centre trial, or amendment of the eligibility criteria for 
the trial. In theory, the sample size and the components used in its calculation are 
therefore important markers of a trial's quality and its chances of successful accrual. In 
this study, trials with a completely or partially documented sample size calculation in the 
protocol consistently appeared in the multivariate regression models as being 
significantly less likely to selectively report the primary outcome when compared to 
trials with no sample size calculation documented. This variable would therefore 
appear to be a proxy measure for the quality of the trial based on the protocol. 
Other issues 
It is evident from the trials included in this study that important aspects of the design 
and conduct of clinical trials (such as the method of randomization and details of how 
blinding of the intervention will be achieved) are not always documented in clinical 
trial protocols, and it would be unwise to rely solely on these documents (as submitted 
to an ethics committee) to determine the quality and validity of a clinical trial. The 
best quality trial protocols appeared to be multi-centre, international trials with a 
commercial funding source - perhaps not surprising given the significant resources 
required to adequately support the conduct of high quality clinical trials research. 
Given the anticipated financial outlay, commercial sponsors are likely to want to 
invest in the conduct of a sound study and hence adequately resource the design and 
development phase through the employment of appropriately qualified statisticians 
and other methodologists. 
Limitations 
At the time the trials included in this follow-up study were submitted to the ethics 
committee the standards expected of trial protocols were somewhat different to those 
expected now, a decade later. While researchers were becoming more aware of the 
problem of publication bias, the movement behind the prospective registration of 
trials was in its infancy. Neither the CONSORT statement (CONSORT Group 1996) 
nor the ICH guidelines (International Conference on Harmonisation 1996) would 
emerge until 1996. The main reasons for compiling a protocol at the time that the 
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protocols included in the follow-up study were prepared were likely to have been to 
impress potential funding agencies, obtain ethics approval, to attract site investigators 
to participate in multi-centre studies, and to assist in the conduct of the study at each 
site by providing some basic rules. In the case of some of the trials included in this 
study the "protocol" was simply the grant application subsequently submitted to a 
potential funding agency such as the NHMRC. The notion that the protocol could be 
used as a mechanism for addressing publication bias and other issues in the conduct of 
clinical trials would not have been widely recognised or discussed at the time. While 
the actual protocol document is still not required today in order to register a trial in a 
prospective trials register, there are key items required that can only be obtained from 
documents. These items include the health condition being studied, the details of the 
intervention, the key inclusion and exclusion criteria, the target sample size, the 
primary outcome and secondary outcomes (World Health Organization 2006). 
Given the era in which the trials included in this cohort were designed and conducted, 
it could be said that the issues identified in this protocol are of historical interest and 
not relevant in the current context, where the guidelines provided by documents such 
as the guidelines for good clinical research practice (GCRP) produced by the 
International Conference on Harmonization, and the CONSORT statement, both 
mentioned previously. While the CONSORT statement may have impacted on the 
quality of reporting in the publication arising from a clinical trial, it is unlikely to have 
had an impact on the quality of the trial protocol, given that the issues identified by 
this cohort study were disparities between the protocol and the publication. 
In relation to GCRP it is important to note that they are guidelines and hence 
primarily voluntary unless an organization such as a regulatory agency mandates 
compliance. This has happened recently in the case of the European Directive on 
clinical trials (European Commission. 200 I). The degree to which clinical trial 
protocols comply with the various guidelines produced by ICH (including ICH E9: 
Statistical principles for clinical trials (International Conference on Harmonisation 
1998» is unknown, as is whether or not compliance with such guidelines leads to 
improvements in the quality of clinical trials research. In addition, compliance has 
generally been a requirement of the private sector, and adoption by the public sector 
has not been widespread, or even possible, given the significant resources required for 
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their implementation. Indeed, when the European Directive was introduced and made 
applicable to all clinical trials research, concern was expressed by prominent 
international researchers that it would "effectively end all clinical research except for 
those trials which are commercially-inspired, and drug-company sponsored" 
(www.saveeuropeanresearch.org; accessed 23'd March 2006). Hemminki and 
Kellokumpu-Lentinen reported in 2006 that the Directive appears to have had a 
negative impact on the amount of investigator-initiated research conducted 
(Hemminki & Kellokumpu-Lehtinen 2006). 
Any retrospective investigation of clinical trial protocols should take the changes in 
expectations over time into account. It should also be kept in mind that the best we 
can hope to achieve by looking back is an assessment of the qual ity of documentation, 
not the quality of the clinical trials the documentation is associated with. Absence of 
information on allocation concealment and sequence generation in the trial protocol, 
for example, does not signify that the method of randomisation actually implemented 
can be judged to be inadequate. As demonstrated by Soares et at for example, in a 
study that compared 56 protocols for trials conducted by a US-based collaborative 
oncology group with their resulting publications, the reporting of methods in the 
publications does not necessarily reflect the methodological quality of the associated 
protocols (Soares et al. 2004). 
Owing to the complexity of outcomes with multiple time points or mUltiple 
dimensions (global outcomes) these were excluded from the analysis of completeness 
of reporting. It is possible that these complex outcomes may be more prone to 
incomplete reporting for the very reason that they are complex, and that the size ofthe 
problem of complete reporting has been underestimated in this study. 
An important issue not addressed in this study is the impact of the lack of an analysis 
plan in clinical trial protocols (including lack of a priori declaration of sub-groups of 
interest). An original intention was to examine sub-groups, however none ofthe trials 
examined in the feasibility study had an analysis plan in the protocol and hence this 
project was subsequently abandoned. While it is expected that an analysis plan will be 
developed and documented before the analysis is conducted, the need to include an 
analysis plan in the trial protocol submitted to an ethics committee is unclear. While it 
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could be argued that including an analysis plan in the protocol would improve the 
quality of clinical trials and the quality of reporting, it is not clear whether detailed 
plans are available at the beginning of most trials. The lack of an analysis plan could 
make it easier for a statistical test to be selected based on the results obtained from 
multiple tests. Readers currently rely on the authors of manuscripts to declare the 
nature of their analysis plan (including whether subgroups investigated were declared 
a priori). Regulatory agencies such as the US Food and Drug Administration (FDA) 
may suggest that the analysis plan be included as part of the documentation of the 
quality of evidence supporting an effectiveness claim. (U.S Food and Drug 
Administration 1998) Even then, the lodgement of the analysis plan would appear to 
be a suggestion rather than a requirement. 
Implications 
There is a need for all those associated with the conduct of clinical trials, and the 
evaluation of clinical trial protocols, to pay more attention to the documentation of 
key issues in the protocol. This includes the documentation of the sample size 
calculation and the rationale for the choices made for each of the components, and the 
methods used to achieve randomization and blinding of the interventions (if used). In 
particular, there needs to be an improvement in the way in which trial investigators 
declare which outcomes are the primary outcomes, as well as how those outcomes are 
to be measured. 
Implications for research ethics committees 
Ethics committees have a unique opportunity to improve the quality of the trials they 
approve, particularly single-centre trials, before the trial starts recruiting participants. 
A relatively simple measure for them to take may be to encourage trial investigators 
to improve the way in which they calculate and document their sample size, as the 
adequacy of documentation of the sample size in this follow-up study was associated 
with an increase in the odds of selective reporting. It is possible that adequate 
documentation of the sample size calculation may simply reflect the resources that 
were available to the trial investigators at the time the trial was designed, including 
appropriate statistical support. Whatever the mechanism is behind this apparent effect 
it would seem logical that trials would benefit from the early active involvement of a 
statistician or other methodologist. 
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An important initiative implemented by the REC whose trials were included in this 
study in the late 1990's, was a "clinic" held once a week to provide statistical and 
methodological support to individuals in the institution embarking on a clinical 
research project. This service was abandoned in 2005 due to lack of funds which is 
unfortunate for many reasons, particularly the lost potential to strengthen the 
methodological quality of trials that do not have a commercial sponsor. Appropriate 
statistical and methodological support could make these smaller, single-centre studies 
less vulnerable to selective analysis and reporting. Chapter 6 and Chapter 7 will 
discuss the role and responsibility of ethics committees to ensure the conduct of high 
quality research, and possible mechanisms to ensure they are able to do so. 
A role for prospective trial registers 
There may be a role for the slowly increasing number of prospective clinical trial 
registers to act as repositories for the registration of protocols, protocol amendments, 
analysis plans and other trial-related information (such as minutes of safety and data 
monitoring committees) about individual clinical trials not required or available at the 
beginning of the trial by funding agencies or ethics committees. Despite the best of 
intentions, however, even prospective lodgement of an analysis plan would essentially 
be an honour system, as the only people who will really know if a trial was conducted 
according to protocol, or if subgroups and other aspects of the analysis were truly 
declared a priori, are the people in control of the trial's data. 
Implications for trial investigators and systematic reviewers 
The relationship between statistical significance and completeness of reporting is a 
logical one given the desire of trial investigators to place their trial in a positive light so 
that journals will publish the results, journal subscribers will read the results, and health 
care practitioners and policy makers will incorporate the results into practice. However, 
the fact that we might be getting the full picture for the "positive" news, but only an 
incomplete picture for the "negative" news, is a matter of considerable concern. 
The users of the published results of randomised trials (including systematic 
reviewers) should be acutely aware that they may only be seeing part of the story in 
the trial publication, and hence of the bias that may ensue as a result. Before relying 
on the results of one or more trials, they should be cognisant of the outcomes they 
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consider to be of primary clinical relevance, and should question the absence of those 
outcomes in the publications of trials addressing the question of interest. 
The trials included in this follow-up study were a subset of all the randomised trials 
submitted to the REC over a 5 year period. The subset was selected based on the 
ability of the trial investigators to publish the results in a peer-reviewed journal rather 
than the full cohort of commenced studies. The process of peer-review may itself lead 
to improvements in the quality of reporting in a manuscript and by the time the 
manuscript has been published major discrepancies may have been queried and dealt 
with. It is likely that the same cannot be said for conference abstracts and other 
interim or unpublished reports from randomised trials which may therefore be even 
more prone to selective reporting. 
Future research 
There are many questions unanswered by this follow-up study that would be worthy 
of further investigation. The first would be to examine the impact initiatives such as 
Good Clinical Practice (introduced in 1996) or the European Directive (introduced in 
2001) have had on the quality of randomised clinical trial protocols. (International 
Conference on Harmonisation 1998) (European Commission. 2001) Although GCP 
primarily targets commercial industry trials, it would be interesting to see if or how it 
has impacted on the design and conduct of non-commercially funded studies. As GCP 
recommends that protocols contain statistical analysis plans it would also be worth 
investigating whether it has had an influence on the reporting of this information in 
protocols considered by ethics committees since 1996. 
The aim of those involved in the conduct of systematic reviews and meta-analysis is 
to identify and include information from all of the available, high quality evidence 
(ideally randomised controlled trials). This includes information that may only be 
available in the form of conference abstracts and other grey literature. In a study of 
494 abstracts published in the proceedings of the American Society of Clinical 
Oncology, for example, it was found that key methodological information was often 
missing from trial abstracts, including information on allocation concealment, 
blinding, eligibility criteria and the description of the interventions. (Hopewell & 
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Clarke 2005) Further, a systematic review of studies that had evaluated the effect of 
the inclusion and exclusion of grey literature on the results of meta-analyses of 
randomised trials concluded that the inclusion of data from conference abstracts can 
be problematic as the relevant data may often be incomplete. (Hopewell et al. 2002) 
At the same time, others have suggested that excluding grey literature can "lead to 
exaggerated estimates of intervention effectiveness". (McAuley et al. 200 I) 
A study comparing the protocol with the conference abstracts would be a worthwhile 
undertaking. This would enable the size of the problem of selective reporting in 
conference abstracts to be quantified, particularly in relation to the selection of 
outcomes for reporting in the abstract. Such a study has not been undertaken to date, 
possibly due to problems in obtaining access to trial protocols and the challenge of 
identifying corresponding abstracts. (Chan A W et al. 2006) 
Statistical methods to aid in the assessment of and adjust for selective reporting of 
outcomes in meta-analyses need to be developed evaluated. Methods suggested as 
being useful in assessing publication bias include the graphical (such as funnel plots) 
and others such as the imputation of missing data, the trim-an-fill method, regression 
methods, etc. (Rothstein, Sutton, & Borenstein 2005;Williamson & Gamble 2005) 
It seems logical that providing methodological support to trial investigators at the time 
the trial is being designed would lead to improvements in that design. It is likely, 
though, that those who are most in need often do not have access to the resources 
necessary to pay for that expertise - specifically non-commercial, single-centre trials. 
If resources could be found there is potential to both improve the methodological 
quality of research, and to save the time and efforts of ethics committees, funding 
agencies, participants who consent to take part and others by ensuring that the 
standard of research is high. Such support comes at a financial cost and health 
authorities and others responsible for providing support to researchers may be 
unwilling to make the necessary investment. An investigation of the value of such 
support would therefore be worth pursuing. 
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Conclusion 
Selective reporting of the results of clinical trials leads to the dissemination of 
incomplete and hence misleading information to those who rely on the published 
results of clinical trials. Trial investigators have a scientific and a moral responsibility 
to ensure that a true and accurate picture of their trial is presented. Initiatives such as 
the Public Library of Science's online journal "Clinical Trials ", which promises that 
"publication decisions will not be affected by the direction of results, size or 
perceived importance of the trial", will hopefully start to overcome the difficulties 
some investigators have publishing negative or inconclusive research 
(hltp:/lclinicaltrials.plosjournals.org/index.html). Internet publishing also has the 
potential to overcome the problems caused by restrictive word limits on published 
manuscripts, with the ability to supplement publications with additional data online. 
The recent acceptance by many health sectors of the need to prospectively register 
clinical trials has been encouraging. (Berlin & Ghersi 2005) Registration early in the 
history of a clinical trial could provide those of us interested in trial quality with a 
unique opportunity to address some of the issues arising from poor documentation 
(including inadequately developed trial protocols) and thus possibly prevent (or at 
least minimise) problems caused by the selective reporting of trial outcomes and other 
trial details. 
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Chapter 6: Impact of shared scientific or ethical review 
of multi-centre clinical research on the quality and 
process of clinical research (A systematic review) 
This chapter reports all aspects of the design, conduct and reporting of a systematic 
review aiming to evaluate the impact of central scientific and/or ethical review of 
multi-centre clinical trial protocols on the clinical research process. The details will be 
presented as follows: 
• Background to the systematic review 
• Methods, including: 
o Eligibility criteria for studies, participants, interventions and outcome 
measures 
o Objectives 
o Search strategy to identify studies 
• Results 
• Discussion 
Background to systematic review 
Modem researchers accept that in order to comply with the requirements of the 
Declaration of Helsinki, which in tum informs the various guidelines for the conduct 
of ethical research in place around the world, research involving human subjects 
needs to be evaluated and approved by an appropriately constituted research ethics 
committee (REC: See Glossary on page xiv). (World Medical Association 2000) The 
most recent ratification of the Declaration of Helsinki specifically states that: 
"The design and performance of each experimental procedure involving 
human subjects should be clearly formulated in an experimental protocol. This 
protocol should be submitted for consideration, comment, guidance, and 
where appropriate, approval to a specially appointed ethical review 
committee, which must be independent of the investigator, the sponsor or any 
other kind of undue influence. This independent committee should be in 
conformity with the laws and regulations of the country in which the research 
experiment is performed. "(World Medical Association 2000) 
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As described in Chapter I, the volume of clinical trials research being conducted has 
increased considerably over the last decade. As most advances in clinical medicine are 
relatively modest, evaluating the effectiveness of new treatments usually requires 
large-scale clinical trials, ideally involving thousands of patients, often across 
multiple centres in multiple countries. To improve their efficiency, the design ofthese 
trials can be complicated and involve a baffling array of methodological and other 
scientific challenges. 
As the volume and complexity of clinical research increases it is inevitable that the 
workload of research ethics committees (RECs) will also increase. In a Review of 
Institutional Review Boards (lRBs) in the USA in 1998 it was reported that the 
volume of work of most IRBs had increased by 42% since 1974-5 when the average 
number of proposals reviewed by an IRB was 43 per annum. In 1998 some IRBs 
reviewed as many as 2000 proposals. (US Dept Health and Human Services 1998) A 
study of a single hospital-based REC in the UK reported a steady increase in 
workload over ten years from 66 protocols per year to 302 ten years later. (Cookson 
1992) 
The work of RECs is not restricted to reviewing proposals as they also monitor 
studies they have previously approved, review amendments to research protocols, 
review adverse events and perform other tasks (see Figure 6: Ethics approval process). 
Some commentators believe that RECs are in crisis and that their effectiveness is in 
jeopardy. (US Dept Health and Human Services 1998) The USA IRB Review 
concluded that the major challenges facing RECs are the changing research 
environment (the increase in the number of research proposals, multi-site research, 
commercialised research and patient consumerism) and the fact that they are 
"reviewing too much, too quickly, with too little expertise". (US Dept Health and 
Human Services 1998) 
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FIgure 6: Ethics approval proeess 
A. Pre-REC requirements (note In some countries these may occur after the REC deadline for applications) 
·MREC 
• Scientific evaluation 
• Funder evaluation 
• Clinical Trials sub-committee 
• Pharmacy sub-committee 
• Other SUb-committees 
B REC deadline for applications 
C. First meeting of REC at which application IS considered 
D. Correspondence between REC and applicant 
t: ::;ubsequent meetln gs ot f.!I::.C 
-0--- I .-.~ 
....................... 
F. Final decISion of REC 
G. Annual monitoring 
H. Study completion 
When Savulescu and colleagues posed the question "are research ethics committees 
behaving ethically?" it provoked an appropriately varied range of responses: from 
researchers who could relate to the frustrations of the authors to REC members 
overwhelmed by the expectations placed on a group who are essentially 
"conscientious, sincere and disinterested" amateurs. (Pierce 1 997;Savulescu, 
Chalmers, & Blunt 1996;Stone & Blogg 1997) Membership of ethics committees is 
expected to include members of the lay community and other non-scientists, yet these 
individuals are required to have significant scientific knowledge in order to meet their 
ethical obligations, scientific inadequacies having recognisable ethical implications. 
(NHMRC 2001)Jt could be argued, for example, that it is unethical to recruit patients 
to a study that is poorly designed and which cannot provide an unbiased answer to the 
question posed. In many cases, RECs themselves recognise that they do not have the 
expertise necessary to assess scientific and safety issues, a problem that is exacerbated 
by the expectation that RECs act independently, which has been interpreted in some 
countries as including acting independently of each other. (Commonwealth 
Department of Health and Ageing 1999) The workload burden of RECs is further 
complicated by the pressure they are under to make decisions within relatively short 
time frames, and by an increasingly litigious society, with legal and indemnity issues 
taking up growing amounts of time on REC agenda. (Hendrick 2001) 
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From the perspective of clinical researchers, a common complaint is the amount of 
time and effort it takes for multi-centre clinical research to be submitted to and 
processed by RECs. The research protocol must be approved by the ethics committee 
at every institution participating in the study. If the study is being conducted in 20 
hospitals there are usually 20 associated ethics committees, often with 20 different 
application forms, all with different requirements of the researchers. If the study 
involves more than one country then the cross-cultural issues can further complicate 
matters. As a result, there is a perception amongst clinical researchers that there is 
unnecessary duplication of effort across multiple ethics committees for the same 
multi-centre clinical trial. (Burman, Reves, Cohn, & Schooley 2001 ;Crooks, Colman, 
& Campbell I 996;Levine 2001;Wolf, Croughan, & Lo 2002) 
A number of countries have implemented centralised systems aimed at improving the 
evaluation process, primarily in terms of the time taken for trials to obtain ethics 
approval and hence commence recruitment. (Christian, Goldberg, Killen, Abrams, 
McCabe, Mauer, & Wittes 2002;UK National Health Service 1997) The systems vary 
in detail and involve centralisation of the entire ethical review process (in the UK, for 
example), or elements of the process, particularly scientific review (for example, a 
pilot project being conducted in Australia: http://www.health.nsw.gov.au/public-
health/rad!Ethics/Sharedassess/sharc index.htm!). Critics of some centralised review 
systems suggest that they increase the burden on researchers and ethics committees by 
adding another level of bureaucracy. (Alberti 2000) The reason for this is possibly 
difficulties encountered achieving a balance between aspect of research that are 
reviewed centrally, and those that are reviewed locally. In addition, models for 
reviewing the scientific aspects of a trial protocol vary across countries, with some 
requiring review and approval by a funding agency prior to ethical review (the 
assumption being that the funder has conducted a review of the science and 
considered it to be adequate), and others requiring ethical approval before the funding 
agency gives approval. An assumption in the whole process is that ethics committees 
and funding agencies have the same expectations regarding scientific quality. 
The intention of the peer review process is to confirm the scientific validity of the 
research that has been (or will be) conducted. It has also been suggested that there is 
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an ethical basis for peer review, in that "they are sustained in the course of careful 
examination, vigorous exchange of views, sound argument, and connections to the 
values of the society in which they occur". (Fletcher & Fletcher 1999) The 
effectiveness of peer review may be influenced by quality of the referees selected, the 
number selected, the instructions they are given, and whether or not they are masked 
to the identity of the manuscript authors. 
As demonstrated by 2 relevant systematic reviews, the impact of peer review on the 
quality of research or research publications is uncertain. (Demicheli & Di Pietrantonj 
2003;Jefferson et al. 2006) Both reviews attempted to identify comparative evidence 
addressing the value of peer review. Both categorised the processes of peer review as: 
i) different ways of assessing, assigning or masking submissions, ii)) different ways of 
eliciting internal or external opinions, iii) different decision-making procedures 
(group or single person) or iv) different types offeedback to authors and subsequent 
revision of submissions. 
The review by Demicheli and Di Pietrantonj set out to identify comparative studies 
investigating the effectiveness of editorial peer review (defined as "procedures aimed 
at assessing and ensuring the scientific quality of output") in improving the quality of 
grant applications (Demicheli & Di Pietrantonj 2003). No studies were found that 
compared the effects of peer review with doing nothing and hence it is not possible to 
make a judgement about the impact of peer review of grant applications on the quality 
of research. 
Jefferson et al concluded that there was insufficient evidence to be able to make a 
judgement about the value of editorial peer review in ensuring the quality of 
biomedical research publications. (Jefferson, Rudin, Brodney Folse, & Davidoff 
2006) Of the 28 studies included in this review, only 4 specifically assessed the 
effects of peer review on study validity, only one of which was a randomised trial.ln 
this study, 82 manuscripts submitted for publication were randomly allocated to either 
joint statistical-clinical review or clinical review only (Arnau et al. 2003). The authors 
of the report of this trial concluded that adding statistical review improved the quality 
of the final manuscript. 
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There is a need for more efficient and effective systems to facilitate the ethical review 
of multi-centre clinical research. It is apparent that a number of countries have 
developed and implemented their own unique systems and it is important that their 
impact be evaluated to determine whether they help or hinder the clinical research 
process. At the same time it should be possible to ascertain whether these systems 
ultimately influence the quality of approved clinical research. 
Note: a protocol for this review has been published on the Cochrane Library (Ghersi 
& Dickersin 2004) The format of this chapter follows that required of a Cochrane 
methodology review. 
Objectives of systematic review 
To evaluate the impact of central (or "shared") scientific and/or ethical review of 
multi-centre clinical trial protocols on the clinical research process. That is, does 
centralising all or part of the ethical review process improve the quality of approved 
research, minimise unnecessary delay and result in improved decision-making. 
Criteria for considering studies for this review 
Types of studies 
Prospective or retrospective comparative studies with two or more comparison groups 
were considered potentially eligible for inclusion in this review. That is, studies that 
compared a centralised ethical review process with a non-centralised process. These 
groups may be generated by random or other methods and could include historical 
comparisons. All studies must have reported original data. All potentially eligible 
studies were considered regardless of publication status. 
It was decided a priori that if no comparative studies could be identified then single-
armed studies would be described, recognising the limitations of such studies. As all 
studies ultimately identified by the search strategy can be described as either case 
studies or case series, the following definitions of these study types was applied: 
Case study: describes an experience with a single study submitted to I or more 
committees. 
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Case series: describes an experience with 2 or more studies submitted to (usually) I or 
more committees. 
The method used to select cases for inclusion in case series, when reported, has been 
documented in the Table of Included Studies using the following classification. 
• Selected case series: studies where it is clear that information on a selected or 
incomplete set of trials were reported 
• Consecutive case series: studies where it is clear that the intention was for 
information on all trials within a specified time period to be included. eg first 
100 applications in a particular year, all applications in a particular year. 
• Case series unknown: case series where it is not possible to tell how cases 
were selected 
Types of participants 
Clinical trials submitted to one or more human research ethics committees for 
approval. It was expected that studies and participants would be identified in the 
following combinations: 
• a single trial protocol considered by multiple committees 
• multiple trial protocols considered by mUltiple committees 
• all trial protocols submitted to a single committee 
• all trial protocols submitted to mUltiple committees 
Types of interventions 
• Centralized or shared review 
where the entire review process (scientific and ethical review) is shared or 
centralised 
institutional ethics committees may then be responsible for reviewing the 
study from a local perspective but should not repeat the work performed 
centrally 
this may include systems where ethical review is performed centrally and 
institutional ethics committees monitor the study locally after it has been 
approved centrally 
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• Mixed review 
where part of the review process is shared (eg scientific review) and other 
parts of the review process are decentralised (eg ethical review) 
• Decentralized review 
where the entire review process (scientific and ethical review) is 
performed by multiple institutional ethics committees. There is no sharing 
of processes. 
Types of outcome measures 
• Impact on clinical research 
o impact on study quality 
o type of problem identified (type of change requested) 
o time to first patient recruited 
o time to last patient recruited 
o rate of accrual/recruitment period 
• ethics committee decision 
o time to ethics committee decision (defined as the period between the date 
that the application was received by REC and the date of their decision) 
o time to actionable approval document 
o approved (un/conditional yes or no) 
• Impact on the ethics committee 
o time taken to review each protocol 
o resources consumed 
o average number of re-submissions per protocol 
• Acceptability of process (by investigators and researchers, by sponsors and 
funders, by ethics committees) 
There are a number of potential confounding factors that may be associated with the 
time it takes to obtain ethics approval. These include: 
• Administrative tasks unrelated to ethical review but expected of RECs. These vary 
across countries but include: 
o indemnity issues 
o regulatory issues 
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• Resource issues (eg number of staff and workload at the "secretariat" of each 
REC) 
• REC processes (even RECs within a single country function differently. For 
example, if they have an "executive" or other mechanism to expedite review, in 
the way they distribute work to REC members, how many REC members review 
each protocol, if a primary reviewer is identified, etc) 
An attempt was made to collect data on these confounding factors to aid in the 
interpretation of the results ofthe review. 
Search strategy for identification of studies 
The Cochrane Methodology Register was searched as well as the databases 
MEDLINE, PREMED LINE, EMBASE and CINAHL. The first search strategy 
defined in Table 62 was applied to MEDLINE (via Ovid) on 24th March 2003 and 
was updated on 4th March 2005. Before applying the updated search the keywords 
and MeSH headings of the previously identified eligible studies were examined and it 
was discovered that almost all eligible studies had been allocated the term 
"multicenter studies", and that attempts to narrow the search based on study design 
was of limited use. When updating the search the second strategy in Table 62 was 
therefore applied. The reference lists and bibliographies of eligible studies were also 
searched. 
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Table 62: Search strategy 
Search 1 
1 exp ethical review! or exp ethics committees! or exp ethics, institutional! or exp ethics, 
research! (12179) 
2 exp Advisory Committees! (4983) 
3 exp Professional Staff Committees! (12791) 
4 exp Peer Review! (7148) 
5 or!1-4 (27025) 
6 (ethic$ adj review).mp. [mp=title, abstract, cas registry!ec number word, mesh subject 
heading] (193) 
7 (ethic$ adj committee).mp. [mp=title, abstract, cas registry!ec number word, mesh 
subject heading] (1405) 
8 or!6-7 (1575) 
95 or 8 (27740) 
10 limit 9 to (controlled clinical trial or randomized controlled trial) (249) 
11 exp epidemiologic studies! or exp clinical trials! or exp feasibility studies! or exp 
intervention studies! or exp pilot projects! or exp sampling studies! or exp Epidemiologic 
Research Design! (1049656) 
12 evaluation.mp. (356471) 
13 audit.mp. (8925) 
1411 or 12 or 13 (1328863) 
159 and 14 (3693) 
1610 or 15 (3791) 
Search 2 
1 exp ethical review! or exp ethics committees! or exp ethics, institutional! or exp ethics, 
research! or Ethics Committees, Research! (9373) 
2 exp Advisory Committees! (3326) 
3 exp Professional Staff Committees! (9952) 
4 exp Peer Review! (7625) 
5 (ethic$ adj review).mp. (1523) 
6 (ethic$ adj committee).mp. (1341) 
7 IRB$.mp. (1908) 
8 or!1-7 (26150) 
9 exp Multicenter Studies! (8866) 
108 and 9 (224) 
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Methods of the review 
All citations were imported into a Reference Manage database. Two individuals (DG 
and a research assistant) separately examined all citations (including the abstract) 
identified by the search strategy and screened out clearly ineligible studies. Full 
papers were extracted for citations where both individuals agreed that the reference 
might relate to a potentially eligible study, as well as for those where there was 
disagreement. These full reports were read to determine the design of the reported 
study. 
The intention was to evaluate the quality of any non-randomised controlled studies we 
found using the criteria outlined in the MERGE instrument. As we were unable to 
identify any controlled studies it was not possible to use this instrument. The only 
study types identified were case studies and case series (as described above) and the 
type of each study has been documented in the Methods column of Appendix 8.1: 
Characteristics of included studies. 
Two reviewers (DG, KD) extracted outcome data for each eligible study. Data 
extracted included: 
• study design, method of allocation concealment (if applicable), inclusion and 
exclusion criteria, interventions (including the characteristics of each committee, 
if available) and recorded outcomes for each study 
• descriptive data about each study (study population, intervention, outcomes, etc) 
• information on potential confounders 
Statistical pooling of the results of studies was not appropriate or feasible given the 
nature of the studies identified. A table has been created for each outcome, 
summarising the information available for each outcome, by study (see Appendix 8.3: 
Data tables: systematic review). 
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Description of studies 
The above search strategy was applied on the 24th April 2003 resulting in the 
identification of 2,531 references. These were imported into bibliographic software 
(Reference Manager). A duplicate check performed using Reference Manager reduced 
the number of references to 1,922. The updated MEDLINE search performed on 4th 
March 2005 resulted in the identification of an additional 74 citations. After 
preliminary screening of the abstracts to identify potentially eligible studies, 1720 
references were excluded. The full paper was retrieved for the remaining 276 citations 
and each was assessed for inclusion in the review by DO. 
As already noted, no controlled studies were identified. Of the 34 studies included, 23 
were case studies and 11 were case series. An additional 23 potentially eligible studies 
were excluded for reasons outlined in Appendix 8.1: Characteristics of included 
studies. The remaining 219 short-listed studies were deemed to be ineligible mainly 
because the full article did not report original data. Studies that had the potential to 
contribute information to the review but were not strictly eligible were excluded. The 
details for these studies are described in Appendix 8.2: Characteristics of excluded 
studies (page 235). 
Studies identified in the intervention category "Centralized or shared review" were all 
case studies of a single trial submitted to a central committee and then to multiple 
local committees. The intervention for these studies is therefore referred to in this 
review as "Central then local REC/s". No studies were identified in the intervention 
category "mixed review". Decentralized review included studies describing the 
experiences of a central review committee only (referred to as "Central REC") or a 
local ethical review committee only (referred to as "Local REC/s"). The intervention 
category for each study is described in the Intervention column of the table 
"Characteristics of included studies" (See Appendix 8.2: Characteristics of excluded 
studies, page 229). 
Of the 11 case series, 7 were classified as Local RECls and 4 as Central REC (Table 
63). Of the 23 case studies, 14 were classified as Local RECls, and 9 as Central then 
Local REC/s. Note: One article «Dunn, Arscott, & Mann 2000a)) reported 2 case 
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studies: one classified as Local RECls, the second classified as Central then Local 
REC/s. 
Table 63: Type of study by intervention 
Study type Type of intervention Total 
Local REC Central then Central REC 
Local RECls 
Case study 14 9 0 23 
Case series 7 0 4 11 
Total 21 9 4 34 
The oldest study identified was a case series of 79 projects submitted to a local REC 
between 1969 and 1970. (Gray 1975) However, the majority (17) of studies in this 
review reported experiences during the 1990's. Many studies were performed in the 
UK, with others performed in other European countries including Spain and Finland. 
There were also studies involving ethics committees in the USA, Canada, Australia 
and New Zealand. 
The quality of available studies was poor. Most case studies appear to be 
opportunistic reports of experiences with a single study with no stated a priori 
objectives. Where identifiable, the objective of the reported study has been 
documented in the "Notes" column of Appendix 8.1: Characteristics of included 
studies. The quality of case series was variable. One study was conducted, for 
example, by an individual member of a REC reviewing his files and another examined 
only projects in selected specialties (Boyce 2002b;Gray 1975). Others examined all 
studies submitted over a defined period (eg (Faccini, Bennett, & Reid 1982;Keinonen 
eta!' 2001) 
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Results 
Impact on clinical research 
Although 12 studies reported the changes requested by ethics committees in order for 
the trial to obtain approval, it is not possible to determine if the requested 
modifications were reasonable or resulted in an improvement in the quality of the 
studies submitted (Appendix 8.3: Data tables: systematic review; Table 72, Table 73 
and Table 74). The nature of the changes requested include those that could be 
described as "classic" ethical issues, such as the wording of patient information 
sheets, consent forms, safety, etc. Methodological issues included the choice of 
comparator, statistical issues (including the sample size calculation), compliance 
issues, selection criteria, etc. This would suggest that RECs consider the quality of 
trials important in their decision to approve or reject an application. 
Two studies suggested that the ethical review process resulted in a delay in the time 
taken to recruit participants to their studies but evidence was not provided. 
Ethics committee decision 
Most studies (19) reported on the time taken to receive ethics approval, with a diverse 
range of reported approval times (see Appendix 8.3: Data tables: systematic review; 
Table 77, Table 78 and Table 79). Some studies reported approval times as long as 
298, 346 and 408 days although if these studies are generalisable, these would appear 
to be extreme cases. It is not possible to tease out where the time was spent or why -
the time from submission to approval usually involving activity on the part of both the 
applicant and the ethics committee. One case series involving a central REC reported 
a median time from first meeting to approval of 64 days (Boyce 2002a). The two case 
series involving more than 2 studies reported median times from submission to 
approval of 64 days (Dal Re, Espada, & Ortega 1999) and 45 days (Ortega & Dal Re 
1995b), with the former also suggesting that trials without queries take less time to 
obtain approval. 
Most studies would appear to be approved without change or be given conditional 
approval at the first meeting of the ethics committee (See Appendix 8.3: Data tables: 
systematic review; Table 80, Table 81 and Table 82). Most studies would also appear 
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to be successful in obtaining ethics approval (See Appendix 8.3: Data tables: 
systematic review; Table 83, Table 84 and Table 85). 
Impact on the ethics committee 
None of the included studies reported on the impact that sharing part or all of the 
review process between a central REC and local RECs has on the work or decisions 
made by ethics committees. 
Acceptability of process 
None of the included studies reported on the acceptability of the process by 
investigators, researchers, sponsors, funders, ethics committees or others with a vested 
interest in the outcome of ethics review. 
If resources consumed by applicants in order to make a submission are considered a 
measure of acceptability, then 14 studies provided estimates of resource usage (Table 
86). The costs incurred include preparing the documentation (photocopying, postage, 
telephone), the time used to prepare and handle requests for changes (research staff, 
secretarial support, etc), fees charged by ethics committees to consider an application, 
and the impact of having to prepare multiple copies of multiple applications for 
multiple ethics committees. 
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Discussion 
Given the importance of the ethical review process in the conduct of high quality 
clinical research, and the criticisms of this process, the poor quality of studies 
investigating their effectiveness is disappointing. Most of the information supporting 
debate is based on selected case studies of bad experiences that are unlikely to provide 
unbiased assessments of any problems that mayor may not exist. 
Performing any task adequately will take time, and one could question the 
appropriateness of "benchmarking" the time it should take for an ethics committee to 
perform the tasks with which it is charged, particularly considering the nature of those 
tasks. On the other hand, researchers are generally working within a restricted time 
frame (whether this is due to commercial pressures, the requirements of non-
commercial funding agencies, or other reasons) and often need to demonstrate 
adequate progress in order to justify the resources expended. Obtaining ethics 
approval might be a deliverable in a funding contract, for example, and it can be 
exasperating for researchers when delays are for reasons that are out of their control. 
Commercial pressures do not, however, carry much weight with ethics committees, 
with one commentator suggesting that commercial practice "is not a matter of the 
greatest importance for patients taking part in research projects". (Ross 1994) 
One apparent cause of delay would appear to be the time taken to respond to requests 
for changes. Again, it can be frustrating when requests are made to alter a trial that 
has already been reviewed by numerous committees, particularly in the case of multi-
centre research when requests for changes to details such as design features (such as 
the intervention) may not be possible or practicable. Requests for clarification or 
change may, in some instances, reflect the lack of expertise available to the committee 
at the time the study was being considered. In other instances, the requests for change 
may be reasonable, and researchers should take their share of responsibility for delays 
that occur as the result of incomplete or carelessly compiled submissions. As a result 
of his review of 353 applications to an ethics committee between 1997 and 2000, 
Boyce concluded that "More care and effort by researchers in preparing applications, 
particularly information leaflets, would shorten approval time". (Boyce 2002b) 
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One reason for lack of consistency of decision making across ethics committees may 
be the remit of local ethics committees to consider "local issues" when they consider 
studies. Although these local issues may not always be obvious to the researcher, the 
resulting variability across RECs "is not inherently inappropriate". (Silverman, Hull, 
& Sugarman 2001) It is also not particularly surprising given that each committee is 
composed of different individuals, with their own values and beliefs. Local RECs are 
autonomous bodies and are given reasonable leeway by their governing agencies to 
interpret and apply the rules and regulations that apply to them. 
One of the local issues assessed by RECs is the ability of the researcher making the 
submission to conduct the research appropriately. In some cases, rejection of the study 
may in fact be rejection of the researcher. Watling and Dewhurst cite a case where the 
reason for the rejection of a study was the lack of suitability of the local investigator. 
(Watling & Dewhurst 1995) The "committee felt unable to state this objection and 
opted instead for a less credible alternative", the reasons being to avoid the risk of 
being sued for defamation and "to avoid local controversy and confrontation". 
(Watling & Dewhurst 1995) Whether rejection of a submitted study is an appropriate 
way to handle situations such as these is debatable: researchers have the right to know 
if they have been deemed to be inappropriate as investigators by an ethics committee. 
While some complaints made by researchers may be justified, it is possible that the 
ethical review process may be the only opportunity researchers have to express their 
discontent with what is becoming an increasingly regulated and monitored research 
environment. In 1999, for example, a member of an ethics committee that had been 
subjected to criticism suggested that the complaint submitted by the researchers was 
"misdirected, mistimed and possibly harmful". (Alexander 1999;Larcombe & Mott 
1999) The proposal submitted by the researchers was perceived to have a number of 
problems, including issues around confidentiality, and was submitted at a time of 
major change in the local research ethics committee system in the UK, including the 
implementation of international standards for good clinical research practice. 
(Alexander 1999;International Conference on Harmonisation 1996) The author goes 
on to remind readers that "not all proposals are acceptable and members of ethics 
committees, especially lay members, spend much effort protecting the interests of the 
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patients for no discemable reward. Repetitious criticism will erode the willingness 
necessary to perform this necessary function". (Alexander 1999) 
It is of interest to note that some researchers may approach the ethical review process 
expecting to have problems. Druml et aI, for example, surveyed a group of physicians 
to assess the reputation and acceptance of a University-based research ethics 
committee in their region. They found that most of the respondents who had 
experience in the submission of an application gave the committee satisfactory 
ratings, while respondents without the experience of submitting and application 
tended to judge the committee negatively. (Drum I et al. 1999) 
There are many ways in which the relationship between researchers and RECs can be 
improved. It is important that the effect that the changing research environment has 
had on the process of ethics approval be recognised and openly discussed by 
researchers, ethics committees and others involved in the clinical research process. 
Appropriate investment needs to be made in the infrastructure necessary for RECs to 
function effectively and efficiently, including adequate funding of REC secretariats. 
There is also a need for researchers to be willing to contribute their scientific expertise 
to the process of ethics review. For researchers to volunteer to be part of the REC 
process they will, however, need to perceive REC membership as an activity that 
holds both appeal and reward. An improvement in the quality of submissions would 
also be useful, perhaps starting with standardisation of the various parts of the 
application process-including the forms used-and through improved education of 
both RECs and researchers. 
RECs provide a valuable yet undervalued service to both researchers and participants. 
Researchers are, after all, ultimately accountable to the people who will consent to 
participate in their research. The difficulty is how to achieve a balance between the 
core function of an REC to review ethics, and the associated paperwork and 
bureaucracy. There is clearly room for improvement and the only way to be sure that 
any mechanisms introduced with the intention of making such improvements are 
evaluated appropriately. 
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Chapter 7: Evaluation of the NSW Health Shared 
Scientific Assessment Scheme 
This chapter reports all aspects of the design, conduct and reporting of a prospective, 
single-ann, follow-up study of multi-centre clinical drug trials submitted to the NSW 
Health Shared Scientific Assessment Scheme (SSAS) between 1 st January 2003 and 
31 st December 2003. The aim was to assess the influence of SSAS on Human 
Research Ethics Committees as well as on multi-centre clinical trials. The details will 
be presented as follows: 
• Background to shared assessment 
• Methods 
• Results 
• Discussion 
Background 
In 1996 a report was published by the National Health and Medical Research Council 
(NHMRC), which presented the results of a review of the role and functioning of 
Institutional Ethics Committees. (NHMRC 2002) This comprehensive report raised a 
number of important issues, including the problems caused by the lack of clarity 
regarding the ability of one REC to accept the decisions made by another. As a result, 
it is common practice in Australia for multi-centre research applications to be 
reviewed separately by multiple institutions. This may in tum result in (whether real 
or perceived) delays in obtaining approval, inconsistencies across RECs (submission 
processes, decisions made, changes requested) and unnecessary duplication of effort. 
Traditionally, ethical review committees [also referred to as Health Research Ethics 
Committees (RECs)] have functioned in isolation from other RECs. The membership 
of an REC is expected to include representatives from the lay community and other 
non-scientists, yet these individuals are expected to acquire quite a detailed 
understanding of the methodology of clinical research in order to meet their ethical 
obligations. The 1996 review reported that: 
"In assessing a research proposal, IECs are concerned primarily with ensuring 
that the rights of the research subject take precedence over expected benefits 
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to knowledge. An understanding of the scientific and safety or privacy aspects 
of a protocol is an essential component of this review. From the submissions, 
many IECs do not believe they have the necessary expertise to assess science 
and safety issues. (NHMRC 2002) 
Further: 
"One submission noted that " ... a central review of scientific merit could 
improve efficiency, decrease approval time, and take some the burden from 
ethics committees" ... This approach could streamline the review process, 
reduce duplication of effort by IECs and allow more efficient use of the 
available expert opinion." (NHMRC 2002) 
Shared Assessment Schemes Internationally 
Recent years have seen a number of countries, including the United Kingdom (UK), 
Czechoslovakia, Germany and New Zealand, implement centralised systems aimed at 
improving the evaluation process, primarily in terms of the time taken for trials to 
obtain ethics approval and hence commence recruitment. Critics of centralised review 
systems suggest that the opposite is the case, with such systems being accused of 
increasing the burden on researchers and ethics committees by adding another level of 
bureaucracy. 
The only system to have been reported in any detail is in the UK where Multi-centre 
Research Ethics Committees (MRECs) were implemented in 1997. The goals of 
MRECs were to simplify and speed up the process of ethical review for multi-centre 
research, and to improve consistency between ethics committees. (Tully et al. 2000) 
At that time, the UK was divided into II health care regions and an MREC was 
established for each region. The principal researcher submitted the research proposal 
to their designated MREC who then considered the proposal. It was expected that 
scientific peer review would be completed prior to submission to the MREC. An 
approval letter was issued and disseminated by the principal researchers to local 
researchers who then submitted it with their application to their local research ethics 
committee (LREC). The LREC was permitted to change the consent form or patient 
information sheet but could not change the protocol. 
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In 2000, Alberti discussed some of the early anecdotal feedback on the MREC 
system, The concern expressed by researchers and ethics committees in the UK was 
that the new system, far from achieving its goals, may have added "yet another layer 
of bureaucracy, .. making the process even more labyrinthine". (Alberti 2000) A 
major problem appeared to be the LREC's perceived loss of independence, and it was 
felt that this may have primarily been due to poor communication between MRECs 
and LRECs. Mechanisms were put in place to improve this. 
Alberti's anecdotal findings were supported by a study reported at the same time by 
Tully et al who conducted a prospective study aimed at evaluating the MREC system. 
(Alberti 2000) This case study involved a single, multi-centre research proposal, 
submitted to an MREC in September 1998. After approval by the MREC, the 
proposal was submitted to 125 LRECs (50 (40%) of which had executive sub-
committees that could consider expedited review). The authors were interested in a 
number of outcomes, including the time to approval by each LREC, and the number 
of non-local changes that were requested. 
Approximately 88% of proposals were approved within 8 weeks of submission (50% 
approved within 4 weeks) if the LREC had an Executive subcommittee. Those 
without an Executive subcommittee took almost twice as long (15 weeks, 25% 
approved within 4 weeks). Non-local changes requested included changes to 
information sheets (18% of committees), changes to consent procedure (10%), 
changes to questionnaire (7%) and changes to methods of recruiting subjects (7%). 
The authors concluded that improvements in the system had occurred. Although some 
problems remained they were primarily structural and logistic and not due to 
substandard work ofLRECs. 
Shared Assessment Schemes in Australia 
In 1999 the NHMRC released its National Statement on Ethical Conduct in Research 
Involving Humans incorporating many of the recommendations made in the 
review.(NHMRC 200 I) Section 3 of the National Statement is dedicated to multi-
centre research and allows RECs to "accept a scientific/technical assessment of the 
research by another institution or organization". This clause has resulted in various 
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models for sharing scientific or ethical review. At least one state is looking at 
implementing a single, central ethical review where RECs would not be responsible 
for initial approval but would monitor trials. In Victoria, a group of hospitals involved 
in the treatment of patients with cancer are investigating shared ethical review, 
agreeing to abide by the decision made by anyone of the ethics committees in the 
group. NSW will be piloting a process for sharing review of scientific and safety 
aspects, leaving RECs with responsibility for reviewing the trial from a local ethical 
perspective. 
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About the NSW Health Shared Scientific Assessment Scheme 
In February 2003 NSW Health established the Shared Scientific Assessment Scheme, 
the intention being to provide a central committee that would review the scientific 
components of a clinical trial before submission to any of the 22 RECs affiliated with 
NSW Health. LRECs remained responsible for reviewing the ethics of the trial at a 
local level. It was hoped that the activities of the committee would not prolong the 
time taken to obtain ethics approval and might alleviate some of the workload of 
LRECs (particularly those without access to scientific expertise at a local level). 
For a clinical trial to be eligible for consideration by SSAS as part of the pilot it 
needed to be randomised and potentially involve 3 or more RECs affiliated with the 
NSW Department of Health. The trial could either be submitted by the Sponsor (see 
Glossary on page xiv for definition) before they submitted to any institutional RECs 
(RECs) or, if the Sponsor did not submit the trial to SSAS, a REC could choose to 
submit the trial to SSAS themselves. 
The Shared Scientific Assessment Committee (SSAC) met once a month to discuss 
submitted trials. Submission deadlines were published on the SSAS web site and 
circulated to all REC Executive Officers. 
Following each SSAC meeting a response was sent to the relevant Applicant 
informing them of the result of the meeting. Correspondence continued until a Final 
Report was agreed on, the intention being that this report would be submitted with the 
application to each REC. The Final Report could be sent by SSAS to the Sponsor for 
dissemination to RECs, or directly to RECs who the Sponsor had indicated would be 
participating in the trial on the SSAS Application Form. It was the Sponsor's decision 
as to who would ultimately provide the REC with the SSAS Final Report. 
The RECs were advised to consider the trial as per usual practice for that REC, 
replacing their normal scientific review process with the SSAS Final Report. 
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Complete details of the SSAS process are described in the SSAS Manual. This is 
available from the NSW Health website. (http://www.health.nsw.gov.auJpublic-
hcalth/rad/Ethics!Sharedassess/sharc index.html). 
Aim 
The aim of this study was to evaluate the NSW Health Shared Scientific Assessment 
Scheme (SSAS) by assessing its influence on Human Research Ethics Committees as 
well as on multi-centre clinical trials. It was hypothesised that Human Research Ethics 
Committees affiliated with NSW Health would find SSAS to be useful in the ethical 
review of multi-centre clinical drug trials. and that the SSAS process would not 
significantly prolong the time taken for multi-centre clinical drug trials to obtain 
ethics approval. 
Methods 
The study was a prospective, single-arm, follow-up study of multi-centre clinical drug 
trials submitted to the NSW Health Shared Scientific Assessment Scheme (SSAS) 
between 1 st January 2003 and 31 st December 2003. 
Trials were followed for at least 4 months or until a final decision was made by each 
REC, whichever occurred first. Based on the experience of Multi-centre Research 
Ethics Committees (MRECs) in the UK it was anticipated that a final decision would 
be made by each REC within 4-5 months of submission in 90% of cases (Tully, Ninis, 
Booy, & Viner 2000). 
If 25 trials were submitted to SSAS during the pilot, and the percentage of trials 
where SSAS made a difference to an outcome was 50%, this would provide 95% 
confidence intervals of ± 19 .6%. 
Ethical issues 
Ethical approval to conduct this study (known as "the Evaluation") was obtained from 
the University of Sydney Human Research Ethics Committee. Written informed 
consent was obtained from all Applicants submitting eligible trials to use their trial in 
the evaluation of the SSAS as part of the application process to the SSAS. Written 
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informed consent was also obtained from RECs who were asked to consider 
participating in the Evaluation at one of their meetings. The Chair then signed the 
consent form on behalf of the REC and sent it to the SSAS Secretariat, along with a 
completed Baseline Information form. 
Data Collection 
When the Final Report was returned to the Applicant it was accompanied by one 
SSAS Evaluation Form (EF) for each REC listed by the Applicant in the SSAS 
Application Form. The Applicant was asked to include an EF with each application 
made to each REC, and to keep a log of forms to enable them to be tracked. 
RECs were asked to treat trials that had been through SSAS as normal, replacing their 
usual scientific review process with SSAS and the Final Report. After making a 
decision regarding the trial at their meeting, RECs were asked to allocate a maximum 
of 10 minutes in total to discuss the following 3 questions: 
• In the general opinion of the REC, did the SSAS Final Report reduce the 
overall time taken to consider the trial at the meeting? 
• In the general opinion of the REC, did the SSAS Final Report improve the 
committee's confidence in their decision? 
• Was the information provided by the SSAS Final Report useful? 
Following this discussion, the EF was then completed by the Executive Officer or 
Chair on behalf of the REC. They were asked to ensure that the opinions expressed 
were those of the committee as a whole and not of the individualls completing the 
form. Completed forms were sent to the SSAS Secretariat who then masked the 
identity of the individual trials, Applicants and RECs and forwarded the forms to the 
Evaluator (DG). 
Please note that all contact with ethics committees and trial sponsors was performed 
by staff at NSW Health. The author was blinded to the identity of both the ethics 
committee and the trial sponsors and was unable to contact individuals directly. 
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Results part 1: About the RECs 
There are 22 RECs affiliated with NSW Health eligible to participate in the pilot. All 
but one indicated their agreement to participate in the SSAS Evaluation in writing, 
and provided baseline information on committee membership, the relevant standard 
practices oftheir committee and their workload experience during the year 2002. 
Each REC reviewed an average of 132 research proposals in 2002 (range 5 - 446; see 
Table 64) Fifteen RECs were able to provide information on the approximate 
proportion of research projects that were multi-centre drug trials. On average 35% of 
research projects reviewed by RECs are clinical drug trials, and about half of these 
(45%) are multi-centre. (See Figure 7). 
The average number of members on a REC is 15. Most committees (13) committees 
meet once each month, 5 meet every second month, 2 every 6 weeks and I REC 
meets once every 3 months. 
Table 64: About RECs in NSW 
Item Totel aero .. Average Range 
RECs 
Number of members 261 15 members 9 - 27 members 
Average length of meetings nfa 3 1.5 - 5.5 hours 
Number of research projects reviewed in 2766 132 15 - 446 projects 
2002 
- Clinical drug trials 695 35 0-140 
- Multi-centre clinical drug trials ,,~., 313 16.5 0-55 
Average time REC Secretariats spend nfa 3.35 1 - 8 hours 
preparing each multi·centre drug trial for an 
REC meeting Note 3 
Average time REC members spend n/a 5.4 2 -10 hours 
preparing for meetings Note 3 
Note I: 3 RECs did not review any clinical drug trials. The average for this and the foHowing questIOn 
is therefore calculated based on 18 RECs. 
Note 2: One REC with a larger workload (>300 projects) answered this question as "lots" so unable to 
include this data. The estimated proportion of trials that are multi-centre is therefore likely to be an 
underestimate 
Note 3: 2 RECs did not answer these questions 
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Figure 7: Proportion of trials that are multi-centre and/or drug trials 
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Note: Two commiuees are closely affiliated and filled out one baseline fo rm between them. 
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Access to specialist expertise 
Fourteen RECs indicated that they either have a specialist committee, use external 
experts, or both. Seven of the 21 RECs stated that they had access to a committee 
formed to give them specialist advice on the scientific / technical aspects of clinical 
drug trials. The scientific committees meet with the same regularity as the REC with 
which they are associated (ie if the REC meets once each month, so does the scientific 
committee). Ten RECs use external experts (some RECs with scientific committees 
also use external experts). 
Thirteen RECs indicated that they assign members to look at applications in more 
detail. Individuals are usually assigned according to their content expertise and/or to 
ensure that a minimum number of members have looked at a submission in detail. 
Table 65: About scientific advice obtained by RECs in NSW 
Item Total across RECs Average Range 
How many people 80 11 4-19 
are on the scientific 
committee (7 
responses)· 
Average length of nla 2.2 hours 1 - 3 hours 
scientific committee 
meetings (7 
responses) 
How many hours of 449 50 1 - 100 hours 
external expertise 
would you access 
each year (8 
responses) Note 1 
Note 1: 2 of the 10 RECs using outside experts did not indicate the number of hours accessed each year 
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Estimated resources 
The average REC expended a total of 953 person-hours per year preparing for 
meetings, plus 485 hours per year attending REC meetings. This is the full-time-
equivalent of just over 4 days a week per committee which, when extrapolated to all 
22 RECs, is comparable to a full-time state-wide committee composed of at least 16 
people. Added to this is an estimated 2,315 person-hours spent on specialist review in 
NS W, equivalent to at least 1.4 people dedicated full time to this task state-wide. 
Table 66: Person-hours spent on REC or scientific review 
Item 
Estimated person-hours per year spent 
attending REC meetings (21 responses) 
(number of REC members in NSW x 
length of meetings x number of meetings 
each year) 
Estimated person-hours per year 
preparing for meetings (19 responses) 
(number of REC members in NSW x 
average time REC members spend 
preparing x number of meetings each 
year) 
Estimated person-hours per year for 
scientific review meetings 
(number of members of scientific 
committees in NSW x length of meetings 
x number of meetings each year) 
Estimated person-hours per year for 
external scientific review 
(as estimated by REC) 
Estimated person-hours per year spent 
by REC secretariats preparing multi-
centre drug trials for REC meetings 
(number of multi-centre drug trials x time 
REC secretariat spends preparing each) 
Total across 
RECs 
10,181 
FTE6.06 
18,098 
FTE 10.77 
1,866 
FTE 1.11 
449 
FTE 0.27 
1,055 
FTE 0.63 
Average Range 
485 54 -1,254 
953 243 - 3,240 
133 0-540 
50 1-100 
59 0-184 
Assumption: FTE are calculated assuming a 35 hour week, 48 weeks per year (ie 4 weeks annual leave) 
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Results Part 2: About the Submitted Trials 
The first meeting of SSAC was held on loth February 2003. As of 26th February 2004, 
27 projects had been submitted to SSAS, of which 22 have been approved and hence 
have a final report available. One project has been rejected, one has been withdrawn 
and 3 have yet to be approved. 
SSAS takes an average of 9 days to respond to an Applicant following a SSAC 
meeting, and Applicants take an average of 24 days to respond for the first time to 
specific queries. (See Figure 8 and Table 67). The application is the responsibility of 
the applicant for an average of 33 days (range 3 to 125 days; median 3 1 days), and the 
responsibility ofSSAS for an average of44 days (range 24-81 days; median 41 days). 
The average time from submission to the first response to the applicant by SSAS is 25 
days (range 17 to 53 days, median 25 days). 
As outlined on page 5, Sponsors were asked to keep a log of RECs and document the 
date they received an actionable approval document. Unfortunately only one of these 
log fOllllS was returned to the SSAS Secretariat and it is not possible to report on the 
time taken to obtain an actionable approval document. 
Figure 8: Time from submission to SSAS to Final Report 
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Table 67: Time taken for eacb step oftbe SSAS process 
Time interval 
Time to 1st SSAC meeting 
Time to I st response from SSAC 
Time to I st response from applicant 
Time to 2nd response from SSAC 
Time to 2nd response from applicant 
Time to final report 
Overall time from submission to SSAS to Final 
report 
Average number 
of days (median) 
17 (\ 7) 
9 (8) 
24 (\3) 
II (12) 
19 (15) 
IS (13) 
75 (71) 
Range 
17 -18 
2-36 
2- \07 
1-21 
1- 63 
4-32 
25 -175 
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Results Part 3: the evaluation 
Trial by REC Data Available for Evaluation 
Completed Evaluation Forms (See Appendix 9: SSAS invitations and data collection 
forms and Figure 9) are available for the 13 trials submitted to SSAS between 
February and August 2004. The Applicants of all 13 trials agreed to the inclusion of 
their trial in the SSAS Evaluation. 
Figure 9: Dow chart of studies suhmHted to SSAS 
27 projects submitted (February 2003 to February 2004) 
- 1 rejected 
- 1 withdrawn 
- 3 yet to be approved 
22 projects approved 
, 
- 9 approved after August 2004 
13 projects approved by August 2004 
- 58 instances of submission to research ethics 
committees (completed evaluation forms 
ava ilable for 24) 
In the application to SSAS, Sponsors are asked to list those RECs to which they 
intend to submit the trial. Based on information included in SSAS application forms 
there were potentially 70 instances when the 13 trials should have been submitted to 
eligible RECs. It is known that in 12 ofthese instances the trial was not submitted to 
the nominated REC, and that completed evaluation forms are available for 24 of the 
58 instances when the trial was submitted to the nominated REC; a response rate of 
47%. It is not known if the reason for this is that Sponsors did not make the Final 
Report available to RECs, or if RECs did not complete the EF for trials considered by 
their committee. Staff at NSW Health continued to encourage Sponsors and Ethics 
Committees throughout the duration of the pilot. Meetings were held with members of 
ethics committees and representatives of trial sponsors to further educate individuals 
on the reason for the pilot and the need for evaluation. NSW Health staff also 
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followed up individuals with at least I telephone call in an attempt to obtain 
completed forms. 
Six RECs reviewed 3 or more of the SSAS evaluated trials, and 4 trials were 
submitted to 3 or more RECs. Unfortunately, 9 completed EFs were for trials where 
the REC indicated that the Final Report had been submitted to SSAS after the trial had 
been considered by the REC. These will be referred to as "late" EFs and the 
remainder will be referred to as "on-time". In the case of three of the late EFs the 
RECs considered the SSAS report after the meeting and suggested additional changes, 
if necessary, in their second response to the applicant. 
On 8 occasions the date of the Final Report was after the date of the REC meeting. 
Six of these were "late" EFs as stated above, and the remaining 2 appeared to defer 
their decision until the Final Report became available. There were 16 on-time 
evaluation forms for II trials submitted to 6 RECs. 
SSAS Evaluation Form for RECs 
The main results are based on data provided by the 16 on-time EFs plus the 2 EFs 
relating to trials where the decision of the REC was deferred until the Final Report 
became available. Results are reported for the 9 late EFs if relevant and available. 
Each question on the form will be addressed in order, with a summary of responses 
from each REC. Some of the comments made on the evaluation forms by RECs are 
included for additional information. These were selected based on their relevance to 
the question being addressed. 
In the general opinion of the REC, did the SSAS Final Report reduce the overall 
time taken to consider the trial at the meeting? 
Seventeen EFs indicated that the Final Report reduced the overall time taken to 
consider the trial at the REC meeting. One REC was uncertain of the Final Report's 
influence on the time taken to consider the particular trial at the meeting, but the 
points raised by SSAS were discussed by that REC in some detail, specifically in the 
context of the study being carried out at that REC's institution. 
143 
"The SSAS Final report assessed the scientific merit of the study and hence 
did not require review by our Clinical Trials Sub-Committee. The project went 
directly to our Ethics Committee for ethical review" 
"It reduced the time undertaken by the REC considering scientific issues and 
raised important areas for the REC to discuss" 
"A study such as this would normally be reviewed by 2 people and discussed 
at the scientific sub-committee meeting. Approximate time saved = 8 hours. " 
In the general opinion of the REC, did the SSAS Final Report improve the 
committee's confidence in their decision? 
All 18 EFs indicated that the SSAS Final Report improved the RECs confidence in 
their decision. In addition, in 4 of the 9 occasions when the Final Report was late, the 
RECs involved reported that it improved the committee's confidence in their decision. 
" ... the report confirmed that the RECs decision was the correct one ... " 
Was the information provided by the SSAS Final Report useful? 
17 EFs indicated that RECs found the report to be either "very useful" (13) or 
"reasonably useful" (4) (this question was not answered on the remaining form). Four 
of the late evaluations also found the Final Report to be either very or reasonably 
useful. 
"Information very usefol in clarifYing some issues raised by REC" 
"It would have been very usefol if it had been received prior to the review" 
Decision made at the REC meeting 
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Three applications were approved unchanged, 14 were approved with changes and 
one was 'decision pending'. Eight of the nine late EFs related to trials approved with 
changes and one decision pending. 
The changes requested by RECs, other than those relating to ethics, could be 
categorised as issues relating to: 
• Changes to Patient Infonnation Sheet and/or Consent F onn 
• Insurance and Indemnity 
• Restrictions placed by Sponsors on publication I presentation I data ownership 
• Clarification regarding trial and local context (eg drug storage, availability of 
specific tests within health service, etc) 
• Funding and financial issues (eg who pays for the intervention) 
• Trial management (access to data, data collection fonns, clarification of the 
existence of a Data and Safety Monitoring Board 
and 
• Science 
When the SSAS Final Report was available (and the Sponsor had not made changes 
requested by SSAS) it was not uncommon for RECs to explicitly ask for SSAS 
recommendations to be incorporated. 
Other issues that may have caused a delay in the review of the trial by the REC 
The issues causing delay were similar to the changes requested following the first 
REC meeting. The most common issues reported that may have caused delay in 
review were legal issues and incomplete applications (eg missing clinical trial 
agreements, copies of data collection forms, etc). 
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SSAS Evaluation Form for Applicants 
All applicants were asked to complete an evaluation form for each trial submitted to 
SSAS. Unfortunately only 3 applicants completed this form. It is not clear why 
Applicants did not complete and return this form. 
Applicants were asked to rate, on a scale from 1 (very satisfied) to 10 (very 
dissatisfied), their experience with SSAS regarding their trial. The three applicants 
were very satisfied with their experience with an average score of 3 (range 2-4). 
Aspects of SSAS the applicants are happy with were: 
"Compared to other states the SSAS Report appears to speed ethical approval 
of the trial up, as the 3 NSW sites were amongst the first sites to receive 
approval - so seems to assist! All interactions with SSAS were pleasant and 
professional. Glad to only have to answer the scientific questions once for 3 
sites rather than 3 times over" 
"Easy, straightforward application form. Good idea to have a central 
committee that will have the expertise not necessarily available at all RECs. 
Sponsor being able to apply and have direct contact is beneficial. " 
"The scientific review was sound. The time scale and communication was 
good. " 
Aspects of SSAS the applicants are not happy with include: 
"Required follow up by CRA to obtain questions posed by the committee and 
the Final Report quickly" 
"Increased length of time for submission, all RECs needing SSAC approval 
are initially held up. " 
"It's a whole other form to complete and copies to make. Still have to do the 
full ethics application. " 
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Other issues that may have caused a delay in the review of the trial by RECs include: 
"Because REC meetings are not aligned to the SSAC meetings this process 
can take a lot longer. Would be better if the SSAC meeting output could feed 
into a round of REC meetings at all the NSW RECs" 
"Additional process required by University ethics committee costing 6-8 
weeks" 
147 
Results Part 4: End of study 
In January 2004 End of Study forms were sent to the participating RECs and members 
of the SSAS Committee with a request to return them to the Secretariat by 27th 
February 2004 (see End of Study Forms on pages 255, 257 and 259). All 2 I of the 
participating RECs, and 7 of the 8 SSAS Committee members completed End of 
Study forms. Please note: one institution has 2 RECs and each REC is considered as a 
separate entity although baseline details were reported on one form. 
Medicines Australia is the national association representing the prescription medicines 
industry in Australia. They were asked to by the SSAS Secretariat to distribute the 
End of Study forms to all their members. RECs were also asked to distribute the End 
of Study forms to their researchers. This resulted in the completion of 21 End of Study 
forms, and 17 of these were completed by Sponsors who had submitted trials to the 
SSAS Committee as part of the Pilot. 
Participation in Pilot 
Of the 21 RECs that completed end of study forms, 16 indicated that they had 
reviewed a trial that had been submitted to SSAS. The 5 that had not reviewed any 
SSAS reviewed trials all indicated that no trials that were eligible for SSAS had been 
submitted to their committee. Three RECs insisted that Sponsors use SSAS, 6 
suggested it and 1 did not answer the question. The remaining 6 RECs indicated that 
they had either been provided with the Final Report by the Sponsor as part of the 
application (2), or dealt with each trial on a case-by-case basis. One REC mentioned 
the difficulty they had determining the eligibility of a trial for SSAS, particularly 
regarding the criterion that trials needed to involve 3 or more sites in NSW. Some 
RECs also mentioned the difficulty they had determining if a trial that had been 
submitted to them had also been submitted to SSAS. 
17 of the 21 Sponsors that completed end-of-study forms indicated that they had 
submitted a trial for consideration by SSAS as part of the pilot. One Sponsor did not 
answer the question and the remaining 3 did not submit a trial for the following 
reasons: 
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"Company had no relevant studies at the time of the evaluation scheme, 
however, I would be concerned about adding to the evaluation time for EC 
review- even though I understand the aim of SSAS is not to do this. Discussion 
with larger hospitals with "established" ECs indicate that there is likely to be 
a strong preference for "in-house" review due to potential medico-legal issues 
with running studies at the sites. " 
"No perceived advantage to direct application to RECs" 
"The only information I received was at the NHMRC Conference in 2002 and 
so was not familiar with the submission process. Also, there was some concern 
that this was an "extra step" in the EC approval process, adding additional 
weeks to the approval process" 
Eight Sponsors submitted trials to SSAS because at least one REC insisted they use it 
(plus one Sponsor who indicated that "a couple of REC preferred that we used the 
SSAS prior to submission to the REC'), and 8 chose to use SSAS without prompting 
by an REC (one of which indicated that they thought it was compulsory). 
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Resources and Support 
Satisfaction with advice and support by NSW Health 
RECs, Sponsors and SSAC members were all asked to rate their satisfaction with the 
advice and support provided by NSW Health regarding the SSAS on a Likert scale 
marked from I (very dissatisfied) to 10 (very satisfied). The level of satisfaction was 
generally high with an average rating of 7 for Sponsors (range 3 to 10), 8 for RECs 
(range 3 to 10) and 9 for REC members (range 7 to 10). 
Two RECs reported low levels of satisfaction «4). One was concerned with the speed 
of the SSAS response and the other received the Final Report after the project had 
been considered by SSAS, pointing out the problem RECs have determining if a 
project had been submitted to SSAS. 
Two Sponsors also reported low levels of satisfaction «4). One had been informed of 
SSAS by an REC and felt that "information regarding this pilot scheme could have 
been distributed in better/more timely manner". The other Sponsor was concerned 
about the expertise of the individuals on SSAS: 
"For studies in highly specialised areas, where the SSAC clearly has limited 
expertise, external experts should be chosen to ensure that the opinion of the body 
which the expert represents is reflected. This may require opinions from more than 
one external expert; The selection of external expert(s) should be more transparent 
and should have input from the sponsor of the study; There should be a clear appeals 
process. This should be communicated to the sponsor when the decision isforwarded; 
The sponsor should have access to the minutes of the SSAC meeting relevant to the 
application; Applications should be considered in a more expedient manner. " 
Suggested improvements to support structure 
RECs appeared to be frustrated when the SSAS Final Report was made available to 
them after the trial had been considered by the REC. The other issue identified was 
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the lack of information available to RECs on the progress of trials through the SSAS, 
particularly reasons for delay. 
"need more communication between SSAS coordinator and peripheral REC 
sites and investigators. ie when approvals are delayed" 
"companies planning multi-centre studies should submit the protocol to SSAS 
before it is sent to any RECs" 
"SSAS report received after project was considered by REC; REC not always 
aware if project submitted to SSAS" 
There was one response from a non-participating REC: 
"most ... multi-centre trials we review are across the states - would be useful 
to have shared assessment arrangement with the other states (/ know - a big 
ask) " 
The suggested improvements to the support structure made by Sponsors were more 
varied. Most (but not all) indicated that they had submitted at least one trial to the 
scheme. Two respondents did not think the scheme had improved the process. Two 
indicated that they were only made aware of the scheme by an REC and a third 
suggested that RECs should "advise at the time of submission of a protocol of the 
existence of the SSAS". One Sponsor felt that they questions they had been asked were 
ambiguous (it is unclear whether these questions related to the Application Form or to 
correspondence relating to the Final Report), one had difficulty finding the web site, 
and two Sponsors would have liked to have received more prompt assistance from the 
Secretariat. 
The SSAC members did not suggest any changes to the support structure. 
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Information provision 
Most RECs (16) indicated that they felt adequately informed of the SSAS and its 
processes (4 did not answer the question). One did not feel adequately informed, 
feeling unclear about the time frame of the process. One of the adequately informed 
respondents indicated that they were "not aware of individuals on the committee or 
their expertise" (although this information is on the SSAS web site). 
13 RECs found the manual useful and 9 found the web site useful. The remainder 
either did not find these resources useful or did not answer the question. 14 Sponsors 
felt adequately informed about the SSAS and its processes (2 did not answer the 
question). The 5 who did not made the following comments: 
"inconsistent advice" 
"It was through one particular REC that I found out about SSAS and I 
therefore did my own search on internet to obtain additional iriformation " 
" ... the only information I received was at the NHMRC coriference. It was also 
difficult to see the benefits of the scheme except for reducing the burden on 
smaller ECs" 
"Appeals process was inadequately explained. It appeared to be non-
existent. " 
"It was only through an REC that I was notified of this scheme. I feel that 
information regarding this pilot scheme could have been distributed in 
better/more timely manner" 
Time spent by SSAC members preparing for meetings 
SSAC members were asked to indicate how much time, an average, they spent 
preparing for each SSAC meeting. The average time spent preparing was 5 hours 
(range 2-12 hours; median 4 hours). All 7 members providing feedback indicated that 
they felt the meetings were held at an acceptable time. 
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The Final Report 
RECs, Sponsors and SSAC members were all asked to consider their experience with 
SSAS during the Pilot and indicate whether there was anything about the Final Report 
they would like to see changed. The majority did not think any changes were 
necessary and only 7 suggested changes (see Table 68). One REC suggesting no 
change be made to the Final Report made the following comment: 
"The committee found that the report helped them to quickly expedite the 
application and prevented them from becoming entrenched in having to seek 
technical advice about highly complex scientific issues, the committee were 
therefore more able to quickly assess the application on the ethical issues, in 
the light of the technical advice from the SSAS. " 
Table 68: Suggestions for the final report 
Missing No Yes If yes, changes suggested 
REC 5 12 4 Conclusion/summary placed at front of report, 
recommendations at the beginning 
A list of members could be useful with their area of 
expertise. Names of reviewers and their comments 
could be useful. 
Sponsor 7 11 3 Come earlier 
A more detailed explanation for the decision taken 
by the SSAC needs to be provided. This should 
discuss all data taken into consideration in reaching 
the decision. 
In our experience, clinical advice that is not yet 
accepted clinical practice anywhere should not be 
binding 
SSAC 1 6 0 No changes suggested 
Total 13 29 7 
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Continuation of the SSAS Scheme 
Applicants, RECs and SSAS were all asked the same questions regarding continuation 
of the scheme. 
Do you think the scheme should continue? 
and 
If the scheme continues, are there any changes to the process that should be made? 
The majority of responding RECs (16 of21) and SSAC (6 of 7) members thought the 
scheme should continue, the remainder being undecided (see Table 69). The majority 
of responding Sponsors (9) also thought the scheme should continue or were 
undecided - only 4 thought the scheme should cease. The reasons given for this 
included a preference for centralisation of the entire ethical review process and a 
concern that centralised scientific review leads to longer approval times: 
"Only worthwhile if all EC buy in to the output of SSAC. Otherwise it's just 
adding another step and slowing whole process down. " 
.. Very easy to use, and if all NSW RECs would accept it, this would give a 
consistent review across the state as well as potentially speeding the process 
up, if RECs will accept the scientific evaluation and only focus on other issues 
such as patient informed consent etc" 
If the scheme continues, whatform should it take? 
and 
If you feel the scheme should continue in an expanded form, in what way do you 
think it should expand? 
Respondents were divided as to the form SSAS should take if it continues in an 
expanded form with 16 respondents suggesting that it should continue in its current 
form, 17 in an expanded form and II suggesting another form (see Table 70). 
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There responses were not consistent in identifYing any single, preferred way in which 
the scheme should expand (see Table 71). Some respondents suggested that the 
committee's role should expand beyond scientific review to provide expert opinion on 
an ad-hoc basis to RECs, or to full ethical review for multi-centre trials. 
Sponsors made the following suggestions: 
"Would need to continue in aform that was accepted and supported by sites 
should make sure that RECs are aware of the scheme and will use it" 
"After learning more about the scheme and now that more RECs are aware if 
the scheme also, it will help in improving timelines" 
"Replace site by site ethics approvals. Be a true multi-centre ethics review 
committee" 
"Submission to SSAS should be optional" 
Suggestions made by SSAC members included: 
"I would consider requiring all drug trials with 3 or more centres to go to the 
SSAC. The exact threshold (3, 4 or 5 centres) should be set to ensure that the 
SSAC considers no more than 4 new trials per meeting" 
"To have an impact this (all multicentre research) should be the ultimate goal. 
However, I'm not convinced that our experience so far tells us that this is 
possible" 
"Probably need 2+ sites for review of protocol; interstate cooperation" 
"It would be beneficial if the committee could look at some of the smaller 
studies being conducted" 
155 
"Provide expert opinion to those RECs who require a second opinion for a 
single site trial. Some RECs do not have the expertise available to them. " 
Suggestions made by RECs included: 
"Consulting role for "difficult" single-centre studies 
"Matters of risk management, hospital drug budgets and embedded research 
costs are a quasi jUnction and no alternative system exists to monitor such 
issues" 
"Accept referrals when institution feels it des not have expertise to assess a 
particular multicentre trial" 
"Possible use as a quality control function for scientific subcommittee; as a 
reference panel for RECs with difficult cases to refer for assistance" 
Table 69: Do you think the scheme should continue? 
Yes No Undecided MissinQ 
REC 16 0 4 1 
~onsor 9 4 7 1 
SSAC 6 0 1 0 
lota~ 31 4 12 2 
._-
Table 70: H the scheme continnes, what form should it take? 
Current form Expanded form Other 
Note 1 
REC 6 7 5 
~onsor 8 6 5 
SSAC 2 4 1 
Total 16 17 11 
Note I: Some of the respondents ticking "other" ticked all boxes. 
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Table 71: Bow should the scheme expaod? 
All multi- All multi- All multi-centre Expand to all Other 
centre drug centre research options 
trials clinical (including 
research epidemioloQicall 
REC 1 1 2 6 3 
Note 1 
Sponsor 3 0 1 0 5 
Note' 
SSAC 0 0 1 1 4 
Note 3 
Total 4 1 4 7 12 
Note I: 2 suggested all multi-centre drug and device trials; I suggested all multi-centre drug trials plus 
referrals when REC does not have expertise required to assess. 
Note 2: 3 Sponsors suggested centralised ethical review; I suggested the fonn taken should be 
acceptable to sites; and I suggested that SSAS should be optional 
Note 3: I SSAC member suggested multi-centre drug trials with 3 or more centres; I suggested 
looking at smaller studies; I suggested all multi-centre drug trials and research as well as providing 
expert opinion for single-site trials when required by RECs without access to necessary expertise. 
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Other issues raised 
Other issues raised by Sponsors included: 
"There is no point in having the system if it just makes doing research in NSW 
harder / less competitive however / do think a centralised review is a good 
idea but not at a cost of delaying study start up" 
"The Secretariat was fantastic to work with, very approachable and 
contactable, very helpful with completing the forms and discussing the 
processes, etc. / realise that it is difficult to ask RECs to alter their practises, 
however it would be so useful to have a tick-box on all REC application forms 
to state whether the study has already gone to the SSAC and if so, please 
attach final report. We sent the report to all sites but found that not all RECs 
received it (where applicable) so it seemed wasted. Perhaps this is a 
sponsor/investigator education issue though. " 
"Patient information sheet - either SSAS rules or should not be involved" 
"The SSAS should not necessarily consider all multi-centre trials, as only 1 
NSW site may be involved and the usefolness of the SSAC reviewing the trial 
may not be appropriate as it will tie up resources with little contribution" 
"/ found the criticisms raised in certain issues to be very doubtful but the 
concept is very good" 
"On attempting to resolve a number of issues raised by the SSAC, the 
Secretary and Chairman were inadequately informed about the appeals 
process; Request to provide details of the external expert (qualification, 
background, etc) was declined. Need more transparency an option for face-to-
face meetings between the sponsor and the Chairman. " 
"Trial submitted by Sponsor- greatly improved approval process" 
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The issues raised by SSAC include: 
"Process is still duplicated by the individual ethics committees" 
"We run the risk of another bureaucracy unless we can get "buy in" from 
Ethics Committees" 
"The REC need better access to our comments etc" 
"lfthe role expands, the membership should expand" 
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Additional questions asked of Applicants 
Is the application process easy to understand? 
Seventeen applicants indicated that the application process was easy to understand, 
although one indicated that the appeals process was not. One applicant felt that it is 
not clear when SSAS should, or should not, be used. 
Does the application process involve an acceptable amount of work? 
Fifteen applicants indicated that the process involved an acceptable amount of work, 
and 3 felt it was extra work or duplication. There were 2 missing responses to this 
question. 
"Very easy and user friendly application form" 
"Easier than a regular REC" 
Was the SSAS consistent in the feedback it provided 
Eight applicants felt that the feedback provided by SSAS was consistent. The 
remaining applicants either did not answer this question or only saw I SSAS-
reviewed trial and felt unable to comment on consistency. One applicant was 
concerned about the merit of some of the criticisms. 
Additional questions asked of RECs 
Would you be prepared to replace your current system of scientific assessment 
with the SSAS evaluation? 
Eleven RECs indicated that they would be prepared to replace their current method of 
scientific assessment with the SSAS evaluation. Five were uncertain and 4 would not 
replace their current method. There was one missing response to this question. 
The reasons given by most of the committees for their willingness to replace their 
current scientific assessment with SSAS were: 
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• The SSAS process was more rigorous and thorough than most RECs were able 
to perform themselves 
• Lack of access to the necessary expertise locally 
• Confidence in the SSAC members, and 
• Increased efficiency and reduced duplication across RECs 
For example: 
"Multi-centre clinical drug trials are increasingly complex and advice from SSAS 
on the scientific aspects are invaluable, especially to a committee which due to its 
rural location would not necessarily have easy access to such invaluable advice. 
We would for the reasons stated welcome continuance of such a valuable source 
of technical information and advice. " 
Although 9 RECs were uncertain or unwilling to replace their current scientific 
assessment with SSAS, 3 RECs indicated that this was due to the lack of opportunity 
to test the scheme (lack of trials that meet the eligibility criteria), and another was 
unsure what replacing their current assessment would mean. Two RECs were satisfied 
with their current in-house assessment, and one indicated that the "process could well 
be adopted if processing time was faster." One committee made the following 
comment: 
"REC review forms are one aspect of risk management of research - science 
review is a necessary aspect of this process. (REC) Scientific review is a key 
mode of learning for clinical researchers. To devolve, even if in part, this 
responsibility would equal a loss of research skill. The system of research 
governance is already deregulated. " 
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Additional questions asked of SSAC 
If SSAS continues, are there any changes to the process that should be made? 
SSAC members made the following suggestions for changes to the SSAS process: 
"It would be great to have 2 expert reviewers. Also we need a neurologist on 
the committee. " 
"Most of the issues raised by the SSAC not adequately addressed by 
companies / sponsors but accepted by SSAC" 
"The process continues to be too slow to provide timely feedback to the 
RECs" 
"It is essential that Ethics Committees have the information from the SSAS 
before they hand out their schedules for their meetings" 
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SSAS Evaluation Discussion 
Before commencing this evaluation of SSAS it was hypothesised that RECs would 
find it useful in the ethical review of multi-centre clinical drug trials. Based on the 
experience of most of the 21 participating RECs this would indeed appear to be the 
case. Most reported that they found the SSAS Final Report to be useful and that it 
improved their confidence in their decision making regarding the trial. They also felt 
that the Final Report reduced the time taken to consider the trial at their meeting. Both 
RECs and Sponsors thought the scheme should continue in some form, although there 
were some issues identified that needed to be resolved if their full support was to be 
obtained. 
The first of these issues was the perceived time taken to obtain ethics approval at 
multiple sites and whether SSAS has a negative impact on this. Unfortunately it was 
not possible to quantify the impact SSAS has on the time it takes to obtain ethics 
approval in the Pilot, because Sponsors did not return the log form that would have 
provided data on the time to an actionable approval document. In addition, the 
evaluation did not have a concurrent control arm of trials not submitted to SSAS to 
which the trials submitted to SSAS could be compared. 
Caution needs to be taken when interpreting time delays in the scientific and ethical 
review process as there are many factors that may contribute to a delay in approval. 
For example, most RECs publicise submission deadlines which potential applicants 
may miss. As is evident from the trials in this evaluation, at least some delay can be 
attributed to the Sponsor - in this case delays resulting from the time taken to respond 
to queries made by SSAS. Insurance, legal and indemnity issues, as well as 
incomplete applications, are also factors that result in review delays. It is important to 
note that, unlike RECs in many other countries, Australian RECs carry a significant 
proportion of the regulatory burden. For example, for clinical trials submitted as part 
of the Clinical Trial Notification (CTN) scheme, RECs are expected to assess 
toxicological and safety data (Commonwealth Department of Health and Ageing 
1999). Obtaining approval to proceed with the trial from the TGA, once REC approval 
has been obtained and the CTN form has been signed by all the relevant parties, is a 
163 
simple process of forwarding the completed CTN fonn with a fee to the TGA 
(Commonwealth Department of Health and Ageing 200Ia). By way of contrast, 
Institutional Review Boards (IRBs) in the United States are expected to consider if the 
trial protocol is scientifically sound when reviewing drug research but this is "not the 
IRB's primary concern ... [and] an IRB may rely on the FDA, institutions, scientific 
review committees, funding agencies (e.g., NIH), or others for this detennination" ( 
2001 ;U.S Food and Drug Administration 2002). 
Preconceived notions concerning the value of the SSAS process is a problem that can 
only be addressed through demonstrating the reliability, usefulness and timeliness of 
the scheme (or not) over time. It is possible that the impact of SSAS on factors such 
as the time taken to obtain ethical approval may only be seen once acceptance of the 
scheme becomes more widespread, and RECs develop trust and confidence in the 
SSAS process and its product. We should also consider the quality of ethical review 
and the possibility that pressure to hasten the process, and the workload burden 
experienced by some committees, could impact on the quality of ethical review. There 
will be occasions when delay in ethical approval resulting from requests for 
clarification or change will be appropriate. 
It is important to note that, while SSAS may result in an initial delay this may wash 
out in the longer tenn as multiple sites may approve trial sooner - initial delay may be 
misleading. 
Moves have already been made to address some of the resource and support issues 
encountered during the conduct of the pilot. A mechanism for communicating 
infonnation to RECs about the status of applications made to SSAS has been put into 
place. There is a need to continue to disseminate infonnation about SSAS to Sponsors 
although the best way to go about achieving this is open to debate. 
There are some limitations in the design of this evaluation. One is the method used to 
obtain the data used to estimate resource usage. While some data are relatively 
accurate (eg number of projects reviewed) others will be estimates only, based on the 
experience of the Executive Officer. The estimated time spent by REC members 
preparing for meetings, is one example. Although a guesstimate, the data can still 
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provide us with a best estimate of resource expenditure in the absence of a more 
detailed resource utilisation study, the latter being beyond the scope ofthis evaluation. 
Another limitation is the poor response rate (47%) regarding the return of Evaluation 
Forms on individual trials by RECs. By cross-referencing the End of Study Forms 
with the Evaluation Forms we know that at least two of the missing EFs relate to trials 
where the SSAS Final Report was received after the REC meeting, and that the RECs 
of about one third of the missing EFs indicated that they would be happy to replace 
their current system of scientific review with SSAS. 
A methodological challenge was identifying the best way to obtain valid and useful 
information about aspects of decision-making when the entity making that decision is 
a group of individuals, and considering the restricted access by the investigator to 
those entities. While RECs were asked to discuss the questions as a group, the forms 
were completed by individuals and it is therefore inevitable that some responses may 
not truly represent the opinions of the entire group. Another limitation, particularly in 
the estimation of workload, is that RECs were asked to make some "best guesses" 
rather than conduct detailed time-and-motion studies. 
Even though the majority of RECs felt adequately informed, and most were satisfied 
with the support provided by the Department of Health, it is evident that there were 
some problems experienced during the pilot regarding the communication of 
information relating to the trials being considered by SSAS, and the expected 
timeframes. Surprisingly few seemed to have access the manual or the SSAS web site 
and reasons for this need to be explored further. The SSAS web site could be a 
valuable tool in the dissemination of information to RECs, but only if RECs have the 
ability and the inclination to visit the site. 
Based on the findings of the End of Study survey, there was clear support for SSAS to 
continue beyond the initial 12 month pilot. It was recommended that further 
evaluation be carried out in order to: 
• Increase the number of studies submitted to SSAS and hence available for 
evaluation. 
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• Investigate the potential impact of expanding SSAS to include all multi-centre 
trials or all multicentre research. This may require the formation of more than 
one committee. 
• Obtain data on the time taken to obtain REC approval, perhaps obtaining this 
information from RECs rather than Sponsors. 
• Explore further the other factors that may contribute to delay in ethical 
approval, particularly regulatory, legal and indemnity issues. 
• Explore the best way in which to communicate information to RECs about 
SSAS and trials submitted to SSAS, and identify possible barriers to 
communication. 
It was also recommended that mechanisms for disseminating information about SSAS 
to Sponsors be investigated, as it was evident that information was not filtering 
through the relevant people within each organisation. 
An issue facing RECs and SSAS is the need to share information in a way that does 
not divulge aspects of a trial that are considered to be confidential, but at the same 
time enables RECs to be aware of trials that have been submitted to SSAS. This 
would save resources by avoiding unnecessary duplication across RECs. It would also 
be useful if RECs could check the status of a particular application, thereby helping 
them to anticipate submissions and effectively manage their workload. 
In conclusion, there would appear to be a potentially valuable role for centralised 
scientific review of multi-centre clinical research. It could improve the consistency of 
decision-making across ethics committees by ensuring an underlying minimum 
scientific standard, as well as ensuring that individual ethics committee's meet their 
ethical obligation to consider the science of a trial in its deliberations. At the same 
time, central scientific review allows individual RECs to maintain their autonomy and 
to focus on their primary task: that is, to ensure the conduct of ethical clinical research 
in the context of the community they represent and serve. Evaluation is required to 
determine whether centralised scientific review has an impact on the quality of 
research, as well as whether it unreasonably extends the time required to obtain ethics 
approval. 
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Chapter 8: Thesis overview, discussion and 
conclusions 
As I argued at the start of this thesis, there is an ethical obligation on the part of all 
those associated with clinical trials research to ensure the methodological rigour and 
scientific integrity of this research. There is also an obligation to ensure that the 
results are made publicly available in a manner that is not misleading and does not 
misrepresent the data. This will ensure that the best quality research is available as the 
basis for health care decisions. 
Quality and randomised controlled trials 
Interest in the quality of randomised clinical trial research is not restricted to those 
directly involved in their design and conduct. A government body or charitable 
organisation funding a clinical trial will want to ensure that their money is being invested 
wisely in a trial that is of direct relevance to health care practice, has a reasonable chance 
of reaching a valid conclusion, with its findings being made available to people making 
decisions about health care preactice. A pharmaceutical sponsor will also want to 
comply with the appropriate regulatory requirements, particularly ICH GCP. 
Institutional ethics committees in their role as patient representatives, need to ensure that 
the patients on whose behalf they act are participating in research that is ethically sound. 
The concept of "quality" for a randomised clinical trial is therefore multi-dimensional, 
and the emphasis given to anyone dimension will depend on the viewpoint of the 
individual or group. Dimensions of quality include: 
• Methodology 
• Relevance 
• Conduct 
• Reporting 
Methodology and Reporting 
This thesis concentrated on the quality of methodology by considering the design of 
trials, and the quality of reporting by considering the content of published articles. It 
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is composed of 3 substantial studies, the first of which identified and quantified issues 
relevant to trial quality by comparing the protocol and related document lodged with an 
ethics committee with resulting publications (Chapters 2 to 5). This helped to highlight 
areas in both methodology and reporting where there is room for improvement. The 
second study investigated the published experiences with shared scientific or ethical 
review of multi-centre research in an attempt to evaluate the impact this has on the 
quality of clinical trials and of decision making. The study found that evidence of the 
effectiveness or not of these systems was lacking. The third study addressed some of 
these deficiencies, evaluating the impact of a shared scientific assessment scheme 
implemented in NSW had on the functioning and decision-making of human research 
ethics committees. 
Key factors which have been shown to have a direct impact on the quality of 
randomised clinical trials were all poorly documented in the protocols of trials in my 
study, and the content of a protocol was not always consistent with the information 
subsequently reported in the publication. These factors include the methods used to 
generate the sequence in which interventions were allocated, allocation concealment, 
the methods used to blind interventions including inadequate descriptions of placebos, 
and the sample size calculation. All of these factors should be considered a 
fundamental component of any decision to approve a trial made by an ethics 
committee, but it is possible that at least some investigators consider them to be more 
"administrative" issues that relate to the conduct but not the science of the trial. 
My follow-up study demonstrated that selective reporting existed in some form in a 
significant proportion of the included trials. This selective reporting included: 
• selection of which outcomes were reported (discrepancy in identity), and 
• selection of the amount of information reported for an outcome (completeness 
of reporting) 
• selection of how an outcome is defined (discrepancy in definition) 
It is to be expected that there will be some differences between the protocol and the 
publication given that trials usually occur over prolonged periods (sometimes several 
years). For example, the results of other research may become available while a trial 
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is ongoing, which might require justifiable alterations in one or more aspects its 
design or conduct. A new, more sensitive technique for measuring the outcome of 
interest may become available, again requiring an alteration to the trial protocol. 
There could, however, be more insidious reasons for changes to the methodology and 
selective reporting. These include deliberate manipulation of one or more aspects of a 
trial to allow it to be portrayed in a manner that authors may perceive to be more 
appealing to journal editors or readers, possibly making an intervention look more or 
less effective than it really is. The main cause for concern is when any differences and 
the reasons for them are not mentioned in the publication, because the end user ofthe 
trial publication is then unable to make an informed jUdgement about the validity of 
the changes in design of study itself, or its relevance to their decision-making needs. 
Relevance 
The perfectly designed trial that is seeking a conclusive answer to a question that will not 
be of interest in practice could be considered to be of poor "quality". It is also possible 
that such trials would also have difficulties recruiting participants. The concept of 
relevance is important in anyone (or all) of the components of a question: that is, the 
patient population, the intervention and comparator, and the outcome. Examples of 
problems would be eligibility criteria that exclude those participants who would benefit 
most from the identification of an effective new intervention; the choice of a comparator 
that is not accepted standard practice; or an outcome measure using a technique that is 
not widely available. 
There are also societal consequences of the conduct of irrelevant trials. The resources 
consumed by such a trial could have been used more efficiently and to greater benefit 
elsewhere. Some may also question the ethics of recruiting patients onto a randomised 
trial if the results of that trial are unlikely to be incorporated into practice. The same 
ethical question could be asked of trials that are unable to recruit a sufficient number of 
patients to answer the question posed, trials with a sample size calculation that 
considerably over (or under) estimated the potential size of the treatment effect, or trials 
based on an outcome that is not clinically relevant. 
169 
Conduct 
A range of rules and regulations exist that can (and in some cases must) be applied 
when clinical trials research is being conducted. The most widely known are the 
International Conference on Harmonisation (ICH) Guidelines for Good Clinical 
Practice (GCP). These guidelines recommend minimum standards of practice for the 
various aspects of the conduct of a clinical trial, and they include recommendations 
for the trial protocol. The recommendations made by GCP are not mandatory, but 
regulatory agencies and some ethics committees may insist on compliance with the 
guidelines if a trial is to be approved. 
Guidelines such as GCP have an important role in establishing a benchmark for trials. 
While such guidelines can be important and relevant, their impact on the any aspect of 
the quality of clinical trials research is not known. The value of undertaking some 
tasks has certainly been questioned, particularly given the cost entailed in their 
achievement. Concerns have been expressed, in particular, by academic researchers in 
relation to the potentially negative impact of the European Commission Directive 
2001l20lEC on clinical trials introduced in May 2004. Many were concerned at the 
time, and this concern remains today that the Directive would have a negative impact 
on publicly funded clinical trials research in Europe. The intention of the directive 
would appear to be to "simplify and harmonise the administrative provisions 
governing such trials by establishing a clear, transparent procedure and creating 
conditions conducive to effective coordination of such clinical trials in the 
Community". (European Commission. 2001) The fear was that the "labour intensive, 
bureaucratic and expensive endeavour of running a clinical trial would become 
worse", and that only the commercial sector would have the resources to conduct 
trials. (Hemminki & Kellokumpu-Lehtinen 2006) In a recent 8MJ editorial it was 
reported that, since the introduction of the Directive, the number of new trials 
conducted by a large independent European cancer trials organisation had fallen, 
fewer patients had been enrolled, costs had increased (including insurance costs), and 
trial initiation had slowed, "mostly the result of the increased workload of ethics 
committees". (Hemminki & Kellokumpu-Lehtinen 2006) 
While guidelines such as GCP are intended to ensure the quality of the conduct of 
clinical trials, it is arguable that improving conduct results in an improvement in the 
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other (arguably more important) aspects of trial quality. In at least some cases it 
would appear that overly onerous regulation of conduct has a negative impact on the 
quality of clinical trials, specifically on relevance, by making it more difficult to 
initiate and successfully complete publicly funded (investigator initiated) studies. 
Who is responsible for trial quality? 
Responsibility for all aspects of a clinical trial should remain with the trial 
investigators, who are ultimately accountable to the trial sponsors (financial and non-
financial) and to the people who consent to participate. The effectiveness of self-
regulation is debatable though, and there needs to be a third party willing to act on 
behalf of the community to ensure the integrity of research is maintained. The obvious 
agencies to take on this. responsibility would be research ethics committees. 
Although the scientific validity of a clinical trial is clearly pertinent to its ethical 
integrity, at least some ethics committees admit they do not have the skills necessary 
to evaluate adequately the science of the trials they are asked to assess. Modern ethics 
committees also have daunting workloads and are under significant pressure to deliver 
expedient decisions within tight timeframes. 
Many modern trials are multi-centre (68% of trials in the follow-up study in this 
thesis) and will therefore be reviewed by more than one ethics committee. It would 
therefore seem logical that one way to reduce the workload of ethics committees 
would be to reduce unnecessary repetition, particularly the repetition of those tasks 
they consider themselves to be ill-qualified to conduct effectively. A mechanism that 
would allow non-local tasks to be performed centrally, leaving local committees to 
consider local issues, is therefore appealing - although experience with such 
mechanisms has been variable, as I have shown in my systematic review in Chapter 6. 
As indicated by this review, the studies that were identified provide insufficient 
evidence to determine whether centralised scientific or ethical review improves the 
quality of trials or the quality of decisions made by RECs. However, the pilot of a 
shared scientific review in NSW, described in Chapter 7, does suggest that there is 
certainly potential for such systems to lead to improvements, but there is clearly more 
that needs to be learned. 
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There is potentially a greater role for health care journals in ensuring the quality of the 
clinical trials research they publish. The CONSORT statement and its implementation 
by many key journals has already gone some way to improve the quality of reporting, 
although this in itself will not address the issue of selective reporting (CONSORT 
Group 1996). Some journals (such as BioMed Central) encourage trial investigators to 
publish their full protocols (in the case of BioMed Central this is online publication). 
One journal editor has suggested that publication of the protocol "allows reviewers 
and readers to suggest improvements to be made to the study before it begins"(Godlee 
F 2001). 
By demonstrating a commitment to the prospective registration of trials, journals 
affiliated with the International Committee of Medical Journal Editors (ICMJE) have 
increased the acceptance and utilisation of the existing registers, forcing trial 
investigators to register minimum information about their trials (at inception) as a 
precondition for publication. The Australian Clinical Trials Registry, for example, 
saw the number of trials submitted for registration increase from 346 to 651 during 
the 2 weeks period immediately prior to the deadline for registration set by the ICMJE 
of 13th September 2006 if the trial was to eligible for future publication in these 
journals (Australian Clinical Trials Registry 2005). 
Some journals have taken this commitment a step further. The British Medical Journal 
(BMJ), for example, requires authors of manuscripts reporting the results of 
randomised trials to not only comply with the CONSORT statement, but also to 
submit their protocol with the manuscript, so the editors and reviews can refer to the 
former if necessary as part of the peer review process. (Jones & Abbasi 2004) The 
belief is "that identifying deviation from the protocol is another important step in 
ensuring that the findings of a study are reported with honesty and transparency". 
Unfortunately, the BMJ has found that authors are reluctant to provide their protocols, 
but the reasons for this reluctance do not appear to have been reported. 
What can be done to improve quality? 
There are many opportunities that could be taken advantage of to improve the quality 
of clinical trials, at all stages of the research process, involving all of those with a 
vested interest in clinical trials research. The first is to improve the expertise of the 
172 
principle investigators for trials, as well as those directly involved in the day-to-day 
conduct of research, perhaps restricting the ability to undertake clinical trials to those 
who are "certified" to do so. 
To maximise the relevance of trials, barriers to investigator-initiated clinical trials 
research need to minimised, while at the same time ensuring the methodological 
quality of that research. Investigator access to methodological and biostatistical 
expertise could be improved, starting with raising the profile (and recognition) of the 
importance of this type of expertise in the development of a trial protocol. This would 
require the allocation offunding to allow investigators to procure this expertise. 
As discussed in Chapters 6 and 7, quality could also be addressed by improving REC 
access to the necessary expertise (such as shared scientific review) as well as by 
improving the quality of data reported in published manuscripts (through 
consideration of protocol at time of manuscript submission, for example). 
Further research 
If some aspects of ethical review (including scientific review) for multi-centre clinical 
research could be shared or concentrated in a single committee, this should lead to 
improvements in trial quality and facilitate the whole process of clinical research. The 
effectiveness of centralised review has not been adequately evaluated, as was shown 
in Chapter 6. The best way to do this would be through a randomised trial in which 
individual ethics committees (as a 'cluster') would be randomised to either continue 
as normal (that is, the entire ethical review process is conducted locally for all trials) 
or to a process of local review following central review. Randomising individual trials 
for consideration, or not, by the central committee would be cumbersome and not 
practicable. There is a possibility of "contamination" across RECs who may want to 
share information but measures could be taken to minimise the problems this might 
cause. Trial investigators, for example, would need to be kept unaware of the identity 
of the "intervention" to which each ethics committee had been allocated. The 
intervention in the trial outlined here would need to be well defined, as would the 
distinction between the role of the central committee and that of the local committee. 
Outcomes of interest would include the quality of the trial protocol after it has been 
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approved at a local level, the time taken to obtain approval and the costs involved in 
the approval process. 
The impact of making the original protocol available to journal editors and referees 
could also be evaluated in a randomised fashion. If a condition of submission is that 
the protocol be provided along with the manuscript, trials could then be randomly 
allocated so that some referees would receive the protocol along with the manuscript 
and others would only receive the manuscript. The instructions given to the referee 
regarding the use of the protocol would need to be defined, and could be either 
prescriptive or pragmatic (possibly no instruction at all). If differences between the 
protocol and the manuscript were detected, authors could then be asked to address 
these differences in their manuscripts, thereby improving the quality of the report. The 
outcomes would include the quality of the published article and resource implications 
such as the time taken for the peer-review process. 
Research in selective reporting and forms of publication bias has largely focused on 
randomised trials. The problem is probably worse for observational studies but there 
is a dearth of research in this area (God lee F 200 I). There is a need for further 
research in order to describe and quantify the selective reporting of observational 
studies, particularly given their increased use in systematic reviews in areas where 
randomised trials are not possible or feasible. 
Conclusion 
Trial investigators have a scientific and a moral responsibility to ensure that a true and 
accurate representation of their trial is made available to the ethics committees who 
are being asked to approve the research, to the people who are invited to participate in 
that research, and to the readers of any report produced as a result. This will ensure 
that health care decisions are made based on research of the highest quality - in all its 
dimensions. 
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Appendix 1: Expectations of a Human Research Ethics 
Committee regarding the science of a clinical trial 
The/ollowing has been extractedfrom the Human Research Ethics Handbook 
((NHMRC 2002)) 
RECs need to be satisfied that the research design can produce valid results and can 
protect the welfare and rights of research participants. To be satisfied, an REC may 
seek or receive advice from an individual, a scientific committee in its institution, an 
external expert, or it may include an additional person who has specific expertise in 
the particular type of research. It is not possible to provide a comprehensive list of 
relevant considerations for every research approval. However, the following matters 
will usually require consideration: 
The project 
• Is there a clear hypothesis? 
• Is the research question useful? Is the research worthwhile? 
• Is the research likely to yield new infonnation, enhance understanding or clarify 
existing uncertainty? 
• Has this, or similar, research been carried out before in the same, or similar, 
contexts? 
• Can the research proposal be supported by a systematic review of the literature 
that would demonstrate the importance of the research question and that it builds 
upon the results of previous research? 
• I f indicated, have perspectives of potential participant groups, the wider 
community, or other disciplines been incorporated into the research proposal? 
• Are the aims of the proposal clear? 
• Does the value of the project appear to be adequate to justify its conduct with 
humans? 
Research methodology 
• Are all aspects of the research methodology clearly described? 
• Is the REC satisfied that the methodology is appropriate to the achievement of the 
aims of the project? 
NS 12.2 
An REC must consider all aspects of the design of a clinical trial and be satisfied that: 
(a) the trial is directed to answering a specific question or questions; 
(b) there is a scientifically valid hypothesis being tested which offers a realistic 
possibility that the interventions being studied will be at least as effective as standard 
treatment; 
(c) where the research is therapeutic, and is therefore intended and likely to be of 
direct benefit to participants, there is an acceptable balance between the risks and 
benefits of the trial; 
(d) the methodology provides: 
(i) a rationale for the selection of appropriate participants; 
(ii) an appropriate method of recruitment; 
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(iii) adequate, understandable information for the purpose of obtaining 
participant consent; 
(iv) a clear description of the intervention and observation to be conducted; 
(v) a sample size adequate to demonstrate clinically and statistically 
significant effects; 
(e) it has access to adequate expertise or advice to consider the safety of the drugs, 
medical devices or other intervention under investigation; and 
(f) it is familiar with the requirements of the Therapeutic Goods Administration 
(TGA) in relation to unregistered drugs and devices, particularly the Clinical Trial 
Notification (CTN) and Clinical Trial Exemption (CTX) schemes, where relevant. 
12.2(a) 
The complexity of design in some clinical trials does not relieve an REC of the need 
to be satisfied that a research question is identified and set out clearly in information 
sheets for participants. 
12.2(b) 
The study design should be appropriate to the clinical question being asked. 
12.2(c) 
Risks may not be confined to adverse effects on physical health but could extend to 
emotional, economic and other types of disadvantage. In seeking to establish whether 
benefits and risks associated with a trial are acceptably balanced, an REC should 
consider whether such a balance is struck not only at the level of the entire participant 
population but also for individual participants. For instance, planning of a trial should 
seek to avoid situations in which the likelihood of benefits is predictably higher than 
average for one identifiable group of participants whilst risks are predictably higher 
for another. 
12.2( d) (i) and (ii) 
The proposal should clearly identify how the classes of participants have been 
selected so as to permit the best extrapolation of trial results to the patient groups to 
whom the new treatment, if successful, is to be administered. 
12.2( d) (iii) 
The REC should scrutinise the participant information statement carefully. Medical 
terminology and abbreviations should be avoided or explained in plain language. The 
document should clearly explain the purpose of the trial and give a detailed account of 
the nature of interventions and procedures to be employed, as well as any risks 
involved. The latter include possible effects of drugs, medical devices or any changes 
to existing therapies, as well as the interventions to be used in assessing these effects. 
Where applicable, it should be stated that interventions will be randomly assigned and 
that participants may receive inactive or unproven interventions. Special care should 
be taken with vulnerable participants, such as those with incurable diseases, who may 
be particularly disposed to try new therapies, as well as those with whom 
communication is difficult. Potential participants should be informed about available 
alternative treatments and advised that they may discontinue participation in the study 
at any time without prejudice to their ongoing medical treatment. 
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The REC should also consider the ongoing availability of a drug that is proposed for 
incorporation in a clinical trial. It would be reasonable for the REC to seek assurances 
from the sponsor that, in the absence of observation of detrimental side effects or of 
inefficacy, the drug will remain available until the trial is completed. Details should 
also be provided about: 
• compensation and treatment available in the event of trial-related injury to the 
participant; 
• issues of confidentiality; 
• contact details in case of emergency; and 
• the name of an independent person with whom concerns about the study could be 
discussed. 
12.2(d) (iv) 
It should be clear to an REC precisely what the amounts and frequency of dosages of 
the drug will be, and the kinds and frequency oftests or monitoring involving hospital 
or clinic attendance that will be required. 
Dosages of unmarketed drugs should be based upon pre-clinical and early phase 
clinical trial data. Care should be taken to ensure that these are consistent with earlier 
studies. Often, the duration of therapy is much longer in later phase studies than in 
earlier ones. If the proposed treatment period is significantly longer than those for 
which data exist interim safety reports will be necessary and should be built into the 
study design. 
12.2(d)(v) 
A justification of the proposed sample size, based on the primary endpoint of the 
study, should be provided. Details should be given about expected clinically important 
differences between the test and control therapies and the expected variability of the 
outcome variables. Calculations of the required sample size based on such 
information are referred to as 'power calculations'. The sample size required for the 
conduct of any comparative study is directly proportional to the 'power' of the study 
and the natural variation in the outcome of interest in the population, and inversely 
proportional to the size of the difference the researcher wishes to detect. 
An ethics committee should be satisfied, usually on the basis of expert opinion, that a 
clinical trial design indicates that the trial can reliably show a reasonable comparative 
benefit in relation to the new drug or device simply because sufficient participants are 
to be studied. 
12.2(e) 
RECs need to receive competent advice about the scientific details of a proposed 
project. This includes all of the items listed in NS l2.2(d), that is, the protocol, study 
design, inclusion and exclusion criteria, endpoints and outcome measures, sample 
size, dosages and duration of therapy, and methods for analysing results. When 
seeking advice from non-members, an REC should ensure that confidentiality about 
all aspects of the proposal is preserved and that the intellectual property of the sponsor 
is not jeopardised (see also NS 2.19-2.20 on the avoidance of conflicts of interest). 
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Appendix 2: Australian RECs and monitoring responsibilities 
From National Statement on Ethical Conduct in Research Involving Humans 
(NHMRC 200 I) 
12.8 An institution or organisation and its REC must require the researcher: 
(a) to conduct the trial in compliance with the approved protocol; 
(b) to provide reports of the progress of the trial to the REC at a frequency directed by 
the REC that is related to the degree of risk to participants, but at least annually; 
(c) to inform the REC of, and seek its approval of, amendments to the protocol 
including any: 
(i) proposed or undertaken in order to eliminate immediate hazards to participants; 
(ii) that may increase the risks to participants; or 
(iii) that significantly affect the conduct of the trial; 
(d) to inform the REC and the TGA of all serious or unexpected adverse events that 
occur during the trial and may affect the conduct of the trial or the safety of the 
participants or their willingness to continue participation in the trial; 
(e) to inform the REC as soon as possible of any new information from other 
published or unpublished studies which may have an impact on the continued ethical 
acceptability of the trial or which may indicate the need for amendments to the trial 
protocol; 
(f) to inform the REC, giving reasons, if the trial is discontinued before the expected 
date of completion; and 
(g) in relation to trials with implantable medical devices, to confirm the existence of 
or establish a system for tracking the participant, with consent, for the lifetime of the 
device, and to report any device incidents to the TGA. 
12.9 The institution or organisation and its REC must determine the type and 
frequency of review appropriate to the drug or device being investigated and to the 
degree of risk to participants provided that the review occurs at least once a year. 
12.10 It may be unethical for a researcher to continue a trial if: 
(a) there are or have been substantial deviations from the trial protocol; 
(b) side effects of unexpected type, severity, or frequency are encountered; or 
(c) as the trial progresses, one of several treatments or procedures being compared 
proves to be so much better, or worse, than other(s) that continuation of the trial 
would disadvantage some of the participants. 
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Appendix 3: About CSAHS REC 
Extracted from the web site: 
http ://www.cs.nsw.gov.aulOJalRcsearch/ethics/default.htm 
The CSAHS Ethics Committee (RPAH Zone) reviews research conducted at: 
• Royal Prince Alfred Hospital 
• Canterbury Hospital 
• Balmain Hospital 
• Rozelle Hospital 
• Institute of Forensic Medicine 
• Sydney IVF Pty Ltd 
• CSAJ-IS Division of Population Health 
• Institute of Respiratory Medicine 
• Heart Research Institute 
• Centenary Institute of Cancer Medicine & Cell Biology 
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The ERC meets each month and, over an average year, considers more than 300 new 
protocols as well as reviewing progress and compliance of all currently approved 
studies. 
In undertaking an ethical assessment of a proposed project, the ERC considers a 
number of issues: Is the purpose of the study such that it will usefully advance 
medical/scientific knowledge? Has it been designed so that a valid conclusion will be 
reached? What procedures will subjects undergo? Are they unnecessarily painful, 
arduous, risky or time-consuming? Are questionnaires phrased in such a way that they 
do not cause anxiety or alarm to subjects? Is any undue inducement being offered to 
encourage prospective subjects to participate? Have the Subject Information 
Statement and Consent Form been prepared in clear, concise, plain language giving 
full details of the procedures, risks and benefits which the subject will face if he/she 
agrees to participate? Have suitable arrangements been made to ensure that subjects of 
non-English speaking backgrounds also have the opportunity to take part in the study 
and to give informed consent to their participation? 
Research studies which involve the clinical trial of drugs or devices are assessed by 
the Clinical Trials Sub-eommittee of the ERC, which also meets monthly. This sub-
committee comprises senior clinicians and clinical academics, and has the 
responsibility for reviewing all the scientific data (such as toxicology, pharmacology 
and previous clinical experience) on new products to ensure that the expected benefits 
to subjects outweigh the possible side effects. The sub-committee then forwards the 
protocol, together with its advice and recommendations, to the ERC for its further 
consideration. 
Clinical Trials Sub-committee 
Members of the Clinical Trials Sub-committee have expertise in a wide range of 
disciplines relevant to clinical trials. All proposed studies involving drugs and devices 
are reviewed by this Sub-committee before consideration by the Ethics Review 
Committee. Issues reviewed include safety, technical aspects and scientific validity. If 
necessary, the Sub-committee can request evaluation by independent (internal or 
external) assessors. 
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Appendix 4: Completeness of reporting of primary outcomes 
Chan et at defined a fully reported outcome as one with enough data for meta-analysis 
«Chan A W & Altman 2003)). That is, there was sufficient data to: 
• derive the sample sizes per group, 
• the effect size, and 
• a measure of precision/variability (for continuous outcomes) 
o The standard error could also be derived if sample sizes, effect size, and 
precise p-value are available. 
Incompletely reported outcomes had insufficient data for meta-analysis and were 
classified: 
• partially reported (some data provided), 
• qualitatively reported (only the p-value or statement about statistical 
significance was provided), and 
• unreported (no data given). 
Figure: Hierarchy of the ~els of outcomee..--_____________ ~ 
Full ( ) 
Reported 
outcomes Partial 
n and effect size, 
plus precision I p 
value for 
continuous data 
Effect size or 
precision (+/- n or 
p value) 
Qualitative 
Incompletely 
reported 
outcomes 
Unreported 
Note: reporting (n = number of participants per group) 
I aOle: Amount aT aata r QUlfeO Tor meta-analYSIS aT rully reoartea outcomes (aaaptea Tram t,;nan et all 
Tvee of outcome data Data reauired for meta-analvsis 
Unpaired continuous • Group numbers 
data • Magnitude of treatment effect (group means/medians or difference in 
means); and 
• Measure of precision (confidence interval, standard deviation or standard 
error for means; range for medians) or the precise o-value 
Unpaired binary data • Raw numbers or event rates in each Qroup 
Paired continuous data Either 
• Mean difference between groups and a measure of its precision/exact p-
value; or 
• Raw data for each participant 
Paired bin",},data • Paired numbers of oarticioants with and without events 
Survival data Either 
• Kaplan-Meier curve with numbers of patients at-risk over time; or 
• Hazard ratio with a measure' of precision 
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Appendix 5: Data collection fontls (follow-up study) 
Data collection from the REC 
[ HREC 10: I 
From the HREC Ille 
, Was any funding a ... aoIahie to 2 Date of actJonabie approval do::ument , , 
support lhe w .. duel of the 3 Dilte oIllle Jag arlnlJal r~lXln , , IrISI at the dme d submUiOn 
lOttie HREC? , W'lal was !he SoUIluS d the mal at the lime of the ta!.1 annual lecon? 
J No lundlng Inenl:Olleti 
J Go¥eln/'l'1el11 agency -' Compleli!d (comP'etcn date , , 
J F\lbhc; chanty ()f -' In PlogUISS 
organtSill10n -' Not yet commenced 
J ComrnHClai ! t C'O' -' AbandOned 
J OU'oef (SpI -' 
""'" 
5 15 thete at leOist one deafly d~mgulwbie pnmary outcome on the protocol'> 
-' V .. 
-' No 
Randomisation 
• Is the tllOlII rando~ (see de~rullOn) • Is seque~ genetalion OKIeqU3te? J Truly rancloiiued J Y6 
J au.a5l-~ndoml&ed J No 
-' Nol l;lfldomtea J Unclear 
J Not i'5SeMabie 
• DozF randomQ;iiIbon occur 011 a brroa il5 do 8 10 the , Is allocation Goncealmel'l\ ae' E q.oas:e? ccun-rer.cemenl of treatmen' as po nble? 
J Y6 J Yes 
J No J No 
J Unclear J Unelmlr 
Sample size 
, 0 Is there (J lalgel sample lilze1 
J Yes calc:uiale(i USIng an ltpp'opllate m:.lhem<'llgJ fOfITlUt.1 
J Yes but no evidence of iii samp. SIZe ealcula t:C 11 
J No 
Yeo No 
11 Ate adequate dMalis 01 mil! sample SIZe cal:cusllOn lecordl'd? J 
• ~ OllfODme ur.ed to ok:ulaie sample foIZe J 
b Ole expected 11I!31menl eIf~ J 
, a enOl' pre·st! :~fed J 
d 11 error pr.-speclf~ J 
• The alrernalIYe treatmenl h),P()(hesls J 
Use of blinding and placebo 
12 The WailS 
J 0,:.." label 
J Pallent 150 bllIlcied 
, Is II po$91b6e 101 the patMtnt (0 kHmtlly Il\ejr ueafment? 
J PertiOn atimtllStenng lreab "ant IS b',t1cfe(t 
• Is It POSSIble lor the pract(J(lne: to Idenl<ry lhe tlailtrnent? 
13 Isapl;cebolX'lngU5e'O? •• II yn, ~ there a <lUCl,ption of •• ISIne Ot'KI'ipbofi of Ihe I 
" 
Y .. \he placebo? piacebo adequate? • 
J No J y" 
" 
V .. i • 
• 
J Unclear J No J No , I J Unclear J Uncle .. , 
Adverse events and withdrawals 
" 
Dc es tho ptotccol50tatO thai aclvel6C! ~ent$ VoOuid 15 DoE'S the plC/IOCOI mellOde a secoon on Ule harodlln 
be lnonlloled (rOUl lne l.aboratory tests)? ot Withdrawals (not as. an outcome)" 
.J Y .. -' Y .. 
-' No -' No 
Note: for Question I, up to 2 responses were collected. I f more than 2, the 2 major Iypes of funder were 
collecled. 
See glossary for clarification oftenns. 
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Data collection from the publication 
From the publication 
Publication characteristics 
1. Journal type 
o General 
o Specialty 
2. Type of report 
o full publication 
1:1 short report 
Q Iette, 
Q ""'~ 
Trial characteristics 
HRECID: 
3 Declared funding (tick aU that apply) 
o No funding mentioned 
Q Government agency (eg NHMRC, Department of Health) 
o Public charity or organisation (eg National Heart Foundation, 
Cancer CounciQ 
o Commercial sector (including pharmaceutical or device 
industry) 
a Other (please specify): 
4. The nurrber of subjects randemised" ((scad number) 
5 The reporting of the pov.er calculation is 
o adequate 
o inadequate 
6 The number of trial ""n>;,,, 
7. Patient 8 A<m1 
population (con:':':'::;:rrll 
12 The trial was reported is 
o Single centre 
o Mu1ticentre 
13. and 
o National 
1:1 International 
14 Reported study design 
[J Parallel 
[J Factorial 
[J Crossover 
[J Equivalence 
[J Cluster 
[J Other (please specify) 
15 The purpose of the trial is: 
o Exploratory 
[J Pragmatic 
16 Is a placebo used? 
Q Yes 
Q No 
17 If a placebo is used, the description is 
[J Adequate 
[J Inadequate 
Q Unclear 
18. Ifno placebo, is masking used? 
Q y~ 
Q No 
19 If masked. the description of masking is 
[J Adequate 
Q Inadequate 
Q Unclear 
9 Arm 2 
,,~ "d number) 
10. Arm 3 
20. Handling of attrition 
a Adequate 
a Inadequate 
a Unclear 
'1, Arm4 
Reporting of randomisation 
21. The description of sequence generation 
Q Adequate 
o Inadequate 
o Unclear 
22. The description of aUocation concealment 
o Adequate 
Q Inadequate 
o Unclear 
23. Is there at least one clearly distinguishable primary 
outcome in the publication 
Q Yes 
Q No 
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Data collection on primary outcome 
PrImary Outcome (number of ___ -' 
Name 
2. Howesn you tell it is the rimary outcome? 
" " """~. publicetioo 
Clearly staled 0 0 
Rea$Ollably inferred 0 0 
Used III C4/1cu/ete sa",* 0 0 
... 
I :':inBimsor 0 0 
, .. " 
Oil>« 0 0 
Net stated 0 0 
3 Outcome declaration 
Outcome in rQl:ocoi Outcome In ublicallon 
Q Y.1" Q Y.1" 
Q Y.2" Q Y. t' 
Q Y. unsp Q Y, unsp 
Q N Q N 
4. Outcome type 
Q SOfoty 
Q Efficacy 
Q OItler f Unclear 
10. I/I/as the outcome measured across multiple time 
points? 
DYes 
Q No 
11 Data type reported as' 
a Callinuous 
[) Binary 
a Categorical 
Cl Timetoevenl 
12. Elements reported' 
Q "N 
o effed size 
a /1'le8.$Ura of prec::isionlvariabillty 
o precise p value 
a Other(sp) 
13. Wlat is the p value: 
HRECID: 
5. Defined in protocol as 
6. Defined in publication as 
7. Are the definitions the same? 
Q YM 
Q Unable tojudge 
Q No - minor change 
Q No - major change 
a If No, how they are different 
9 Was the change in definition reported in the 
publication? 
Q Yo. 
Q No 
14. Completeness of reporting' meta-analyst 
o Fully reported 
Q Partially reported 
o Qualitative 
o Named but no data reported 
a Nd repated 
15. Is this primary outcome mentioned in the abstract? 
o Ves 
Q No 
16. Is this primary outcome used as a basis for any 
conclusions? 
Q YM 
Q No 
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Data collection: Intention to treat and exclusions 
I ntention to treat 
~ states ITT 
c: does not state ITT 
Exclusions 
A. Explicitly reported no exclusions 
o Eg stated "intention to treat" and evidence provided 
o Eg explicitly stated that there were no deviations from random allocation 
B. Gave impression that no exclusions had taken place 
o Eg stated "intention to treat" but no evidence provided 
o Appeared to analyse as randomised 
• Explicitly reported analysed according to random allocation 
• Did not explicitly report analysed according to random allocation 
D C. Explicitly reported that there were exclusions 
o Report number excluded by treatment arm 
o Report that entry criteria applied identically to each group (eg committee 
revising all eligible cases) 
o Did not analyse as randomised 
I, D. Exclusions not mentioned 
E. Other (details documented) 
Reasons for exclusions: 
(If there were exclusions I did not analyse as randomised, did they exclude© 
Patients who did not start the allocated intervention 
Non-compliers 
D False inclusions (ineligible) 
Other 
Not applicable 
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Appendix 6.1: Univariate analyses for discrepancy in the identity of 
the primary outcome 
Note: These analyses are based on the 97 trials with at least one identifiable primary 
outcome. 
Appendix 6.1.1: Threshold for discrepancy in the identity of the 
primary outcome = 100% 
~ ....... . , 
B S.E. Wald df 
Step designcode 
-.034 .742 .002 1 
1 (a) Constant 
.693 .707 .961 1 
..... , .... v<;,,,_ 
B S.E. Wald df 
Step purpose code 
.227 .511 .198 1 
1(a) Constant 
.486 .449 1.167 1 
Administration 
B S.E. Wald df 
Step administration 2.718 
1(a) administration(1 ) 
.303 .637 .226 
administration(2) 
.791 .487 2.637 
Constant 
.208 .373 .309 
- -----
.... u,'" ..... , ....... , , ... , ....... , , .... ""''"'''''' 
B S.E. Wald df 
Step RECdrugfundcode 
.999 .446 5.024 
1 (a) Constant 
.057 .338 .029 
................................... _ ... 
B S.E. Wald df 
Step RECss200code 
.750 .436 2.966 
1(a) Constant 
.274 .304 .813 
Sig. 
.964 
.327 
Sig. 
.657 
.280 
Sig. 
2 .257 
1 .634 
1 .104 
1 .578 
Sig. 
1 .025 
1 .866 
Sig. 
1 .085 
1 .367 
0: <100% 
1: 100% 
95.0% C.l.for 
EXP(B) 
Exp(B) Lower UDDer 
.967 .226 4.139 
2.000 
95.0% C.i.for 
EXPIB) 
Exp(B) lower UDDer 
1.255 .461 3.420 
1.625 
95.0% C.l.for 
EXP(B) 
Exp(B) Lower UPDer 
1.354 .388 4.722 
2.205 .649 5.728 
1.231 
95.0%,T~ifOr 
EXP B 
Exp(B) Lower UPDer 
2.715 1.134 6.504 
1.059 
95.0% C.l.for 
EXP(B) 
Exp(B) Lower UPDer 
2.117 .902 4.972 
1.316 
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(;omoleteness ot tne samole size calcUlation 
95.0% C.l.for 
EXP'Bl 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step sscompcode2 9.821 2 .007 
1(a) sscompcode2(1) 1.977 .823 5.775 1 .016 7.222 1.440 36.224 
sscompcode2(2) 2.242 .716 9.798 1 .002 9.412 2.312 38.312 
Constant -1.204 .658 3.345 1 .067 .300 
Allocation concealment 
I 
95.0% C.l.for 
EXPIB) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step RECalioccode 
.306 .436 .492 1 .483 1.357 .578 3.187 
1 (a) Constant 
.531 .282 3.546 1 .060 1.700 
-- -_ .. _- _ .. _._ .. _ .. 
95.0% C.l.for 
EXP'Bl 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step RECseqgencode 
.044 .465 .009 1 .924 1.045 .420 2.601 
1 (a) Constant 
.649 .257 6.356 1 .012 1.913 
_ .... _ ... 
95.0% C.l.for 
EXP Bl 
B S.E Wald df Sig. Exp(B) Lower UDDer 
Step RECblindcode 
.440 .431 1.041 1 .308 1.553 .667 3.617 
1(a) Constant 
.425 .312 1.856 1 .173 1.529 
'---_ .. - - _. 
Number of outcomes 
95.0% C.l.for 
EXPIB) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-2.506 .511 24.019 1 .000 .082 .030 .222 
1(a) Constant 4.359 .834 27.322 1 .000 78.155 
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Appendix 6.1.2: Threshold for discrepancy in the identity of the 
primary outcome = 100%: adjusted for number of outcomes 
Proportion of trials with a discrepancy in the 
identity of a primary outcome 
uc:;:;ICI!. 
B S.E. 
Step numoutgrp2 
-2.513 .513 
1 (a) designcode 
-.233 .874 
Constant 4.581 1.188 
, ... , "" ....... 
B S.E. 
Step numoutgrp2 
-2.503 .512 
l(a) purposecode 
.168 .609 
Constant 4.223 .960 
Administration 
B S.E. 
Step numoutgrp2 
-2.489 .518 
1 (a) administration 
Wald df 
24.026 
.071 
14.874 
Wald df 
23.939 
.077 
19.365 
Wald 
23.125 
1.562 
Sig. 
1 .000 
1 .789 
1 .000 
Sig. 
1 .000 
1 .782 
1 .000 
df Sig. 
1 .000 
2 .458 
0: <100% 
1: 100% 
95.0% CHar 
EXP(B) 
Exp(B) Lower Upper 
.081 .030 .221 
.792 .143 4.393 
97.603 
95.0% CHar 
EXP(B) 
Exp(B) Lower Upper 
.082 .030 .223 
1.183 .359 3.903 
68.248 
95.0<Yo,~Bli for 
EXP B 
Exp(B) Lower Upper 
.083. .030 .229 
administration(l) 
.086 .761 .013 1 .910 1.090 .245 4.846 1 
administration(2) 
.670 .577 1.347 1 .246 1.953 .631 6.051 
Constant 3.978 .918 18.761 1 .000 53.407 i 
.................................... , ..... v ....... 
95.0% )~81/or 
EXP B 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-2.635 .547 23.174 1 .000 .072 .025 .210 
1(a) RECdrugfundcode 1.253 .555 5.107 1 .024 3.502 1.181 10.388 
Constant 3.791 .862 19.348 1 .000 44.306 
"'" """" ............. '" , ....... , ....... 
95.0% CHar 
EXP'Bl 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-2.687 .551 23.776 1 .000 .068 .023 .200 
1 (a) RECss200code 1.134 .549 4.271 1 .039 3.109 1060 9.118 
Constant 4.040 .851 22.527 1 .000 56.846 
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(;OmDleteness OT the sa mDle size calculation 
95.0% C.l.for 
EXPIBI 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-3.082 .679 20.614 1 .000 .046 .012 .174 
1 (a) sscompcode2 10.815 2 .004 
sscompcode2( 1) 1.693 .968 3.062 1 .080 5.436 .816 36.217 
sscompcode2(2) 3.040 .935 10.562 1 .001 20.896 3.341 130.668. 
Constant I 2.908 1.085 7.180 1 .007 18.325 I 
Allocation concealment 
- - -~ 
- -----
950o/~T~i'°r EXP B 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Step numoutgrp2 
-2.496 .512 23.766 1 .000 .082 .030 .225 
1(a) RECalioccode 
.176 .515 .117 1 .732 1.193 .435 3.275 
Constant 4.268 .870 24.073 1 .000 71.356 
.............. " ....... .... ', .... ,_., .... ,, 
95.0% C.l.for 
ExpiB) 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Step numoutgrp2 
-2.509 .512 24.001 1 .000 .081 .030 .222 
1 (a) RECseqgencode 
-.057 .552 .011 1 .918 .945 .320 2.789 
Constant 4.380 .859 25.965 1 .000 79.804 
... ""-'" 
95.0% C.l.for 
EXPIBI 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-2.609 .532 24038 1 .000 .074 .026 .209 
1(a) RECblindcode 
.757 .531 2.032 1 .154 2.131 .753 6.033 
Constant 4.103 .847 23.489 1 .000 60.511 
191 
Appendix 6.1.3: Threshold for discrepancy in the identity ofthe 
primary outcome = 66% 
Proportion of trials with a discrepancy in the identity of a primary outcome 
r •• U i.n",,;:;>.., 
B S.E. Wald dl Si9· 
Step purposecode 
.405 .533 .578 1 .447 
1(a) Constant 
.693 .463 2.242 1 .134 
Administrat' u" 
B S.E. Wald dl Si9· 
Step administration 5.439 2 .066 
1 (a) administration(1 ) 
.440 .658 .447 1 .504 
administration(2) 1.216 .526 5.344 1 .021 
Constant 
.348 .377 .853 1 .356 
.................... ~, ._ .. - ... ............... 
B S.E. Wald dl Si9· 
Step RECdru91undcode 
.582 .468 1.544 1 .214 
1 (a) Constant 
.651 .356 3.338 1 .068 
----
I IV .................... '., , ..... "..-
B S.E. Wald dl Si9· 
Step RECss200code 1.124 .479 5.503 1 .019 
1(a) Constant 
.463 .310 2.233 1 .135 
----
Lomoleteness OT tne sa mOle size calcUlation 
B S.E. Wald dl Si9· 
Step sscompcode2 9.136 2 .010 
1(a) sscompcode2( 1 ) 1.243 .754 2.718 1 .099 
sscompcode2(2) 1.955 .654 8.950 1 .003 
Constant 
-.470 .570 .680 1 .410 
Allocation concealment 
- ... _- .. _ .. --------.. ... 
B S.E. Wald dl Si9· 
Step RECalioccode 
.551 .476 1.343 1 .246 
1(a) Constant 
.778 .293 7.045 1 .008 
Sequence generation 
B S.E. Wald dl Si9· 
0: <=66% 
1: >66% 
95.0% CHor 
EXpiB) 
Exp(B) Lower UDoer 
1.500 .527 4.267 
2.000 
95.0%p~BI/or 
EXP B 
Exp(B) Lower UDDer 
1.553 .428 5.640 
3.373 1.203 9.453 
1.417 
95.0% CHor 
EXP(ElL 
Exp(B) Lower ~er 
1.789 .715 4.477 
1.917 
95.0% CHor 
EXP(B) 
Exp(B) Lower ~er 
3.078 1.203 7.875 
1.588 
95.0% CHor 
EXPIB) 
Exp(B) lower UDDer 
3.467 .791 15.197 
7.067 1.963 25.443 
.625 
95.0% CHor 
EXPIBl 
Exp(B) Lower UDDer 
1.736 .683 4.410 
2.176 
Exp(B) 
95.0% CHor 
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I 
I 
EXP(B) 
Lower Upper 
Step RECseqgencode 
.263 .510 .266 1 .606 1.301 .479 3.532 
1 (a) Constant 
.927 .271 11.691 1 .001 2.526 
UII"VII'Y 
95.0% C.l.for 
EXPIB) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step RECblindcode 
.958 .471 4.132 1 .042 2.607 1.035 6.569 
l(a) Constant 
.523 .315 2.751 1 .097 1.688 
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Appendix 6.1.4: Threshold for discrepancy in the identity of the 
primary outcome = 66%: adjusted for number of outcomes 
Proportion of trials with a discrepancy in the identity of a primary outcome 0: <=66% 
1: >66% 
I U, ......... 
95.0% C.l.for 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Slep numoutgrp2 
-1.743 .501 12.083 1 .001 .175 .066 .468 
1(a) purposecode 
.380 .578 .432 1 .511 1.462 .471 4.538 
Constant 3.301 .932 12.558 1 .000 27.148 
Administration 
i 95.0% C.l.for EXPIB\ 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Slep numoutgrp2 
-1.716 .514 11.150 1 .001 .180 .066 .492 
1(a) administration 4.267 2 .118 
adminislralion(1 ) 
.309 .714 .188 1 .665 1.363 .336 5.527 
adminislralion(2) 1.139 .565 4066 1 .044 3.124 1.032 9.456 
Constanl 2.956 .900 10.778 1 .001 19.212 
"-''''''''''<;;'''''01 'U" ... IIIY \I-,VlU....v, 
95.0% C.l.for 
EXP B\ 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Slep numoulgrp2 
-1.741 .504 11.938 1 .001 .175 .065 .471 
1(a) RECdrugfundcode 
.562 .506 1.236 1 .266 1.755 .651 4.728 
Constant 3.248 .874 13.816 1 .000 25.734 
-- .---~ 
• , ................ ",g,'1 'v"', ....... 
95.0% C.l.for 
EXPIB\ 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Slep numoulgrp2 
-1.920 .536 12.641 1 .000 .147 .051 .419 
1 (a) RECss200code 1.361 .536 6.452 1 .011 3.898 1.364 11.137 
Constant 3.201 .853 14.096 1 .000 24.554 
Completeness Of the sample size calculation 
95.0% C.l.for 
EXPIB) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Slep numoulgrp2 
-2.048 .584 12.279 1 .000 .129 .041 .406 
1 (a) sscompcode2 9.429 2 .009 
sscompcode2( 1 ) 
.763 .845 .816 1 .366 2.145 .409 11.239 
sscompcode2(2) 2.142 .749 8.170 1 .004 8.515 1.960 36.987 
Conslanl 2.564 1.050 5.964 1 .015 12.984 
_._._-
Allocation concealment 
I Exp(B) 
95.0%pTEiI/ or EXP B 
B S.E. Wald df Sig. Lower 1 Upper 
194 
Step numoutgrp2 
-1. 728 .503 11.816 1 .001 .178 .066 .476 
1 (a) RECalioccode 
.484 .510 .899 1 .343 1.622 .597 4.407 1 Constant 3.372 .854 15.599 1 .000 29.124 
~C''-tUI:l'II\,ooO:::: ~CIIIC"I ClUUII 
95.0% C.l.for 
EXPIB) 
B S.E. Wald dl Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-1.743 .501 12.126 1 .000 .175 .066 .467 
1(a) RECseqgencode 
.231 .547 .179 1 .673 1.260 .431 3.684 
Constant 3.525 .842 17.517 1 .000 33.968 
DIIIIU"I~ 
95.0'10,761;lor 
EXP B 
B S.E. Wald dl Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-1.922 .533 13.015 1 .000 .146 .051 .416 
1(a) RECblindcode 1.223 .529 5.335 1 .021 3.396 1.203 9.584 
Constant 3.246 .848 14.846 1 .000 25.694 
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Appendix 6.1.5: Threshold for discrepancy in the identity of the 
primary outcome = 0%: unadjusted for number of outcomes 
Proportion of trials with a discrepancy in the identity of a primary outcome 
r ,.HLn""oo;;; 
B S.E. Wald df Sig. 
Step purposecode 
.440 .651 .457 1 .499 
1(a) Constant 1.447 .556 6.779 1 .009 
Administration 
I 
B S.E. Wald df Sig. 
Step administration 8.129 2 .017 
1 (a) administratian(1 ) 1.147 .856 1.797 1 .180 
administratlan(2) 1.995 718 7.728 1 .005 
Constant 
.799 .401 3.958 1 .047 
............................. _ .. , ........ 
B S.E. Wald df Sig. 
Step RECdrugfundcade 1.017 .589 2.986 1 .084 
1(a) Constant 1.216 .403 9.131 1 .003 
, IV ............. "" .... ,. , ....... , ....... 
B S.E. Wald df Sig. 
Step RECss200code 1.715 .689 6.197 1 .013 
1 (a) Constant 1.099 .348 9.957 1 .002 
l,;OmD~eteness OT tne sa mD~e size calculation 
B S.E. Wald df Sig. 
Step sscompcode2 18.519 2 .000 
1 (a) sscompcode2(1 ) 2.144 .849 6.377 1 .012 
sscampcode2(2) 3.499 .821 18.147 1 .000 
Constant 
-.470 .570 .680 1 .410 
Allocation concealment . ... - .. _-- - . -- ... 
B S.E. Wald df Sig. 
Step RECaliaccade 1.768 .795 4.948 1 .026 
1(a) Constant 1.253 .327 14.648 1 .000 
Sequence generation 
B S.E. Wald df Sig. 
0: <=0% 
1: >0% 
95.0% C.l.far 
EXP(B) 
Exp(B) Lower Upper 
1.553 .433 5.564 
4.250 
95'°'lo,Ts'ifar EXP B 
Exp(B) Lower Upper 
3.150 .589 16.859 
7.350 1.801 29.995 
2.222 
95.0% C.l.far 
EXPI~ 
Exp(B) Lower ~er 
2.765 .872 8.767 
3.375 
95.0% C.l.far 
EXP(B) 
Exp(B) Lower UDDer 
5.556 1.440 21.434 
3.000 
95.0% C.l.far 
EXP(B) 
Exp(B) Lower Upper I 
8.533 1.616 45.061 
33.067 6.612 165.366 
.625 
95.0% C.l.far 
EXPIB) 
Exp(B) Lower UDDer 
5.857 1234 27.805 
3.500 
Exp(B) 
95.0% C.l.far 
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! EXP(B) 
Lower Upper 
Step RECseqgencode 1.117 .798 1.957 1 .162 3.055 .639 14.603 
1 (a) Constant 1.522 .319 22.832 1 .000 4.583 
-" .. _ ... 
95.0% C.l.for 
EXPIBl 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step RECblindcode 1.765 .689 6.560 1 .010 5.844 1.513 22.563 
l(a) Constant 1.068 .350 9.334 1 .002 2.909 
Number of outcomes 
95.0% C.l.for 
EXPIB) . 
B S.E. Wald df Sig. Exp(B) Lower Upper I 
Step numoutgrp2 
-.517 .581 .793 1 .373 .596 .191 1.861 I 
1 (a) Constant 2.523 .907 7.728 1 .005 12.461 I 
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Appendix 6.1.6: Threshold for discrepancy in the identity of the 
primary outcome = 0%: adjusted for number of outcomes 
Proportion of trials with a discrepancy in the identrty of a primary outcome 0: <=0% 
1: >0% 
. -, ---
95.0% C.l.for 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-.504 .582 .750 1 .386 .604 .193 1.891 
1 (a) purposecode 
.420 .654 .411 1 .521 1.521 .422 5.486 
Constant 2.187 1039 4.427 1 .035 8.906 
Administration 
- - - --- - ~--
95 Oo/~Te\ for 
EXP B 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-.329 .614 .288 1 .592 .720 .216 2.396 
1(a) administration 7.714 2 .021 
administration(1 ) 1.116 .859 1.690 1 .194 3054 .567 16.440 
administration(2) 1.956 .721 7.355 1 .007 7.069 1.720 29053 
Constant 1.292 1.013 1.627 1 .202 3.639 
........................... wo ........ , ............... 
95.0% C.l.for 
EXPIB) 
B S.E. Wald df Sig. Exp(B) Lower Up~er 
Step numoutgrp2 
-.474 .591 .645 1 .422 .622 .196 1.980 
1(a) RECdrugfundcode 
.997 .591 2.842 1 .092 2.709 .850 8.628 
Constant 1.909 969 3.879 1 .049 6.746 
. .... --_... ......... ..,. -._ ... 
95.0% ,Tel/or 
EXP B 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-.579 .607 .912 1 .340 .560 .171 1.840 
1 (a) RECss200code 1.737 .693 6.290 1 .012 5.681 1.462 22.084 
Constant 1.922 .949 4.096 1 .043 6.832 
l.;omoleteness or tne sa mole size calCUlation 
95.0% C.l.for 
EXPfB\ 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-.423 .715 .350 1 .554 .655 .161 2.659 
1(a) sscompcode2 17.949 2 .000 
sscompcode2( 1) 2.021 .871 5.378 1 .020 7.544 1.367 41.619 
sscompcode2(2) 3.472 .824 17.759 1 .000 32.185 6.404 161.757 
Constant 
.176 1.225 .021 1 .886 1.192 
Allocati nUV\,;CUIUII "'VII cealment 
I Exp(B) 
95.0% C.l.for 
EXP(B) 
B S.E. Wald df Sig. Lower I UDDer 
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Step numoutgrp2 
-.432 .600 .518 1 .472 .649 .201 2.103 
1(a) RECalioccode 1.742 .796 4.783 1 .029 5.706 1.198 27.175 
Constant 1.881 .949 3.930 1 .047 6.559 
.............. , ........... " .............. 
95.0% CHor 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-.499 .587 .721 1 .396 .607 .192 1.920 
1(a) RECseqgencode 1.105 .800 1.907 1 .167 3.019 .629 14.487 
Constant 2.241 .926 5.854 1 .016 9.407 
. 
... ",.'-'", 
95.0% CHor 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numoutgrp2 
-.633 .611 1.074 1 .300 .531 .160 1.758 
1(a) RECblindcode 1.809 .695 6.771 1 .009 6.105 1.563 23.646 
Constant 1.959 .949 4.258 1 .039 7.091 
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Appendix 6.2: Univariate analyses for completeness of reporting 
Appendix 6.2.1: Threshold for completeness of reporting = 100% 
Proportion of trials with fully reported comparisons 
P I U, ......... 
B S.E. Wald df 
Step purpose 
.038 .587 .004 1 
1(a) Constant 1099 .516 4.526 1 
-------
'-----_. 
Administration 
B S.E. Wald df 
Step administration 
.101 
1 (a) administration(1 ) 
.249 .786 .101 
administration(2) 
.076 .551 .019 
Constant 1.050 .439 5.715 
---- -------- ---- ----
Commercial fundina ( rotocol) 
B S.E. Wald df 
Step RECdrugfund 
.671 .498 1.820 
1(a) Constant 
.738 .367 4.048 
................................... _ ... 
B S.E. Wald df 
Step RECss200c 
.054 .493 .012 1 
1 (a) Constant 1.099 .365 9.052 1 
completeness ot the sa mple size calculation 
B S.E. Wald df 
Step sscompcode2 4.732 
1 (a) sscompcode2(1 ) 1.674 .854 3.843 
sscompcode2(2) 1.264 .657 3.697 
Constant 
.000 .577 .000 
Sig. 
.948 
.033 
Sig. 
2 .951 
1 .751 
1 .890 
1 .017 
Sig. 
1 .177 
1 .044 
Sig. 
.913 
.003 
Sig. 
2 .094 
1 .050 
1 .055 
1 1.000 
0: <100% 
1: 100% 
95.0% C.l.for 
EXP(B) 
Exp(B) Lower Upper 
1.039 .329 3.283 
3.000 
95.0% C.l.for 
EXPIB) 
Exp(B) Lower Upper 
1.283 .275 5.984 
1.079 .367 3.175 
2.857 
95.0% Cil,/or 
EXP B 
Exp(B) Lower Upper 
1.957 .738 5.188 
2.091 
95.0% C.l.for 
EXPIB\ 
Exp(B) lower Upper 
1.056 .402 2.774 
3.000 
95.0% C.l.for 
EXP(B) 
Exp(B) Lower Upper 
5.333 1.000 28.435 
3.538 .976 12.832 
1.000 
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Allocation concealment 
95.0% CHar 
EXPIBl 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Step RECalioc 
-.054 .493 .012 1 .913 .947 .361 2.489 
l(a) Constant 1.153 .331 12.117 1 .000 3.167 
..... ~ ....... , ......... ..... " ............. ,' 
95.0%pTEiI/ or EXP B 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Step RECseqgen 
-.388 .519 .558 1 .455 .679 .245 1.877 
1 (a) Constant 1.253 .303 17.089 1 .000 3.500 
u"',u,,' 
95.0% CHar 
EXPIBl 
B S.E. Wald df Sig. Exp(B) Lower UDoer 
Step RECblind 
.177 .491 .130 1 .719 1.194 .456 3. 125 1 l(a) Constant 1.036 .351 8.716 1 .003 2.818 
''' ... 41' ....... ' "'" ...... '" ... ,' .......... 
95.0% CHar 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower Upoer 
Step numbercompgrp2 1.277 .538 5.638 1 .018 3.586 1.250 10.291 
l(a) Constant 
.595 .311 3.647 1 .056 1.813 
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Appendix 6.2.2: Threshold for completeness of reporting = 100%: 
adjusted for number of comparisons 
Proportion of trials with fully reported comparisons 
rUII-'u"", 
B S.E. Wald 
Step numbercompgrp2 1.305 .545 5.735 
l(a) purpose 
-.203 .612 .110 
Constant 
.740 .542 1.868 
Administration 
B S.E. Wald 
Step numbercompgrp2 1.289 .544 5.622 
l(a) administration 
.090 
administration(1 ) 
.097 .817 .014 
administration(2) 
.171 .572 .090 
Constant 
.482 .497 .941 
1..<UI11I11C",",IClI IUI'UU1~ IUlU .... VIJ 
B S.E. Wald 
Step numbercompgrp2 1.306 .545 5.747 
l(a) RECdrugfund 
.723 .518 1.946 
Constant 
.161 .436 .137 
r, v V;'I!:l'U ;::,.::1.1 II III;; ;'ILC' 
B S.E. Wald 
Step RECss200c 
.176 .514 .118 
l(a) numbercompgrp2 1.295 .541 5.724 
Constant 
.490 .434 1.275 
--_ .. -
ComPleteness of the sam Ie size calculation 
B S.E. Wald 
Step numbercompgrp2 1.496 .582 6.602 
l(a) sscompcode2 5.878 
sscompcode2(1 ) 2.035 .920 4.887 
sscompcode2(2) 1.569 .723 4.708 
Constant 
-.864 .711 1.549 
df Sig. 
1 .017 
1 .740 
1 .172 
df Sig. 
1 .018 
2 .956 
1 .905 
1 .765 
1 .332 
df Sig. 
1 .017 
1 .163 
1 .711 
df Sig. 
1 .732 
1 .017 
1 .259 
-
df Sig. 
1 .010 
2 .053 
1 .027 
1 .030 
1 .213 
0: <100% 
1: 100% 
95.0% C.l.for 
EXPIBl 
Exp(B) Lower Upper 
3.687 1.267 10.727 
.816 .246 2.709 
2.097 
95.0% C.l.for 
EXP(Bl 
Exp(B) lower Upper 
3.628 1.250 10.528 
1.102 .222 5.466 
1.187 .387 3.644 
1.619 
95.0% C.l.for 
EXP(Bl 
Exp(B) Lower Upper 
3.693 1.269 10.748 
2.061 .746 5.692 
1.175 
95.0% C.l.for 
EXPIB\ 
Exp(B) Lower Upper 
1.193 .436 3.264 
3.649 1.264 10.539 
1.632 
-- --
--
95.0% C.l.for 
EXP(Bl 
Exp(B) Lower Upper 
4.465 1.426 13.981 
7.650 1.260 46.467 
4.802 1.164 19.810 
.413 
202 
Allocation concealment 
95.0% C.l.for 
EXP'Bl 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Step numbercompgrp2 1.334 .553 5.807 1 .016 3.795 1.283 11.226 
1 (a) RECalioc 
.242 .525 .213 1 .644 1.274 .456 3.562 
Constant 
.462 .421 1.206 1 .272 1.588 
.... .., ...... "...... ""I"""'~IVII 
95.0% C.l.for 
EXP Bl 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numbercompgrp2 1.260 .539 5.464 1 .019 3.527 1.226 10.146 
1 (a) RECseqgen 
-.315 .538 .343 1 .558 .730 .254 2.095 
Constant 
.703 .365 3.702 1 .054 2.019 
.... 1II1 ..... 111~ 
95.0% C.l.for 
EXPIBl 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Step numbercompgrp2 1.406 .580 6.288 1 .012 4.078 1.359 12.232 
1(a) RECblind 
.511 .530 .928 1 .335 1.667 .590 4.712 
Constant 
.274 .452 .366 1 .545 1.315 
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Appendix 6.2.3: Threshold for completeness of reporting = 66% 
Proportion of trials with fully reported comparisons 
10.' "''''v 
B S.E. Wald 
Step purpose 
.581 .612 .901 
1(a) Constant 1.099 .516 4.526 
-------
Administration 
B S.E. Wald 
Step administration 
.547 
1(a) administration(1 ) 
.539 .893 .364 
administration(2) 
.381 .603 .400 
Constant 1.253 .463 7.324 
------- --
Commercial fundina rotocoll 
! 
B S.E. Wald 
Step RECdrugfund 
-.014 .569 .001 
1(a) Constant 1.540 .450 11.725 
-_ .. _-
rluDO~t::U ;)<::1111 Ie :SILt:: 
B S.E. Wald 
Step RECss200c 
.579 .556 1.081 
1 (a) Constant 1.237 .379 10.669 
Completeness Of the sample size calculation 
B S.E. Wald 
Step sscompcode2 8.270 
1(a) sscompcode2(1) 2.140 .945 5.133 
sscompcode2(2) 1.852 .691 7.179 
Constant 
.000 .577 .000 
Allocation concealment 
B S.E. Wald 
Step RECalioc 1.045 .622 2.816 
1(a) Constant 1.153 .331 12.117 
df 
1 
1 
df 
2 
1 
1 
1 
df 
1 
1 
df 
1 
1 
df 
2 
1 
1 
1 
df 
1 
1 
Sig. 
.342 
.033 
Sig. 
.761 
.546 
.527 
.007 
Sig. 
.980 
0: S 66% 
1: > 66% 
95.0% C.l.for 
EXPIB) 
Exp(B) Lower Upper 
1.788 .539 5.933 
3.000 
95.0% C.l.for 
EXPIBl 
Exp(B) Lower UDoer 
1.714 .298 9.869 
1.464 .449 4.775 
3.500 
95.0% C.l.for 
EXPIBl 
Exp(B) Lower UDDer 
.986 .323 3.009 
.002. ..... 4.667 
95.0% C.l.for 
EXpiB) 
Sig. Exp(B) Lower UPDer 
.298 1.783 .599 5.306 
.001 3.444 
95.0% C.l.for 
EXPIB) 
Sig. Exp(B) Lower Upper 
.016 
.023 8.500 1.335 54.127 
.007 6.375 1.644 24.714 
1.000 1.000 
95.0% C.l.for 
EXPIBl 
Sig. Exp(B) Lower Upper 
.093 2.842 .839 9.626 
.000 3.167 
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...... ~-, , ... - -, , ... , -~ ...... 
95.0% CHar 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step RECseqgen 
-.072 .596 .014 1 .904 .931 .289 2.995 
1(a) Constant 1.553 .332 21.908 1 .000 4.727 
UIIII .... III 
95.0% C.I. for 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step RECblind 
.468 .556 .711 1 .399 1.597 .538 4.746 
1(a) Constant 1.299 .376 11.938 1 .001 3.667 
.............. .... .. ' ........... , ... 
95.0% CHar 
EXP(Bj 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numbercompgrp2 
.619 .566 1.194 1 .274 1.857 .612 5.637 
1 (a) Constant 1.253 .359 12.207 1 .000 3.500 
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Appendix 6.2.4: Threshold for completeness of reporting = 66%: 
adjusted for number of comparisons 
Proportion of trials with fully reported comparisons 
rUI~v"'C 
B S.E. Wald 
Step numbercompgrp2 
.553 .575 .926 
1(a) purpose 
.483 .623 .602 
Constant 
.923 .545 2.867 
Administration -_.-- ~.- -
B S.E. Wald 
Step numbercompgrp2 
.630 .573 1.208 
1(a) administration 
.567 
administration(1 ) 
.466 .901 .268 
administration(2) 
.430 .610 .499 
Constant 
.954 .528 3.258 
\,.,UIIIlIIt::'ll,,;ldl IUIIUIII\.I IlJlUlUI,,;UI 
B S.E. Wald 
Step numbercompgrp2 
.619 .566 1.194 
1(a) RECdrugfund 
-.015 .573 .001 
Constant 1.262 .507 6.206 
,IV .... V;:)II::l'U ';'Cilil 1'1; ;:)ILC 
B S.E. Wald 
Step numbercompgrp2 
.687 .575 1.431 
1(a) RECss200c 
.650 .565 1.324 
Constant 
.891 .464 3.688 
Comoleteness of the sam Ie size calculation 
B S.E. Wald 
Step numbercompgrp2 
.852 .621 1.884 
1 (a) sscompcode2 8.784 
sscompcode2(1 ) 2.306 .972 5.622 
sscompcode2(2) 1.998 .721 7.678 
Constant 
-.499 .695 .516 
df Sig. 
1 .336 
1 .438 
1 .090 
df Sig. 
1 .272 
2 .753 
1 .605 
1 .480 
1 .071 
df Sig. 
1 .274 
1 .980 
1 .013 
df Sig. 
1 .232 
1 .250 
1 .055 
df Sig. 
1 .170 
2 .012 
1 .018 
1 .006 
1 .472 
0: <=66% 
1: >66% 
95.0% C.l.for 
EXP{Bl 
Exp(B) Lower Upper 
1.739 .564 5.364 
1.621 .478 5.490 
2.516 
95.0% C.l.for 
EXPIBl 
Exp(B) lower Upper 
1.878 .610 5.778 
1.594 .272 9.324 
1.538 .466 5.080 
2.595 
95.0% C.l.for 
EXPtB) 
Exp(B) Lower Upper 
1.857 .612 5.637 
.986 .320 3.031 
3.532 
95.0% C.l.for 
EXPIBl 
Exp(B) Lower Upper 
1.988 .645 6.132 
1.915 .633 5.796 
2.437 
95.0% C.l.for 
EXP(B) 
Exp(B) Lower Upper 
2.345 .694 7.919 
10.030 1.491 67.449 
7.375 1.795 30.311 
.607 
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Allocation concealment • _0 _________ .... _---
95.0% )~~ifor 
EXP B 
B S.E. Wald df Sig. Exp(B) Lower Uccer 
Step numbercompgrp2 
.912 .597 2.329 1 .127 2.488 .772 8.022 
1 (a) RECalioc 1.272 .649 3.841 1 .050 3.567 1.000 12.722 
Constant 
.657 .446 2.172 1 .141 1.929 
.............. , ..................... u ... ,. 
95.0% C.l.for 
EXPIB) 
B S.E. Wald df Sig. Exp(B) Lower Uccer 
Step numbercompgrp2 
.617 568 1.182 1 .277 1.854 .609 5.543 
1(a) RECseqgen 
-.024 .602 .002 1 .968 .976 .300 3.175 
Constant 1.261 .412 9.377 1 .002 3.528 
..... "' ....... 
95.0% C.l.for 
EXP/B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numbercompgrp2 
.774 .589 1.727 1 .189 2.168 .684 6.875 
1 (a) RECblind 
.650 .579 1.260 1 .262 1.916 .616 5.963 
Constant 
.860 .487 3.123 1 .077 2.384 
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Appendix 6.2.5: Threshold for completeness of reporting = 0% 
Proportion of trials with fully reported comparisons 
rUI v;:)c; 
B S.E. Wald df 
Step purpose 
.000 .845 .000 1 
1(a) Constant 2.197 .745 8.690 1 
Administration 
B S.E. Wald df 
Step administration 
.164 
1(a) administration(1 ) 
.486 1.205 .162 
administration(2) 
.095 .773 .015 
Constant 2079 .612 11.531 
Commercial fundinQ rotoco!) 
B S.E. Wald df 
Step RECdrugfund 
-.215 .743 .084 
1(a) Constant 2.335 .605 14.918 
r ,UJ,JU<:I..,U o:>g" I '''' ;:),"" ... 
B S.E. Wald df 
Step RECss200c 
.496 .707 .493 1 
1 (a) Constant 1.946 .478 16.566 1 
t;ompleteness Of the sa mple Size calculation 
B S.E. Wald df 
Step sscompcode2 3.264 
1(a) sscompcode2(1 ) 1.041 1.002 1.081 
sscompcode2(2) 1.522 .844 3.252 
Constant 1.099 .667 2.716 
Sig. 
1.000 
.003 
Sig. 
2 .921 
1 .687 
1 .902 
1 .001 
Sig. 
1 .772 
1 .000 
Sig. 
.483 
.000 
Sig. 
2 .196 
1 .298 
1 .071 
1 .099 
0: =0% 
1: >0% 
95.0% C.l.for 
EXP(B] 
Exp(B) Lower Upper 
1.000 .191 5.241 
9.000 
95.0% '~sl/or 
EXP B 
Exp(B) Lower Upper 
1.625 .153 17.239 
1.100 .242 5006 
8.000 
95.0%pTslifor EXP B 
Exp(B) Lower Upper 
.806 .188 3.461 
10.333 
95.0% C.l.for 
EXPIBl 
Exp(B) Lower UDoer 
1.643 .411 6.572 
7.000 
95.0% C.l.for 
EXP(B) 
Exp(B) Lower Upper 
2.833 .398 20.179 
4.583 .876 23.974 
3.000 
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Allocation concealment 
95.0% ,Til'ifor 
EXP B 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Step RECalioc 1.129 .832 1.841 1 .175 3093 .605 15.801 
1 (a) Constant 1.815 .408 19.838 1 .000 6.143 
'-'I::' 1,.111:;:11 .... 0:::; YC"llw' ClUUII 
95.0% C.l.for 
EXpiB) 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Step RECseqgen 
-.702 .715 .984 1 .326 .496 .122 2.011 
1 (a) Constant 2.451 .466 27.653 1 .000 11.600 
DIIIIUIII~ 
95.0''',7slifor 
EXP B 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Step RECblind 
.916 .742 1.527 1 .217 2.500 .584 10.696 
1 (a) Constant 1.792 .441 16.511 1 .000 6.000 
''IIUIIILI'C'I VI '-'VII' ClIII~U";' 
95.0% C.l.for 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Step numbercompgrp2 
-.767 .741 1.071 1 .301 .484 .109 1.985 
1 (a) Constant 2.639 .598 19.501 1 .000 14.000 
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Appendix 6.2.6: Threshold for completeness of reporting = 0%: 
adjusted for number of comparisons 
Proportion of trials with fully reported comparisons 
, ... ' ... "",., 
B S.E. Wald df 
Step numbercompgrp2 
-.789 .752 1.100 
1 (a) purpose 
.154 .863 .032 
Constant 2.532 .840 9.092 
Administration 
B S.E. Wald df 
Step numbercompgrp2 
-.809 .747 1.172 
l(a) administration 
.254 
administration(1 ) 
.584 1.214 .231 
administration(2) 
.041 .780 .003 
Constant 2.562 .795 10.381 
....... ,." ............... _ ........ ._ .......... ' 
B S.E. Wald df 
Step numbercompgrp2 
-.768 .742 1.072 
l(a) RECdrugfund 
-.218 .748 .085 
Constant 2.779 .778 12.768 
IIU .... "''''' ... ~III .. ;; ... , ....... 
B S.E. Wald df 
Step numbercompgrp2 
-.731 .745 .964 
l(a) RECss200c 
.438 .713 .377 
Constant 2.397 .699 11.748 
LomOleleness OT me sam Ie size calcUlatiOn 
B S.E. Wald df 
Step numbercompgrp2 
-.716 .755 .901 
1 (a) sscompcode2 3.026 
sscompcode2(1 ) 
.982 1.011 .944 
sscompcode2(2) 1.480 .851 3.022 
Constant 1.548 .843 3.369 
Sig. 
1 .294 
1 .859 
1 .003 
Sig. 
1 .279 
2 .881 
1 .631 
1 .958 
1 .001 
Sig. 
1 .300 
1 .771 
1 .000 
Sig. 
1 .326 
1 .539 
1 .001 
Sig. 
1 .343 
2 .220 
1 .331 
1 .082 
1 .066 
0: =0% 
1: >0% 
95.0% C.l.for 
EXP(Bl 
Exp(B) Lower Upper 
.454 .104 1.984 
1.166 .215 6.334 
12.576 
95.0% C.l.for 
EXP(Bl 
Exp(B) Lower Upper 
.445 .103 1.927 
1.793 .166 19.347 
1.042 .226 4.809 
12.955 
95.0% C.l.for 
EXF'@L 
Exp(B) Lower ~r 
.464 .108 1.985 
.804 .186 3.481 
16.108 
95.0% C.l.for 
EXPIBl 
Exp(B) Lower Upper 
.481 .112 2.072 
1.549 .383 6.269 
10.986 
95.0% C.l.for 
EXP B) 
Exp(B) Lower Upper 
.488 .111 2.145 
2.669 .368 19.349 
4.393 .828 23.304 
4.702 
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Allocation concealment 
95.0% C.l.for 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numbercompgrp2 
-.574 .759 .573 1 .449 .563 .127 2.492 
1 (a) RECalioc 1.008 .847 1.415 1 .234 2.739 .521 14.418 
Constant 2.188 .668 10.714 1 .001 8.917 
.............. , ... " .... _ ....... 
95.0% C.l.for 
EXP([l} 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numbercompgrp2 
-.835 .750 1.240 1 .265 .434 .100 1.887 
1(a) RECseqgen 
-.779 .725 1.154 1 .283 .459 .111 1.900 
Constant 2.960 .699 17.936 1 .000 19.295 
... " ........ 
95.0% C.l.for 
EXP1B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step numbercompgrp2 
-.602 .760 .627 1 .428 .548 .124 2.429 
1 (a) RECblind 
.791 .758 1.088 1 .297 2.205 .499 9.747 
Constant 2.194 .702 9.769 1 .002 8.971 
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Appendix 6.3: Univariate analyses for completeness of 
documentation of the sample size calculation 
(O=incomplete; l=partial or complete) 
B S.E. Wald df Sig. Exp(B) 
Step purposecode 
.795 .575 1.909 1 .167 2.214 
l(a) Constant 1.041 .475 4.810 1 .028 2.833 
B S.E. Wald df Sig. Exp(B) 
Step administration 11.415 2 .003 
l(a) administration(1 ) 
.981 .732 1.796 1 .180 2.667 
administration(2) 2.679 .807 11.033 1 .001 14.571 
Constant 
.560 .362 2.391 1 .122 1.750 
B S.E. Wald df Sig. Exp(B) 
Step RECdrugfundcode 1.388 .558 6.182 1 .013 4.006 
1 (a) Constant 
.898 L_ .358 6.302 1 .012 2.455 
95.0% CHar 
EXP(B) 
Lower Upper 
.717 6.836 
95.0% CHar 
EXP(B) 
Lower Upper 
.635 11.194 
2.999 70.804 
95.0% CHar 
EXP(B) 
Lower Upper 
1.342 11.963 
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Appendix 6.4: Univariate analyses for adequacy of reporting of the 
power calculation 
95.0% CHor 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step purposecode 1.795 .511 12.360 1 .000 6.020 2.213 16.375 
1 (a) Constant 
-.629 .438 2.062 1 .151 .533 
95.0% CHor 
EXPIB) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step administration 15.460 2 .000 
1(a) administration( 1) 
.662 .606 1.195 1 .274 1.939 .591 6.355 
administration(2) 2.033 .521 15.229 1 .000 7.634 2.750 21.188 
Constant 
-.305 .352 .752 1 .386 .737 
95.0% CHor 
EXP~ 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step RECdrugfundcode 
-.103 .436 .056 1 .813 .902 .383 2.122 ! 
1 (a) Constant 
.773 .349 4.908 
, 
1 .027 2.167 
95.0% CHor 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step sscompcode2 7.348 2 .025 
1(a) sscompcode2(1) 1.130 .697 2.624 1 .105 3.095 .789 12.144 
sscompcode2(2) 1.590 .588 7.314 1 .007 4.902 1.549 15.513 
Constant 
-.511 .516 .979 1 .323 .600 
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Appendix 6.5: Univariate analyses for journal type 
Outcome: journal (0 = specialty; 1 = general) 
P I ... ' ......... 
B S.E. Wald df Sig. Exp(B) 
Step purposecode 2.303 1.051 4.804 1 .028 10.000 
1(a) Constant 
-3.091 1.022 9.139 1 .003 .045 
Administration 
B S.E. Wald df Sig. Exp(B) 
Step administration 7.981 2 .018 1 (a) 
administration (1) 2.590 1.147 5.104 1 .024 13.333 
administration (2) 2.965 1.054 7.909 1 .005 19.394 
Constant - 1016 11.647 1 .001 .031 3.466 
--, .... ,-, _._, ._ .. _ ... ._._-_. 
B S.E. Wald df Sig. Exp(B) 
Step RECdrugfundeode 
-.090 .468 .037 1 .848 .914 
1(a) Constant 
-1.030 .368 7.811 1 .005 .357 
ProDosed . . - - "'''''I , ............... 
B S.E. Wald df Sig. Exp(B) 
Step RECss200e 2.703 .779 12.029 1 .001 14.929 
1(a) Constant 
-2.944 .725 16.472 1 .000 .053 
C f th leu I .. ,",,""," , ....... ' ....... "' .... , .. ,e sample size cali.. ............ ,. 
95.0% CHor 
EXPIB) 
Lower Upper 
1.276 78.383 
95.0% CHor 
EXP(B) 
Lower Upper 
1.409 126.150 
2.456 153.140 
95.0% CHor 
EXPIB) 
Lower UDDer 
.366 2.286 
._-- -_ .. _-
95.0%pTsl;for 
EXP B 
Lower UDDer 
3.240 68.779 
95.0% CHor 
EXPIB) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step sscompcode2 2.906 2 .234 
1(a) sscompcode2(1) 1.861 1.142 2.654 1 .103 6.429 .685 60.313 
sseompeode2(2) 1.781 1.068 2.783 1 .095 5.937 .732 48.138 
Constant -2.708 1.033 6.875 1 .009 .067 
Allocation concealment 
95.0% CHor 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step RECalioccode 1.996 .526 14.375 1 .000 7.361 2.623 20.659 
1(a) Constant 
-2.179 .431 25.580 1 .000 .113 
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-'.... ............... .... .................. 
95.0% )~8Ii for 
EXP B 
B S.E. Wald df Si9· Exp{B) Lower UDDer 
Step RECseqgencode 
.511 .477 1.145 1 .285 1.667 .654 4.249 
1 (a) Constant 
-1.253 .283 19.530 1 .000 .286 
............. 
95.0% )~~;,or 
EXP B 
B S.E. Wald df Si9· Exp{B) Lower UDoer 
Step RECblindcode 
.232 .458 .257 1 .612 1.261 .514 3.094 
1{a) Constant 
-1.213 .343 12.476 1 .000 .297 
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Appendix 6.6: Univariate analyses for exclusions 
Outcome: exclusions (0 = patients excluded; 1 = no apparent exclusions) 
Note: this is based on all 103 trials 
............. II 
B S.E. Wald 
Step designcode 
.671 .647 1.075 
l(a) Constant 
-.693 .612 1.281 
-
-- --_ .. --_.-
I .... ' ......... 
B S.E. Wald 
Step purposecode 
.212 .476 .199 
1 (a) Constant 
-.262 .421 .389 
Administration 
B S.E. Wald 
Step centrenationcode 1.212 
1 (a) centrenationcode( 1 ) 
-.051 .606 .007 
centrenationcode(2) 
.419 .447 .878 
Constant 
-.305 .352 .752 
-_ ...... _._._. ,-"-". ._--
B S.E. Wald 
Step RECdrugfundcode 
.181 .410 .194 
1 (a) Constant 
-.211 .326 .419 
•• - ______ , II • __ • __ 
B S.E. Wald 
Step RECssgroup 2.491 
l(a) RECssgroup(1 ) 
-.307 .462 .441 
RECssgroup(2) 
.506 .558 .823 
Constant 
-.065 .359 .032 
completeness ot the sample size calculation 
df Sig. Exp(B) 
1 .300 1.957 
1 .258 .500 
df Sig. Exp(B) 
1 .656 1.237 
1 .533 .769 
df Sig. Exp(B) 
2 .546 
1 .933 .950 
1 .349 1.520 
1 .386 .737 
df Sig. Exp(B) 
1 .660 1.198 
1 .517 .810 
df Sig. Exp(B) 
2 .288 
1 .507 .736 
1 .364 1.659 
1 .857 .938 
95.0% CHor 
EXP(B) 
Lower Upper 
.550 6.957 
95.0% CHor 
EXP(B) 
Lower Upper 
.486 3.146 
95.0% '?slifOr 
EXP B 
Lower UPDer 
.290 3.114 
.633 3.650 
95.0% CHor 
EXP(B) 
Lower Upper 
.536 2.675 
95.0% CHor 
EXPIBI 
Lower UDDer 
.297 1.820 
.555 4.956 
95.0% CHor 
EXP(B) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step sscompcode2 1.793 2 .408 
l(a) sscompcode2(1) -.870 .688 1.599 1 .206 .419 .109 1.614 
sscompcode2(2) -.281 .560 .252 1 .616 .755 .252 2.263 
Constant .251 .504 .249 1 .618 1.286 
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Allocation concealment 
, 
95.0% .~~'i for i 
I EXP B 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Step RECalioccode 
.490 .401 1.489 1 .222 1.632 .743 3.584 
1 (a) Constant 
-.307 .263 1.362 1 .243 .735 
........... "". n...... ...,I .... , ... ~I ... ' I 
95.0% C.l.for 
EXPIB) 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step RECseqgencode 
.417 .432 .934 1 .334 1.518 .651 3.539 i 
1 (a) Constant 
-.223 .237 .885 1 .347 .800 I 
-------- --
.... 111'\..1111 
95.0%,7sl/ or EXP B 
B S.E. Wald df Sig. Exp(B) Lower UDDer 
Step RECblindcode 
-.339 .397 .731 1 .392 .712 .327 1.550 
1 (a) Constant 
.083 .289 .083 1 .773 1.087 
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Appendix 6.7: Univariate analyses for commercial funding in 
protocol 
Note: these analyses are based on all 103 trials 
Commercial funding mentioned in protocol 
ru,t-'v;:)'C' 
B S.E. 
Step purposecode 
-.369 .508 
1 (a) Constant 
.827 .453 
Administration 
- -- -- - ~--
B S.E. 
Step administration 
1 (a) administration(1 ) 1.037 .620 
administration(2) 1.659 .484 
Constant 
-.431 .356 
,IUIJV;::'I:l'U ;::'C::UI'I-L'C' ::tILe' 
B S.E. 
Step RECss200code 
.490 .411 
1 (a) Constant 
.288 .289 
(;ompleteness or the sa mple size calculation 
B S.E. 
Step sscompcode2 
1(a) sscompcode2( 1) 1.407 .715 
sscompcode2(2) 1.643 .602 
Constant 
-.788 .539 
Allocation concealment 
B S.E. 
Step RECalioccode 
.040 .413 
1 (a) Constant 
.520 .269 
'"'<;> uv",""", .... , ..... , ' .... ,u, , 
B S.E. 
Step RECseqgencode 
.953 .491 
1 (a) Constant 
.280 .238 
0: no commercial funding mentioned 
1: commercial fundinQ mentioned 
95.0% CHor 
EXPIB) 
Wald df Sig. Exp(B) Lower Upper 
.527 1 .468 .692 .256 1.871 
3.328 1 .068 2.286 
95.0% )~gl/or 
EXP B 
Wald df Sig. Exp(B) Lower Upper 
11.797 2 .003 
2.796 1 .094 2.821 .837 9.509 
11.736 1 .001 5.256 2.034 13.584 
1.462 1 .227 .650 
95.0% CHor 
EXP(B) 
Wald df Sig. Exp(B) Lower Upper 
1.419 1 .234 1.632 .729 3.655 
.993 1 .319 1.333 
95.0% CHor 
EXPIB\ 
Wald df Sig. Exp(B) Lower Upper 
7.480 2 .024 
3.879 1 .049 4.086 1.007 16.579 
7.452 1 .006 5.170 1.589 16.817 
2.137 1 .144 .455 
95.0% )~Hor 
EXP B\ 
Wald df Sig. Exp(B) Lower Upper 
.009 1 .923 1.041 .463 2.338 
3.729 1 .053 1.682 
95.0'/~TBI/or 
EXP B 
Wald df Sig. Exp(B) Lower Upper 
3.762 1 .052 2.592 .990 6.788 
1.380 1 .240 1.323 
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UIIIIYIII 
95.0% Csi/or 
EXP(8 
8 S.E. Wald df Sig. Exp(8) Lower UDDer 
Step RECblindcode 1.256 .429 8.565 1 .003 3.512 1.514 8.144 
1 (a) Constant 
-.083 .289 .083 1 .773 .920 
. --
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Appendix 6.8: Univariate analyses for commercial funding in 
publication 
Commercial funding mentioned in publication 0: no commercial funding mentioned 
1: commercial fundina mentioned 
Sam ole size achieved 0: <=200; 1: >200) 
I 95.0% )~81/or I EXP B 
B S.E. Wald df Sig. Exp(B) lower UDDer 
Step pubss200code 
.328 .409 .643 1 .422 1.388 .623 3.096 
1(a) Constant 
.314 .302 1.080 1 .299 1.368 
I ""'t-' ..... ", VI un.." ....... ' ...... '<1U..,,1 v." , .......... UCl.U;;', I ....... "" .......... 
95.0% C.l.for 
EXP(B) 
B S.E. Wald df Sig. Exp(B) lower UDPer 
Step pubpowercalccode 
-.164 .435 .142 1 .706 .648 .361 1.992 
1 (a) Constant 
.606 .359 2.853 1 .091 1.833 
~"' ........................ ~ ..... ,I ... ,I., ... ............. 
950o/~Ts'/or 
EXP B 
B S.E. Wald df Sig. Exp(B) lower UDDer 
Step pubacokcode 
-.290 .551 .278 1 .598 .748 .254 2.202 
1 (a) Constant 
.542 .222 5.934 1 .015 1.719 
Seauence generation reported 0: 
95.0% C.l.for 
EXPIBI 
B S.E. Wald df Sig. Exp(B) Lower Upper 
Step pubsgokcode 
-.459 .419 1.202 1 .273 .632 .278 1.435 
1(a) Constant 
.670 .262 6.536 1 .011 1.955 
UIII'U"'H v. I'V' '''''jJVI u::::u Q;:) uvuu'''' 1.,1111'0,.1, I. I '='jJUI LV\.! Ql) '-I"''''V''''' VII' IU 
95.0% C.l.for 
EXP(B) 
B 8E Wald df 8ig. Exp(B) Lower UDDer 
Step pubblindcode 1.340 .430 9.721 1 .002 3.818 1.645 8.864 
1(a) Constant 
, . -.167 .290 .333 1 .564 .646 
.. - _ .._-
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Appendix 7.1: Multivariate models for discrepancy in the identity of 
the primary outcome 
Proportion of trials with a difference in the identity of a primary outcome 0: <100% 
1: 100% 
These analyses are based on the 97 trials with at least one Identifiable primary outcome. Logistic 
regression (beat model) based on slgnilicant covarlates In univariate analyaia. 
B S.E. Wald 
Slep RECdrugfundcode 1.091 .607 3.229 
1 (a) RECss200code 
.827 .622 1.768 
sscompcode2 7.250 
sscompcode2( 1 ) 1.350 1.013 1.774 
sscompcode2(2) 2.556 .969 6.959 
numoulgrp2 
·3.290 .725 20.619 
Constant 2.539 1.131 5.040 
Slep RECdrugfundcode 1.017 .602 2.856 
2(a) sscompcode2 9.315 
sscompcode2( 1 ) 1.600 1.002 2.550 
sscompcode2(2) 2.898 .964 9.029 
numoulgrp2 
·3.171 .701 20.471 
Constant 2.507 1.118 5.025 
Proportion of trials with a difference in the identity 
of a Drimarv outcome 
B S.E. Wald 
Slep numoulgrp2 
·2.292 .634 13.090 
1 (a) RECblindcode 
.958 .575 2.772 
RECss200code 
.984 .592 2.762 
sscompcode2 6.171 
sscompcode2( 1 ) 
.565 .871 .421 
sscompcode2(2) 1.749 .753 5.392 
Constant 2.292 1.092 4.404 
df 
df 
Sig. 
1 .072 
1 .184 
2 .027 
1 .183 
1 .008 
1 .000 
1 .025 
1 .091 
2 .009 
1 .110 
1 .003 
1 .000 
1 .025 
Sig. 
1 .000 
1 .096 
1 .097 
2 .046 
1 .516 
1 .020 
1 .036 
95.0% C.l.for 
EXP(B) 
Exp(B) Lower Upper 
2.978 .906 9.794 
2.287 .676 7.745 
3.856 .529 28.097 
12.886 1.929 86.077 
.037 .009 .154 
12.662 
2.766 .850 9.000 
4.955 .695 35.321 
18.131 2.739 120.020 
.042 .011 .166 
12.262 
0: S 66% 
1: > 66% 
95.0% C.l.for 
EXP(B) 
Exp(B) Lower Upper 
.101 .029 .350 
2.605 .844 8.042 
2.674 .838 8.530 
1.760 .319 9.694 
5.747 1.314 25.148 
9.895 
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Proportion of trials with a difference in the identity 
of a Drimarv outcome 
B S.E. Wald 
Step administration 
.015 
1 (a) administration(1 ) 
.080 1.143 .005 
administration(2) 
-.079 1.428 .003 
RECdrugfundcode 
.022 .852 .001 
RECss200code 1.118 1.124 .990 
sscompcode2 10.185 
sscompcode2(1) 2.500 1.183 4.468 
sscompcode2(2) 3.382 1.061 10.151 
RECalioccode 
.429 1.137 .142 
RECblindcode 2.153 .991 4.722 
Constant 
-1.870 .929 4.050 
Step RECdrugfundcode 
.013 .807 .000 
2(a) RECss200code 1.079 .873 1.526 
sscompcode2 10.203 
sscompcode2(1) 2.469 1.139 4.703 
sscompcode2(2) 3.375 1.059 10.162 
RECalioccode 
.414 .984 .177 
RECblindcode 2.140 .973 4.833 
Constant 
-1.843 .896 4.229 
Step RECss200code 1.079 .873 1.528 
3(a) sscompcode2 10.499 
sscompcode2(1) 2.475 1.080 5.251 
sscompcode2(2) 3.377 1.049 10.372 
RECalioccode 
.415 .983 .178 
RECblindcode 2.144 .934 5.275 
Constant 
-1.840 .876 4.410 
Step RECss200code 1.175 .841 1.952 
4(a) sscompcode2 13.713 
sscompcode2(1) 2.620 1.033 6.437 
sscompcode2(2) 3.564 .971 13.480 
RECblindcode 2.162 .937 5.323 
Constant 
-1.873 .878 4.553 
Step sscompcode2 15.891 
5(a) sscompcode2( 1 ) 2.706 1.011 7.161 
sscompcode2(2) 3.789 .956 15.713 
RECblindcode 2.139 .898 5.677 
Constant 
-1.585 .834 3.611 
- . 
df Sig. 
2 .992 
1 .944 
1 .956 
1 .979 
1 .320 
2 .006 
1 .035 
1 .001 
1 .706 
1 .030 
1 .044 
1 .988 
1 .217 
2 .006 
1 .030 
1 .001 
1 .674 
1 .028 
1 .040 
1 .216 
2 .005 
1 .022 
1 .001 
1 .673 
1 .022 
1 .036 
1 .162 
2 .001 
1 .011 
1 .000 
1 .021 
1 .033 
2 .000 
1 .007 
1 .000 
1 .017 
1 .057 
0: =0% 
1: >0% 
95.0% CHor 
EXP(B) 
Exp(B) Lower Upper 
1.084 .115 10.189 
.924 .056 15.189 
1.023 .193 5.431 
3059 .338 27.689 
12.184 1.200 123.742 
29.419 3.674 235.546 
1.535 .165 14.249 
8.614 1.235 60.080 
.154 
1.013 .208 4.927 
2.942 .531 16.299 
11.812 1.268 110.014 
29.230 3.669 232.859 
1.513 .220 10.417 
8.500 1.261 57.280 
.158 
2.941 .532 16.269 
11.880 1.431 98.652 
29.297 3.751 228.819 
1.514 .221 10.389 
8.537 1.369 53.216 
.159 
3.238 .623 16.833 
13.734 1.815 103.927 
35.313 5.267 236.736 
8.685 1.384 54.489 
.154 
14.972 2.063 108.663 
44.193 6.789 287.664 
8.488 1.461 49.302 
.205 
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Appendix 7.2: Multivariate model for completeness of reporting 
Proportion of trials with fully reported comparisons I I 0: <100% 
1: 100% 
This analysis Is based on the 90 trials with at least one Identifiable primary outcome that Is not 
global or Involving more than 2 time pOints 
Beat model based on significant covarlatea in univariate analysis 
B S.E. Wald df Sig. 
Step numbercompgrp2 1.496 .582 6.602 1 .010 
1 (a) sscompcode2 5.878 2 .053 
sscompcode2( 1) 2.035 .920 4.887 1 .027 
sscompcode2(2) 1.569 .723 4.708 1 .030 
Constant 
-.864 .711 1.549 1 .213 
Proportion of trials with fully reported comparisons 
B S.E. Wald df Sig. 
Step sscompcode2 5.400 2 .067 
1 (a) sscompcode2( 1) 1.974 1.009 3.829 1 .050 
sscompcode2(2) 1.665 .775 4.620 1 .032 
RECalioc 
.754 .712 1.120 1 .290 
numbercompgrp2 
.980 .634 2.385 1 .123 
Constant 
-.575 .703 .668 1 .414 
Step sscompcode2 8.784 2 .012 
2(a) sscompcode2( 1) 2.306 .972 5.622 1 .018 
sscompcode2(2) 1.998 .721 7.678 1 .006 
numbercompgrp2 
.852 .621 1.884 1 .170 
Constant 
-.499 .695 .516 1 .472 
Step sscompcode2 8.270 2 .016 
3(a) sscompcode2(1) 2.140 .945 5.133 1 .023 
sscompcode2(2) 1.852 .691 7.179 1 .007 
Constant 
.000 .577 .000 1 1.000 
Proportion of trials with fully reported comparisons 
95.0% C.l.for 
EXP(B) 
Exp(B) Lower UDper 
4.465 1.426 13.981 
7.650 1.260 46.467 
4.802 1.164 19.810 
.413 
0: S66% 
1: > 66% 
95.0% C.l.for 
EXP(B) 
Exp(B) Lower UDper 
7.196 .997 51.956 
5.285 1.158 24.116 
2.125 .526 8.581 
2.664 .768 9.237 
.563 
10.030 1.491 67.449 
7.375 1.795 30.311 
2.345 .694 7.919 
.607 
8.500 1.335 54.127 
6.375 1.644 24.714 
1.000 
0: =0% 
1: >0% 
A multivariate model was not compiled for the threshold of 0% for the outcome 
"completeness of reporting" as no variables were significant in univariate analysis. 
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Appendix 7.3: Multivariate models for completeness of 
documentation of the sample size calculation 
Completeness of documentation of the sample 
size calculation 
B S.E. 
Step purposecode .150 .694 
1 (a) administration 
administration(1 ) 
.764 .771 
administration(2) 2.338 .889 
RECdrugfundcode 
.860 .654 
Constant 
.162 .631 
Step administration 
2(a) administration( 1) 
.802 .751 
administration(2) 2.408 .830 
RECdrugfundcode 
.809 .609 
Constant 
.264 .421 
Step administration 
3(a) adminislralion(1 ) 
.981 .732 
administration(2) 2.679 .807 
Constant 
.560 .362 
Wald df Sig. Exp(B) 
.047 1 .828 1.162 
6.956 2 .031 
.981 1 .322 2.146 
6.920 1 .009 10.361 
1.728 1 .189 2.364 
.066 1 .797 1.176 
8.546 2 .014 
1.140 1 .286 2.230 
8.421 1 .004 11.111 
1.763 1 .184 2.245 
.394 1 .530 1.302 
11.415 2 .003 
1.796 1 .180 2.667 
11.033 1 .001 14.571 
2.391 1 .122 1.750 
95.0% C.l.for 
EXPIBl 
Lower Uooer 
.298 4.530 
.474 9.722 
1.815 59.148 
.655 8.523 
.512 9.712 
2.185 56.502 
.680 7.410 
.635 11.194 
2.999 70.804 
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Appendix 7.4: Multivariate model for adequacy of reporting of the 
power calculation 
Adequacy of reporting of power calculation 
B S.E. Wald 
Step purposecode 1.261 .612 4.240 
1(a) administration 4.948 
administration(1 ) 
.286 .654 .191 
administration(2) 1.313 .612 4.603 
sscompcode2 2.223 
sscompcode2( 1) 
.901 .848 1.129 
sscompcode2(2) 
.969 .654 2.195 
Constant 
-1.637 .706 5.383 
Step purposecode 1.179 .558 4.462 
2(a) administration 8.560 
administration( 1) 
.517 .631 .672 
administration(2) 1.620 .559 8.408 
Constant -9~ .496 3.882 
df Sig. 
1 .039 
2 .084 
1 .662 
1 .032 
2 .329 
1 .288 
1 .138 
1 .020 
1 .035 
2 .014 
1 .412 
1 .004 
1 .049 
0: inadequate 
1: adeauate 
95.0% CHar 
EXP(B) 
Exp(B) Lower Upper 
3.528 1.063 11.712 
1.331 .369 4.799 
3.719 1.120 12.345 
2.463 .467 12.978 
2.636 .731 9.507 
.195 
3.250 1.089 9.698 
1.677 .487 5.777 
5.054 1.691 15.111 
.376 
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Appendix 7.5: Multivariate model for journal type 
[ Joumal type 
B S.E. Wald df Sig. 
Step purposecode 
.282 1.331 .045 1 .832 
1 (a) administration 1.779 2 .411 
administration(1 ) 1.577 1.249 1.594 1 .207 
administration(2) 
.955 1.227 .606 1 .436 
RECss200code 1.892 .915 4.275 1 .039 
RECalioccode 1.588 .579 7.524 1 .006 
Constant 
-4.447 1.424 9.755 1 .002 
Step administration 1.775 2 .412 
2(a) administration( 1) 1.578 1.247 1.600 1 .206 
administration(2) 
.967 1.226 .622 1 .430 
RECss200code 1.991 .805 6.113 1 .013 
RECalioccode 1.597 .577 7.666 1 .006 
Constant 
-4.280 1.154 13.748 1 .000 
Step RECss200code 2122 .679 9.777 1 .002 
3(a) RECalioccode 1.655 .560 8.743 1 .003 
Constant 
-3.435 .695 24.459 1 .000 
TO:Specialty 
l....:L.aeneral 
95.0% CHor 
EXPIB\ 
Exp(B) Lower Upper 
1.326 .098 18.012 
4.840 .418 55.984 
2.599 .235 28.768 
6.634 1.104 39.882 
4.893 1.573 15.217 
.012 
4.845 .420 55.843 
2.630 .238 29.071 
7.322 1.511 35.488 
4.938 1.594 15.295 
.014 
8.347 2.208 31.561 
5.232 1.747 15.670 
.032 
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Appendix 7.6: Multivariate model for commercial funding in 
protocol 
Commercial funding mentioned in protocol 
B S.E. 
Step administration 
1(a) administration( 1) 
.810 .663 
administration(2) 1.086 .544 
RECseqgencode 
.555 .564 
RECblindcode 
.952 .473 
sscompcode2 
sscompcode2( 1) 
.924 .797 
sscompcode2(2) 
.827 .697 
Constant 
-1.453 .619 
Step administration 
2(a) administration(1 ) 
.997 .641 
administration(2) 1.325 .511 
RECseqgencode 
.715 .531 
RECblindcode 
.918 .460 
Constant 
-.911 .421 
Step administration 
3(a) administration( 1) 
.957 .636 
administration(2) 1.399 .504 
RECblindcode 
.958 .456 
Constant 
-.767 .401 
0: no commercial funding mentioned 
1: commercial fundina mentioned 
95.0% C.l.for 
EXP1B) 
Wald df Sig. Exp(B) Lower UDDer 
4.111 2 .128 
1.496 1 .221 2.249 .614 8.242 
3.980 1 .046 2.962 1.019 8.606 
.969 1 .325 1.743 .577 5.266 
4.057 1 .044 2.592 1.026 6.548 
1.640 2 .440 
1.345 1 .246 2.520 .528 12.022 
1.406 1 .236 2.286 .583 8.968 
5.506 1 .019 .234 
7.004 2 .030 
2.420 1 .120 2709 .772 9.507 
6.739 1 .009 3.764 1.364 10.238 
1.812 1 .178 2.043 .722 5.764 
3.981 1 .046 2.505 1016 6.173 
4.686 1 .030 .402 
7.832 2 .020 
2.265 1 .132 2.604 .749 9.060 
7.692 1 .006 4.050 1.507 10.883 
4.414 1 .036 2.608 1.066 6.376 
3.654 1 .056 .464 
- . 
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Appendix 8: Systematic review tables
Appendix 8.1: Characteristics of included studies
Studv Methods Participants Interventions Outcomes Notes
Ahmed 1996 (Ahmed Case study A single study submitted Local RECis Time to approval Objectives: to compare the
& Nicholson 1996) to an LREC and then 36 Expedited review v full practices ofLRECs and the
otherLRECs committee time they take to obtain ethical
Year: 1989-1990 approval for a multi-centre
Country: England study
al Shahi 1999 (AI- Case study A single study submitted Central then local Time to receipt by EC Objectives: not stated
Shahi & Warlow to an MREC then RECis to LREC meeting,
1999) multiple LRECs (15) initialLREC decision
Year: 1998 and final LREC
Country: Scotland approval
Objections
Resources
Ashford 1987 Case study A single study submitted Central then local Approval Objectives: not stated
(Ashford 1987) to an independent ethics RECis Conditions of approval
committee (organised by
3 pharmaceutical
companies) then 25
LRECs
Year: 1984-1986
Countrv: Enzland
Bennett 2001 Case study Single study Local REC/s % IRBs approving Objectives: not stated
(Bennett et al. 200 I) (retrospective medical study
record review) submitted
to 104+ IRBs in 1990
and a follow-up ofthis
study submitted to 74+
IRBs in 1997
Year: 1990 and 1997
Country: USA
Benster 1993 (Benster Case study A single study submitted Local RECis Time to approval Objectives: not stated
& Pollock to 28 LRECs Conditions ofapproval
1992;Benster & Year: 1991
Pollock 1993) Country: England
229
Boyce 2002 (Boyce Case series 353 new applications to a Central REC Approval status (first Objectives:
2002b) (member of singleMREC meeting) Individual did not have access
MREC Year: between Oct 1997 Changes requested to complete MREC records. It
reviewing his and Nov 2000 Other outcomes was not possible to determine
records) Country: England collected but not how cases were selected
relevantto this review
Burman 2003 Caseseries 2 trials submitted to 25 Local REC/s Timeto approval Objectives: not stated
(Burman et al. 2003) sites Resources
Year: not reported Changes requested
Country: USA and (specifically changes to
Canada the consent form and
impact on readability)
Christian 2002 Case series 20 studies submitted to a Central REC Expedited review v full Objectives: not stated
(Christian, Goldberg, centrallRB with review Pilot of C1RB - limited data
Killen, Abrams, expertise in specific Approval available.
McCabe, Mauer, & disease
Wittes 2002) Year: 2001
Country: USA
Dal Re 1999 (Dal-Re, Case series First 100 applications for Local REC/s Time to approval Objective: to review the
Espada, & Ortega multicentre drug trial characteristics andperformance
1999) protocols submitted by a of research ethics committees in
pharmaceutical company Spain in the evaluation of
(SKB) in particular year multicentre clinicaltrial drug
15 protocols submitted to protocols
41 RECs
Year: 1995
Country: Spain
Dockerty 1992 Case study Single study submitted to Local RECls Timeto approval Objectives:not states
(Dockerty & Elwood 14 RECs (approval Changes requested
1992) obtained from I then
submitted to remaining
13)
Year: 1990
Country: New Zealand
Druml 1999 (Druml, Case series All studies submitted to Local REC/s Approval Objectives: not stated
Svolba, Singer, ethics committee of the
Bonkovsky, & Bauer medical faculty ofthe
1999) University of Vienna
230
Year: 1993-1997
Countrv: Austria
Dunn 2000 (Dunn, 2 Case studies One study submitted to Local RECls Number of copies of Objectives: not stated
Arscott, & Mann 197 LRECs in 1996- Central then local application
2000b) 1997 and a second study REC/s Fee charged
submitted to 1 MREC
then 26 LRECs in 1999.
Restricted to 21 LRECs
that reviewed both
studies.
Year: 1996-7 and 1999
Country: England
Faccini 1984 (Faccini, Case series First 294 protocols Central REC Decision made Objectives: not stated
Bennett, & Reid submitted NOTE: ethical review
1982) Year: commenced 1977 committee established and
Country: 9 European funded by pharmaceutical
countries companies
Garfield 1995 Case study Single study submitted to LocalREC/s Time to approval Objectives: not stated
(Garfield 1995) an LREC and (following Queries
approval) then submitted Changes requested
to 13 other LRECs
within a region
Year: not stated
Country: England
Gray 1975 (Gray Case series 79 projects in selected LocalRECIs Approval Objectives: not stated (possibly
1975) medical specialties Type of objection declared in methodology paper)
submitted to an Impact of REC on
institutional REC proposed research
Year: 1969-1970 Impact ofREC on
Country: USA conduct ofresearch
Hotopf1995 (Hotop~ Case study Single study submitted to Local REC/s Time to reply Objectives: not stated
Wessely, & Noah 6LRECs Approval
1995) Year: not reported Changes requested
Country: England
Humphreys 2003 Case study Single study submitted to Local RECis Resources Objectives:not stated
(Humphreys, Trafton, 8 LRECs Published as letter.
& Wagner 2003) Year: not reported
Country: USA
231
Jamrozik 1999 Case study Single study submitted to Local RECis Time to reply Objectives: not stated
(Jamrozik & a University EC then 29
Kolybaba 1999) IECs
Year: 1997
Countrv: Australia
Keinonen 200 I Case series All (666) protocols of Local RECIs Descriptive data (study Objectives: to determine the
(Keinonen, Nieminen, clinical studieson phase, subjects, design, amount and type of deficiencies
Saareks, Saano, & medicinal products etc) and questions the ECs pointed
Ylitalo 200 I) submitted to 2 University Approval out to investigators. andfind
hospitals Questionsraised / out if the ECs had been notified
Year: 1992, 1994, 1996, modifications of study completion (or not)
1998 requested
Countrv: Finland
Larcombe 1999 Case study Single study submitted to Central then local Time to response (not Objectives: not stated
(Larcombe & Mott MREC then 51 LRECs REC/s defined) Note: new MREC system
1999) Year: 1998 resources introduced half way through
Countrv: Enaland Chanzes reouested studv
Lewis 2001 (Lewis, Case study Single-centre study Central then local Time to approval Objectives: to assess the
Tomkins, & Sampson involving geographically RECis Volume of paperwork processinvolved in obtaining
2001) dispersed subjects Resources required ethical approval
submitted to MREC then Expedited review v full
53 LRECs committee
Year: 1998 Changes requested
Countrv: Wales
Lux 2000 (Lux, Case study Single study submitted to Central then local Expedited review v full Objectives: not stated
Edwards, & Osborne MREC then 99 LRECs RECis committee
2000) Year: 1998-1999 Time to approval
Country: England (response time)
Approval status
McWilliams 2003 Case study A single genetic Local RECis Expedited review v full Objectives: to assess the burden
(McWilliams et al. epidemiology study committee imposed by (IRB) review on
2003) submitted to 42 centres Time to approval multicentre studiesby
Year: not reported Resources submitting a common protocol
Country: USA Changes requested to multiple IRBs. Participating
centreswere surveyed.
Note: reports on a number of
riskfactors
Nafria 1998 (Nafria, Case series 22 trials snonsored bv a Local RECis Time to aonroval Obiectives: to describethe time
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Ferragud, & Navarro single drug company required to obtainethics
1998) submitted to 107 LRECs approval for a clinical trial in
Year: 1993-1996 Spain
Country: Spain Note: also reports the results of
a survey conducted to ascertain
the fees charged for submission
to an ethics committee
Note: oublished in Soanish
Ortega 1995 (Ortega Case series First 10 protocols Local REC/s Time to approval Objectives: not stated
& Dal Re 1995a) submitted by a drug Clarifications I Subgroups: number ofREC
company to 26 clinical modifications mem bers, Frequency of
trials committees (same requested meetings, Advance fee (yes/no)
as RECs)
Year: from July 1992
with approvals before
July 1993
Countrv: Soain
Penn 1995 (Penn & Case study 1 trial submitted to 26 Loca1REC/s Time to approval Objectives: not stated
Steer 1995) RECs (although not defined
Year: not reported and possible problems)
Country: UK Approval status
(overall)
Redshaw 1996 Case study A single study submitted Local REC/s Time to approval Objectives: not stated
(Redshaw, Harris, & to multiple LRECs Approval
Baum 1996) Year: not reported Changes requested
Country: England
Sandhu 2001 (Sandhu Case study Two studies submitted Central then local Resources Objectives: not stated
& Okasha 2001 ) MREC then 225 and 137 REC/s
LRECs
Year: not reported
Countrv: UK
Smith 1994 (Smith et Case study Single case-control study Local RECls Approval status first Objectives: not stated
al. 1994) submitted to 15 lECs meeting
Year: not reported Resources
Countrv: Australia
Stair 2001 (Stair et al. Case study Single (collaborative LocalRECls Time to approval Objectives: To describe lRB
2001) group) study submitted Modifications responses to one standard
to 441RBs requested protocol and thereby gain
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Year: 1998 insight into the advantages and
Country: USA and disadvantages ofiocallRB
Canada review
Tully 2000 (Tully, Case study Single study submitted to Central then local Time to reply Objectives: to assess the
Ninis, Booy, & Viner MREC then 125 LRECs REC/s Time to approval function of the new system of
2000) Year: 1998 Changes (number of) review by MRECs and to
Country: England highlight areas where
improvement is still needed
Subgroup: Executive sub-
committee v not
Watling 1993 Case study Single study submitted to Central then local Time to approval Objectives:not stated
(Watling & Dewhurst RCGP REC then 26 REC/s Accepting central
1993) LRECs approval v requiring
Year: not reported local review
Country: England Approval
Changes requested I
queries
Wise 1996 (Wise & Case series First 100 general practice Central REC Approval Objectives: to assess the
Drury 1996) basedmulticentre Amendments outcome of 100generalpractice
research projects Reasons fornon- based, multicentre research
Year: 1984-1989 approval projects submitted to the ethics
Country: UK Study success (started committee of the Royal College
Royal College ofGeneral recruitment, of General Practitioners by
Practitioners clinical recruitment, pharmaceutical companiesor
research ethics publication) their agents between 1984 and
committee 1989
234
Appendix 8.2: Characteristics of excluded studies
Studv Reason for exclusion
Bortolussi 2002 (Bortolussi & Nicholson 2002) Reports on the results of audits of the procedures used by 6 RECs in Canada performed between 1992 and
2000
Bruinsma 1999 (Bruinsma, Venn, & Skene 1999) Insufficientdatareoorted. Reoorted exoerience with2 cohort studies.
Crooks 1996 (Crooks, Colman, & Campbell 1996) Reports on questionnaire sentto 60 physicians who had notentered patients or had withdrawn participation
from 2 multi-centre trials. 17 reported reason for non-participation as difficulty obtaining local ethics approval
Dickersin 1992 (Dickersin, Min, & Meinert 1991) A follow-up studv of737 studies approved bv two RECs. Does not report outcomes of relevance to this review.
Easterbrook 1991 (Easterbrook, Berlin, Gopalan, A retrospective survey of487 research projects approved by a REC. Does not report outcomes of relevance to
& Mattbews 1991) this review.
Easterbrook 1992 (Easterbrook & Matthews 1992) A follow-up study of all (720) research protocols approved by a REC. Does not report outcomes of relevance
to this review.
Goldman 1982 (Goldman & Katz 1982) 3 deliberately flawed protocols were submitted to IRBs at 22 academic institutions in the USA. The authors
expected to find that different IRBs reached similar judgements on identical protocols and individual1RBs
would apply the same standards to each protocol. They found that IRBs were consistent in their non-approval
of the protocols, were inconsistent in the reasons offered in support of similar decisions,and inconsistent in the
application of ethical, methodological and informed consent standards.
Gray 1978 (Gray, Cooke, & Tannenbaum 1978) Interviews with research investigators whose proposalshad been reviewed, IRB members and subjects who
had consented to take part in research approved by 61 (of 420) institutions with review committees between
1974 and 1975. The committees were all approved by the US Department of Health, Education and Welfare.
The study investigated IRBs (composition, policies and procedures), modifications of research proposals, risks
andbenefits of approved research, selection of subjects in approved projects, informed consent, involvementof
IRBs after initial review, the performance ofIRBs and the attitudes of research subiects.
Hahn 2002 (Hahn, Williamson, & Hutton 2002) A follow-up study of all 56 submissions to an LREC in the UK in a particular year (year not specified). Did not
collect outcomes relevant to this review (studv to investigate within-studv selective reporting).
Holley 1998 (Holley & Foster 1998) 27 researchers were sent a questionnaire asking for theirviews on the substanceofethicalreview andtheir
experiencesofthe processof ethicalreview.
Keinonen 2002 (Keinonen et al. 2002) This study aimed to investigate the validity of clinical drug study notifications by the regulatory agency in
Finland durina the 1990s. The overlao with ethics committees was recognised butnot evaluated.
Lardot 2002 (Lardot et al. 2002) Reports on a central protocol review committeeof a disease-specific European organisation that functionsas
an internal review of ideas in development,not as a scientific review as Part of the ethics approval process.
Lynn 1994 (Lynn, Johnson, & Levine 1994) Surveyof 50 institutions not selected to participate in project. Opportunity "to examine how a number of
teaching hospitals responded to informed consent issues in health services research".
McNay 2002 (McNay et al. 2002) International, US-based trial where all sites (including non-US sites) required assurance of compliance with the
Code of Federal Regulations with the Office of Human Research Protection of the US Department of Health
andHuman Services. Once available, sites could submitstudvfor consideration for ethics aooroval.
Nicholl 2000 (Nicholl 2000) Single study submitted to MREC then unsoecified number of local RECs in the UK. Did not renort anv usable
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outcome data
Pelerin 1992 (Pelerin & Hall 1992) Single epidemiological study submitted to a national ethicscommittee on conditionthat district committees be
annroached. An advertisement was placed in a relevant publication to which 47 RECs resoonded.
Pich 2003 (Pich, Came, Arnaiz, Gomez, Trilla, & Survey sent to the principal investigators of protocols submitted to the REC in 1997
Rodes 2003) Objective: to assess the outcome of all protocols submitted to the HCEC (Hospital Clinic ethics committee)
during 1997
Silverman 2001 (Silverman, Hull, & Sugarman Single study submitted to 16 IRBs in the USA. Objective: to determine the extent of variability among IRBs on
2001) their approved research practices within the context of a specific multi-centre trial. Specifically reported the
various nractices relatina to informed consent.
Stone 1997 (Stone & Blozz 1997) Insufficient data reported. Report of 1 site's experience with 1 multi-centre trial and their local REC.
Takayanagi 2001 (Takayanagi et al. 200 I) Experience of a single ethics committee in Tokyo (The University of Tokyo Hospital) that introduced a prior
review system forclinicaltrials in that institution.
Taooin 1992 (Tappin & Cockburn 1992) Studv that alizns dates ofREC aooroval with incidence of HIV in each district.
Thomquist 2002 (Thomquist et al. 2002) Proposes using single-study cooperative agreements to facilitate approval of multi-centre trials, specifically to
facilitate approval of post-hoc sub-studies conducted on the large datasets collected as a result of multi-centre
clinical trials. Does not report outcome data.
While 1995 (While 1996) 43 district ethics committees were asked to indicate whether a proposed study required formal ethical approval.
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Appendix 8.3: Data tables: systematic review 
Table 72: Impact on clinical researcb: Cbanges requested foUowing first meeting of REC 
(Central REq 
Studv Nature of aneries 
Boyce 2002 Of the 339 applications conditionally approved, deferred or rejected at first meeting: 
- 287 (85%) queries related to information leallet (such as inadequate information, 
jargon, poor clarity, need for proofreading) 
- 171 (50%) queries related to study design (such as use ofplaceho, stopping current 
treatment, choice of comparator drug) 
Wise 1996 Of the 100 studies (applications) 82 were eventually approved of which 45 required 
amendment and resubmission, with an average of 1.5 amendment items per protocol. 
For 15 resubmissions chairman's approval was given (subject to later endorsement of the 
parent committee). Reasons for amendment (number of studies (% of requests for 
amendment» were: 
- safety aspect or inappropriate drug dose: 15 (33%) 
- remuneration considerations: 14 (31%) 
- logistics or cost of pathology: 9 (20%) 
- inadequate information sheet: 8 (18%) 
- statistical clarification or modification: 4 (9%) 
- imprecise diagnostic criteria: 4 (9%) 
- age limit considerations: 3 (7%) 
- pregnancy safety aspects: 2 (4%) 
- no run-in phase: 1 (2%) 
c<>ther: 3 (7%)_ 
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Table 73: Impact on clinical researcb: Cbanges requested foUowing IIrst meeting ofREC (Local 
REc/s) 
Study Nature of queries 
Burman Median of 46.5 changes per consent fonn ([QR 11-62) 
2003 - small changes (involving <I sentence): median 26 (IQR 8-45) 
- large changes (lor more contiguous sentences): median \0 (IQR 5-21) 
Analysed consent fonns in detail and found the [RB changes made consent fonns less 
readable 
Dal Re Type and number of queries for phase Il/phase III trialss 
1999 Protocol related issues: 
- study design: 0/3 
- selection criteria 3/0 
- study procedures 1/5 
- statistics: 2/1 
- other: III 
Informed consent: 
- wording of the patient infonnation sheet: 513 
- consent fonn sign-off: 311 
Insurance cover: 1/3 
Medication: 5/0 
others: 3/5 
TOTAL: 24/22 
Garfield Median number of changes requested 1.5 (range 0-4) 
[995 
Hotopf 5 of the 6 RECs requested changes. 
1995 
Keinonen Site I 
2001 - no complementary questions = 158 (55%) 
- study protocol only = 14 
- + subject information + consent form = 109 
- other = 4 
Site 2 
- no complementary questions = 298 (78%) 
- study protocol only = 22 
- + subject information + consent form = 48 
- other = 13 
McWilliams Mean number of changes requested: 
2003 - expedited review = 5.7 
- full review = 8.6 
Ortega 1995 There were 13 requests for clarification or modification for 6 of the 10 protocols by 8 
RECs. These related to: 
- Design / methodology 
Re: objectives/endpoint 6 items in 4 protocols by 20 RECs 
Re: sample size: 1 item in 1 protocol by 5 RECs 
Re: other: I item in I protocol by 4 RECs 
- Additional infonnation on investigational drug: I item in I protocol by 4 RECs 
- Miscellaneous: 4 items in 4 protocols by 4 RECs 
Stair 2001 The 44 IRBs requested an aberage of 3.5 changes, categorised as: 
- logistics and supervision: 20 (45%), most commonly the use of a different application 
fonn (32%) 
- research protocol: 19 (43%), most commonly the inclusion/exclusion criteria (9%) and 
issues to do with patient recruitment (9%) 
- consent fonn: 40 (91 %): 30 (68%)grammer, syntax, readability; 15 (34%) risk 
information about the intervention- 12 (27%) risk information no~ part of trial. 
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Table 74: Impact on clinical research: Changes requested foUowing first meeting of REC 
(CentraltbenlocalREC) 
Study Nature of Queries 
Tully 2000 52 RECs (42%) approved without change. 
·64% ofRECs with an Executive subcommittee v 53% of those without gave 
uncontested approval (ie approved without change) (RR lA, 95% CI 0.9-2.1, p~0.23) 
Of the RECs asking for amendments 67% asked for non-local amendments. 
Non-local changes requested were: 
- changes to information sheets: 22 (18%) 
- changes to consent procedures: 12 (10%) 
- changes to questionnaire: 9 (7%) 
- changes to methods of recruiting subjects: 9 (7%) 
- changes to protocol (5 (4%) 
- confidentiality issues: 4 (3%) 
Local changes requested were: 
- local staff to be notified: 11 (9%) 
- ethnic mix to be considered: 10 (8%) 
- local investigator to be identified: 6 (5%) 
- information sheets to be on locally headed paper: 4 (3%) 
Various other reasons accounted for 2% or less each. 
Watling Responses from 26 local RECs: 
1993 Accepted central approval: 7 (27%) 
Required local review 19 (73%) 
- changes to patient information leaflet 4 (21%) 
- toxicity/safety of trial drug 3 (16%) 
- efficacy of trial drug/comparator 2 
- need for chest radiograph 2 
- suitability of investigator 1 
- confidentiality 1 
- indemnity 1 
- financial 1 
- none 8 
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Table 75: Time to accrue patients: Local RECiI 
Stndy Details 
Bennett Authors estimate that the IRB process resulted in a delay in conducting and reporting the 
2001 first study by 6 years, and the follow-UD studv bv 3 vears. 
Table 71i: Time to accrue patients: Central then local REC 
Stndy Details 
Tully 2000 Authors state that delay receiving ethics approval "had a significant effect on study 
commencement and recruitment" and the 17% of patients referred at the time of reporting 
"were not recruited because ethical approval had not been granted by the relevant 
research ethics committee". 
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Table 77: Ethics committee decision: Time to approval (Central REq 
Study Definition Results Notes 
Boyce 2002 Time from first Median 64 days (range 7-386) [nfonnation only 
meeting to approval available for 266 of 
the 353 applications 
Time from Median 62 days (range 21-408) for the 122 
conditional applications deferred 
approval to or rejected at the first 
approval meetin.e I 
Table 78: Ethics committee decision: Time to approval (Local REC/s) 
Study Definition Results Notes 
Ahmed 1996 Time from i) Range 6 - 208 days Submission date 
submission to: ii) Mean 35 days; range 6-70 days described as date 
i) receiving iii) Mean 77 days; range 18-208 days application sent. No 
approval description of 
ii) chairman's One third of RECs were unable to "receiving approval". 
approval approve the study within 3 months, and 
iii) full committee 3 RECs took longer than 6 months 
approval 
Benster 1993 Time from request i) mean I \'9 weeks 
for application fonn ii) <4 to 16 weeks 
to obtaining written iii) <4 to >20 weeks 
ethical approval 
i) all RECs 
ii) RECs at teaching 
hospitals 
iii) RECs at non-
teaching hospitals 
Bunnan 2003 Time (days) from Median 104.5 days (range 31-346) "CDC - Center for 
the date the (similar for both studies) Disease Control 
centrally approved "Could not determine 
protocol and how much of the 
consent form was time required to 
sent from the CDC obtain local approval 
to local sites, to the was needed for the 
date the locally local IRB review 
approved consent versus the time spent 
form was submitted by the local study 
back to the CDC for site to prepare the 
review [RB submission and 
submit the completed 
review back to the 
CDC 
Dal Re 1999 Time from i) Mean 87 (SO 54) days Submission date not 
submission to Median 70 days defined, Also reports 
arrival of REC's Range 23-238 days for the following 
decision form ii) Mean 78 (SO 46) days subgroups: 
i) all 100 Median 69 days - Evaluation fee (Y 
applications Range 23-238 days orN) 
ii) for applications iii) Mean 95 (SO 61) days - Number of REC 
without queries Median 75 days members (>= 13 or 
raised Range 24-236 days <\3) 
iii) for applications - high v lower 
with queries raised volume RECs 
-
Time from i) Mean64@51)days ~--~ 
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submission to Median 46 days 
approval Range 1-231 days 
i) all \00 ii) Mean 56 (SO 42) days 
applications Median 42 days 
ii) for applications Range 1-231 days 
without queries iii) Mean 78 (SO 61) days 
raised Median 50 days 
iii) for applications Range 10-229 days 
with queries raised 
Time from approval i) Mean 21 (SO 20) days 
to arrival Median 14 days 
i) all \00 Range 1-104 days 
applications ii) Mean 22 (SO 20) days 
ii) for applications Median 15 days 
without queries Range 1-102 days 
raised iii) Mean 17 (SO 21) days 
iii) for applications Median 10 days 
with Queries raised Range 1- \04 days , 
Oockerty Time to approval Range 2 - 22 weeks 
1992 (not defined) 
Garfield Time from Median 9 weeks; range 2-14 weeks 
1995 application to final 
approval (not 
defined) 
Time from Median 4 weeks; range 0.3-8.6 weeks 
application to REC 
meeting 
Time from REC Median 0.4 weeks (3 days); range 0.1-3 
meeting to reply weeks . 
Hotopf 1995 Time to reply (not mean 47 days; range 15-125 days 
defined 
Jamrozik Time from initial Public Hospitals (n-18): median 6.5 
1999 application to weeks (range 2-11 weeks, 75th centile 
receipt of decision 8.6 weeks) 
from REC Private Hospitals (n~II): median 5 
weeks (range I-52 weeks, 75th centile 
II weeks) 
McWilliams Time to obtain Expedited review: Authors stated that 
2003 approval (not Mean 32.3 days (range 9-72 days) "Days to approval, 
defined) Full review: an indicator of the I 
Mean 81.9 days (range 13-252 days) difficulty of review, 
correlated with the 
number of changes 
requested when both 
review types were 
combined (p~0.004) 
, and with full review 
(p~O.OI) when the 
data were stratified 
by review type. No 
other significant 
correlations were 
observed." 
Ortega 1995 time from Mean 45 (SO 30) days Also reports for the 
submission (by Median 40.5 days following subgroups: 
investigator) to Range 7-110 days - number of 
approval (not members «9 or >= 
defined) 9) 
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- Frequency of 
meetings (monthly or 
variable) 
- Advance fee (yes or 
no) 
- trial phase (II or Ill) 
time from Mean 58 (SD 35) days 
submission to Median 52 days 
receipt of approval Range 9-136 days 
in investigator's 
office 
Penn 1995 Time to approval Mean 13 weeks "A major cause of 
(not defined) Median 9 weeks delay was difficulty 
Range 3-30 weeks in obtaining the 
application forms. 
Acquisition took an 
average of 9 weeks, 
and in one case it 
took 38 weeks." 
Redshaw Time from i) Mean 109 days; range 22-298 days 
1996 submission to ii) Mean 102 days; range 36-149 days 
approval (not iii) Mean III days; range 22-298 days 
defined) 
i) all applications 
ii) teaching districts 
iii) other districts 
Stair 2001 Time from Median 38 days (IQR 26-62 days) 
submission to final 
IRB approval (no 
terms were defined) 
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Table 79: Etbics committee decision: Time to approval (Central tben local REC) 
Study Definition Results Notes 
al Shahi 1999 Time from receipt Median 39 days (range 21-209 
of application by days) 
an REC to final 
REC approval. 
Date of receipt 
defined as next 
working day after 
its postage by 
first-class mail. 
Time from receipt Median 28 days (range 14-97 days) The authors report 
of application by that the expected 
an REC to first time-scale for 
REC meeting. MREC-approved 
Date of receipt applications is that 
defined as next an REC meeting 
working day after should be called 
its postage by within 2 weeks of 
first-class mail. receipt of an 
application, and a 
decision 
communicated to 
the applicant 
within 5 working 
days ofa 
subcommittee 
meetin~. 
Lewis 2001 Time for approval Median 39 days (range 12-132 
(not defined) days) 
- Executive Committees (fast track 
) median 34 days 
- No executive median 42 days 
7 RECs responded within the 
recommended 21 davs 
Lux 2000 Response time: In all sites (n-99) The authors report 
number of days Median 28 days (5th, 95th centiles that the relevant 
between arrival of 4,73 days) guidelines suggest 
the submission 33 (33%) responded within 21 an upper limit of 
and the date on days. 21 days or less for 
which written response time. 
confirmation of In sites with an Executive 
the committee's subcommittee (n:044): 
decision was Median 30 days (5th, 95th centiles 
typed 4,85 days) 
14 (32%) resDOnded within 21 days 
In sites without an Executive 
subcommittee (n~55): 
Median 25 days (5th, 95th centiles 
7,64 days) 
19 (35%) responded within 21 
davs. 
Tully 2000 Response time In all sites (n~125) The authors report 
(not defined - - 39 (31%) replied within 21 days that the relevant 
refers to In sites with an Executive guidelines suggest 
guidelines) subcommittee (n~50): an upper limit of 
- 40% replied within 21 days 21 days or less for 
In sites without an Executive response time. 
subcommittee (n~75): There was no 
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- 25% replied within 21 days statistically 
significant 
difference in 
response times 
between RECs 
with and without 
an Executive. 
Time to approval In sites with an Executive RECs with an 
(not defined) subcommittee (n~50): Executive 
- Median 28.5 days subcommittee were 
In sites without an Executive significantly 
subcommittee (n~75): quicker to give 
- Median 46 days approval than those 
without (p~O.OOO2) 
Watling 1993 Time from initial i) mean 54.7 days; range 14-84 The time period 
contact to days reported only 
approval (from the ii) mean 91 days; range 43-168 includes time 
time the REC days attributable to the 
received the process of review. 
application) Time spent 
i) for committees preparing or 
accepting central submitting data and 
approval postal time 
ii) for committees excluded. 
requiring full local 
submission 
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Table 80: Approval status at first meeting (Central REq 
Study Total approved no conditional deferred rejected Otber i 
change approval 
Boyce 353 14 (4%) 217(62%) 103 (29%) 19 (5%) 
2002 
Christian 20 0 19 (2 of which I still being 
2002 were reviewed at 
substantive time of 
revisions) publication. 
Assumed 
that these 
were 
decisions 
made at 
first 
meeting: 
time period 
not stated. 
Table 81: Approval status at first meeting (Local RECls) 
Study Total approved no conditional deferred rejected Otber 
change approval 
Benster 28 17 11 0 0 
1993 
DalRe 100 59 38 0 3 
1999 
Dockerty 14 10 4 
1992 
Druml 1531 not reported not reported 664 (43.4%) not 
1999 applications reported 
over 5 
years 
Keinonen Site I: 195 130 (46%) Approved with Pending 0 
2001 Site 2: 381 234 (61%) comments: 29 (10%) 23 (6%) 
28 (10%) 6(2%) 
63(17%) 
Request for 
Modifications: 
98 (34%) 
55 (14%) 
Redshaw 24 14 6 3 
1996 
Smith 15 4 - 6 requested I 
1994 changes to 
consent forms 
andlor 
information 
i letters 
- 5 requested 
changes to 
protocol 
(unclear if 
these overlap) 
Stair 44 4(9%) 26 (59%) 
2001 plus 4 (9%) returned to 
approved with applicant once 
only minor for revision 
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consent form 7 (16%) 
changes returned twice 
requested 2 (5%) returned 
3 times 
1 (2%) returned 
4 times 
Table 82: Approval status at first meeting (Central tben local RECls) 
Study Total approved no conditional deferred rejected Otber 
cbanl/e aDDroval 
Ashford 21 est 8 est \0 (not clear 3 
1987 if changes listed 
relate to 
overlapping 
studies) 
Larcombe 51 23 12 (minor 16 
1999 changes to 
letters or 
consent forms) 
Lux 2000 99 82 (83%) included with all those not 
- fast - 35 (80%) approved no approved at 
track - 47 (85%) change first REC 
n~44 Note: Number meeting 
- standard (%)of 
n~55 submissions 
approved after 
first review by 
REC) 
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Table 83: Final approval status (Central REC) 
Study Total approved not approval deCerred reiected 
Boyce 2002 353 330 (93%) 9 (3%) not 0 1 (0.3%) 
pursued by 
researchers 
Faccini 1984 294 37 without 14 
amendment 
243 with 
amendment 
Table 84: Final approval statua (Local REC/s) 
Study Total approved not approval deCerred reiected 
Bennett In 1990: \04 87% not reported not reported not reported 
2001 Follow-up 77% 
study in 1997: 
74 
Druml1999 1531 not reported not reported 117 (7.6%) 19 (1.5%) 
Penn 1995 26 22 4 
- 2 local REC 
demand for 
changes to 
protocol 
. 1 no response 
fromREC 
- 1 trial 
abandoned 
before issues 
resolved 
Table 85: Final approval status (Central then 10 ... 1 REC) 
Study Total approved not approval deC erred rejected 
Larcombe 51 50 1 
1999 
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Table 86: Resource issues 
Study Details 
Ahmed 1996 Estimate cost to researchers of completing applications to be 
GBP25.5 per district, GBP900 for the study. This includes cost of 
photocopying, postage, telephone, travel, time of research worker 
al Shahi 1999 Median number of copies of each application required 10 (range 1-
18) 
Paper: 5,789 pages weighing 26.9 kg 
Photocopying and printing: GBP231.56 
Postage: GBP77.15 
Person-hours: salaried secretary. research fellow and research 
projects coordinator 
Burman 2003 Study sites estimated that the process of obtaining initial local 
approval required a median 000 hours of staff time (range 10-48 
hours) 
Dal Re 1999 Mean number of copies of complete application required 6 (range 
1-16, medican 4) and 9 of the protocol alone (range 2-23, median 
10) 
Dunn 2000 Median number of copies of each application required for Study I 
was 13 (range 1-34) and for Study 2 was 4 (range 1-16). 
Number of pages: Study I ~ about 1000 sides of A4; Study 2 ~ 
mean 450 sides of A4 
Fees charged by RECs: Study I ~ 14 of20 LRECs (70%) did not 
charge and the maximum amount charged was GBP500; Study 2 ~ 
II of21 LRECs (52.4%) did not charge and the maximum amount 
charged was GBP940. 
Note: Study 2 had previously been seen by an MREC before 
submission to each local REC 
Humphreys 2003 Estimated cost of each IRB action (initial review, continuing 
review, amendments, adverse event reports) to estimate the money 
spent on IRB review after the "home" IRB had approved the study. 
Est $US56,191 in 2001 dollars): inel $USI6,95I for coordinating 
centre personnel, space, and supply costs. 
Larcombe 1999 Estimate: 
- researcher's time: 2 weeks: GBPI025 
- photocopying and postage: GBP400 
Lewis 2001 Paper: 53 local RECs required 1-24 copies of the 62 page 
application, a median of620 pages (range 62 to 1488 pages). Total 
pages photocopied to apply to all local RECs ~ 24,552. 
Resources: approximately 2 months of a clinical research fellow 
with secretarial support 
Lux 2000 Local RECs with an Executive subcommittee (fast track) required 
a significantly lower number of copies of protocols and documents 
than those without. 
Median number of document copies required: 
- fast track: 3 (5th, 95th centiles 2, 13) 
- standard: II (5th, 95th centiles I, 15) 
McWilliams 2003 Mean preparation time: expedited review - mean 5.8 hours (range 
not stated); full review ~ 8.6 hours (range 2-40 hours). 
Redshaw 1996 Estimated cost minimum GBP4,000 including 280 hours recorded 
work time, telephone calls, postage and photocopying but no 
overheads 
Sandhu 2001 2 studies submitted to 225 and 137 local RECs, each application 
averaged 47 pages. 
Paper: estimated 109,000 sheets of paper. Estimated that 59,000 
sheets could have been saved if each REC had a subcommittee of 
3 people. 
Smith 1994 Estimated cost over $AUD20,000 and more than one year to: I 
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"complete and generate multiple copies of the different application 
forms, questionnaires, protocols, consent fanns and subject 
infonnation letters and resDondin~ to lEe requests for changes". 
Tully 2000 Total number of pages used: 105,888 (1,103 applications of96 
pages each l. 
Total cost of application GBP6, \32.90 
- photocopying: GBP2,950 
- postage: GBPI,200 
- paper: GBPI,982.90 I 
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Appendix 9: SSAS invitations and data collection forms 
Appendix 9.1: REC baseline form 
[ Trial 10: 
HREC Baseline Information 
HRECname 
2. Howoften does the HREC roeet 
3. Howloog. on average, do HREC meemgs lasl tot? 
5. Does your HREC halle leO' 7' 10 II committee fOfl,osd to gl'le)'OU If'! : 1iI1i&t 
advice on the saenOOc I technical aspe ,115 d eNneal drug trials? 
• . If yes. 
I HaNottan does the SCientific committee meer? 
i I low many people a re on thiS COii"lillLa? 
iii ~k\rwlong. on average, do ",eetings run lor? 
Evef}'month 
o Every -r month 
[J OthM 
Ves No 
16. Does you COI'I)(l .. Uee use expelts outside your institution? I Yes No 
a "yes, how many hours of eMpertise would you access each yeaE? 
7 How much time, on al/orage, v.ould the HREC Secretariat spend prepanng 
• mulb-centre drug trral lor an HREC meeting? Please consider all tasks that 
might be It'lYot.ted IUdl as photooopying. organiling COf\$lJitants, etc 
8. Do you aSSign HREC mernbers to look at apphcatiOns in rrDfe detail? 
a. If yes. please d 15 • i ibe 
9 Howrnuch time, on averaRe, 'M)Uld eadl cotm'Iittee member Sflend 
prepanng for iii flEeting? 
p8f5On- tO.HS 
Va No 
o 0 
10 Ale there any ttl .. , Issues that oontnbute to the v.orldoad 01 your HREC that you tNght like to mention? (Flease 
c;oOOnue on te.Cl3e t requrectJ 
Completed by _________ _ Date completed I '-c= 
.. ~ 'Iffl 
1011181 coupleteplease retum to. The Sacretanat, Shared ScientirlC Assessment Schsme, Heelth EthICS 
(hnch, NSW HNIh DeparlrntMt 73 M,_ 51) E sf North S}ldney NSW 2OtJO 
I 
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Appendix 9.2: SSAS Evaluation Form for RECs 
SSAS Evaluation Form for HRECs 
1 Tnal name: 2_ 
3. HREC name 
Section 2: Tobecom leted~HRECExecI.iN80IfictJl' 
, Dew suomiMIOn reeeived by HREC 
5. Date of HREC" oeetng at ·,·.tuch the tflal ..... 5 first considered 
6. In the genenll opiniOO 01 the HREC, did the SSAS Final Report reduce the 
oyera. time taken to consider the tnal at the meeting? 
F'Itl"ft c:omtrIfHI!. 
7 In the general opinIOn of the HREC, did the SSAS Final Repeat irnproYe the COi,.,.tiM'. confidence In their decision? 
PI'! 'se tx:III'7JITIfMt 
8. Was the information prOYided by the SSAS Finill Report uMfut? 
[ TriallD: 
" 
dd 
1 
I I 
~ 
I I 
~ 
-=-
V.s No Unotrtllin 
V.,. No ~1U1n 
o 0 0 
2 3 4 
Ir.ditferent Nd 
Fld,secomment 
9. DecisIOI'I made al the meebirg 
e APPI'oved ..J AppfooIed ¥14th chal'9H 
e Rejected ..J Ded'5ion pendIng (subJect 10 clarification) 
10 If changes requested, please summarise. Alternatively, a copy cA the letter or approval can be attached to and sent to 
the $SAS Secretariat ...... th thIS foon. 
l' I low much (me dKl you 5pend preparing this applicatIOn lor th ... Lilting? 
Arc there any !SCI.es that may t\iilve ~U5ed a 6elay in the fIN_of ltd tnli by your HREC (ag indemmty issues, legal 
ISsues)? PIe : e descnbe 
Thank you for participating In this Evaluation. 
When complete please retum to. The Secretanat, Shared Scl8tltrrlC Assessment Scheme, H6tJhh Elhics 
Ebnch, NSWHefJIth Department, 73 Miler SII sst Nath Sydney NSW2OCJO 
I 
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Appendix 9.3: SSAS Evaluation Form for Sponsors 
Trial 10: 
SSAS Evaluation Form for Sponsors 
,. Trial name" 
2. Sponsor name: 
3. On a scale of 1 to 10 please rate how satisfied are you with your experience with the SSAS regarding this 
trial? 
1 2 3 4 5 6 7 8 9 10 
Very Very 
satisfied dissatisfied 
4. V'II'hat aspects are you happy with? 
5 What aspects are you not happy with? 
6. Ate there any issues that may have caused a delay in the review of the tlial I:¥ HRECs (e9 indemnity 
issues, legal issues)? Please describe 
Completed by: ____________ _ Date completed: __ , __ , __ _ 
dd rum yyyy 
Thank you tor participating In this Evaluation. 
~ complete please return to: The Secretariat, Shared Scientific Assessment Scheme, Research & 
Development Policy Branch, NSW Health (}epal1ment, 73 Miller Street North Sydney NSW 2060 
! 
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Appendix 9.5: SSAS End of Study Form: RECs 
SSAS End of Study Forlll: HRECs 
The SSAS Scheme has reached the end of its one-year pilot. We would like to ask those 
v..tlo have used the scheme, as welt as those who chose not to use the scheme. to provide 
us with Information that WIll help us 10 determine whether or not the scheme should continue 
and, if 5 0 . if there are "laYS in which it could be improved. 
Participation in SSAS PIlot 
1 HREC name (optimal) 
2 Old youl HRE!C partICipate In the SSAS pllol? (That IS did your HREC revIeW any 
!rials that had been Slbmltled to the SSAS)? 
• If no please lell us why 
b If yes ad yOI¥ HREC 
J If'lSIst spor15Of&Jlnve&tlgators U6e the SSAS 
J Sur1:JesI (but not 1I"IS15t) sponsors f neshgalors use the SSAS 
..J Oher (please ~"eClrYI 
Resources and Support 
Y$' ~Io u..c.rUlIn 
o 0 0 
3 On a scale of 1 10 10 please rate hOw ~hsfjed you are vlllh the advice and support prO\·,cied by NSW 
Health regardng the SSAS 
123 
Ve~ 
ClI55i11ls1I1~d 
• 5 6 
4 II you Ihu* lI'TIpfOvell'lEnlS could be made pI~ase specify 
7 
5 Old you feel adc ql.lalety donned about IT'll!: SSAS and Its processes? 
• If no In what areas dKt you f.nd n Inadequa te? 
6 was the Manual useful? Yes tlo Uneel1,1II 
o 0 0 
7 was the Web sne usefI,J/? Y.' No IJnCflfUin 
o 0 0 
B 9 
Yas No 
o 0 
~ t»' • .,lr(e ~"~Hfjhl" 10 The Seo~. 1111 Sh#rrd s.:16/1I~£"U~.U"'fjfll Sc/'ltnfJtl 
Htt;,/Jh Evw:. Srtncn NSWH,II!fJ1 Oepal/hllt'nt 1J AWI!r S uel /IIa/ll Sfllner NSW2060 
10 
Very 
sanslied 
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The Final Report 
F'tease think beck 10 the I1IaIs you have seen during the p0st year whICh ha .... e been IlYough !he SSAS 
proc.ess and lor whICh an SSAS Final Repot1 was avallab!e 
8 Is there anytl'mg aboullhe FInal Report tnal youwoulCl like to see changeo? 
..J No All of the Lnformabon requued was InCluded In the FINI Report 
.J Yes I would like 10 suggest the follOWIng charigEi 
The scheme 
9 WOlJd you be prepareo to repl<!JCe your cunenl method a sc,ertrfiC assessment 
With the SSAS evaluation? 
a If yes please tell ua wrr., 
o 1  I'D Of undecldeCf. please lell us why 
10 00 you Ihlllk the scheme $l'IOuld continue? Yn NO ~n .. n 
o 0 0 
,1 lithe sc.neme COnln.JeS wtet ~Olm should It take? (please hCII; alltha! appty) 
.J Gonunue In lUi curent tarm 
:J Continue In an expandeo ronn 
..J Other (pie no speedy) 
l'Ci NO ~eoOed 
o 0 0 
12 If yOU feeillie scheme should continue In an exparned Form In wt'lat way do you think if Should expand 
(lICk al1 lhat apply) 
J The SS,o.s should conSider all mulu-cenUe randoml$ed cllneal aug tnals 
.J The SSAS Should consider aU multi-centre lanoomlsed Inals 
.J The SSItS shOuld conSIder all multi cenlfe clinical aug IrlalS 
.J TOO SSAS shOuld conSIder all mula centre cbncal rcscard'l 
..J Other ways II'w! $$AS sholJd cons(ief expenciflg ats role 
Name of ~rson OOI'll'Ietng Ihl" form ________________________ _ 
0. .. 
--' '---
Th~nk you for participating in this Evaluation. 
W1>en (:OI,,,IIHI! pM'''f~~fI 10 T~ S.o'e~".tt Sh;Jtetl S"I~:lU.c "u.un..." SCfIIrnll! 
IlEillH1l EI1I1CI g,oIncll nSWfoj"oI/(ft ~".,rftlo!ll( 1) MI4« S.~r Norlh sydne'l NSW 2060 
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Appendix 9.6: SSAS End of Study Form: Applicants 
SSAS End of Study Form: Applicants 
The SSAS Scheme has reached tt\(): end of its one-yea r pilot. VVe would like to ask those 
YAlo have used the scheme, 3$ well 3$ those who chose not to use the scheme, to provfde 
us with Informatton that -Mil help us 10 deternlne whether or not (he scheme should continue 
and, if $ 0 , if there are ways in which it could be improved 
ParttClpatlon in SSAS Pilot 
1 ApplCanl name (opllonal) 
2 Old you tiubmt art( Illais ror conalCierallOll by the SSAS as pari of the PlIoI? 
ill If not pleaae leW us wt'rf 
b If you parbClI>8ted rn the pilot how did 1h1$ corne abOut? 
J fJJ. least one HREC Irl6tSted thai we use the SSAS 
J '!Ne chose to use the SSAS wdholJ P-O"lXlng tv an HREC 
.J Cld'ler (please specify) 
Resources and Support 
v., No \Jrle«l .... 
o 0 0 
3 On a scale of 1 10 10 please f81e how S81,sfted you are with the advice and suppon provided by NSW 
HeaUn regarding the SSAS 
,23 
VCly 
ClSsatlsflect 
, 5 6 
4 If you ttUrM lI'I"IprO'IemlH liS could be made please specify 
7 
5 Dto you feeladequale/y Inlol l ll(:d about the SSAS and Its processes? 
• If no In what areas dlCl you rind It tnadequale? 
6 was the Manuel useoful? Yu rio Un"ot • ., 
o 0 0 
7 was the VYeb slle useful? Yes tlo Ununall'l 
o 0 0 
8 9 
Yu 1'10 
o 0 
W1I<m (Oo'WJIeIe p"~'_ " fUn 10 rhe S~~'UlI SN/led S~lrnlF~ Asseument Seneml! 
HNtJJ, EIIK' "" • ..:h NSWtw.1rh Orp.l lmetll 13 Molle' SUe-' Nam SjXI", NSW lO6O 
10 
Very 
sansl!ed 
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The Final Report 
PI~se think beck to the tnalS you submitted 10 the SSAS dUring the pest year and for which an SSAS FInal 
Report was available 
8 Is there anyumg aboullhe FInal Report thai you woule like 10 see changed? 
.J No All of the Informabon required was InCluded In the FInal Report 
.J Yes I would like 10 SLggesl t~ followl"3 changes 
The scheme 
9 00 you Ihlnk the scheme ShOuld conllnue? V,n No Unu_ded 
o 0 0 
'iI Please teM us why you Ihlnk Ihls way 
10 II the SCheme cortttnJes wtlal form StlOUid II lake? (~ease lick aliitlat appf'f) 
.J CClritlnuE- In lIS. current form 
.J ContInue In an expanded form 
.J Othet' (p/e3S8 spec/ftl 
11 If you feel the scheme should COnlinue In an e)(panded lorm In what way do you It'unk It should expand 
(bCk alilhal apply) 
.J The SSAS shOUld conSider all mulh-cenlre random.sed chl"llCal aug trialS 
oJ Tne SSAS should con&Ider all multi centre randomlsed lnals 
.l The SSAS should conSIder 311 mulu cenlre chmcal cn.g (nals 
.J The SSAS shOlild COnSider all multl·centre CWrt\C81 research 
.J Other ways lhe SSAS sroud consder e)Cpanang its role 
12 Ate ttere any ol~r "s .. ~ you would hke to raISe? 
Name of per50ll COf1'llI&III"9 this form. __________________________ _ 
0. .. __ I , __ _ 
Thank you ror participating in this Evaluation. 
~ (OI1¥I1iI!~ pllNR/r lll/l'O The $1<1_111 S/NJIed SerrN/.c A ..... nllMl SCNme 
HHfm EltW. &~lCn NSIVHul!h ar,."tr'Ul 7JM~St~ IINlt"Ih sfdMf NSW2060 
, 
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Appendix 9.7: SSAS End of Study Form: SSAS members 
SSAS End of Study Form: SSAS 
The SSAS Scheme ha$ reached the end of its one-year pilot We would like to ask those 
who have used the scheme, as 1Ne1l as those who chose not to use the scheme. to provide 
us vvith Information that WlH help us to determine 'Nholher or not the scheme should continue 
and, if so , if there are Vlay$ in """'ICh It could be improved. 
Resources and Support 
1 On i3 scale of 1 10 10 p/eZtSe rate hem satISfIed you are v'I11h lhe advIce and support prOVided t1t the SSAS 
Secretan3t at NSV'I/ Health regarding the SSA$ process 
1 2 3 4 5 6 7 8 9 10 
Very 
Glsubsfled 
2. If you th./i( rmpl'OY'Stl"lOmlS COUld bit mad& plene specdy 
3 How rn.x:h hme on average did you spend prepanng for each SSAS meehng 
(readrl"g applicatIOns etc) 
4 Were the .. neetlngs (IncliA:j,r'g tet~rt~s) h:ekJ alan accc:plable t~? 
The Final Report 
V"Y 
""5t...c 
---"""" 
'f'u No 
o 0 
Ptease think back 10 the Inal5 you have seen dUring the paS! year whICh have been ttYovgn the SSAS 
process and for whICh an $SAS Flflal Report was a .... allable 
5 16 there anyttlng .,txlut tl'Ie FIn.11 Report ItIaI you wouklltke to $CE! changed? 
J No All of the Information required was lflCIuded In the FII'la1 Reporl 
.J Yes 1 WOUld like to SUQgeiolll'le folJo.Vlng cnar.ges 
wn-COf~ /W"./ltlllrl 10 nt& Stcel.ittlllll SNtItd Sc~>I~ie "u~.tsnlelll SCnt,.", 
JItI;alllt EIhC, iriHtth /\/SW Hellltll Otp"lmetU 11 MIIIrr SYH! :V~/II Sf'J'~ NSW2060 
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The scheme 
6 00 you think tre &Cheme shOuld continue? Yu No UoodeOdII!d 
o 0 0 
• ~se tel us wtrt you thlri< thiS Wif'( 
7 If the SChErne contW'lUes what form should It lake? (please lick all that apply) 
:J Continue In its current form 
..J Conllnue In an expanded form 
..J OI.her (pleaso Sf'9Clfy) 
8 II you feel tile scherr!!! should conllnue In an alCpaflCed form In what way do you think n Should expand 
(lICk all thai apply) 
..J The SSAS Should conSider Bil rrult....centre ranoomrsed clneal aug tnalS 
.J The SSAS should conSIder .111 multI ·centre randof1'll5ed lnals 
..J The SSAS 5hOuid COO61der all multi centre cllT"IICal aug tnalS 
J The SSAS shOUld comuder aU muln·centre chncal rese.lfen 
..J Other WlIVS lne SSAS snoUid con5>der ~xpardng il8 role 
9 If the S$AS conclnue au~ lI"1ele art( ch.,nges to the process lml Should ~ ma~? 
'0 Ate there any other issues you would like 10 fl!llSe? 
Nam~ of pefSOO ~etll"lg this lorm ________________________ _ 
"" .. 
--' '---
Thank you for participating in this Evaluation. 
WlII!tI rCWl1)~r .. 1*""'/11111111 10 Tilt! S«rllllll, trt Shat4ld Sc"""I'~ .... eJSmerl' Senen!!! 
Hr,,1It1 E/IW!j 9~1> NSWrle .. /Ih OiIIpII/lnII!IIt 7J J.11/!1111 S'~I.'W1I!tI Syd<tej' NSW 2060 
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Appendix 10: SSAS invitations to participate and consent 
forms 
-,1'" , .... NHMRCC1b*:aJ Trials Centre 
U,.. The Unive~of~ 
Locked Bag 77 
CillTperdown NSW2050 
Tel: +61·2 96625000 
F.uc:-Kil·2 95651863 
E-mail: enquiry@j:c.usyd.eduau 
:' Hroc NSW 'Jw 'YF' ~: y Y $&;" 
S SAC Se cm:ariat 
Health Ethics Brancn 
NSW Health Depill1ment 
73 MiUer Street 
ri:Jnh Sydney NStIII2060 
Telephone (02) 9391 9S!S4 
«current date» 
Name and 
address of 
chair of REC 
Dear «name of chair» 
Re: Evaluation of the Shared Scientific Assessment Scheme (SSAS) 
In February 2003 NSW Health will commence a one-year pilot of a Shared Scientific 
Assessment Scheme (SSAS) for multi-centre clinical drug trials, At the end of the pilot a 
decision will be made as to whether or not to continue the work of the SSAS and, if so, if the 
remit should be expanded to include other multi-centre research, To aid NSW Health in its 
decision it will be necessary to evaluate the SSAS during the pilot phase, An information 
sheet on the evaluation has been included with this letter as well as the complete protocol 
should you like to read further, The protocol includes the data collection forms to be used, 
As your REC may partiCipate in the SSAS Pilot we would like to ask your REC to participate 
in the Evaluation of the SSAS Pilot It is anticipated that workload involved in the Evaluation 
would be minimal, 
Please read the REC Information Sheet and, if you agree to take part, complete the enclosed 
Agreement to Participate form, This should then be returned to: The Secretariat, Shared 
Scientific Assessment Scheme, Health Ethics Branch, NSW Health Department, 73 Miller 
Street North Sydney NSW 2060, 
If you require any further information, have any questions or would like to discuss the 
evaluation further please contact the SSAS Secretariat at NSW Health by telephoning (02) 
93919854, 
Yours Sincerely, 
Davina Ghersi 
Research Fellow, NHMRC Clinical Trials Centre 
SSAS Evaluator 
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-#" ,.... NHMRC Clinical TritJ/s Centre 
~ The Unive~of 8ytlney 
locked Bag 77 
Carrperdown NSW2050 
Tel: -t61·2 95625000 
Fax: -+61·2 9565 1863 
E-mail: enquiry@ctc:.usyd.edu.au 
NS\l""~'HtS-lH .-,:",,';1 .~r ~="" 
SSAC Seaetari;rt 
Health Ethics Branch 
NSW Health Department 
73 Miller Street 
tbrth Sydney N SVb' 2060 
Telephone (02) 9391 9854 
REC Agreement to Participate 
in the Evaluation of the NSW Health Shared Scientific Assessment Scheme 
This is to confirm that _____ .,---_----::-::-__ .,--_________ _ 
(name of Sponsor) 
gives permission for the trial __ ----,::::-----:,.,.-;---::-____________ _ 
(title of trial) 
to be used in the Evaluation of the NSW Health Shared Scientific Assessment 
Scheme. 
Name: 
Signature: Date: __ , __ , __ _ 
On behalf of the Committee 
When complete please return to: The Secretariat, Shared Scientific Assessment Scheme, 
Health Ethics Branch, NSW Health Department, 73 Miller Street North Sydney NSW 2060 
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Evaluation of the NSW Health Shared Scientific 
Assessment Scheme (SSAS) 
Information Sheet for RECs 
The National Statement on Ethical Conduct in Research Involving Humans released by 
the NHMRC in 1999 makes it possible for RECs to "accept a scientific/technical assessment 
of the research by another institution or organization". This clause has resulted in various 
models for sharing scientific or ethical review being implemented across the country. 
As your REC may participate in the SSAS Pilot we would like to ask your REC to 
participate in the Evaluation of that pilot. The Evaluation will enable NSW Health to decide at 
the end of the pilot whether or not to continue the work of the SSAS and, if so, if the remit 
should be expanded to include other multi-centre research. 
If shared scientific review is effective it could improve the quality of clinical trials 
research, reduce the workload of RECs by reducing unnecessary duplication of effort, and 
reduce the time it takes for clinical trials to start recruiting. If not effective it could actually 
increase the burden on researchers and RECs by adding another level of bureaucracy. 
The aim of the study is to evaluate the NSW Health Shared Scientific Assessment 
Scheme (SSAS) by assessing its influence on i) Health Research Ethics Committees and ii) 
Multi-centre clinical trials. If you agree to take part you will be asked to: 
1. Complete an REC Baseline Information form 
2. Complete an SSAS Evaluation Form for RECs for each eligible trial submitted to your 
REC. The form will be sent to you by the Sponsor when they submit the trial for 
consideration by your REC 
Individual trials, the results of individual trials, Sponsors and RECs will not be 
identified or identifiable in any report or publication produced as a resutt of the SSAS 
Evaluation. 
Participation in the Evaluation is voluntary. If your REC agrees to take part, please 
complete the attached Agreement to Participate form and send to: The Secretariat, Shared 
Scientific Assessment Scheme, Health Ethics Branch, NSW Health Department, 73 Miller 
Street North Sydney NSW 2060. RECs may withdraw from the Evaluation at any time without 
penalty or prejudice. 
The Evaluation is being conducted by Davina Ghersi, Research Fellow at the 
NHMRC Clinical Trials Centre and will form the basis for the degree of Doctor of Philosophy 
in Medicine at the University of Sydney under the Supervision of Professor John Simes. All 
aspects of the study, including results, will be strictly confidential and only Davina Ghersi and 
the Secretariat of the SSAS will have access to information on participants except as required 
by law. A report of the study may be submitted for publication, but individual participants 
(trials, investigators or RECs) will not be identifiable in such a report. 
If you require any further information, have any questions or would like to discuss the 
Evaluation further please contact the SSAS Secretariat at NSW Health by telephoning (02) 
93919854. 
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-I/"" ,,.,,. NHMRC Clinical Trials Centre 
~ The Unive~of~ 
Locked Bag 77 
Carrperdown NSW2050 
Tel:+61·2 95625000 
Fax:+61·295651863 
E-mail: enquiry@ctc.usydiiiduau 
Name and address of 
Sponsor 
Dear «name of Sponsor representative» 
NSU".j,.~UCA( W&: ,-:l' iJ h0~ <%;Dc\? 
SSAC Secretariat 
Health Ethics Brandl 
NSW Health Department 
73 Miller Street 
r-brth Sydney NS'IlV 2060 
Telephone (D2) 9391 9854 
«current date» 
Re: Evaluation of the Shared Scientific Assessment Scheme (SSAS) 
In February 2003 NSW Health will commence a one-year pilot of a Shared Scientific 
Assessment Scheme (SSAS) for multi-centre clinical drug trials. At the end of the 
pilot a decision will be made as to whether or not to continue the work of the SSAS 
and, if so, if the remit should be expanded to include other multi-centre research. To 
aid NSW Health in its decision it will be necessary to evaluate the SSAS during the 
pilot phase. An information sheet on the evaluation has been included with this letter 
as well as the complete protocol should you like to read further. The protocol includes 
the data collection forms to be used. 
As a Sponsor submitting a trial for consideration by the SSAS Pilot you are being 
asked for permission for your trial to be used in the Evaluation of the SSAS Pilot It is 
anticipated that workload involved in the Evaluation would be minimal. 
Please read the Sponsor Information Sheet and, if you agree to take part, complete 
the enclosed Agreement to Participate form. This should then be retumed to: The 
Secretariat, Shared Scientific Assessment Scheme, Health Ethics Branch, NSW 
Health Department, 73 Miller Street North Sydney NSW 2060. 
If you require any further information, have any questions or would like to discuss the 
evaluation further please contact the SSAS Secretariat at NSW Health by 
telephoning (02) 9391 9854. 
Yours Sincerely, 
Davina Ghersi 
Research Fellow, NHMRC Clinical Trials Centre 
SSAS Evaluator 
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Evaluation of the NSW Health Shared Scientific 
Assessment Scheme (SSAS) 
Information Sheet for Sponsors 
As a Sponsor submitting a trial for consideration by the SSAS Pilot you are being 
asked for permission for your trial to be used in the Evaluation of the SSAS Pilol. The 
Evaluation will enable NSW Health to decide at the end of the pilot whether or not to continue 
the work of the SSAS and, if so, if the remit should be expanded to include other multi-centre 
research. 
If shared scientific review is effective it could improve the quality of clinical trials 
research, reduce the workload of RECs by reducing unnecessary duplication of effort, and 
reduce the time it takes for clinical trials to start recruiting. If not effective it could actually 
increase the burden on researchers and RECs by adding another level of bureaucracy. 
The aim of the study is to evaluate the NSW Health Shared Scientific Assessment 
Scheme (SSAS) by assessing its influence on i) Health Research Ethics Committees and ii) 
Multi-centre clinical trials. If you agree to take part you will be asked to: 
3. Distribute an SSAS Evaluation Form along with the Final Report from the SSAS with 
your application to each REC 
4. Keep a log of SSES Evaluation Forms to make it possible to track each trial through 
each REC 
5. Complete an SSAS Evaluation Form for Sponsors for each eligible trial submitted to 
the SSAS 
Individual trials, the results of individual trials, Sponsors and RECs will not be 
identified or identifiable in any report or publication produced as a result of the SSAS 
Evaluation. 
Participation in the Evaluation is voluntary. If you agree to take part, please complete 
the attached Agreement to Participate form and submit with your completed SSAS Application 
to: The Secretariat, Shared Scientific Assessment Scheme, Health Ethics Branch, NSW 
Health Department, 73 Miller Street North Sydney NSW 2060. Sponsors may withdraw from 
the Evaluation at any time without penalty or prejudice. 
The Evaluation is being conducted by Davina Ghersi, Research Fellow at the 
NHMRC Clinical Trials Centre and will form the basis for the degree of Doctor of Philosophy 
in Medicine at the University of Sydney under the Supervision of Professor John Simes. All 
aspects of the study, including resu~s, will be strictly confidential and only Davina Ghersi and 
the Secretariat of the SSAS will have access to information on participants except as required 
by law. A report of the study may be submitted for publication, but individual participants 
(trials, investigators or RECs) will not be identifiable in such a report. 
If you require any further information, have any questions or would like to discuss the 
Evaluation further please contact the SSAS Secretariat by telephoning (02) 9391 9854. 
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